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Abstract 
 
The main aims of this thesis were to develop and characterise monomer modified oxygen 
(O2) sensors that could withstand the harsh setting of an in-vivo environment, without the 
risk of alteration of the sensor components and the characterisation of nitric oxide (NO) 
sensors in-vitro, followed by the complete in-vivo characterisation under physiological 
conditions. The main result sought after for development of these novel O2 sensors, was the 
potential utilisation in a clinical setting. Chapter 1 introduces the background behind the 
monitoring of NO and O2 in the brain, the biosynthesis of NO in the brain, the biosynthesis 
of NO through the N-methyl-D-aspartate receptor (NMDA) and the potential role of NO in 
neurovascular coupling. Chapter 2 discusses the theory behind the project and Chapter 3 
describes the experimental protocols utilised throughout this research.  
Chapter 4 discusses the development and characterisation of the monomer modified O2 
sensors. The subsequent characterisation of the novel O2 sensors in-vivo is discussed in 
Chapter 5. The use of various perturbations to alter the O2 concentration for characterisation 
of the O2 sensors is described. The characterisation of the NO sensor types (Type 2 and 
Type 3 NO sensor) is discussed in Chapter 6, with response times, sensitivity and 
selectivity discussed in detail. The subsequent characterisation of these sensors in-vivo is 
described in Chapter 7. Systemic and local administrations of various inducers and 
inhibitors of nitric oxide synthesis were carried out to determine the sensors viability in 
monitoring the analyte in a physiological environment. 
In Chapter 8, another aspect of this research involving the simultaneous recording of the 
NO and O2 analytes in-vivo is described, which utilises a combination of the styrene 
modified carbon paste electrodes (SMCPEs) and methyl methacrylate modified carbon 
paste electrodes (MMCPEs) for the detection of O2 and the Type 2 and Type 3 sensors for 
the detection of NO. These results yield valuable information about the possible 
relationship between the two molecules. The final chapter (Chapter 9) details a summary of 
all of the chapters and concludes with a final discussion on the results attained.       
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The focus of this thesis is the design and characterisation of microelectrochemical sensors 
that can reliably detect oxygen (O2) and nitric oxide (NO) in-vitro, with the main goal being 
the neurochemical recording of these substrates in-vivo. The long-term aim is the in-vivo 
recording of tissue O2 in a clinical setting which deems the in-vitro and in-vivo 
characterisation of this sensor vital. However, since the regulatory hurdles are so high for 
neurochemical recording in a clinical environment (see Section 1.2.2), the primary area of 
focus is peripheral tissue. NO is further back in terms of clinical uptake since most 
clinicians express little interest in measuring this novel marker in patients. However, the 
bioanalytical laboratory team believes that they will overcome this clinical inertia in the 
near future but as it currently stands it is out of the scope of this thesis. With this is mind, it 
is imperative to determine the behaviour and subsequent capabilities that these sensors may 
possess for recording in a very complex milieu that is the human body. The in-vivo 
characterisation of both sensor types were undertaken in the brain since this is our area of 
interest and expertise and it is firmly believed that the findings can translate across into 
peripheral tissue.    
 
 
 
Figure 1: An image of the brain inset: a depiction of a neuron, 
http://scientopia.org/blogs/scicurious/2011/05/04/science-101-the-neuron/ 
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1.1 The Brain 
 
Understanding the mechanisms behind how the brain functions is one of science‘s biggest 
challenges. Comprehension of the interplay between the electrical and chemical pathways 
responsible for behaviour, feelings or thought, is at the forefront of the science 
communities unanswered questions and eagerly awaited understanding. The real-time 
measurement of chemicals in the brain environment, utilising electrochemical sensors, is an 
advanced and significant technique. It allows for specific neurochemicals to be targeted and 
detected, giving sub-second information about how that molecule functions and what role it 
plays in the body, during specific experiments (O'Neill & Lowry, 2006). The brain is a very 
complex organ that comprises of over 12 billion neurons (see Figure 1) and 50 million glial 
cells. The largest part of the brain is the cerebrum and it is separated into four paired lobes; 
frontal, temporal, occipital and parietal. Each of these lobes control separate functions that 
regulate bodily processes (Baggaley et al., 2001). 
In order to comprehend how the brain works, an understanding of the different cells that 
compose this multifaceted organ needs to be gained. The cells that elicit a chemical and 
electrical signal are called neurons and they are the basic unit of the nervous system. These 
neurons function by sending and receiving messages to and from other nerve cells. The 
main communication points on the surface of the nerve cells are called synapses (see Figure 
1.1). The transfer of messages occurs through synaptic transmission, which secretes a 
chemical called a neurotransmitter, which carries the message from neuron to neuron 
(Bloom & Lazerson, 1988). A stimulus is needed to trigger the neurons, creating nerve 
impulses which cause the charge on the inside of the cell membrane to alter from negative 
to positive. A nerve impulse then travels down to the end of the axon triggering the release 
of the neurotransmitters which cross the gap from the neuron to the target cell producing 
the response (Baggaley et al., 2001). Depending on the type of neuron involved, the 
impulse either excites the post synaptic receptor (glutamate/dopamine) and continues on to 
the next neuron or inhibits the post synaptic receptors, causing the impulse to cease firing. 
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Figure 1.1: An image displaying the structure of neurons  
(http://www.drugdevelopment-technology.com/projects/dimebon/dimebon3.html) 
 
1.2 Micro-electrochemical O2 Sensors 
 
O2 is the most vitally important molecule that sustains life on earth. The human body is 
beautifully orchestrated in receiving and delivering O2 to the many of the uncountable cells 
that comprise our bodies (Lane, 2002). The brain consumes about 20% of the total amount 
of O2 produced by the body and the tissue concentration is conditional on the blood supply 
and local utilisation of O2 (Lowry et al., 1997). The concentrations of O2 in cerebral tissue 
ranges from 40 µM to 80 µM (Lowry & O'Neill, 2006). Insulated metal polographic 
cathodes that continuously recorded O2 availability in feline subjects achieved the first time 
O2 recordings in-vivo by the technique of voltammetry using metal electrodes (Clark et al., 
1958). The utilisation of noble metal electrodes and carbon-based electrodes for the 
detection of this analyte have been extensively reported over the years (Lowry et al., 1996; 
Luebbers, 1996; Dittmar et al., 1997; Bolger & Lowry, 2005; Lowry et al., 2010; Kealy et 
al., 2013). 
 
 Chapter 1: Introduction 
 
4  
 
1.2.1 Carbon Paste Electrodes (CPEs) 
 
In 1958, a short one-page report that introduced the CPE, was published by Ralph Norman 
Adams (Adams, 1958). The preparation of a mixture of carbon powder and a binder was 
presented as a promising electrode material. Since that time, CPEs have undergone many 
developments. The modification of the CPE was attractive, due to the ease of manipulation 
in their production. In 1964, Kuwana and French developed the first type of CPE that 
contained an electroactive organic substance dissolved within the binder (Kuwana & 
French, 1964). In 1965, Marcoux et al., prepared a modified CPE, by rubbing a modifier 
into the paste which enhanced the performance of the sensor (Marcoux et al., 1965). Still to 
this day, the modification of the CPE is an attractive concept as demonstrated in recent 
literature (D‘Souza et al., 2013; Fathirad et al., 2013; Soysal et al., 2013; Bahrami et al., 
2014). 
The modification of the CPE in this body of research was undertaken to try and produce a 
sensor that was more robust and not as easily modified when in the presence of elements 
that compose a biological milieu. The CPE is known to alter from a CPE to a carbon 
powder electrode when placed in the in-vivo environment. This is due to lipids and other 
endogenous species removing the silicone oil from the carbon paste. This characteristic of 
the CPEs is one that makes them so advantageous in-vivo, as the extraction of the oil from 
the carbon paste removes some of the fouling that can occur at the surface of the electrodes 
when placed into a complex biological setting. This then provides the sensor with long term 
stability in-vivo (Ormonde & O'Neill, 1989, 1990). CPEs are more desirable to use than 
metal based sensors, as they do not require protective membranes to defend against surface 
poisoning (Bolger & Lowry, 2005). 
The utilisation of CPEs for the detection of O2 in-vivo has been previously demonstrated 
within our research group (Lowry et al., 1997; Bolger et al., 2011b; Kealy et al., 2013). 
Even though the CPEs work very efficiently in the detection of O2 over long periods of 
time, more recently, the focus of our group has concentrated on the integration of 
electrochemical sensors into the clinical environment. For a sensor to be utilised in a 
clinical setting, sensitivity to interfering lipophilic ions or charged surfactants should not be 
an issue for the electrode (Czaban, 1985). Leeching of constituents or risk of the removal of 
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components from the sensors structure should not be a problem when trying to use an 
electrode in a clinical environment. Therefore, the CPEs would never be considered an 
optional sensing device for O2 within human tissue. 
In the research undertaken in this thesis, the introduction of the monomers styrene (Sty) and 
methyl methacrylate (MMA) into the CPE design was performed to produce a more robust 
and solid composite that would not be easily altered in a complex biological setting. The 
Sty and MMA monomers have been utilised previously in the design of sensors. The 
addition of Sty into the construction of carbon nanotube sensors with the goal of 
synthesising and characterising Sty grafted carbon nanotubes and its polystyrene 
nanocomposites has been demonstrated previously (Nayak et al., 2007). MMA has been 
incorporated into the production of dental appliances, which demonstrates a compatibility 
with human tissue (Douglas & Bates, 1978; Murray & Darvell, 1993; Sarac et al., 2006). 
Also a graphite/poly(MMA) sensor was designed for the detection of vitamin C (Dai et al., 
2008). The modification of the CPEs with the monomers MMA and Sty was successful and 
created a robust and solid electrode for the detection of O2 in a complicated in-vivo 
environment (see Chapter 5). 
 
1.2.2 Real-Time Clinical Monitoring of O2 
 
The O2 sensor described within this body of work has been designed with peripheral tissue 
monitoring in mind, since the regulatory hurdles surrounding human brain monitoring are 
so high. Despite this, an extensive characterisation of the sensor was undertaken in brain 
extracellular fluid and described in detail in this thesis. It is predicted that the technology 
will translate from brain tissue to peripheral muscle tissue without any complications. 
Clinicians have expressed their desire for continuous real-time monitoring of vital 
metabolites such as O2; however, to date such a technology is not available. The majority of 
techniques for measuring O2 in hospitals suffer from low temporal resolution and have 
limited utility in medical emergencies. For example, blood gas analysis requires the 
undesirable removal of blood samples from patients resulting in slow sampling times, 
however, despite this limitation; it is one of the most common tests performed on patients 
in intensive care units.  
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Pulse oximetry is another standard technique utilised in intensive care units that provides an 
indirect reading of O2 saturation of the patient‘s blood. However, unlike the 
electrochemical tissue O2 sensor, pulse oximetry fails to inform the clinician about how 
much O2 is actually utilised by the patient‘s tissue. Currently there is no electrochemical O2 
sensor utilised in peripheral tissue monitoring but the commercially available LICOX
®
 
probe (see Figure 1.2.2), has been extensively utilised in brain tissue monitoring (Mulvey et 
al., 2004; Stevens, 2004; Huang & Obenaus, 2011). This probe displays a lot of similarities 
to the O2 sensor described in this body of work; however, the LICOX
® 
O2 sensing 
component functions by diffusion of O2 through a permeable membrane surrounding the 
probe and into an electrolyte solution where a signal is generated. The LICOX
®
 probe is 
designed with brain monitoring at its core and is fixed carefully in position using a bulky 
housing component. The fragile membrane surrounding the probe is unsuitable for 
orthopaedic surgery due to risk of damage during implantation and leakage of the 
electrolyte into the surrounding tissue.  
Despite this limitation Hansen and colleagues have reported for the first time the benefits of 
measuring intramuscular tissue oxygenation in the diagnosis of compartment syndrome 
(CS) using the LICOX
®
 probe (Hansen et al., 2013). CS is a very serious condition that 
results from increased pressure in a muscle compartment following trauma that can lead to 
muscle and nerve damage and a compromise in blood flow. The most common cause of CS 
is trauma to the muscle following extremity fractures. The pathophysiology of CS involves 
pressure-induced ischemia of muscle suggesting that the real-time monitoring of tissue 
oxygenation represents a potential method for diagnosing its onset. Ischemia is defined as 
being a restriction in blood supply to tissues, causing a shortage of O2 and glucose needed 
for cellular metabolism. O2 is an extremely relevant real-time indicator of CS since it is 
transported to the muscle via blood supply and if the blood supply is interrupted then no O2 
can reach the muscle. The use of an intramuscular sensor to directly measure the level of O2 
represents a key advancement in diagnosing tissue ischemia complications such as CS 
especially since the level of muscle O2 was found to respond rapidly to ischemia and 
correlate with biochemical markers of muscle ischemia including ATP and pH (Hansen et 
al., 2013).  
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Due to the inherent limitations of the LICOX
®
 probe for intramuscular monitoring the 
design and development of a novel O2 sensor has massive potential for addressing this 
medical emergency. 
Despite the manufacturing of a sensor from biocompatible materials, the sensor assembly 
itself may not be suitably compatible. This leads to the need for separate testing of the 
sensor to determine the biocompatibity of the intact sensor design. The cytotoxic testing of 
implantable devices is required by all regulatory bodies and will be performed prior to any 
scheduled clinical studies (Koschwanez & Reichert, 2007). 
 
 
 
 
 
 
 
 
 
Figure 1.2.2: (A) An image displaying the LICOX
®
 brain tissue monitoring probe and (B) the LICOX
®
 
probe inserted into brain tissue. 
http://www.digitallamb.com.au/projects/flash-animation/licox.html 
 
1.3 Micro-electrochemical Nitric Oxide (NO) Sensors 
 
Detecting the free radical NO, is a very challenging task for electrochemical sensors for a 
variety of reasons. It has a very short half-life (typically < 10 s) due to the reactions with 
different molecules (Lancaster Jr, 1997). The concentration of NO in-vivo has been 
established as around 0.1 µM (Hall & Garthwaite, 2009) and when one is trying to detect 
such a small and reactive molecule in the presence of a myriad of endogenous interferents, 
it can prove very difficult. NO has a role in the regulation of vascular tone and has been 
linked to a variety of diseases that include hypertension, Parkinson‘s disease and 
Alzheimer‘s disease (Brown et al., 2005). It was characterised as the endothelium derived 
A B
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relaxing factor (EDRF) in the late 80‘s, (Ignarro et al., 1987; Palmer et al., 1987). Since 
this discovery, many researchers have attempted to understand and unravel the various 
roles of NO in physiology. The production of NO occurs endogenously from L-arginine by 
a family of enzymes called nitric oxide synthases (NOSs) (Dinerman et al., 1993; Schmidt 
et al., 1993), which is discussed in more detail in Section 1.4.  
In order for NO to be detected by electrochemical sensors, the sensors must encompass 
certain characteristics that enable the recording of NO in-vivo. These include, good 
selectivity and efficient discrimination between other electroactive species encountered by 
the sensor, good sensitivity towards the target analyte, fast response time and long term 
stability (Bedioui & Griveau, 2013). The first direct oxidation of NO on a platinum (Pt) 
electrode was reported by Shibuki et al., using a miniature Clark-type electrode (Shibuki & 
Okada, 1991). Since then, there have been numerous reports of research groups using 
carbon, glassy carbon, Pt or gold electrodes covered by different types of membranes, to 
detect NO (Friedemann et al., 1996; Pontié et al., 1999; Pontié et al., 2000; Ferreira et al., 
2005; Kato et al., 2005; Ho Shim et al., 2010).  
The use of the polymeric ion exchanger Nafion
®
, which is a perfluorinated sulfonic acid 
ionomer, to provide a barrier for a variety of anionic interfering species, has been 
successful in the detection of NO. Within our research group the detection of NO has been 
undertaken with a Pt-Nafion
®
 sensor and a Pt-Nafion
® 
sensor that incorporates a layer of o-
phenylenediamine (o-PD) as an extra interference rejection layer (Brown et al., 2009; 
Finnerty et al., 2012a; Finnerty et al., 2012b). These sensors provide real-time NO 
detection, with great sensitivity, a quick response time and great selectivity over a wide 
range of electroactive species in-vivo. NO detection in-vivo continues to be seen as an 
important objective and the more reports being produced on the monitoring of this analyte, 
the more we will gain a better understanding of how it functions and to what extent it is 
implicated in disorders like Alzheimer‘s disease, Parkinson‘s disease and hypertension. 
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1.4 Biosynthesis of NO  
 
As already stated, NO is a very reactive molecule, which is synthesised by a family of 
enzymes, called NOS, which are located in many of the cells in the body (Guix et al., 
2005). There are three principle isoforms of the NOS enzyme: 
 
 Neuronal NOS (nNOS)  
 Endothelial NOS (eNOS) 
 Inducible NOS (iNOS) 
 
All of the NOS enzymes have similar structures and they contain both an oxygenase 
domain and a reductase domain. The oxygenase domain allows for the binding of L-
arginine, heme and tetrahydrobiopterin (BH4) and the reductase domain allows for flavin 
adenine dinucleotide (FAD), flavin mononucleotide (FMN) and nicotinamide adenine 
dinucleotide phosphate (NADPH). Both of these domains are connected through a binding 
site for calmodulin (Marletta, 1993; Alderton et al., 2001). nNOS and eNOS are calcium-
calmodulin dependant enzymes, that produce NO in a transient manner, whereas iNOS, is 
independent of calcium and calmodulin (Mungrue et al., 2003). The production of NO 
through the iNOS enzyme occurs following immunological or inflammatory stimulation in 
macrophages, astrocytes and other cells. The NO produced from this stimulation lasts hours 
or even days (Iadecola et al., 1995). It is imperative that all of the aforementioned co-
factors are available for the biosynthesis of NO to proceed. (Dinerman et al., 1993; Schmidt 
et al., 1993). L-arginine, in the presence of molecular O2 binds to its site on the NOS 
isozyme to produce NO and L-citrulline, Figure 1.4, displays this process by which NO is 
biosynthesised (Guix et al., 2005). 
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Figure 1.4: A schematic displaying the biosynthesis of NO by NOS (Guix et al., 2005) 
 
It has been observed that upon activation of the N-methyl-D-aspartate receptor (NMDA) 
receptors, the release of NO occurs (Garthwaite et al., 1988). This is discussed in more 
detail in Section 1.7. It has been implicitly stated that nNOS is the main source of NO in 
neurons and localises to synaptic spines (Zhou & Zhu, 2009). It has also been demonstrated 
that in the striatum, NO is mainly produced via the nNOS enzyme (Bredt et al., 1990; Bredt 
et al., 1991), however these theories have yet to be confirmed. The release of NO from 
endothelial cells is believed to be an essential vasodilator mechanism that is responsible for 
the maintenance of vasomotor function. In both the cerebral and peripheral blood vessels, 
the decrease in NO production results in a major alteration of vascular function which 
includes vasoconstriction and increases in arteriole blood pressure (Katusic & Austin, 
2013). There is clear evidence that confirms a role for NO synthesised mainly from eNOS 
in the regulation of vascular tone in studies undertaken by Furchgott and Zawadzki 
(Furchgott & Zawadzki, 1980). 
 
1.5 Neurovascular coupling 
 
The tight coupling between neuronal activity and the local regulation of cerebral blood flow 
(CBF) through intricate vasoactive mechanisms, collectively named neurovascular coupling 
has long been recognised (Piknova et al., 2011). When there is a rise in CBF under 
physiological stimulation, the supply of O2 will exceed the utilisation, resulting in a net 
increase in O2 (Lowry et al., 1997). CBF is fundamental to the living brain and there is an 
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increase in the need for more blood flow upon a rise in neuronal activity (Liao et al., 2013). 
The principle behind neurovascular coupling is to make sure that homeostasis of the 
cellular environment is sustained at all times (Piknova et al., 2011). This occurs through the 
action of neurons, glial cells and blood vessels which form the ‗neurovascular unit‘ 
performing at the cellular level to control CBF (Iadecola, 2004; Attwell et al., 2010; Cauli 
& Hamel, 2010). When these functions are disrupted it can lead to brain dysfunction and 
disease which can be observed in disorders like hypertension and Alzheimers disease 
(Girouard & Iadecola, 2006). 
Functional neuroimaging methods utilise the mechanisms of neurovascular coupling in 
order to map brain activity, therefore making the understanding of how neurovascular 
coupling works, very important. Examples of neuroimaging methods include, functional 
magnetic resonance imaging (fMRI), diffuse optical imaging and positron emission 
tomography (Piknova et al., 2011). The primary technique utilised for brain imaging 
carried out in humans is fMRI (Moreno et al., 2013). Despite the advantages that it 
possesses, such as being a quick and non invasive technique, it faces challenges in a clinical 
setting. It does not directly calculate neuronal activation, but instead, calculates the related 
signals that are connected with neuronal activity. Also, not all patients fulfil the required 
criteria for the imaging protocols. Patients with movement disorders and patients that have 
difficulty with completing the tasks needed for fMRI analysis due to cognition impairments 
are excluded and this is a limitation of fMRI (Faro & Mohamed, 2010).  
Figure 1.5, displays a redrawn summary of the basic physiological changes that link neural 
and vascular responses. The need for energy in the form of adenosine triphosphate (ATP) is 
required for the diverse cellular processes that occur within neurons. The synthesis of ATP 
occurs by glycolysis initially which produces a small amount of ATP. Subsequent to this, 
ATP is then synthesised by the oxidative glucose metabolism which needs O2 in order to 
produce a large amount of ATP. A constant supply of glucose and O2 is necessary and is 
maintained by CBF, which delivers these two energy substrates to neural tissue. Upon 
neuronal activation, an increase in the consumption of glucose and O2 is followed by an 
increase in CBF. The release of by-products such as potassium (K
+
), NO, adenosine and 
carbon dioxide (CO2) amongst other products may directly or indirectly alter blood flow 
with the constriction or vasodilation of the blood vessels. On the other hand, 
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neurotransmitter release of glutamate by neuronal activation could lead to the activation of 
the NMDA receptors which cause the NOS enzymes to produce NO through the synthesis 
with L-arginine (Pasley & Freeman, 2008). The results set out in Chapter 8 focuses on the 
theory that the production of NO is through the NMDA receptor acting on the nNOS 
enzyme (which is discussed in greater detail in Section 1.7). 
 
 
 
Figure 1.5: A redrawn image displaying a basic summary of the physiological changes connecting 
neural and vascular responses (Pasley & Freeman, 2008). 
 
1.6 eNOS, blood flow and O2 
 
It is widely known that NO is an important regulator of blood flow (Rees et al., 1990a; 
Tanaka et al., 1991). The characterisation of NO as the EDRF in the 1980‘s was a 
remarkable advancement, which shed some light on the function of NO. The similarity 
between NO and the EDRF was indistinguishable (Ignarro et al., 1987; Palmer et al., 
1987). Upon the production and release of the EDRF, smooth muscle relaxation is 
promoted (Furchgott & Zawadzki, 1980). The eNOS enzyme is the primary isoform of 
NOS expressed in the cardiovascular system. It is situated mostly in the vascular 
Vasoactive chemical agents,
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(e.g., K+ , NO, adenosine)
Neural activation
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consumption
Cerebral Blood 
flow
Neurotransmitter release
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O2 consumption 
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endothelium and plays an important part in the maintenance of vascular tone and tissue 
perfusion (Mungrue et al., 2003). Many variables determine the production and 
physiological action of endothelial NO, such as substrate availability, co-factors and the 
presence of NO scavengers (Chatterjee & Catravas, 2008).  
N
G
-nitro-L-arginine methyl ester (L-NAME) has been utilised as a means of decreasing the 
production of NO. It was found to be an effective inhibitor of eNOS and nNOS in the 
1990‘s (Miilsch & Busse, 1990; Rees et al., 1990b). The use of L-NAME as an NO 
synthesis inhibitor has been demonstrated by many research groups (Rees et al., 1990b; 
Miller et al., 1993; Losonczy et al., 1996). Upon administration of L-NAME, a decrease in 
the NO levels can be observed, along with a concurrent decrease in O2 (see Chapter 8, 
Section 8.3.8). This demonstrates a close connection between NO and O2. Upon observing 
a decrease in CBF, an O2 decrease will also be observed. It has been stated that the 
excellent correlation between CBF and brain tissue O2 shows that the monitoring of brain 
tissue O2 can be utilised as a true representation of CBF (Doppenberg M.D et al., 1998). 
This has been demonstrated within our research group also (Lowry et al., 1997). 
 
1.7 NMDA receptor 
 
Many theories behind the production of NO discussed in the scientific literature, involves 
NMDA receptors (Buisson et al., 1992; Iadecola, 1993; Drake & Iadecola, 2007; Tonetto et 
al., 2009). NMDA receptors are among the most strictly regulated glutamate-gated cation 
channels. They consist of sites for endogenous ligands that bind to the channel and increase 
the probability for the opening of the channel. There are two different agonist-recognition 
sites, one for glutamate and another for glycine/D-serine (Brady et al., 2005). Glutamate 
binds to NMDA receptors located on interneurons that express nNOS and upon activation 
of the NMDA receptors, calcium channels are subsequently opened. The influx of calcium 
leads to the nNOS activation and subsequent NO production (Piknova et al., 2011). Upon 
the activation of neurons, the release of glutamate is the main signal in the neurovascular 
response, which is then followed by a number of neurochemical pathways and the release 
of vasoactive chemicals like NO (Girouard & Iadecola, 2006; Attwell et al., 2010; Cauli & 
Hamel, 2010). It has been identified that the activation of the NMDA receptor leads to the 
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activation of nNOS (Khaldi et al., 2002) and triggering NMDA receptors increases nNOS 
activity which in turn produces NO (Kosenko et al., 2003). 
It has also been demonstrated that the use of certain drugs can affect the NMDA receptors 
expression and activation, thus leading to a diminished production of metabolites such as 
NO. The NMDA receptors have been suggested as targets of anaesthetic agents in the 
central nervous system and that some of the biological actions created by the anaesthetics 
affect the function of the receptors also. A loss of surface expressed NMDA receptors was 
demonstrated in a study undertaken by LacKamp et al., using chloral hydrate (LacKamp et 
al., 2009). A decrease in glutamate release and a decrease in the activation of glutamate 
receptors was also found after chloral hydrate administration in another study undertaken 
by  Kreuter et al., (Kreuter et al., 2004). A decrease in pH has also been suggested as a 
potential inhibitor of the NMDA receptor activation and has been reported in the literature  
(Tang et al., 1990; Traynelis & Cull-Candy, 1990).  
 
Figure 1.7: An image displaying the possible nNOS production pathways (Santos et al., 2012). 
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Figure 1.7 displays a summary of the possible nNOS production pathways (Santos et al., 
2012). It summarises the synthesis of NO subsequent to the entry of calcium into the post 
synaptic density, following the glutamate activation of NMDA receptor. nNOS is activated 
by calcium through the binding of calmodulin (CaM) to the enzyme. The NO is then 
diffused very quickly to neighbouring tissue which inactivates it by both O2 dependent 
mechanisms and through scavenging by circulating erythrocytes (RBCs) for use in vascular 
processes.  
 
1.8 Overview of thesis 
 
The brain is the most complex organ in the human body. The development and 
implementation of analytical instruments that can elucidate some of the most intricate 
mechanisms in the living brain, has been sought by many scientists around the world.  
Utilisation of real-time micro-sensors to try and gain knowledge of the brains specific 
functions and processes by targeting certain analytes is a very promising and exciting 
technique that gives advantages over other conventional methods. This thesis describes the 
in-vitro and in-vivo characterisation of monomer modified O2 sensors with the end goal 
being a potential use in a clinical environment. The characterisation of the Type 2 NO 
sensor (see Section 3.4.5.4) and Type 3 NO sensors (see Section 3.4.5.5) in-vitro and in-
vivo is also described. As the NO concentration is a vital biomarker for vasodilation and 
neurovascular coupling, sensors that can simultaneously and selectively measure the NO 
and O2 contents in the brain can potentially answer questions about the specific NO and O2 
processes and mechanisms. 
The current Chapter (Chapter 1) gives an introduction to the brain, the detection of O2 and 
NO using micro-electrodes, the complex world of the clinical environment, the biosynthesis 
of NO and its subsequent roles in neurovascular coupling, blood flow and production 
through the activation of the NMDA receptor. Chapter 2 describes the background theory 
that is relevant to the research undertaken in this thesis, with Chapter 3 detailing the 
techniques and methods used in the manufacture and characterisation of the various sensor 
types studied throughout the course of this project. Chapter 4 introduces the beginning of 
the results sections with the in-vitro development and characterisation of the monomer 
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modified O2 sensors. Chapter 5 then leads on to the characterisation of the O2 sensors in the 
in-vivo environment. Chapter 6 describes the in-vitro characterisation of the NO sensor and 
Chapter 7 gives an account of the characterisation experiments undertaken with the NO 
sensors in the in-vivo environment.  
Chapter 8 describes the implantation of the O2 and NO sensors simultaneously in-vivo, in 
order to determine whether a correlation exists between the two molecules. It has been 
postulated in literature that there is a strong correlation between these two analytes, 
however, experiments are carried out in order to determine whether NO possesses an 
independent function. The final Chapter (Chapter 9) gives an overall conclusion to the 
thesis and discusses the main findings of the work undertaken. 
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2.1 Introduction 
 
The principal purpose of this thesis is the in-vitro characterisation and development of O2 
and NO sensors for the subsequent monitoring of O2 and NO in-vivo. In order to achieve 
this, two voltammetric techniques were utilised throughout the course of the research, these 
being CV and CPA. The main technique utilised was CPA. This technique was chosen 
because of its high time resolution. This is of the utmost importance with regards to NO, 
because of the very reactive nature of the molecule and its very short half life of seconds in-
vivo (Lancaster Jr, 1997). The two voltammetry methods are discussed in more detail in 
Section 2.3 and Section 2.4. The O2 and NO sensors developed in this thesis were 
characterised using voltammetry, by their sensitivity (nA/µM) to the substrate, R
2
 values 
and rejection of interferents. 
Electrochemical analysis is based on the reactions taken place on the electrode surface. The 
working electrodes properties and characteristics can have a significant effect on the 
efficiency of the reactions that take place at the surface (Li & Miao, 2013). There are many 
factors affecting the electrodes reactions rate, like mass transport and electron transfer at 
the surface of the electrode (Bard & Faulkner, 2000). This is discussed in more detail in 
Section 2.2. In a general reaction at an electrode surface, a series of steps take place which 
cause the transformation of the dissolved oxidised species, ‗O‘, to the reduced form, ‗R‘ 
also in solution. Once all of the rates of the reaction steps in a series are equal, a steady, 
stable state is observed. The number of electrodes is denoted as the letter n. Equation 2.1 
(a) and Figure 2.1, display the reaction equation and pathway of reaction (Li & Miao, 
2013).  
 
 
O + ne            R          (2.1 (a)) 
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Figure 2.1: A redrawn schematic displaying the pathway of a general electrode reaction, taken from 
Bard et al., (Bard & Faulkner, 2000). 
 
 
The change in the concentration of a certain analyte in the extracellular fluid (ECF) over 
time is investigated in in-vivo voltammetry (Lowry et al., 1996; Bolger et al., 2011b; 
Finnerty et al., 2012a). The Nernst equation is an essential equation formulated by Walther 
Nernst at the end of the nineteenth century. It is fundamental to electrochemistry and 
portrays the deviation of the electrode potential with the concentrations of oxidised and 
reduced species, [O] and [R], for an electrochemical reaction, assuming equilibrium 
conditions. The equation is depicted in Equation 2.1 (b), where  is the standard electrode 
potential, R, T, F and n  denote the gas constant, temperature, the Faraday constant and the 
number of electrons, respectively (Bard et al., 2012).  
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2.2 Mass Transport 
 
Mass transport as stated previously, is a factor that affects the rate of a reaction at the 
surface of an electrode. It is described as the movement of substances from one place in 
solution to another. It can come about due to a varying electrical or chemical potential at 
the two places or from movement of a volume factor of solution. Migration, diffusion and 
convection are the three processes involved with mass transport. 
 
2.2.1 Migration 
 
Migration is defined as the movement of charged species due to the presence of a gradient 
of electrical potential. Conversely, in these studies the presence of a large amount of 
background electrolyte (PBS, pH 7.4, see Section 3.7) removes the migration effects. 
 
2.2.2 Diffusion 
 
Diffusion takes place in all solutions and arises from the unbalanced concentrations of 
reagents. It is defined as the movement of molecules from an area of high concentration to 
a region of low concentration. The rate of the diffusion movement can be determined by 
Fick‘s first law depicted in Equation 2.2.2 (a) which states that the flux is proportional to 
the concentration gradient. 
 
 
 
Where J denotes the diffusional flux of the species, D is the diffusion coefficient, the 
negative sign signifies the material moving down a concentration gradient i.e. moving from 
a high concentration to a low concentration and ∂c/∂x stands for the concentration gradient 
in direction x. However, in many experiments it is necessary to determine how the 
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concentration of the material differs as a function of time and that is where Fick‘s second 
law comes in. It is formulated from Fick‘s first law and is depicted in Equation 2.2.2 (b). 
 
 
 
 
During the progression of a reaction, a concentration gradient may be created due to one of 
the species being consumed. However, in the case of microelectrodes that contain diameters 
in the 5-300 µm range (O'Neill et al., 1998), currents are small and minimal substrate is 
consumed yielding a steady state response i.e. , no change in c with t.  
For planar electrodes, which are equally available to species from the bulk solution, the 
changing current with time calculated from Fick‘s second law, results in the Cottrell 
equation (Equation 2.2.2 (c))  
 
 
 
 
 
with I the current measured at time t at the electrodes active surface of area A, being 
directly proportional to , the bulk concentration of the electroactive species. J is the flux, 
n is equal to the number of electrons, D is the diffusion coefficient and F is the Faraday 
constant. 
For any coordinated system, a Laplace operator is substituted into Equation 2.2.2 (d) to 
determine the flux for all electrode geometries giving, 
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and as a result, Fick‘s second law of diffusion for any geometry, becomes  
 
 
 
In this thesis, since all electrodes utilised had disk surfaces, the equation assigned was  
 
 
 
 
 
The solution to all the diffusion equations requires that initial conditions (values at t = 0) 
and two boundary conditions (conditions associated with certain values of the spatial 
coordinates) be obeyed. 
 
 
Initial conditions (t = 0) and boundary conditions 
 
 
Initial conditions: 
 
Prior to the beginning of experiments at time 0 (t = 0), homogeny of the solution can be 
expressed by these conditions. If species O has a bulk concentration of C
*
0 that is 
distributed evenly, the initial condition for all x values can be expressed as  
 
 
 
If R is not present initially then for all values of x 
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Semi-infinite boundary conditions: 
 
The electrochemical cell walls are usually large distances away, contrasting to the diffusion 
path of the electrode, so one can hypothesise that the concentration reaches a constant value 
at large distances from the electrode at all values for t. 
 
 
 
 
 
As R is not present in solution at the beginning of the experiment, the equation then 
becomes, 
 
 
 
 
 
Boundary conditions: 
 
When determining the diffusion limited current subsequent to a controlled potential, a 
current response arises when there is no electrode reaction occurring, to when all the 
electroactive species have reacted. 
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If the current is controlled, the variation in potential is registered 
 
 
 
  
 
with i denoting current, n representing the number of transferred electrons, F signifying the 
Faraday constant and A indicative of the area of the active surface of the electrode.  
 
2.2.3 Convection 
 
Convection is defined as the stirring or the motion of fluid from an external source. Fluid 
can flow from a cause of natural convection which involves density gradients and can also 
occur from forced convection. These types of movement of species can be discounted from 
the thesis as all steady state currents were only recorded in quiescent solutions. 
 
2.3 Cyclic Voltammetry (CV) 
 
CV is the most broadly used measuring method in electrochemistry. It is most often the 
first technique utilised for attaining qualitative information regarding electrochemical 
reactions. It can offer information about the thermodynamics of redox processes, the 
kinetics of electron transfer reactions and the adsorption processes. In this thesis, CV was 
utilised to determine the redox potentials of the electroactive species in question (i.e. O2). A 
CV is performed in a quiescent (unstirred) solution, were only diffusional transport of 
material influence the scan and the potential is scanned linearly using a triangular 
waveform, which is depicted in Figure 2.3 (a). 
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Figure 2.3 (a): Potential vs. time triangular shaped waveform signal in a CV experiment, redrawn from 
(Wang, 2006). 
 
From an initial potential (Ei) where no oxidation takes place, a potential is applied using a 
fixed scan rate (ν) until a maximum potential (Emax) is reached, where electron transfer 
occurs more quickly. The species that has been oxidised in the forward scan is then reduced 
back to the starting potential by inverting the sweep. There is generation of two types of 
current when operating CV called the Faradaic current (if) and the capacitance current (ic). 
The (if) is produced from the electrochemical reactions that take place at the surface of the 
electrode at the varying potentials whilst the (ic), otherwise known as the background 
current, does not involve any chemical reactions and never dissipates. It is necessary to 
subtract the background current from the overall current in order to determine a 
characteristic CV of a specific analyte in question. 
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Figure 2.3 (b): Typical current-potential profile for a CV of a reversible redox species redrawn from 
Wang, 2006) 
 
Figure 2.3 (b) illustrates the general response obtained for a reversible redox couple during 
a single potential cycle and describes the system in Equation 2.1 (a). The voltammogram 
begins at a value where no electron transfer takes place. As the applied potential is swept to 
more positive potentials, values are reached that are capable of inducing electron transfer, 
until a peak is reached. After traversing the potential region where the reduction process 
takes place, the reduced (R) molecules are reoxidised back to the oxidised (O) molecules, 
resulting in an anodic peak (Wang, 2006). 
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2.4 Constant Potential Amperometry (CPA) 
 
During the course of this project, CPA was the most frequently employed technique. In 
CPA, the current is held at a constant potential that has been previously determined by CV 
to cause oxidisation or reduction of the substance of interest at the surface of the sensor. 
The electroactive species that are under investigation undergo electron transfer at this 
potential and give rise to a current. CPA is similar to CV in that diffusion is assumed to be 
the only form of mass transport in the system (see Section 2.3), which leads to a steady-
state diffusion-limited current. Amperometric currents can be constantly measured at the 
electrode, as the current due to analyte oxidation or reduction is directly proportional to the 
analyte concentration at all times. With CPA, high temporal resolution can be achieved and 
also the sampling rate can resolve signals on a sub-millisecond time scale (Hermans, 2007). 
All of the qualities associated with this technique make it ideal for the in-vitro/in-vivo 
experiments undertaken in this body of research. 
Adsorption of reactants onto the surface of the sensor is not a concern with CPA, as the 
species are electrolysed rapidly when they come in contact with the electrode. Therefore 
adsorption processes do not hamper the response to the concentration changes of the 
analyte as it occurs. Amperometry can be regarded as a sweep technique where ν = 0 and 
Emin is at high overpotential values. With ν = 0, the diffusion-limited current for a reversible 
or irreversible reaction is given by Equation 2.4 (a). 
 
 
 
  
where the iss is the steady-state current, n is the number of electrons, A is the electrode area, 
D is the diffusion coefficient, F is the Faraday constant, C is the concentration and r is the 
radius. However, additional factors such as the geometry or the insulation thickness 
(Dayton et al., 1980) of the electrode have an effect on the steady-state current and as a 
result a geometric factor, G, is incorporated into Equation (2.4 (b)) 
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The resulting current is directly proportional to the diffusion coefficient and the substrate 
concentration.  
 
2.5 Measurement of dissolved O2 
 
The O2 reduction reaction (ORR) plays a vital role in life processes such as biological 
respiration and in energy converting systems for example, fuel cells (Song & Zhang, 2008). 
A number of mechanisms have been proposed for the reaction of the electrocatalytic 
reduction of O2 at the surface of noble metal working electrodes; however, there is still 
uncertainty as to which mechanism is accurate. Originally, Damjanovic, et al., proposed a 
four-electron transfer mechanism (Damjanovic et al., 1967), which is depicted in Equation 
(2.5 (a)). 
 
 
 
 
 
However, a two-step mechanism for the reduction of O2 at the surface of a metal electrode 
has also been proposed also (Hoare, 1968) and they are illustrated in Equation (2.5 (b)) and 
(2.5 (c)). 
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The four-electron transfer pathway includes a number of steps where O2 is reduced to OH
-
 
or H2O. A peroxide intermediate may be involved in the reduction steps which adsorbs on 
the surface of the electrode, however, this does not result in peroxide in the solution phase. 
With regards to the two electron transfer pathway, peroxide species are present in the 
solution phase. The resulting O2 from the decomposition of these species (see Equation 2.5 
(b)) in the solution is recycled through the reaction depicted in Equation 2.5 (c) and then 
the overall reaction is the four-electron pathway. 
 
 
 
 
 
2.6 Polymerisation of Methyl methacrylate (MMA) 
 
 
 
Figure 2.6 (a): Illustration of MMA molecule 
 
 
 
The polymerisation of MMA can be produced utilising a variety of polymerisation 
mechanisms. The most common technique is the free radical polymerisation of MMA. The 
free radical polymerisation of acrylates and methacrylates is a chain polymerisation across 
the double bond of the monomer (Figure 2.6 (a)). Application of an initiator such as 
azodiisobutyronitrile (AIBN) has been demonstrated for the polymerisation of MMA and is 
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very common (Zhu et al., 1990a; Hong et al., 2002; Chen et al., 2004; Yoshida, 2010). 
Figure 2.6 (b) displays the mechanism by which MMA is polymerised with AIBN. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 (b): Mechanism of radical polymerisation of MMA with AIBN as the initiator (A): Initiation 
(B): Propagation and (C): Termination. 
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The polymerisation of MMA can be initiated with light or δ-radiation. The photo initiation 
of MMA using ultraviolet (UV) or visible light can be performed independently, without 
the use of sensitizers. It has not yet been determined whether the photo induced 
polymerisation is by a free radical mechanism or by an excited state mechanism (Gruber, 
1992). In this body of research, the polymerisation of MMA was undertaken to try and 
achieve a more solid composite within the cavity of the CPE. Thus, MMA was polymerised 
under UV light when manufacturing the MMA modified CPE (see Section 3.4.2).   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 (c): The polymerisation of MMA by UV light 
 
 
2.7 Electropolymerisation of o-Phenylenediamine (o-PD) 
 
Poly-o-phenylenediamine (PPD) can be integrated into the design of a sensor by using it 
either as a conducting polymer or an insulating polymer. Ariffin et al., incorporated it into a 
sensor design as a conducting polymer film, for the detection of H2O2 using 
Electrochemical Impedance Spectroscopy (Ariffin et al., 2012). Utilising PPD as an 
insulating polymer layer has been demonstrated with glucose oxidase biosensors (Lowry et 
al., 1994; Lowry & O'Neill, 1994). The NO sensors (Type 2 and Type 3 NO sensor) 
investigated in this body of research contain an insulating layer of PPD in their design also. 
The PPD layer was applied by the electropolymerisation in a neutral electrolyte (see 
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Section 3.4.5.2). This procedure was demonstrated by Malitesta et al., (Malitesta et al., 
1990). This insulating layer has demonstrated the ability to block out any unwanted species 
that are larger than the o-PD monomer (Friedemann et al., 1996; O‘Neill et al., 2008; 
Govindarajan et al., 2013). The PPD layer was incorporated into the design of these novel 
sensors to allow for a reduction in the number of Nafion pre-coats annealed onto the 
electrode surface without compromising the selectivity of the sensor. This is important as it 
will decrease the thickness of the diffusion layer surrounding the electrode surface and 
allow for quicker response times in comparison to the extensively characterised Type 1 NO 
sensor.  
Two different structures of the insulating form of PPD have been hypothesised, as it has not 
been determined what the actual structure looks like. A ‗ladder‘ like structure where the 
amino groups are condensed within the benzene rings adjacent to each other along the 
polymer chain (Chiba et al., 1987) (see Figure 2.7, structure A) and an ‗open‘ 1.4-
substituted benzenoid-quinoid structure (Yano, 1995) (see Figure 2.7, structure B) have 
been assumed. The speculated ‗open‘ structure of PPD has been reported as the more 
dominant structure (Losito et al., 2003). 
 
 
 
 
 
 
Figure 2.7: Possible structures for the polymeric form of o-PD 
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2.8 Ascorbic acid (AA) 
 
AA is essential for normal physiological function and is vital for tissue growth and the 
healing of wounds (Iqbal et al., 2004). It is the main electroactive compound that can 
inhibit an electrode‘s ability to detect a particular analyte of interest. It is in abundance in 
the ECF of the brain at a concentration of approximately 500 µM (Miele & Fillenz, 1996b). 
It is readily oxidised at metal electrodes having an E1/2 between -100 to +400 mV vs. SCE 
(O'Neill et al., 1998). A 2e
- 
process that results in the production of L-dehydroascorbic acid 
is the mechanism associated with the reaction of AA. An electro-inactive open chain 
product (L-2-3-diketogulonic acid) is formed upon hydrolyses of L-dehydroascorbic acid. 
The mechanism for the reaction is illustrated in Figure 2.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Reaction scheme for the oxidation of ascorbic acid 
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2.9 Data Analysis 
 
On cessation of the experiments undertaken with CPA, the data was analysed using linear 
regression. The regression was applied after the average steady state current value was 
obtained and this value was then plotted graphically, current response against substrate 
concentration.  
 
2.9.1 Linear Regression 
 
Linear regression is effectively the plotting of the line that minimises the sum of the 
squares of the vertical distances of the points from the line utilising GraphPad Prism (see 
Section 3.2).  
 
2.9.2 Statistical Analysis 
 
Statistical analysis is carried out in order to determine whether two results are statistically 
different. The t-tests and one-way ANOVA tests were utilised as the method of analysis 
during the course of this research. The two forms of t-tests utilised were paired t-tests and 
unpaired t-tests. If the electrodes differed only by an intervention (i.e. time, as per time 
stability experiments) paired t-tests were employed. Unpaired t-tests were performed on 
electrodes that differed by their treatments (i.e. comparing electrodes with different designs 
or different outer membranes). One-way ANOVA was utilised when multiple comparisons 
needed to be carried out. These tests were performed using GraphPad Prism and yielded a 
resulting P value. Table 2.9.2, details how the P value correlates to how significantly 
different/not significantly different, a result is. This value allows one to decide whether the 
results observed are significantly different.  
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P value Significance No. of asterisks 
< 0.001 Extremely significant *** 
0.001 to 0.01 Very significant ** 
0.01 to 0.05 Significant * 
> 0.05 Not significant ns 
 
Table 2.9.2: A table displaying a summary of the correspondence of the P value to the number of 
number of asterisks. 
 
 
The R
2
 value is a fraction between 0.0 and 1.0 that has no units. It is the measure of the 
goodness of fit of the data points to a line where 0 < R
2 
> 1. An R
2
 value of 0 means that 
knowing x does not help one predict y, there is no linear relationship between x and y data 
values in the graph. An R
2
 value of 1 indicates that all points lie exactly on the straight line 
with no scatter. Knowing x will allow one to predict y. 
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3.1 Introduction 
 
In this chapter, details of the in-vitro and in-vivo design and characterisation of both O2 and 
NO sensors are described. The O2 and NO sensors are based on CPE‘s (Lowry et al., 1996) 
and platinum (Pt) electrodes (Brown & Lowry, 2003) respectively. A CPE that included the 
monomers styrene (Sty) or methyl methacrylate (MMA) was developed in order to prevent 
the removal of the pasting oil from the CPE. Ormonde and O‘Neill have demonstrated that 
when the CPEs are in the in-vivo environment, lipids present, remove the oil from the CPE 
surface leaving a carbon powder electrode  (Ormonde & O'Neill, 1990). The incorporation 
of MMA and Sty has been demonstrated previously in the development of sensors by other 
research groups, (Chatzandroulis et al., 2004a; Chatzandroulis et al., 2005; Xu et al., 2011). 
To prevent the potential interference from species found in the in-vivo environment, an o-
phenylenediamine (o-PD) layer was incorporated into the NO sensor design. It was also 
hoped that this would decrease the diffusion layer of the existing Type 1 NO sensor (Brown 
et al., 2009), thus improving the response time without compromising the sensitivity and 
selectivity. The inclusion of an o-PD layer for such purposes has been previously 
demonstrated in the design of glucose biosensors (Malitesta et al., 1990). Porterfield and 
co-workers have previously described use of an NO selective probe system to monitor NO 
release from cultured macrophages which also incorporates NO and o-PD in the sensor 
design (Porterfield et al., 2001). 
Section 3.2 outlines the computer based instrumentation and equipment. A description of 
all the chemicals and solutions that are utilised throughout this project, are represented in 
section 3.3. Section 3.4 describes the manufacture of the sensors and the sensor 
modification is depicted in Section 3.5. The treatments and in-vitro characterisation of the 
sensors are presented in sections 3.6 and 3.7 respectively. Section 3.8 gives a detailed 
account of the procedures followed for the utilisation of these sensors in-vivo. The use of 
scanning electron microscopy (SEM) is outlined in Section 3.9. The synthesis of NO is 
presented in section 3.10 and any additional equipment used throughout the project is listed 
in section 3.11. 
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3.2 Computer Based Instrumentation and Computer Programs 
 
Throughout the project, the data was collected via three main components. These included 
a computer, a powerlab
® 
or e-corder and the potentiostat (biostat or quadstat). 
Electrochemical experiments (constant potential amperometry, (CPA) and cyclic 
voltammetry, (CV)) utilised the software packages LabChart
® 
6 and LabChart
®
 for Mac 
version 6.1 (ADInstruments Ltd; Dunedin, New Zealand), eDAQ chart version 5.5.15 and 
EChem version 2.1.12 (eDAQ Pty Ltd; Denistone East, Australia).
  
The graphical and 
statistical analysis of the data was performed using Microsoft Office Excel 2007 and 
GraphPad Prism
®
 version 5.01 (GraphPad Software Inc. CA USA). This analysis included 
linear regression analysis and statistical analysis including paired and unpaired t-tests and 
one-way ANOVA analysis. For the statistical analysis carried out, a P value was obtained, 
which is the probability value indicating if the results obtained are significantly different. 
Table 3.2 details a summary of the significance values. The individual instrumentation 
components are described further in this Section. An image presenting the in-vitro set-up is 
displayed in Figure 3.2.  
 
 
P value Significance No. of asterisks 
< 0.001 Extremely significant *** 
0.001 to 0.01 Very significant ** 
0.01 to 0.05 Significant * 
> 0.05 Not significant ns 
 
Table 3.2: A table displaying a summary of the correspondence of the P value to the number of 
asterisks. 
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Figure 3.2: The in-vitro experimental set-up. 
 
 
3.2.1 The Computer 
 
3.2.1.1 In-Vitro data: A logiQ M760TG notebook with an Intel dual core processor 
running at 1.8GHz was utilised in the collection of the data. 
 
3.2.1.2 In-Vivo data: A MAC OS X with an Intel core 2 duo processor running at 2.4GHz 
was employed for in-vivo data acquisition. 
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3.2.2 The Interface 
 
An eight channel powerlab
®
 8/30 from (AD instruments Ltd; Dunedin, New Zealand) or an 
eight channel e-corder 821 from (eDAQ Pty Ltd; Denistone East, Australia) was employed. 
The e-corder 821 is displayed in Figure 3.2.2 below. 
 
Figure 3.2.2: An image displaying the e-corder 821. 
 
 
3.2.3 The Potentiostat 
 
A four channel biostat from (ACM instruments; Cumbria, UK) or a software controlled 
four channel quadstat from (eDAQ Pty Ltd; Denistone East, Australia), was utilised 
throughout the project. The four channel quadstat is displayed in Figure 3.2.3. 
 
 
 
 
Figure 3.2.3: An image displaying the quadstat 164. 
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3.2.4 Movement Meter 
 
The movement meter (Figure 3.2.4) was employed during the in-vivo experiments to 
correlate the real-time monitored currents with movement of the animal. It comprises of a 
passive infrared (PIR) detector (Elite Security Products, Unit 7, Leviss Trading Estate, 
Station Road, Stechford, Birmingham B33 9AE, UK), which connected directly to the data 
acquisition system (Powerlab
®
). The PIR detector consists of pyroelectric sensors and an 
electronic system. The sensors convert the optical signal that is being observed into an 
electrical signal that is processed within its electrical compartment and then analysed in the  
microprocessor (Kastek et al., 2008). It was modified in-house with a microprocessor to 
enable a greater enhancement of the sensor, thereby recording more movement per second.  
 
 
 
 
Figure 3.2.4: Schematic of the PIR Sensor. 
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3.3 Chemicals and Solutions 
 
3.3.1 Chemicals 
 
A list of in-vitro and in-vivo chemicals along with the relevant suppliers that were utilised 
throughout the course of the research project is shown below.  
 
3.3.1.1 In-Vitro Chemicals 
 
 Ascorbic acid      Sigma Aldrich® Co. 
 Bovine serum albumin     Fluka Chemical Co. 
 L-cysteine       Sigma Aldrich® Co. 
 Dehydroascorbic acid     Sigma Aldrich® Co. 
 3, 4-Dihydroxyphenylacetic acid    Sigma Aldrich® Co. 
 Dopamine       Sigma Aldrich® Co. 
 L-glutathione      Sigma Aldrich® Co. 
 Graphite powder      Sigma Aldrich® Co. 
 Homovanillic acid     Sigma Aldrich® Co. 
 Hydrogen peroxide 30% w/w ACS reagent  Sigma Aldrich® Co. 
 5-Hydroxyindoleacetic acid     Sigma Aldrich® Co. 
 Methyl methacrylate 99 % solution   Sigma Aldrich® Co. 
 Nafion® 5% in aliphatic alcohol    Sigma Aldrich® Co. 
 N-1-naphthyl-ethylenediamine    Sigma Aldrich® Co. 
 Nitric oxide gas      In House Synthesis 
 Nitric oxide gas      BOC Gases 
 Nitrogen gas      BOC Gases 
 Oxygen gas      BOC Gases 
 o-Phenylenediamine     Sigma Aldrich® Co. 
 L-α-phosphatidylethanolamine    Sigma Aldrich® Co. 
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 Potassium hydroxide     Sigma Aldrich® Co. 
 Pyrogallol       Sigma Aldrich® Co. 
 Serotonin        Sigma Aldrich® Co. 
 Silicon oil       Aldrich Chemical Co. 
 Sodium chloride      Sigma Aldrich® Co. 
 Sodium hydroxide     Sigma Aldrich® Co. 
 Sodium nitrite      Sigma Aldrich® Co. 
 Sodium phosphate monobasic    Sigma Aldrich® Co. 
 Styrene ≥ 99 % solution     Sigma Aldrich® Co. 
 Sulfanilamide      Sigma Aldrich® Co. 
 Sulphuric acid (97%)     Fisher Scientific 
 Triton® X-100      Sigma Aldrich® Co. 
 L-tryptophan      Sigma Aldrich® Co. 
 L-tyrosine       Sigma Aldrich® Co. 
 Uric acid       Sigma Aldrich® Co. 
 
3.3.1.2 In-Vivo Chemicals  
 
 Acetazolamide (Diamox)     Sigma Aldrich® Co. 
 L-arginine       Sigma Aldrich® Co. 
 Buprenorphine hydrochloride (Temgesic®)  Sigma Aldrich® Co. 
 Chloral hydrate      BDH Laboratory Supplies, UK 
 Dentalon®       Heraeus Kulzer Gmbh 
 Dimethyl sulfoxide     Sigma Aldrich® Co. 
 Isoflurane       Abbott Laboratories, IRL.  
 N (G)-nitro-L-arginine methyl ester   Sigma Aldrich® Co. 
 Sodium L-ascorbate     Sigma Aldrich® Co. 
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3.3.2 Solutions 
 
All solutions were prepared on the day that an experiment was carried out, unless otherwise 
stated. All solutions were made with deionised water denoted by H2O, unless mentioned 
otherwise. The procedures for making each solution are outlined below in a separated in-
vitro and in-vivo list. 
 
3.3.2.1 In-Vitro Solutions 
 
Bovine serum albumin (BSA) 
A 10% (w/v) solution was prepared by dissolving 0.1 g in 1 mL H2O. 
 
Carbon paste  
A solution containing 0.71 g of graphite powder and 250 µL of silicone oil was thoroughly 
mixed together. To ensure complete unification of the two components, a pestle and mortar 
were used to carry out the procedure for three hours. 
 
Carbon (MMA) paste  
A mixture of 0.0125 g of carbon paste was mixed with 10 µL of MMA (99 % solution) in 
order to get a uniform combination of the two components.  
 
Carbon (Sty) paste 
A solution of 0.0125g of carbon paste was mixed with 9 µL of Sty (≥ 99 % solution) to 
ensure full mixture of the paste and monomer. 
 
Neutral Griess reagent 
A reagent consisting of 0.4 mM N-1-naphthyl-ethylenediamine (NEDD) and 0.017 mM 
sulfanilamide (SULF) was prepared in air saturated 100 µM PBS, pH 7.4, containing 0.293 
g SULF and 0.0104 g NEDD in 100 mL. 
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Nitric oxide (NO) 
A stock solution of NO was prepared by bubbling it into H2O and its subsequent 
concentration determined by UV spectroscopy. 
 
o-Phenylenediamine (o-PD) 
A 300 mM stock solution was made up using 0.324 g of o-PD in 10 mL of N2 saturated 
phosphate buffer saline (PBS). 
 
Phosphate buffered saline (PBS) 
PBS was prepared by dissolving 8.9 g of sodium chloride (NaCl) (0.15 M), 1.76 g of 
sodium hydroxide (NaOH) (0.044 M) and 6.06 g of sodium phosphate (NaH2PO4.H2O) 
(0.044 M) in 1 L of H2O. The pH was then adjusted accordingly to 7.4.   
 
L-α-phosphatidylethanolamine (PEA) 
A 10% solution was prepared by dissolving 0.1 g in 1 mL H2O.  
  
Potassium hydroxide (KOH)   
A 4 M KOH solution was prepared by dissolving 224 g of KOH in 1000 mL. 
 
Pyrogallol 5% alkaline 
A 5% stock solution was prepared in 4 M KOH (5 g/ 100 mL). 
 
Sodium nitrite (NaNO2) 
A saturated stock solution of NaNO2 was prepared in H2O.  
 
Sulphuric acid (H2SO4) 
A 6 M H2SO4 stock solution was prepared from a 97% H2SO4 commercial solution. 329 
mL of H2SO4 was added very carefully to H2O and then made up to 1 L.  
 
Triton
®
 X-100 
A 10% solution was made up by dissolving 0.1 mL in 1 mL H2O.  
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3.3.2.2 Interferent Solutions 
 
Ascorbic acid (AA) 
A 0.1 M stock solution of AA was prepared by dissolving 0.176 g in 10 mL of H2O.  
 
L-cysteine 
A 50 µM solution of L-cysteine was made up by mixing 0.024 g in 10 mL H2O.  
 
Dehydroascorbic acid (DHAA) 
A 50 µM solution of DHAA was prepared by dissolving 0.0696 g in 10 mL H2O. 
 
3, 4-Dihydroxyphenylacetic acid (DOPAC) 
A 100 µM solution of DOPAC was prepared by mixing 0.013 g in 10 mL H2O. 
 
Dopamine  
A 0.05 µM solution was prepared by dissolving 0.000038 g in 10 mL H2O. 
 
L-glutathione 
A 50 µM glutathione solution was made up by mixing 0.122 g of glutathione in 10 mL 
H2O. 
 
Homovanillic acid (HVA) 
A 10 µM solution of HVA was prepared by dissolving 0.0073 g in 10 mL H2O.  
 
Hydrogen peroxide 30% w/w ACS reagent (H2O2) 
A 100 mM stock solution was prepared by dissolving 0.56 g of H2O2 in 50 mL H2O. 
 
5-Hydroxyindoleacetic acid (5-HIAA) 
A 50 µM solution was prepared by dissolving 0.038 g of 5-HIAA in 10 mL H2O. 
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Nitrite (NO2
-
) 
A 100mM solution of NaNO2 was prepared by mixing 0.17 g of NaNO2 with 25 mL H2O.  
 
Serotonin (5-HT) 
A 0.01 µM solution was made up by dissolving 0.0085 g of 5-HT in 100 mL H2O. 
 
L-tryptophan 
A 100 µM solution was prepared using 0.082 g of L-tryptophan in 10 mL H2O.  
 
L-tyrosine 
A 100 µM solution was prepared by dissolving 0.072 g of L-tyrosine in 10 mL H2O. 
 
Uric acid (UA) 
A solution was prepared by mixing 0.038 g of UA in 10 mL H2O. 
 
3.3.2.3 In-Vivo Solutions 
 
Acetazolamide (Diamox) 
A 50 mg/kg solution was prepared by dissolving acetazolamide in a solution of 1 mL saline 
and 0.5 mL DMSO. 
 
L-arginine 
For systemic administration, 300 mg/kg was dissolved in 1 mL saline solution. 
 
Buprenorphine hydrochloride (Temgesic
®
) 
A solution of 0.3 mg/mL Buprenorphine hydrochloride was injected in a volume of 1 
mL/kg. 
 
Chloral hydrate 
A 350 mg/kg solution was prepared by dissolving chloral hydrate in 1 mL saline. 
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N (G)-nitro-L-arginine methyl ester (L-NAME) 
For systemic administration, 30 mg/kg was made up in 1 mL saline solution. 
 
Saline solution 
A 0.9% solution was prepared by dissolving 0.9 g NaCl in 100 mL H2O. 
 
Sodium ascorbate 
A 1 g/kg dose in a volume of 1 mL of saline was prepared. Sodium ascorbate is the 
preferred interferent to use, as AA can cause a significant irritation to the animal. 
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3.4 Electrode Preparation 
 
3.4.1 Carbon Paste Electrode (CPE) 
 
The construction of the CPEs involved 5 cm of Teflon
®
 coated silver wire (200 µm bare 
diameter, 270 µm coated diameter (8T), Advent Research Materials; Oxford, UK). Using a 
scalpel blade, one end of the wire was carefully cut at a 90
º
 angle. In order to solder the 
silver wire into a gold clip, 3 mm of Teflon
® 
was taken from the opposing end of the silver 
wire for introduction to the clip. The gold clip provided electrical contact and rigidity for 
connection to the crocodile clips. The Teflon
®
 was carefully pushed up the wire in order to 
create a 2mm cavity. The carbon paste (Section 3.3.2.1) was then packed into the 
compartment by intermittently dipping the electrode into a small portion of the paste and 
using a bare length of silver wire the carbon paste was pushed into the cavity of the 
electrode. This method was ceased when the paste was condensed into the cavity. Finally, a 
flat active surface was obtained by tapping the electrode on a hard surface. Figure 3.4.1 
below displays an image of the CPE. Using a scalpel blade the two opposing ends of the 
wire were cut. 
 
 
 
Figure 3.4.1: A schematic representation of a CPE 
 
 
 
 
 
Gold Clip Solder Silver Wire Teflon® Insulation Carbon Paste
5 cm 2 mm
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3.4.2 Methyl Methacrylate Modified CPE (MMCPE)  
 
The CPE was constructed as described previously in Section 3.4.1. The CPE was then 
placed overnight in 2.5 mL of MMA in the fridge. Following this, the electrode was dipped 
into a homogenised mixture of MMA and carbon paste (Section 3.3.2.1), until it was fully 
compact. Finally, a flat active surface was obtained by tapping the electrode on a hard 
surface. Once the flat surface was obtained the electrodes were placed in an ultraviolet light 
(UV) cabinet (CV-006, UVItec Ltd, Cambridge, England) for thirty minutes. Below is an 
image representing the MMCPE (Figure 3.4.2). 
 
 
 
 
 
Figure 3.4.2: A schematic representation of a MMCPE. 
  
 
3.4.3 Styrene Modified CPE (SMCPE) 
 
The CPE was constructed as described previously in Section 3.4.1. The CPE was then 
placed overnight in 2.5 mL of Sty in the fridge. Following this, the electrode was dipped 
into a homogenised mixture of Sty and carbon paste (Section 3.3.2.1), until it was fully 
compact. Finally, a flat active surface was obtained by tapping the electrode on a hard 
surface. An image representing the SMCPE is depicted in Figure 3.4.3. 
 
 
 
 
Gold Clip Solder Silver Wire Teflon® Insulation Carbon Paste (MMA)
5 cm 2 mm
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Figure 3.4.3: A schematic representing a SMCPE 
 
 
3.4.4 Platinum (Pt) Working Electrodes 
 
The platinum electrodes were constructed using 4 cm of Teflon
®
 coated Pt/Ir (90%/ 10%) 
wire (125 µm bare diameter, 175 µm coated diameter (5T), Advent Research Materials, 
Oxford, UK). Using a scalpel blade, one end of the wire was carefully cut at a 90
º
 angle to 
ensure an accurate flat active surface. In order to solder the wire into a gold clip, 3 mm of  
Teflon
® 
was removed from the opposing end of the Pt wire for introduction to the clip. The 
gold clip provides electrical contact and rigidity for connection to the crocodile clips. The 
schematic of the Pt working electrode is shown in Figure 3.4.4. 
 
 
 
 
Figure 3.4.4: A schematic of a Pt electrode 
 
 
 
 
 
Gold Clip Solder Silver Wire Teflon® Insulation Carbon Paste (Sty)
5 cm 2 mm
Gold Clip Solder Pt/Ir Wire Teflon® Insulation
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3.4.5 Nitric Oxide (NO) Sensors 
 
The NO sensors manufactured in this project were all Pt based electrodes modified by 
different combinations of Nafion
® 
and o-PD. The manufacture of the Pt electrode prior to 
modification can be seen in Section 3.4.4. A pre-coat application method was utilised in the 
construction of each NO sensor, along with the modification of the electrodes with o-PD 
(see Section 3.4.5.1 and 3.4.5.2, respectively). 
 
3.4.5.1 The Nafion
®
 Pre-Coat Application 
 
The pre-coat application method involved placing a fixed volume (5µL) of Nafion
®
 on a 
clock glass using a syringe. The application of a Nafion
®
 droplet was allowed to air dry at 
room temperature for five minutes. After solvent from the initial droplet had evaporated, 
further applications were placed on top of the original droplet. A concentrated layer of 
Nafion
®
 was then formed on the clock glass. After 1-5 applications (depending on the NO 
sensor type) had been placed on the clock glass, a final application of Nafion
®
 was placed 
onto the concentrated pre-coat of Nafion. The active surface of the electrode was then 
placed through the concentrated layer of Nafion
®
 on the clock glass. The electrodes were 
then placed in the oven and annealed for 5 minutes at 210 ºC. After the annealing process 
had been completed, the electrode was coated again, by using the same procedure i.e. 
placing another application of Nafion
®
 onto the concentrated layer and then dipping the 
electrode through the layer to obtain a further Nafion
®
 pre-coat. The modified electrode 
was then annealed again at 210 ºC for 5 minutes. 
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3.4.5.2 Application of o-PD 
 
The electropolymerisation of o-PD onto the Nafion
® 
modified Pt disk electrodes, was 
carried out by applying a constant potential of +700 mV vs. SCE. A 300mM solution made 
up in N2 saturated PBS was utilised. The electrodes were polymerised for 30 minutes and 
the electrochemical cell (Figure 3.7) was kept under a N2 atmosphere as the monomer is 
readily oxidised in air. The resulting membrane that formed over the active surface was 
black in colour. 
 
3.4.5.3 Type 1 NO Sensor 
(5 pre-coats, 2 applications of Nafion
®
) 
 
The design of this sensor was based on previous work carried out by our research group 
(Brown & Lowry, 2003; Brown et al., 2009). The Nafion
®
 modified Pt electrodes were 
constructed using the method for manufacturing the Pt electrodes (see Section 3.4.4). A 
pre-coat application method (explained in Section 3.4.5.1) was then employed to modify 
the surface of the Pt electrode. Once the annealing process was ceased the electrodes were 
placed into the gold clips. A representation of the sensor is shown in Figure 3.4.5.3. 
 
 
 
 
Figure 3.4.5.3: A schematic of a Type 1 NO Sensor. 
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3.4.5.4 Type 2 NO Sensor 
(1 pre-coat, 2 applications of Nafion
®
, annealed after each coat at 210 ºC, followed by 
polymerisation with o-PD for 30 minutes) 
 
This NO sensor was manufactured utilising the Pt working electrode (see Section 3.4.4). 
The pre-coat method was then employed (see Section 3.4.5.1). Finally, the addition of an o-
PD layer (see Section 3.4.5.2) was utilised after the annealing process. The o-PD layer was 
incorporated after the method of annealing as it was found that the annealing temperature of 
210 ºC compromised the selectivity of the o-PD polymer in the sensors (Friedemann et al., 
1996). An image of the Type 2 NO sensor is displayed below (Figure 3.4.5.4). 
 
 
 
 
 
Figure 3.4.5.4: A schematic of the Type 2 NO Sensor. 
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3.4.5.5 Type 3 NO Sensor 
(2 pre-coats, 1 application of Nafion
®
, annealed at 210 ºC followed by 1 dip into 5% 
Nafion
®
 solution, annealed at 210 ºC and finally polymerisation with o-PD for 30 
minutes) 
 
This NO sensor was manufactured utilising the Pt working electrode (see Section 3.4.4). 
The pre-coat method was then employed (see Section 3.4.5.1). After the first annealing of 
the Nafion
®
 onto the electrode was completed, they were dipped in a 5% solution of 
Nafion
®
 and annealed again. Finally an o-PD layer was incorporated into the design, by 
electropolymerisation as described in Section 3.4.5.2. Figure 3.4.5.5 below represents an 
image of the Type 3 NO sensor. 
 
 
 
 
Figure 3.4.5.5: A schematic of the Type 3 NO sensor. 
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3.5 Electrode Modification 
 
3.5.1 Monomer Modified CPEs (Sty and MMA) 
  
The manufacture of modified CPEs has been demonstrated by many research groups. The 
first modifications of a CPE detailed the incorporation of the organic compounds, ferrocene 
and antraquinone, in the liquid component of the paste (Kuwana & French, 1964). 
Enzymes, for example glucose oxidase, have also been introduced into the carbon paste of a 
CPE (Matuszewski & Trojanowicz, 1988). Monomer modified carbon paste electrodes for 
the trace determination of Cu (II) has also been demonstrated by Khoo and Guo (Khoo & 
Guo, 1999). The incorporation of Sty into the manufacture of carbon based sensors can be 
observed in the research carried out by Xu et al. (Xu et al., 2011) and Nayak et al. (Nayak 
et al., 2007). The inclusion of MMA in a carbon based biosensor has also been utilized for 
the detection of Vitamin C (Dai et al., 2008). The fabrication of the two sensors (MMCPE 
and SMCPE) is described in Section 3.4.2 and 3.4.3, respectively. 
 
3.5.2 PPD and Nafion
®
 Modified NO Sensors 
 
The inclusion of Nafion
®
 in the manufacture of NO sensors has been demonstrated 
previously in our research group (Brown & Lowry, 2003). The application of the Nafion 
layers is discussed in Section 3.4.5.1. To combat interference from endogenous species in 
the in-vivo environment, the electropolymerisation of o-PD is incorporated into the design 
of the two types of NO sensor (see Section 3.4.5.2 for the application of the method). The 
electropolymerisation of o-PD is discussed comprehensively by O‘Neill et al. (O‘Neill et 
al., 2008).  
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3.6 Electrode Treatments 
 
To determine the effects that the components of the in-vivo environment may have on the 
sensors, biocompatibility and the stability of the sensors were investigated. These 
treatments were carried out on both the O2 sensors and the NO Sensors. In order to try and 
mimic the in-vivo environment, the sensors were treated with a protein (BSA), a lipid 
(PEA), a surfactant (Triton
®
 X-100) and then finally a homogenised sample of ex-vivo 
brain tissue (BT). The procedure followed for each treatment is further detailed in this 
section. 
 
3.6.1 BSA Treated Sensors 
 
Prior to treatment of each of the sensors, calibrations to determine the sensitivity towards 
O2 (SMCPE and MMCPE) and NO (Type 1, 2 and 3 NO sensor) and selectivity against 
AA, were carried out on the sensors. AA was chosen for selectivity experiments, as it is the 
most copious analyte in the in-vivo environment (Agus et al., 1997). Once these parameters 
were established, the sensors were placed in the solution of BSA. The sensors were kept in 
the solution of BSA, in the refrigerator at 4 
º 
C, for a certain amount of time and once that 
time had elapsed, they were intermittently tested for sensitivity and selectivity.  
 
 
 
 
 
 
 
 
 
 
 Chapter 3: Experimental  
 
67  
 
3.6.2 PEA Treated Sensors 
 
The sensors were treated with PEA, following the same protocol as described in Section 
3.6.1. 
 
3.6.3 Triton
®
 X-100 Treated Sensors 
 
The sensors were treated with Triton
®
 X-100, in the same manner as described in Section 
3.6.1. 
 
3.6.4 BT Treated Sensors 
 
The working electrodes were carefully placed in a homogenised solution of ex-vivo BT. 
Concurrently, the procedure outlined in Section 3.6.1 was adhered to. 
 
3.6.5 Long-Term Stability Studies 
 
For these studies the electrodes were placed in various storage conditions between specified 
time periods and intermittently tested. 
 
3.6.6 Post-Implanted Sensors 
 
Following implantation of the electrodes in-vivo, the sensors were removed and re-
calibrated to further verify the long term stability of the sensor in the brain environment.  
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3.7 Electrochemical Experiments 
 
 
Figure 3.7: A schematic representing the experimental in-vitro set-up. 
 
3.7.1 Electrochemical Cell Set-Up 
 
The above display (Figure 3.7) represents the three electrode cell set-up. The diagram 
consists of a reference electrode, an auxiliary electrode and four working electrodes. The 
reference electrode which is a saturated calomel electrode (SCE), maintains a fixed 
potential against which the working electrodes can be measured. The electrochemical 
reactions take place at the working electrode surface and it is these changes that are 
analysed and investigated. The auxiliary electrode employed, acts as a source or sink for 
electrons. Any conducting wire where the electrochemical properties do not interfere with 
the reactions occurring at the working electrode can be utilised for the auxiliary. The 
auxiliary used in our case was a bare silver wire. A Teflon
®
 cap that had individual 
compartments for placement of each of the electrodes and an inlet for injections and gas 
Gas Inlet
Working 
electrodes
Reference 
electrode
Auxiliary 
electrode
Teflon®
Cap
Magnetic 
stirrer
PBS
Working 
electrode 
Adapter
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was utilised. All in-vitro experiments were carried out in PBS and at room temperature (ca. 
25 
º 
C), unless otherwise stated. 
 
3.7.2 Experimental Techniques 
 
The main experimental technique utilised during the course of this project, was CPA. CPA 
involves the application of a constant potential and the subsequent observation of the 
change in current, as a function of time (Jiang, 2007). This experimental technique allows 
for real-time detection of an array of electroactive analytes. It is imperative that the sensor 
being designed excludes interference from other electroactive species, as the applied 
voltage will detect all species with oxidation/reduction potentials within the same range as 
the target analyte. The other technique utilised was CV (see Section 2.3). It is used for the 
study of redox processes and is based on varying the applied potential at a working 
electrode in both forward and reverse directions, while the current is monitored. 
 
3.7.2.1 AA Calibrations 
 
PBS (20 mL) was placed into a glass cell using a syringe. The PBS was then N2 saturated 
for 30 minutes prior to experimental set-up (see Figure 3.7). Throughout the experiment N2 
was kept over the solution of PBS to retain N2 saturation. A potential of 900 mV vs. SCE 
was then applied to the working electrodes, as generally the AA calibrations were 
undertaken subsequent to the NO calibrations. This potential was utilised throughout the 
research as it is the optimum potential for NO oxidation at the electrode. Upon application 
of the potential a capacitance current was instantly observed. A stable current baseline was 
achieved prior to the start of the calibration. In general, the more complex the sensor design 
was, the longer it needed for the current baseline to dissipate. AA was then introduced to 
the cell through the injection port in the Teflon
®
 cap using pre-determined aliquots (see 
Table 3.7.2.1). The solution was agitated for ca 5 seconds by the magnetic stirrer. 
Intermittent injections of AA followed once the current value had reached a new steady 
current response. 
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[AA], µM 
0 
200 
400 
600 
800 
1000 
 
Table 3.7.2.1: A table displaying the AA concentrations utilised in the calibration. 
 
3.7.2.2 Oxygen Calibrations 
 
O2 calibrations were set up in the same manner as AA calibrations. A potential of -650 mV 
vs. SCE was applied to the working electrodes. Concentrations of N2, Air, and O2 were 
introduced to the cell (see Section 4.2). The concentrations are displayed below in Table 
3.7.2.2.  
 
[O2], µM 
0 
240 
1200 
 
Table 3.7.2.2: A table representing the concentrations used in the O2 calibrations. 
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3.7.2.3 NO Calibrations 
 
NO calibrations were carried out in the same manner as AA calibrations. The potential 
utilised for the detection of NO was +900 mV vs. SCE (Brown et al. 2009). The 
concentrations of NO introduced to the cell are outlined in Table 3.7.2.3. 
 
[NO], µM 
0 
0.2 
0.4 
0.6 
0.8 
1.0 
 
Table 3.7.2.3: A table displaying the concentrations of NO utilised in the NO calibrations. 
 
3.7.2.4 Post-Implanted Calibrations 
 
Following removal of the headpiece, calibrations were carried out using the same procedure 
as described in Section 3.7.2.2 for O2 sensors and Section 3.7.2.3 for NO sensors. The 
headpiece was connected to the potentiostat via the pedestal (see Figure 3.8.2). 
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3.8 In-Vivo Experiments 
 
In this Section, the procedures followed and materials utilised for the implantation of the 
sensors into the brain of male Wistar rats, will be described. All experiments carried out on 
the animals were completed under licence (B100/2205). All procedures were approved by 
the NUI Maynooth Ethics Committee (Animal Experimentation) in accordance with the 
Council of the European Parliament Directive 2010/ 63/ EU and Irish Statutory Instrument 
SI 543/2012. All in-vivo experiments were recorded continuously over a 24 hour period 
with animals assessed for good health according to published guidelines (The Guide for the 
Care and Use of Laboratory Animals, NIH Publication No. 85-23; and The Handbook of 
Laboratory Animal Management and Welfare, ISBN 1-4051-1159-3) immediately after 
recovery from anaesthesia and at the beginning of each day. All efforts were made to 
minimise animal suffering and the number of animals used for the study.  
 
3.8.1 Subjects 
 
The animals utilised throughout this project were male Wistar rats (Charles River UK Ltd., 
Manston Rd., Margate, Kent CT9 4 LT UK). Each animal weighed between 200 and 300 g 
on arrival. They were then housed in a temperature controlled (17-23 ºC), humidity and 
light controlled (12 hr light/ 12 hr dark) environment. Access to food and water was ad 
libitum prior to surgery.  
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3.8.2 Surgical Protocol 
 
All surgical procedures were carried out using aseptic techniques. The surgical bench tops 
and equipment were sterilised and the equipment was autoclaved prior to commencement 
of the surgery. The anaesthetic utilised to anaesthetize the subject was a volatile anaesthetic 
(Isoflurane). The animal was placed in an induction chamber for 3-4 minutes, to be 
anaesthetized before being transferred to the stereotaxic frame in the laminar flow hood. 
The nose piece was utilised for administration of the anaesthesia throughout the surgery. 
The head of the animal was positioned carefully in the nose piece and levelled between 
lambda and bregma. The anaesthesia was constantly maintained by the use of a vaporiser 
(Univentor). The level of anaesthetic provided to the subject in the induction chamber and 
in the nose piece is outlined below in Table 3.8.2 (a). 
 
 
Table 3.8.2 (a): The level of anaesthetic and air provided to the subject during surgery. 
 
A confirmation that the subject was under anaesthetic was carried out (checking tail and 
paw reflexes), prior to commencing the surgery. A rectal probe was inserted into the animal 
and normal physiological temperature was maintained using a heating pad which the animal 
lay on, during the surgery. A piece of sterile gauze was used to cover the animal‘s eyes to 
prevent them drying or becoming irritated from the laminar flow hood. Sterilisation of the 
animals scalp was carried out using an iodine solution (Videne
®
). An incision was then 
made to the skin along the anterior-posterior plane. Using a cotton swab the underlying 
tissue was pushed back in order to expose the skull fully and to correctly identify bregma. 
Bregma was used as the reference point upon which the co-ordinates of various brain 
regions were found (Paxinos & Watson, 1998). The brain region examined during this 
project is summarised below in Table 3.8.2 (b). 
 
Anaesthetic Chamber 
(Air) 
Chamber 
(Isoflurane) 
Nose piece 
(Air) 
Nose piece 
(Isoflurane) 
Isoflurane 700 – 800 4% 400 – 500 1.5 – 3% 
 Chapter 3: Experimental  
 
74  
 
 
Table 3.8.2 (b): Stereotaxic coordinates for electrode implantation in the striatum. 
 
Clamps were utilised in order to obtain an increased surface area for positioning and 
placement of the electrodes. The relevant co-ordinates were marked, along with the 
positions for the screws, reference and auxiliary. The holes for the support screws and 
electrodes were made using a hand held drill. The screws were then placed into the holes 
followed by the electrodes. A thin layer of cement (Dentalon
®
 Plus) was applied over the 
skull to hold all of the electrodes in place. The cement was built up to the height of the 
screws and allowed to dry. Prior to the cement drying fully, it was pushed away from the 
skin of the animal in order to prevent sticking of the cement to the skin.  
The gold clips of each electrode were placed in a Teflon
®
 pedestal (Plastics One Inc.) (see 
Figure 3.8.2) and cemented into place. This allowed for connection between the gold clips 
and the potentiostat through a six-pinned cable, post-surgery. The electrodes were then 
carefully placed into the centre of the skull and covered with cement until no wire from the 
electrode was visible. The entire construct, apart from the pedestal, was cemented to create 
a headpiece. This alleviates the possible risk of moisture and the possibility of damage 
incurred by the animal to the headpiece. The surgical clamps were removed and the skin 
around the headpiece was sutured. The animal was then taken from the stereotaxic frame to 
a recovery incubator (27
º
C) until he had recovered. The animal was given a subcutaneous 
injection of Temgesic
®
 (see Section 3.3.1.2) and closely monitored while recovering for 24 
hours. The recovery time for each of the subjects will differ and was dependent on the 
volume and length of time exposed to the anaesthetic. The relevant procedures were 
adhered to when caring for the animal post-operatively. 
 
 
Brain Region (A – P) (M – L) (D – V) 
Striatum + 1.0 mm ± 2.5 mm - 5.0 mm 
 Chapter 3: Experimental  
 
75  
 
 
Figure 3.8.2: Images of the Teflon
®
 pedestals; (A) Lower surface and (B) Upper surface 
 
3.8.3 In-Vivo Reference and Auxiliary Electrodes 
 
 
 
 
 
 
 
Figure 3.8.3 (a): A schematic illustrating the auxiliary electrode. 
 
 
 
 
 
 
 
 
Figure 3.8.3 (b): A schematic displaying the reference electrode. 
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Figure 3.8.3 (a) and 3.8.3 (b), display the reference and auxiliary electrodes utilised for the 
in-vivo experiments. Both were manufactured in the same manner as the CPE (see Section 
3.4.1). Once they were soldered into the gold clip, glue was applied to the exposed section 
of the wire, just above the clip, in order to provide the electrodes with stability when 
manoeuvring them during the surgery. To construct the reference electrode 3 mm of 
Teflon
®
 was removed from the opposing end to the gold clip. The bare wire was then 
twisted in such a way so that it could rest against the skull of the animal and guide the 
vertical part of the electrode (see Figure 3.8.3 (b)) in through the reference hole in the skull 
of the subject. The auxiliary electrode was constructed in a similar manner as the reference 
electrode however; the exposed bare wire was soldered to a surgical screw (see Figure 3.8.3 
(a)). 
 
3.8.4 Physiological Stimuli 
 
Neuronal activation was induced in the subject during the in-vivo experiments. These 
stimuli did not negatively affect the animal and the technique and results obtained were 
easily repeated. 
 
3.8.4.1 Tail Pinch 
 
A paper clip was attached to the subject‘s tail for a required time period of 5 minutes. This 
stimuli produced a behaviour pattern of gnawing, licking and eating (Stengård, 1995). The 
animal was distracted away from the paper clip and a piece of wood was placed in front of 
the animal‘s snout, to encourage gnawing actions. The paper clip was then removed 
causing little stress to the animal as possible. 
 
 
 
 
 Chapter 3: Experimental  
 
77  
 
3.8.4.2 Restraint Test 
 
A restraint test was carried out for a period of 5-minutes, holding the animal in place with 
the aid of a towel. The towel gives comfort to the animal without any effect on the 
electrode response. 
 
3.8.5 In-Vivo Injections 
 
3.8.5.1 Intraperitoneal Injection (i.p) 
 
The i.p injection was given into the body cavity at a 45 
º
 angle. It was usually directed in 
the lower left or right of the abdomen. The animal was positioned on its back and tilted so 
that no vital organs were present in the area that the injection was given (Wolfensohn & 
Lloyd, 2013). 
 
3.8.5.2 Subcutaneous Injection (s.c) 
 
Subcutaneous injections are seldom painful to the subject unless the substance being 
injected causes irritation to the animal. The injection was administered at the scruff of the 
neck. A fold of skin was lifted from the body using the thumb and two first fingers of one 
hand, the needle was then passed through, parallel to the body, avoiding tissues beneath 
(Wolfensohn & Lloyd, 2013). 
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3.9 Scanning Electron Microscopy (SEM) 
 
This technique involved the use of a 14 Hitachi S-3200N Variable Pressure SEM. The SEM 
produces a high quality image created by a focused beam of high energy electrons ranging 
from (0 -30 kV), that have interacted with the surface of the sample. The preparation of the 
sample to be analysed involved, taking ca 1cm of the active surface end of the electrode. 
This was then placed on a stub that contained an area of carbon dag that prevented the 
electrode from moving. A thin layer of conducting material was introduced to the sample to 
prevent a build-up of an electrostatic charge on the sample surface. This involved the 
sample being sputtered with a thin layer of gold (10 nm thickness). The sample was then 
placed in the sample compartment of the SEM under high vacuum and the high resolution 
images were obtained. 
 
3.10 NO synthesis and UV Spectroscopy 
 
NO was synthesised in-house using an experimental method previously utilised within our 
research group (Brown et al., 2005). Figure 3.10 (a) portrays the method used for in-house 
NO synthesis. The use of a commercial NO cylinder for obtaining NO was utilised also. 
With this method, pure NO was purged through KOH for 15 minutes and then collected for 
5 minutes in the round bottom flask depicted in Figure 3.10 (a). UV spectroscopy was 
carried out upon collection of the NO in the same way as described by Brown et al., 
(Brown et al., 2005). 
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Figure 3.10 (a): A schematic illustrating the experimental set-up of the NO synthesis. 
 
 
 
 
 
Figure 3.10 (b): A schematic illustrating the experimental set-up of the collection of NO from the 
cylinder. 
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3.11 Additional equipment 
 
Air Pump 
The air pump utilised was a Rena Air 200 (RENA
®
, France) and was used during the O2 
calibrations. 
 
Anaesthesia System 
A Univentor 400 anaesthesia unit that consisted of a vaporiser for induction was utilised 
during the surgery. A Stellar S30 was the air pump used and the induction chamber was a 
1.4 L Perspex box which were all obtained from Agnthos, Sweden. The stereotaxic frame 
(Kopf) allowed for the animal to be kept in an accurate position for brain coordinates to be 
mapped out and sensors implanted into an exact brain region. The laminar flow unit from 
Air Science
TM
 contained the entire system.  
 
Electronic Balances 
A three decimal BP 310P and a four decimal LA 2305 were the electronic balances utilised 
during the project. Both were from Sartorius
®
 AG, Gottingen, Germany. 
 
Incubator 
The animal was placed in a heated incubator at 27 
º
C to recover following surgery. A 
Thermacage MKII from Datesand Ltd, UK, was utilised. 
 
Magnetic Stirrer 
The magnetic stirrer utilised was a Yellowline, MST mini magnetic stirrer, Lennox, Ireland. 
 
Microscope 
All in-vitro experiments utilised the stereomicroscope SZ51 from Olympus America Inc. 
and the SM 33-745-F from Hund
®
 Wetzler, Germany. All in-vivo surgeries utilised the 
SZ61 microscope from Olympus.  
 
 
 Chapter 3: Experimental  
 
81  
 
Oven  
A Binder ED 23 oven (Binder Scientific, Manchester, UK) was utilised for the production 
of the NO sensors. 
 
pH Meter 
The pH meter utilised was the S20 Seveneasy
TM
 from Mettler-Toledo, Switzerland.  
 
Sonicator 
The sonicator used was a Fisherbrand FB11002, Leicestershire, UK. 
 
Vortex 
The vortex was used for the agitation and mixing of solutions (Reax Control from 
Heidolph). 
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4.1 Introduction 
 
CPEs are the most extensively utilised electrodes in electrochemical studies. They have 
numerous appealing qualities like low cost, ease of construction and can be utilised to 
detect various analytes, for example, dopamine (O‘Neill, 2005), AA (Miele & Fillenz, 
1996a) and O2 (Bolger & Lowry, 2005). The advantage of this sensor is the stability over 
long periods of recording time. It has been observed that interactions with lipids alter the 
CPEs to carbon powder electrodes through the extraction of the oil. This gives the CPEs 
great stability as any fouling that has occurred at the surface would be removed with the 
oils, by the lipids (O'Neill, 1993). CPEs are more desirable to use than metal based sensors 
as they do not require protective membranes to defend against surface poisoning (Bolger & 
Lowry, 2005). CPEs utilised for the detection of O2 have been previously demonstrated 
within our research group (Lowry et al., 1997; Bolger et al., 2011b; Kealy et al., 2013) and 
also for the detection of AA (Lowry et al., 1996).  
O2 is an immensely important molecule that is essential for life. Determining O2 levels is 
invaluable in many research fields. An example of this can be seen in the medical domain, 
where the evaluation of a patient‘s O2 levels in the blood or in exhaled air, are key 
parameters in the health and welfare of that person. The brain consumes approximately 
20% of the total amount of O2 produced by the body and the tissue concentration is 
conditional on the blood supply and local utilisation of O2 (Lowry et al., 1997). Clark and 
colleagues were one of the first research groups to detect molecular O2 voltammetrically in-
vivo using metal electrodes. In feline experiments, they implanted insulated metal 
polographic cathodes that continuously recorded O2 availability in the animal (Clark et al., 
1958). 
More recently, the focus of our group has concentrated on the integration of 
electrochemical sensors into the clinical environment. The commercially available LICOX
®
 
probe (see Figure 1.2.2) has been extensively characterised for measuring O2 in brain tissue 
(Purins et al., 2010; Dengler et al., 2011; Keddie & Rohman, 2012; Morgalla et al., 2012).          
Initial deployment of the electrochemical sensors developed in this research will focus on 
peripheral tissue monitoring since the regulatory hurdles associated with brain monitoring 
are so high. The LICOX
®
 probe is electrochemical in nature and displays a lot of 
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similarities to our proposed device; however, the sensing component functions by diffusion 
of O2 through a permeable membrane surrounding the probe and into an electrolyte solution 
where a signal is generated. The LICOX
®
 probe is designed with brain monitoring at its 
core and is fixed carefully in position using a bulky housing component. The fragile 
membrane surrounding the probe is unsuitable for orthopaedic surgery due to risk of 
damage during implantation and leakage of the electrolyte into the muscle, for example. 
Alternative methods of measuring O2 levels currently utilised in hospitals include Pulse 
Oximetry and Arterial Blood Gas (ABG) analysis. 
Severe limitations exist with such techniques restricting their utility in measuring a medical 
emergency such as a patient with ischemia. Ischemia is defined as being a restriction in 
blood supply to tissues, causing a shortage of O2 and glucose needed for cellular 
metabolism. O2 is an extremely relevant real-time indicator of ischemia since it is 
transported to the tissue via blood supply and if the blood supply is interrupted then no O2 
can reach the tissue. ABG focuses on discrete measurements of O2 levels in blood taken 
from the patient at varying time intervals and fails to address the trend in O2 levels on a 
continual basis. This significant time-lag in O2 measurements would have limited benefit to 
―at risk‖ patients since early diagnosis is critical to patient outcome. The continuous real-
time characteristic of the sensor technology within our lab, will allow for millisecond 
changes in O2 levels to be recorded and displayed for the clinician, significantly increasing 
timely intervention.  
Pulse Oximetry, similar to Near Infrared Spectroscopy, measures the O2 saturated content 
of haemoglobin in the blood which has been identified as being indirect in nature and 
having no clear threshold for measuring conditions such as ischemia (Elliott & Johnstone, 
2003). Both techniques would result in false tissue readings due to its limited capability of 
distinguishing between O2 levels within a tissue and those in the circulation surrounding 
that particular tissue. In order for an electrode to be utilised in a clinical environment, 
sensitivity to interfering lipophilic ions or charged surfactants should not be an issue for the 
electrode (Czaban, 1985). Research carried out by Ormonde and O‘Neill describes how the 
CPEs physical and electrochemical characteristics alter, after contact with BT. The oil is 
removed from the carbon paste by lipids and proteins in the brain, changing the sensor from 
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a carbon paste to a carbon powder electrode, thus improving the sensors stability over 
longer periods of time (Ormonde & O'Neill, 1989, 1990). 
However, the CPE would not be a reliable sensor for clinical utilisation, as there is leakage 
of the constituents into the environment in which it is placed. It is for this reason that the 
modification of the CPE is of valuable importance. In order to prevent the CPE surface 
alteration by interactions with the brain environment, the modification of the CPE has been 
detailed in this chapter. The alteration of a CPE is appealing due to the ease of 
manipulation and convenience of modification. The fabrication of modified CPEs began 
when Kuwana and French mixed electroactive organic compounds into the liquid 
constituent of the paste (Kuwana & French, 1964). Since that time, there has been a wide 
range of research carried out involving the fabrication of modified carbon based sensors 
(Khoo & Guo, 1999; Dai et al., 2008; Melak et al., 2013). 
The Sty monomer has been utilised previously in the design of sensors, as an 
immobilisation matrix for a lactate and choline biosensor within our research group. The 
integration of Sty into the construction of carbon nanotube sensors with the aim of 
synthesising and characterising styrene grafted carbon nanotubes and its polystyrene 
nanocomposites has been demonstrated previously (Nayak et al., 2007). MMA has been 
utilised as an immobilisation matrix for the fabrication of biosensors in research carried out 
by Perez et al., (Pérez et al., 2006). MMA has been incorporated into the manufacture of 
dental appliances, which demonstrates a compatibility with human tissue (Douglas & 
Bates, 1978; Murray & Darvell, 1993; Sarac et al., 2006). The purpose behind the 
incorporation of the Sty and MMA monomer into the CPE design in this research was to try 
and create a more robust sensor design. The main goal was to try and produce a sensor that 
was not as vulnerable and as easily modified by a complex biological setting as is observed 
with CPEs.  
This chapter describes the development of the monomer modified CPEs for the detection of 
O2. Firstly, before the fabrication of these sensors was achieved, characterisation of the 
CPE was carried out in order to confirm accurate manufacturing capabilities and to verify 
that all of the parameters and characteristics of the CPE were concurrent with literature. 
These results are subsequently utilised for the comparison against the new monomer 
modified CPEs.  
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4.2 Experimental 
 
The instrumentation and software utilised are described in Section 3.2. All chemicals and 
solutions are detailed in Section 3.3. The manufacture of a CPE, MMCPE and a SMCPE 
are described in Sections 3.4.1, 3.4.2 and 3.4.3 respectively. All modifications to the 
sensors are discussed in Section 3.5. All data was carried out in PBS (pH 7.4) unless 
mentioned otherwise. A working potential of -650 mV vs. SCE was applied to all working 
electrodes involved in the O2 experiments. Three point calibrations were carried out by 
introducing varying concentrations of O2 to the electrochemical cell (see Figure 3.7). It has 
been demonstrated previously that five point O2 calibrations display a similar sensitivity 
slope, to three point O2 calibrations (Bolger et al., 2011a). An O2 concentration of 0 µM 
was obtained by deoxygenating the buffer solution with N2 gas. The appropriate gaseous 
atmosphere was maintained over the cell solution during quiescent recording for each of the 
O2 concentrations (see Figure (3.7)). 
The constant flushing of N2 to achieve sub-micromolar O2 concentrations has been 
demonstrated previously by Dixon et al., using a similar set-up to the electrochemical cell 
set-up utilised in this research (Dixon et al., 2002). It takes approximately ten minutes for 
the buffer solution to reach a new level of gaseous saturation. An O2 concentration of 240 
µM was obtained by bubbling air through the buffer solution for 30 minutes (Lowry et al., 
1996; Bolger & Lowry, 2005; Bolger et al., 2011a). Finally, an O2 concentration of 1200 
µM was achieved, by bubbling pure O2 gas through the buffer solution for 30 minutes 
(Lowry et al., 1996; Bolger & Lowry, 2005; Bolger et al., 2011a).   
These concentrations were utilised in order to obtain regression analysis data. All data 
obtained is reported as mean ± SEM, n denotes number of electrodes, unless mentioned 
otherwise. The goodness of fit of the data points is measured by the R
2
 value. The 
calibration plots obtained are linear, therefore the slope (nA/µM) is utilised as an indicator 
of sensitivity. All statistical analysis is carried out using paired, unpaired t tests and one 
way ANOVA analysis. These tests are performed using GraphPad Prism and yield a P-
value as a result, which is a probability value that indicates if the results obtained are 
significantly different. How significantly different the results are, is denoted by the number 
of asterisks (*). Table 4.2 indicates this in more detail. 
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P value Significance No. of asterisks 
< 0.001 Extremely significant *** 
0.001 to 0.01 Very significant ** 
0.01 to 0.05 Significant * 
> 0.05 Not significant ns 
 
Table 4.2: A table displaying a summary of the correspondence of the P value to the number of 
asterisks. 
4.3 Results and Discussion 
 
In this chapter, the development of monomer modified CPEs for the detection of O2 is 
discussed. Prior to this, CPEs are manufactured, examined and analysed for comparison 
against the new monomer modified CPEs. CPEs have previously been characterised in-
vitro, for simultaneous measurement of changes in O2 and AA in-vivo, by Lowry et al., 
(Lowry et al., 1996). An advantage of CPEs is that they can be utilised over a wide 
potential window (Kalcher, 1990) and they are stable in-vivo for prolonged periods of time 
(O‘Neill, 2005). The development of the SMCPE and MMCPE are subsequently described 
in Section 4.3.2 and 4.3.3 respectively. 
 
4.3.1 Detection of O2 utilising CPEs 
 
CPEs have been extensively utilised for the detection of O2 in-vivo (Lowry et al., 1997; 
Bolger & Lowry, 2005). It has previously been demonstrated that electrodes upon 
encountering lipids and proteins in the brain environment cause an alteration to the 
morphology of the CPE. The oils within the paste are drawn out leaving a carbon powder 
electrode behind (Ormonde & O'Neill, 1989, 1990). This is examined in the next section 
using CPEs for the detection of O2. In Figure 4.3.1 (a), a typical current vs. time response 
raw data trace from an O2 calibration, utilising a CPE, is presented. The results obtained for 
an O2 calibration on CPEs are displayed below in Table 4.3.1 and Figure 4.3.1 (b). 
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Figure 4.3.1 (a): Typical current-time response for an O2 calibration (0-1200 µM; N2, Air, O2-
saturation) at a CPE carried out using CPA at -650 mV vs. SCE in PBS, pH 7.4. 
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Figure 4.3.1 (b): Averaged O2 calibrations performed with CPEs (n = 52) in PBS (pH 7.4) at -650 mV vs. 
SCE. 
 
 
 
 
 
 
 
 
Table 4.3.1: Table of averaged results for O2 calibrations in PBS (pH 7.4) using CPEs (n = 52) at -650 
mV vs. SCE. Background values subtracted. Mean background current = -1.9 ± 0.2 nA. 
 
 CPEs (n = 52) 
[O2] M Mean I, nA SEM 
0.0 0.0 0.0 
240.0 -452.1 16.7 
1200.0 -2152.2 82.6 
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The results in Table 4.3.1 show the averaged currents obtained for an O2 calibration. Linear 
regression analysis was performed from these results. A sensitivity of -1.8 ± 0.1 nA/ µM, n 
= 52, was obtained. An O2 sensitivity of -1.5 ± 0.1 nA/ µM, n = 8, was achieved by Bolger 
et al., using a five point O2 calibration (Bolger et al., 2011a) which is very similar to the 
sensitivity obtained in this section for the three point O2 calibrations undertaken (-1.8 ± 0.1 
nA/ µM, n = 52). The response of the electrodes over the O2 concentration range was linear 
with a R
2 
value of 0.99, n = 52.  
 
4.3.1.1 Biocompatibility studies 
 
The brain environment contains a complex array of substances that may compromise the 
sensors performance. These interact with the electrode, changing the morphology of the 
surface and altering the constituents of the electrode. The CPE‘s sensitivity is also 
compromised, as proteins and lipids adsorb onto the sensor surface, reducing the active 
surface (Ormonde & O'Neill, 1990). To see what effect proteins and lipids had on the 
electrodes, experiments were carried out on the CPEs to try and replicate conditions 
encountered in the brain environment. BT was also utilised, as this best mimics in-vivo 
conditions and restricts mass transport to the electrode. Triton
®
 X-100 was utilised by 
Ormonde and O‘Neill as a method of removing the oil from the carbon paste in-vitro 
(Ormonde & O'Neill, 1990). Experiments in this body of work also involve the use of 
Triton
®
 X-100 to determine the effects on the carbon paste. 
The effect of the protein (BSA), see Section 4.3.1.1.1 and the lipid (PEA), see Section 
4.3.1.1.2 on CPEs is examined. The results obtained from O2 calibrations on BSA and 
PEA-treated CPEs are displayed in Table 4.3.1.1.1 and 4.3.1.1.2 respectively and plotted 
graphically in Figure 4.3.1.1.1 and 4.3.1.1.2 respectively. As the brain comprises of all of 
these substances that are detrimental to the workings of the electrode, BT (see Section 
4.3.1.1.3 and Section 4.3.1.1.4) was also utilised. Finally, Triton
®
 X-100 (see Section 
4.3.1.1.5) was utilised as an added surfactant treatment against the CPEs. These studies 
were carried out either overnight (ON), over 3 days or after 28 days, unless otherwise 
stated. 
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4.3.1.1.1 BSA-treated CPEs 
 
 
 
 
 
 
 
Table 4.3.1.1.1: Table of results for O2 calibrations in PBS (pH 7.4) using CPEs (n = 4) pre- and post-
treatment with BSA (10%) ON at -650 mV vs. SCE. Background values subtracted. Mean background 
current (CPEs) = -1.2 ± 0.2 nA and CPE-BSA (10%) ON = -5.2 ± 0.5 nA. 
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Figure 4.3.1.1.1: A current-concentration profile for O2 calibrations in PBS (pH 7.4) using CPEs pre 
(black) and post (red) treatment with BSA (10%) ON at -650 mV vs. SCE. 
 
 
The results obtained for O2 calibrations using the CPEs pre- and post-treatment with BSA 
(10%) gave sensitivities of -1.8 ± 0.1 nA/ µM, n = 4 and -1.1 ± 0.1 nA/ µM, n = 4 
respectively. The response of the electrodes was linear over the specified range with an R
2
 
value of 1.00 (pre-treatment) and 0.99 (post-treatment). The results pre- and post-treatment 
were significantly different (P = 0.0258, paired t-test). BSA is a large globular protein that 
adsorbs onto the surface of the electrodes. The decrease in sensitivity post-treatment could 
be indicative of the BSA (10%) blocking the active surface on the carbon paste and 
therefore causing a decreased detection of O2. BSA has been utilised by other research 
 CPE (n = 4) CPE-BSA (10%) ON (n = 4) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -427.0 10.9 -286.1 6.4 
1200.0 -2114.8 157.3 -1331.2 28.5 
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groups as a means of blocking the active surface on a CPE (Zhang et al., 2011) and 
biosensors (Sun et al., 2011). 
The fouling of the electrode surface causing a decrease in sensitivity has been observed 
previously by Kane et al., (A. Kane & D. O'Neill, 1998). Kane et al., observed that upon 
treatment of the CPEs with BSA (10%) a significant positive shift (P = 0.02) in the peak 
potential and a 43 % decrease in the sensitivity was recorded. This could possibly be a 
reason for the decrease in sensitivity observed after treatment with BSA (10%) with the 
CPEs. The 10% concentration of BSA utilised is also very harsh and these levels would not 
be encountered in-vivo.  
 
4.3.1.1.2 PEA-treated CPEs 
 
 CPE (n = 4) CPE-PEA (10%) ON (n = 4) 
[O2], µM Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -395.9 16.3 -285.4 5.4 
1200.0 -1942.4 34.2 -1261.8 12.1 
 
Table 4.3.1.1.2: Table of results for O2 calibrations in PBS (pH 7.4) using CPEs (n = 4) pre- and post-
treatment with PEA (10%) ON carried out at -650 mV vs. SCE. Background values subtracted. Mean 
background current (CPE) = -0.9 ± 0.2 nA and (CPE-PEA (10%) ON) = -1.2 ± 0.3 nA.  
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Figure 4.3.1.1.2: A current-concentration profile for O2 calibrations in PBS (pH 7.4) using CPEs pre 
(black) and post (red) treatment with PEA (10%) ON carried out at -650 mV vs. SCE. 
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Figure 4.3.1.1.2 and Table 4.3.1.1.2 display data obtained for O2 calibrations pre- and post-
treatment with PEA (10%) ON with CPEs. Sensitivities of -1.6 ± 0.1 nA/ µM, n = 4 and -
1.0 ± 0.1 nA/ µM, n = 4, were recorded for pre and post PEA (10%) ON treatment, 
respectively. Linear responses of 1.00 (pre-treatment) and 0.99 (post-treatment) over the 
specified range were obtained. A significant decrease in sensitivity (P < 0.0001, paired t-
test) was recorded after treatment with PEA (10%). It has been proposed that the oil is 
removed from the CPE by lipids, which provides the CPEs with better stability over time 
but also increases the rate of electron transfer, thus increasing the sensitivity (Ormonde & 
O'Neill, 1989; A. Kane & D. O'Neill, 1998) however, an increase in sensitivity is not 
observed with this result and could be due to the adsorption of the PEA onto the surface, 
blocking the active surface, thus, leading to a decrease in the overall sensitivity observed.  
A decrease in sensitivity could also be due to restricted diffusion. As Triton
®
 X causes 
similar effects to PEA (as PEA is also a surfactant), the  SEM images in Figure 4.3.1.1.6 
could suggest that the PEA is causing this leeching out of the cavity making it more 
difficult for the analyte to diffuse to the carbon paste. O2 must now diffuse down the cavity 
as opposed to the pre-treated CPE. O2 has a large diffusion coefficient so the restricted 
diffusion may not be the reasoning behind the decreased sensitivity but rather the PEA 
causing the paste to compact back into the cavity giving a more compact surface thus 
reducing the active surface area and hence the sensitivity. A combination of leeching from 
the cavity and a reduced active surface could be the reason for this. 
 
4.3.1.1.3 BT treated CPEs 
 
 
 
 
 
 
 
Table 4.3.1.1.3: Table of results for O2 calibrations in PBS (pH 7.4) using CPEs (n = 4) pre- and post- 
treatment with BT ON carried out at -650 mV vs. SCE. Background values subtracted. Mean 
background currents (CPEs) = -1.9 ± 0.5 nA and (CPE-BT ON) = -2.9 ± 1.4 nA. 
 CPE (n = 4) CPE-BT ON (n = 4) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -568.3 21.4 -428.2 64.4 
1200.0 -2182.7 99.6 -1812.1 199.6 
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Figure 4.3.1.1.3: A current-concentration profile for O2 calibrations in PBS (pH 7.4) using CPEs pre 
(black) and post (red) treatment with BT ON carried out at -650 mV vs. SCE.  
 
The ex-vivo brain tissue studies are more representative of the surroundings that the sensor 
would have to endure, therefore, they give a better understanding as to how the sensor will 
behave in the in-vivo environment. O2 calibrations performed on the CPEs pre and post BT 
ON, displayed sensitivities of -1.8 ± 0.1 nA/ µM, n = 4 and -1.5 ± 0.1 nA/ µM, n = 4, 
respectively. A linear response was obtained over the specified range with an R
2
 value of 
0.99 (pre-treatment) and 0.99 (post-treatment). The results obtained were not significantly 
different pre- and post-treatment (P = 0.1864, paired t-test). There was a slight reduction in 
sensitivity post-treatment in BT ON. This result was not unexpected, as the complex nature 
of BT which embodies proteins and lipids among other interferents and fouling agents 
would cause the sensor to be altered. Leading to the removal of the oil from the carbon 
paste and thus increasing the electron transfer at the electrode. This could be a reason why a 
significant difference is not observed pre- and post-treatment. 
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4.3.1.1.4 BT treated CPEs (28 days) 
 
 
 
 
 
 
 
 
Table 4.3.1.1.4: Table of results for O2 calibrations in PBS (pH 7.4) using CPEs (n = 4) pre- and post-
treatment with BT 28 days carried out at -650 mV vs. SCE. Background values subtracted. Mean 
background currents (CPEs) = -3.9 ± 0.3 nA and (CPE-BT 28 days) = -3.8 ± 0.6 nA. 
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Figure 4.3.1.1.4: A current-concentration profile for O2 calibrations in PBS (pH 7.4) using CPEs pre 
(black) and post (red) treatment with BT (28 days) carried out at -650 mV vs. SCE.  
 
 
The results obtained for O2 calibrations using the CPEs pre- and post-treatment with BT 
over 28 days yielded sensitivities of -1.9 ± 0.1 nA/ µM, n = 4 and -1.6 ± 0.1 nA/ µM, n = 4, 
respectively. This time interval chosen is more representative of how long sensors would 
remain implanted for. A linear response was obtained pre- and post-treatment with the BT 
(28 days) (R
2
 = 0.99). A decrease in sensitivity was observed post treatment, yielding a 
significant difference (P = 0.0152). Again, this result was expected, as the ex-vivo brain 
environment would morphologically change the sensor leading to an altered response.  
 
 CPE (n = 4) CPE-BT 28 days (n = 4) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -398.4 23.6 -404.5 33.1 
1200.0 -2298.6 110.3 -1892.8 141.2 
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4.3.1.1.5 Triton
®
 X-100 (10%) treated CPEs 
 
   CPE (n = 8)                                                                      CPE-Triton® X (10%) (n = 8) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -364.3 29.6 -419.6 59.7 
1200.0 -1938.8 167.4 -1665.1 246.1 
 
Table 4.3.1.1.5: Table of results for O2 calibrations in PBS (pH 7.4) using CPEs (n = 8) pre- and post-
treatment with Triton
®
 X-100 (10%) ON carried out at -650 mV vs. SCE. Background values 
subtracted. Mean background current (CPE) = -1.9 ± 0.3 nA and (CPE-Triton
®
 X (10%) ON) = -4.4 ± 
1.4 nA. 
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Figure 4.3.1.1.5: A current-concentration profile for O2 calibrations in PBS (pH 7.4) using CPEs pre 
(black) and post (red) treatment with Triton
®
 X-100 (10%) ON, carried out at -650 mV vs. SCE. 
 
The results for the O2 calibrations using the CPEs pre- and post-treatment with Triton
®
 X 
(10 %) ON, yielded sensitivities of -1.6 ± 0.1 nA/ µM, n = 8 and -1.4 ± 0.1 nA/ µM, n = 8, 
respectively. The response of the electrodes was linear over the specified range with an R
2
 
value of 0.99 (pre-treatment) and 0.99 (post-treatment). The results pre- and post-treatment 
were not significantly different (P = 0.3270, paired t-test). A slight decline in sensitivity 
was observed, however, pre and post analysis remained similar. This could be due to the 
fact that some electrodes showed a greater sensitivity after treatment, which would be a 
consequence of the removal of the oil causing an increase in electron transfer. Whilst some 
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electrodes either lost connection between the surface wire and the carbon paste or 
decreased in sensitivity on account of the harshness of the surfactant Triton
®
 X. Triton
®
 X 
has been utilised previously as a means of removing the oil from the CPE resulting in a 
carbon powder electrode, which brings about faster electron transfer and greater stability 
over long periods of experimental recording (Ormonde & O'Neill, 1989; A. Kane & D. 
O'Neill, 1998). Figure 4.3.1.1.6 (A) and (B), displays the images of the CPEs pre- and post-
treatment with Triton
®
 X. 
 
4.3.1.1.6 SEM images 
 
SEM was utilised as a means of analysing the surface morphology of the CPEs more 
closely. Triton
®
 X-100 was the harshest substance that the electrode was in contact with 
and has been investigated as a surfactant with CPEs previously (Ormonde & O'Neill, 1990). 
The images display the CPE surface pre and post Triton
®
 X-100 treatment and they 
highlight the effect of the surfactant on the CPEs.  
 
 
 
   
Figure 4.3.1.1.6: SEMs displaying the surface of (A); CPE prior to treatment (B); CPE post treatment 
with Triton
®
 X-100 (10%) ON. 
 
It is obvious from Figure 4.3.1.1.6, image B, that treating the CPEs with the surfactant 
Triton
®
 X-100 completely alters the surface morphology. It is clear from the image that a 
large part of the carbon paste has been removed from the compartment of the electrode 
along with the silicone oil. This was evident, due to some of the carbon paste remaining in 
200 µm 100 µm
A B
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the bottom of the enclosed container were the sensors were kept during the Triton
®
 X 
(10%) treatment. Triton
®
 X (0.1 %) was utilised by Lyne et al., and O‘Neill et al., to mimic 
the outcome of implantation of the CPEs in-vivo, which causes the transformation of CPEs 
to carbon powder electrodes by removal of the oil constituent (Lyne & O'Neill, 1990; 
O'Neill, 1993). A 10 % solution was utilised in the experiments carried out in this thesis in 
order to try and elucidate whether the modified electrodes would withstand modification by 
such a harsh concentration of this surfactant. SEMs displaying post in-vivo effects on the 
CPEs are shown in Figure 4.4 (e). 
 
4.3.2 Sty modified CPE (SMCPE) 
 
The incorporation of the Sty monomer into the design of sensors has been demonstrated 
previously as an immobilisation matrix for a lactate and choline biosensor within our 
research group. Nayak et al., integrated Sty into the manufacture of carbon nanotube 
sensors with the main goal being to synthesise and characterise styrene grafted carbon 
nanotubes and its polystyrene nanocomposites (Nayak et al., 2007). Xu et al., manufactured 
a nanoporous pseudo-CPE with the aid of Sty, for potential use in molecular recognition, 
drug and environmental detection (Xu et al., 2011). Sty has also been implemented in the 
design of molecularly imprinted polymers for the enhanced recognition of ribonuclease A 
(Hsu et al., 2006).  
The purpose behind the implementation of the Sty monomer into the CPE design in this 
research, was to try and create a more robust and tough electrode. The main aim was to try 
and produce a sensor that was not as vulnerable and as easily modified by a complex 
biological milieu as is observed with the CPEs. CPEs were manufactured initially (see 
Section 3.4.1) and then placed in Sty ON at 4 
º
C in the fridge. This time frame was chosen 
as this is the standard protocol used within the lab. O2 calibrations were carried out in order 
to examine how the electrode performed with the addition of the Sty monomer. The results 
for the CPEs that had been placed in Sty ON are displayed in Table 4.3.2 and Figure 4.3.2 
(a). 
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 CPE-Sty (ON) (n = 4) 
[O2], M Mean I, nA SEM 
0.0 0.0 0.0 
240.0 -886.8 128.0 
1200.0 -2472.6 108.7 
 
Table 4.3.2: Table of results for an O2 calibration in PBS (pH 7.4) using CPEs placed in Sty ON, (n = 4), 
carried out at -650 mV vs. SCE. Background values subtracted. Mean background current = -4.3 ± 1.1 
nA. 
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Figure 4.3.2 (a): A current-concentration profile for an O2 calibration in PBS (pH 7.4) using CPEs 
placed in Sty ON (n = 4) carried out at -650 mV vs. SCE. 
 
 
The O2 calibration using the CPEs placed in Sty ON, gave a sensitivity of -1.9 ± 0.3 nA/ 
µM, n = 4. The response of the electrodes decreased in linearity over the specified range, 
mostly due to surface morphology, yielding an R
2
 value of 0.97. A similar yet slightly 
higher sensitivity was observed for the CPEs placed in Sty ON in comparison to the 
unmodified CPEs. This could have been due to the greater surface area that had formed 
when the sensor had dried. The surface of the sensor was examined using SEM and it was 
clear from the image acquired that Sty was causing the surface to dip in the middle when it 
had desiccated, forming a concave appearance. The SEM image of the CPE incorporating 
the monomer Sty ON into the manufacture of the sensor is displayed below in Figure 4.3.2 
(b). 
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Figure 4.3.2 (b): SEM displaying the surface of the CPE placed in Sty ON. 
 
In order to manufacture an electrode that is reproducible, a flat electrode is desirable. Prior 
to the development of the flat surface, O2 calibrations pre- and post-treatment with Triton
®
 
X were carried out. This was deemed necessary to investigate, in order to determine if the 
SMCPE surface remained intact following exposure to the harsh surfactant or did a similar 
trend occur as was observed with the CPEs.  
 
4.3.2.1 Treatments on SMCPE (ON) with Triton
®
 X (10%) 
 
Table 4.3.2.1: Table of results for O2 calibrations in PBS (pH 7.4) using SMCPEs (n = 4) pre- and post- 
treatment with Triton
®
 X (10%), carried out at -650 mV vs. SCE. Background values subtracted. Mean 
background currents (SMCPE) = -4.3 ± 1.1 nA and (SMCPE-Triton X (10%) ON) = -8.5 ± 1.0 nA.  
 
300 µm
 SMCPE (n = 4)  SMCPE-Triton® X (10%) ON (n = 4) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -886.8 128.0 -831.5 77.3 
1200.0 -2472.6 108.7 -3095.5 452.9 
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Figure 4.3.2.1: A current-concentration profile for O2 calibrations in PBS (pH 7.4) using SMCPE pre 
(black) and post (red) treatment with Triton
®
 X (10%) ON, carried out at -650 mV vs. SCE.  
 
 
The results obtained for the O2 calibrations using the SMCPE pre (black) and post (red) 
treatment with Triton
®
 X (10 %) gave a sensitivity of -1.9 ± 0.3 nA/ µM, n = 4 (pre-
treatment) and -2.5 ± 0.2 nA/ µM, n = 4 (post-treatment). The response of the electrodes 
decreased in linearity over the specified range with an R
2
 value of 0.97 (pre-treatment) and 
increased in linearity to 0.99 (post-treatment). The results pre- and post-treatment were not 
significantly different (P = 0.1742). An increase in sensitivity after treatment with the 
surfactant Triton
®
 X (10%) was observed, which could be as a result of the active surface 
being exposed due to the Triton
®
 X removing the monomer from the carbon paste therefore 
increasing the sensitivity. The error bars were also increased after treatment with the 
surfactant which demonstrates that the effects on the electrodes varied.   
An increase in the sensitivity may also be attributable to the increase in surface area of the 
electrode i.e. the concave shape that developed after the sensor had dried. After the 
preliminary results of treating the SMCPE with Triton
®
 X-100, research was undertaken to 
try and obtain a flat reproducible SMCPE surface. 
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4.3.2.2 Optimisation of SMCPE surface 
 
To try and eliminate the concave surface on the electrode, differing volumes of the Sty 
monomer (≥ 99 % solution) were mixed with a consistent amount of carbon paste and 
repacked into the compartment of the electrode after it had been immersed in Sty ON (see 
Section 3.3.2.1). Once the electrodes had dried, they were tested against Triton
®
 X (10%) to 
determine which volume of Sty, preformed the best under these harsh conditions. 
Significant differences were observed for 16 µL (P = 0.0021), 20 µL (P = 0.0005), 24 µL 
(P = 0.0139) and 80 µL (P = 0.0013) Sty volumes pre and post exposure to Triton
®
 X 
(paired t-tests). All volumes apart from 18 µL gave significant results leading to the chosen 
mixture of 18 µL Sty and 0.025 g carbon paste as the optimum result (shown in red).  
Sensitivities of -2.1 ± 0.3 nA/ µM, n = 4 and -2.0 ± 0.1 nA/ µM, n = 4, pre- and post-
treatment with Triton
®
 X (10%) ON were recorded and the results were not significantly 
different (P = 0.7783). The result obtained from the 24 µL Sty concentration yielded an 
increase in the sensitivity post treatment with Triton
®
 X. This was not chosen to continue 
on with because it showed that the electrode surface was compromised more than what was 
seen with the 18 µL Sty volume. From previous results, an increase in sensitivity post 
treatment with Triton
®
 X, correlated to the leeching out of the oil, leading to greater 
electron transfer and an increased sensitivity. The main aim of this research was to produce 
an electrode that could withstand such manipulations, so therefore a volume of 18 µL of 
Sty was chosen. 
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Figure 4.3.2.2 (a): A bar chart displaying the sensitivities obtained from O2 calibrations, using SMCPE 
in PBS (pH 7.4) with varying volumes of the Sty mixture, pre- and post-treatment with Triton
®
 X 
(10%), (n = 4) carried out at -650 mV vs. SCE. 
 
 
  
 
         
Figure 4.3.2.2 (b): SEMs displaying the surface of (A); SMCPE prior to treatment with Triton
®
 X ON 
(B); SMCPE post treatment with Triton
®
 X (10%) ON. 
 
 
A flat and uniform SMCPE surface was obtained following repacking of the chosen volume 
of Sty mixture (see Figure (4.3.2.2 (b)). Upon treatment with Triton
®
 X ON, the surface 
was agitated slightly on one side of the electrode, however, in comparison to the CPEs (see 
Figure 4.3.1.1.6), this result is dramatically improved. The SMCPE demonstrates 
remarkable resistance to the very harsh surfactant which is extremely encouraging for 
future applications of the sensor. 
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4.3.2.3 UV light on SMCPE 
 
Photo-initiated polymerisations can occur with the production of radicals by UV light. 
Initiation by photolysis occurs with monomers (Sty and MMA) that contain a double bond 
linked with other groups (Oster & Yang, 1968). The polymerisation of Sty by UV light has 
been demonstrated by Bai et al., upon which thin polystyrene films were produced on 
polycrystalline Pt (Bai et al., 2001). Sty can also undergo thermal polymerisation and it is 
stated that the polymerisation occurs at a speed of 0.1 % per hour at 60 
º
C and 2 % per hour 
at 100 
º
C (Khuong et al., 2005). Subsequent to the results obtained for the SMCPE, it was 
decided that UV light (which was chosen as the most suitable method of polymerisation), 
would be utilised to try and polymerise the Sty monomer straight after it had been repacked 
with the Sty/carbon paste mixture. A compact and solid mixture in the cavity was the main 
feature sought after by utilising this polymerisation process. The resulting electrode was 
then treated with Triton
®
 X (10%) to determine how the electrode would perform after 
being immersed in a harsh milieu. The results from this are displayed in Figure 4.3.2.3 (a) 
and Table 4.3.2.3. Images are also shown (see Figure 4.3.2.3 (b)), to demonstrate the effect 
of the UV light on the electrode and the Triton
®
 X treatment. 
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Figure 4.3.2.3 (a): A current-concentration profile for O2 calibrations in PBS (pH 7.4) using SMCPE-
UV pre (black) and post (red) treatment with Triton
®
 X-100 (10%) ON, carried out at -650 mV vs. 
SCE.  
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 SMCPE-UV (n = 4) SMCPE-UV-Triton® X (n = 4) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -403.1 144.9 -393.5 149.4 
1200.0 -1826.6 610.5 -1612.8 539.5 
 
Table 4.3.2.3: Table of results for O2 calibrations in PBS (pH 7.4) using SMCPE-UV (n = 4) pre- and 
post-treatment with Triton
®
 X-100 (10%) ON, carried out at -650 mV vs. SCE. Background values 
subtracted. Mean background current (SMCPE-UV-30mins) = -290.2 ± 108.9 nA and (SMCPE-UV-
Triton X (10%)-ON = -175.5 ± 86.4 nA 
 
The results obtained for the O2 calibrations using the SMCPE-UV pre (black) and post (red) 
treatment with Triton
®
 X-100 (10 %) ON, yielded sensitivities of -1.5 ± 0.1 nA/ µM, n = 4 
and -1.3 ± 0.1 nA/ µM, n = 4, respectively. The response of the electrodes was linear over 
the specified range with an R
2
 value of 0.99 (pre-treatment) and 0.99 (post-treatment). The 
results pre- and post-treatment were not significantly different (P = 0.8312, paired t-test). It 
was observed upon exposure to UV light that the components rose out of the cavity of some 
of the electrodes leading to a loss in connection between the composite and the silver wire. 
While other electrodes retained a connection the composite still rose from the compartment 
of the electrode. It is hypothesised that the polymerisation took place too quickly causing 
the cavity components to reduce in size and rise out of the cavity. Following treatment with 
Triton
®
 X (10%) ON, more of the composite was removed from the cavity from some of 
the electrodes and the surfaces were damaged by the treatment.  
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Figure 4.3.2.3 (b): SEMs displaying the surface of (A): SMCPE-UV prior to treatment with Triton
® 
X 
(10%)-ON (B): SMCPE-UV post treatment with Triton
®
 X-100 (10%) ON. 
 
 
Figure 4.3.2.3 (b), displays the SMCPE post treatment with UV light. It is evident from the 
image that the UV light had a negative effect on the SMCPEs. The components in the 
compartment of the electrode had pulled up out of the cavity and some electrodes had lost 
connection with the silver wire surface underneath. After treatment with Triton
®
 X, the 
loose components at the surface of the electrode were removed by the surfactant. UV 
appeared to compromise the sensor performance and so it was decided not to continue on 
with the polymerisation process for the SMCPEs. 
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4.3.2.4 Optimum potential profile of SMCPE 
 
Figure 4.3.2.4, demonstrates an optimum potential profile that was carried out on the 
SMCPE to determine the optimum working potential to apply to the electrodes. The 
purpose of this was to validate that the chosen potential was indeed the correct one. 
Following exposure to different proteins, lipids and surfactant treatments the 
oxidation/reduction potentials have been shown to shift to alternative potentials. Kane et 
al., observed this trait when treating CPEs with the different substances mentioned in 
Section 4.3.1.1(A. Kane & D. O'Neill, 1998). 
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Figure 4.3.2.4: An optimum potential profile carried out on SMCPEs (n = 4), at a potential range of (-
100 mV to -900 mV) in PBS (pH 7.4) using CPA. 
 
 
There was no significant difference between all of the potentials applied to the SMCPEs (P 
= 0.8706, one-way ANOVA). It was observed that the potentials -600 mV vs. SCE and -
700 mV vs. SCE gave a slightly higher sensitivity. A potential of -650 mV vs. SCE was 
initially suggested as the applied potential to use, as this correlated with the potential used 
for CPEs and other O2 sensors in effect in the lab. To further validate that the reduction 
potential had not shifted, CV was performed on the sensor design to investigate this. 
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4.3.2.5 CV of SMCPE 
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Figure 4.3.2.5: A CV from -1 to 0.2 V vs. SCE carried out on SMCPEs and performed in PBS (pH 7.4). 
 
A clear O2 reduction peak is observed at ca. -0.4 V in the SMCPE. The resulting O2 wave is 
much larger than what can be seen in CPEs, possibly due to the different surface 
composition and the monomer Sty. A reduction peak is observed at ca. -0.6 V for CPEs 
which was demonstrated by Bolger et al., and the O2 peak differences in both sensors 
indicate that the rate constant for charge transfer is greater at SMCPEs than at CPEs 
(Bolger et al., 2011a). It was confirmed from both the optimum potential profile and CV 
that a potential of -650 mV vs. SCE could be utilised and this was chosen for the SMCPEs, 
as this is in the diffusion limited region and was the potential utilised for other O2 sensors in 
the lab.  
 
4.3.2.6 Validation of the final SMCPE design 
 
In summary, the final SMCPE design involved placing the CPEs in Sty ON and then 
quickly packing a mixture of the monomer and carbon paste (18 µL and 0.025 g carbon 
paste) into the cavity of the electrode and allowing the electrode to dry. Following the 
results discussed in this section, the final method of manufacturing the SMCPE was 
reproduced.  
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Figure 4.3.2.6: A current-concentration profile for O2 calibrations in PBS (pH 7.4) using SMCPEs (n = 
52), carried out at -650 mV vs. SCE. 
 
 
 
 
 
 
 
Table 4.3.2.6: Table of results for O2 calibrations in PBS (pH 7.4) with SMCPEs (n = 52), carried out at 
-650 mV vs. SCE. Background values subtracted. Mean background current SMCPEs = -7.8 ± 1.1 nA   
 
 
Figure 4.3.2.6 and Table 4.3.2.6, display the data obtained for the O2 calibrations with the 
SMCPE. A sensitivity of -3.1 ± 0.1 nA/ µM, n = 52, was recorded and a linear response 
was observed over the specified range (R
2
 = 0.99). A greater O2 sensitivity was achieved 
with the new monomer modified CPE. Experiments carried out with the surfactant Triton
®
 
X confirmed how intact and robust the cavity components of the SMCPE were in 
comparison to the CPEs, which were totally destroyed by this treatment. It is hypothesised 
that the Sty is causing a much faster electron transfer rate, as supported by experimental 
data, thus creating a higher O2 sensitivity. The next section discusses the development of 
the MMCPE, which was carried out in a similar manner as the SMCPE. 
 
 SMCPE (n = 52) 
[O2], M Mean I, nA SEM 
0.0 0.0 0.0 
240.0 -921.3 37.9 
1200.0 -3782.5 97.5 
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4.3.3 MMA modified CPE (MMCPE) 
 
Poly (MMA) is a clear colourless polymer that has been used in optical applications. The 
integration of the monomer MMA with diffuser plates (which are rough reflectors that are 
used to scatter light and prevent glare), have been used in order to reduce irregularity and 
cloudiness observed in an LCD screen due to high temperatures (Kim, 2005). The 
incorporation of the MMA polymer as an immobilisation matrix for the fabrication of 
biosensors has been demonstrated in research carried out by Perez et al., (Pérez et al., 
2006). Chatzandroulis et al., describes the use of MMA for the fabrication of capacitive 
type chemical sensors  (Chatzandroulis et al., 2004b). Dai et al., utilised poly(MMA) in the 
design of a graphite sensor for vitamin C, the characteristics that the monomer possesses, 
like low price and mechanical stability, were appealing for the manufacture of this sensor 
(Dai et al., 2008).  
The incorporation of MMA into the construction of dental appliances, demonstrates a 
compatibility with human tissue (Douglas & Bates, 1978; Murray & Darvell, 1993; Sarac et 
al., 2006). CPEs were manufactured initially (see Section 3.4.1) and then placed in MMA 
ON at 4 
º
C in the fridge. O2 calibrations were carried out in order to examine how the 
electrode performed with the addition of the MMA monomer. The results for the CPEs that 
were placed in MMA ON are displayed in Table 4.3.3 and Figure 4.3.3 (a). 
 
 
 CPE-MMA(ON) (n = 4) 
[O2], M Mean I, nA SEM 
0.0 0.0 0.0 
240.0 -691.7 120.4 
1200.0 -2998.6 107.3 
 
Table 4.3.3: Table of results for an O2 calibration in PBS (pH 7.4) using CPEs placed in MMA ON, n = 
4, carried out at -650 mV vs. SCE. Background values subtracted. Mean background current of -3.8 ± 
1.6 nA. 
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Figure 4.3.3 (a): A current-concentration profile for O2 calibrations in PBS (pH 7.4) using CPEs placed 
in MMA ON, (n = 4), carried out at -650 mV vs. SCE. 
 
 
The O2 calibration using CPEs placed in MMA ON, displayed a sensitivity of -2.5 ± 0.1 
nA/ µM, n = 4. A linear response was obtained over the specified range (R
2
 = 0.99). A 
slightly higher sensitivity was observed for the CPEs placed in MMA ON in comparison to 
the CPEs. It was noticed that the MMCPEs contained a concave shape at the surface after 
the composite had dried, therefore creating a greater surface area. This may be the reason 
for a slightly increased O2 sensitivity. A similar occurrence was observed with the 
SMCPEs. The surface of the sensor was examined using SEM and it was clear from the 
image acquired that MMA was causing the surface to dip in the middle when it had dried, 
forming a concave appearance. An SEM image displaying the surface of the CPE following 
immersion in MMA ON is displayed in Figure 4.3.3 (b). 
 
 
Figure 4.3.3 (b): A SEM displaying the surface of a CPE that had been immersed in MMA ON.  
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In Figure 4.3.3 (b), the image demonstrates how the surface had dipped in the centre, 
revealing a concave shape. A similar effect was displayed by the CPE that had been placed 
in Sty ON (see Figure 4.3.2 (b)). In order to manufacture a reproducible electrode, a flat 
surface must be obtained. Prior to the development of the flat surface O2 calibrations pre- 
and post-treatment with Triton
®
 X were carried out in order to verify if the MMCPE 
surface remained intact following exposure to the harsh surfactant or did a similar trend 
occur as was observed with the CPEs. 
 
4.3.3.1 Treatments on MMCPE (ON) with Triton
®
 X (10%)  
 
 MMCPE (n = 4) MMCPE-Triton® X (10%) ON, (n = 4) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -691.8 120.4 -797.1 11.9 
1200.0 -2998.6 107.3 -2478.4 63.5 
 
Table 4.3.3.1: Table of results for O2 calibrations in PBS (pH 7.4) using MMCPEs (n = 4) pre- and post-
treatment with Triton
®
 X-100 (10%) ON, carried out at -650 mV vs. SCE. Background values 
subtracted. Mean background current (MMCPE) = -3.8 ± 1.6 nA and (MMCPE-Triton
®
 X (10%) ON) 
= -10.2 ± 1.4 nA. 
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Figure 4.3.3.1: A current-concentration profile for O2 calibrations in PBS (pH 7.4) with MMCPEs pre 
(black) and post (red) treatment with Triton
®
 X-100 (10%) ON, carried out at -650 mV vs. SCE. 
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The results obtained for the O2 calibrations using the MMCPEs pre (black) and post (red) 
treatment with Triton
®
 X (10 %) ON, yielded sensitivities of -2.5 ± 0.3 nA/ µM, n = 4 and -
1.9 ± 0.3 nA/ µM, n = 4, pre- and post- Triton
®
 X treatment. The response of the electrodes 
was linear over the specified range with an R
2
 value of 0.99 (pre-treatment) and 0.98 (post-
treatment). The results pre- and post-treatment were significantly different (P = 0.0052, 
paired t-test). After the preliminary results of treating the MMCPE with Triton
®
 X (10%), 
research was carried out in order to try and obtain a flat reproducible MMCPE surface. 
 
4.3.3.2 Optimisation of MMCPE surface  
 
To try and eliminate the concave surface on the electrode, differing volumes of the MMA 
monomer (99 % solution), were mixed with a consistent amount of carbon paste and 
repacked into the compartment of the electrode, after it had been immersed in MMA ON 
(see Section 3.4.2). Once the electrodes had dried, they were tested against Triton
®
 X to 
determine which volume of MMA preformed the best under these harsh conditions. 
Significant differences were observed for 16 µL (P = 0.0115), 18 µL (P = 0.0007) and 80 
µL (P = 0.0180) MMA volumes pre and post exposure to Triton
®
 X (paired t-tests). There 
was no significant difference between the 20 µL (P = 0.4530) and 24 µL (P = 0.5678) 
MMA volumes pre- and post-treatment with Triton
®
 X (10%) ON (paired t-tests). On 
comparison of the two MMA volumes (20 µL vs. 24 µL), there was no significant 
difference (P = 0.2907, unpaired t-test). The mixture of 20 µL MMA and 0.025 g carbon 
paste was chosen as the optimum result (shown in green), as it utilised less of the monomer 
for manufacture of the sensors. The results of this volume of MMA yielded sensitivities of -
2.3 ± 0.1 nA/ µM, n = 4 and -2.4 ± 0.1 nA/ µM, n = 4, pre- and post-treatment with Triton
®
 
X (10%) respectively.  
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Figure 4.3.3.2 (a): A bar chart displaying the sensitivities obtained in O2 calibrations, using MMCPE in 
PBS (pH 7.4) with the varying volumes of MMA mixture, and post treatment with Triton
®
 X-100 (10%) 
ON, carried out at -650 mV vs. SCE. 
 
 
 
    
Figure 4.3.3.2 (b): SEMs displaying the surface of (A); MMCPE prior to treatment with Triton
®
 X-100 
ON (B); MMCPE post treatment with Triton
®
 X-100 (10%) ON. 
 
 
A flat uniform MMCPE surface was obtained following repacking of the optimum volume 
of MMA mixture (see Figure 4.3.3.2 (b)). Upon treatment with Triton
®
 X ON, the surface 
was altered slightly, however, in comparison to the CPEs (see Figure 4.3.1.1.6), this result 
is considerably improved. The MMCPE demonstrates remarkable resistance to the very 
harsh surfactant which is extremely encouraging for future applications of the sensor. 
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4.3.3.3 UV light on MMCPE 
 
Polymerisation can take place with the creation of radicals by UV light. Initiation by this 
UV mechanism occurs with monomers (MMA and Sty) that contain a double bond linked 
with other groups (Oster & Yang, 1968). An example of polymerisation of MMA at 25 
º
C 
with 5.0 % 2,2‘azobis(2-methylpropionitrile) (AIBN) initiated by UV light has been 
previously demonstrated by Zhu et al., (Zhu et al., 1990b). Another method of 
polymerisation has been discussed by Kruss and Patraboy who utilised intense ultrasound 
to initiate polymerisation of MMA (Kruus & Patraboy, 1985). In a separate study, the 
surface of silica nanoparticles were modified by UV induced graft polymerisation of MMA 
(Kim et al., 2005). It was decided that UV light would be utilised to try and polymerise the 
monomer MMA, straight after it had been repacked with the MMA/carbon paste mixture. 
The resulting electrode was then treated with Triton
®
 X. The results from this are displayed 
below in Figure 4.3.3.3 (a) and Table 4.3.3.3. SEM images are also shown (see Figure 
4.3.3.3 (b)), to demonstrate the effect of the UV light on the electrode and the Triton
®
 X 
treatment. 
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Figure 4.3.3.3 (a): A current-concentration profile for O2 calibrations in PBS (pH 7.4) with MMCPE-
UV, n = 12, pre (black) and post (red) treatment with Triton
®
 X-100 (10%), carried out at -650 mV vs. 
SCE.  
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 MMCPE-UV (n = 12) MMCPE-UV-Triton® X (n = 12) 
[O2], M  Mean I, nA SEM Mean I, nA  SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -739.8 88.2 -693.2 73.5 
1200.0 -3878.6 144.6 -2973.9 153.9 
 
Table 4.3.3.3: Table of results for O2 calibrations in PBS (pH 7.4) with MMCPE-UV (n = 12) pre- and 
post-treatment with Triton
®
 X-100 (10%), carried out at -650 mV vs. SCE. Background values 
subtracted. Mean background current (MMCPE-UV) = -9.4 ± 1.2 nA and (MMCPE-UV-Triton
®
 X 
ON) = -12.8 ± 1.6 nA. 
 
O2 calibrations using the MMCPE-UV pre (black) and post (red) treatment with Triton
®
 X 
(10 %) displayed sensitivities of -3.2 ± 0.1 nA/ µM, n = 12 (pre-treatment) and -2.6 ± 0.1 
nA/ µM, n = 12 (post-treatment). A linear response was obtained over the specified range 
with an R
2
 value of 0.99 (pre-treatment) and 0.99 (post-treatment). The results pre- and 
post-treatment were not significantly different (P = 0.8735, paired t-test). Exposure of the 
electrode to UV light seemed to enhance the sensors O2 sensitivity. The surface was much 
more intact and uniform on inspection after UV treatment. The experiment carried out with 
the surfactant Triton
®
 X, slightly aggravated the surface, but in comparison to the CPEs, the 
electrode compartment displayed a robust and an intact characteristic. 
 
 
 
   
 
Figure 4.3.3.3 (b): SEMs displaying the surface of (A): MMCPE-UV prior to treatment with Triton
® 
X 
(10%) ON (B): MMCPE-UV post treatment with Triton
®
 X-100 (10%) ON. 
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Figure 4.3.3.3 (b) displays the MMCPE post treatment with UV light, it is evident from the 
image that a much improved electrode surface is created with placing the electrode under 
the UV light. After treatment with Triton
®
 X ON, the surface roughness of the electrode 
increased, but not to the extent seen with the CPEs (see Figure 4.3.1.1.6). The final method 
was now fabricated for manufacture of the MMCPE. 
 
4.3.3.4 Optimum potential profile of MMCPE 
 
Figure 4.3.3.4, demonstrates an optimum potential profile that was carried out on the 
MMCPE to determine the optimum working potential at which to apply to the electrodes. 
The main reason for this was to validate that the chosen potential was indeed the most 
correct one.  
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Figure 4.3.3.4: An optimum potential profile carried out on MMCPEs (n = 8), at a potential range of    
(-100 mV to -900 mV) in PBS (pH 7.4) using CPA.  
 
There was no significant difference between any of the potentials applied to the MMCPEs 
(P = 0.2818, one-way ANOVA). It was observed that the potentials -500 mV vs. SCE 
displayed a slightly higher sensitivity than the rest but as there was no significance between 
the results, it was decided to continue with -650 mV. This will allow for direct comparison 
to be made against the standard CPEs, Pt O2 sensors (Bolger et al., 2011a) and also other 
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O2 sensors currently utilised in our laboratory. To further confirm that the reduction 
potential had not shifted, cyclic voltammetry was carried out on the sensor design to 
examine this. 
 
4.3.3.5 CV of MMCPE 
 
-1.0 -0.8 -0.6 -0.4 -0.2 -0.0 0.2
-6000
-4000
-2000
0 N2
Air
O2
E, V
I,
 n
A
 
Figure 4.3.3.5: A CV from -1 to 0.2 V vs. SCE carried out on CMMPEs and performed in PBS (pH 7.4). 
 
The O2 wave details a reduction peak at ca. -0.4 V. The CPEs have been shown as having a 
reduction peak at ca. -0.6 V (Bolger et al., 2011a). This reveals that the rate constant for 
charge transfer is higher at the MMCPEs than at CPEs. It was decided that -650 mV vs. 
SCE was the chosen potential to implement as this is in the diffusion limited region and all 
O2 sensors employed in the lab apply this potential. 
 
4.3.3.6 Validation of the final MMCPE design  
 
The final MMCPE design involved placing the CPEs in MMA ON and then quickly 
packing a mixture of the monomer and carbon paste (20 µL and 0.025 g carbon paste) into 
the compartment of the electrode, subsequent to this, UV light was utilised to initiate 
polymerisation of the surface of the electrode for 30 minutes. The final method for the 
development of the MMCPEs was now elucidated and the resulting O2 calibrations detail 
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an increased sensitivity and produce a more reliable and reproducible electrode for the 
detection of O2.   
0 200 400 600 800 1000 1200
-4000
-3000
-2000
-1000
0
[O2], M
I,
 n
A
 
Figure 4.3.3.6: A current-concentration profile for O2 calibrations in PBS (pH 7.4) using MMCPEs (n = 
52), carried out at -650 mV vs. SCE. 
 
 MMCPE-UV (n = 52) 
[O2], M Mean I, nA SEM 
0.0 0.0 0.0 
240.0 -977.5 37.7 
1200.0 -4002.5 72.6 
 
Table 4.3.3.6: Table of results for an O2 calibration in PBS (pH 7.4) using MMCPE (n = 52), carried out 
at -650 mV vs. SCE. Background values subtracted. Mean background current = -10.21 ± 1.11 nA. 
 
 
The results obtained for the O2 calibrations on the MMCPEs exposed to UV light, n = 52, 
show a sensitivity that exceeds the sensitivity of O2 observed at a CPE. Figure 4.3.3.6 and 
table 4.3.3.6, display the data. A sensitivity of -3.3 ± 0.2 nA/ µM, n = 52, was recorded and 
a linear response was observed over the specified range (R
2
 = 0.99). The monomers Sty and 
MMA seem to be the reason for this increased affinity for O2.  
The fabrication of an oil free carbon based sensor is discussed in the next section, in order 
to determine if the manufacture of the monomer-modified carbon based sensor needed to 
include the oil, as used in CPEs.   
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4.3.4 Oil free carbon based electrodes  
 
4.3.4.1 Methyl methacrylate graphite powder electrode (MMGPE) 
 
The exclusion of the oil from the fabrication of the monomer modified sensors was 
undertaken after other groups had carried out research that involved graphite powder (GP) 
and the monomer MMA. These studies were necessary to carry out as, utilising the GP 
instead of the carbon paste would alleviate some of the production time for the manufacture 
of the monomer modified sensor. Dai et al., and Regal et al., utilised graphite/poly (MMA) 
composite electrodes for the electrochemical detection of vitamin C and dopamine, 
respectively (Dai et al., 2008; Regel & Lunte, 2013). In this thesis, the oil free carbon based 
electrode was made exactly in the same manner as the CPE, however, the carbon paste was 
replaced with GP leading to the results shown in Figure 4.3.4.1. A ratio of 60 %: 40 % was 
utilised for the MMA:GP composite, respectively (Dai et al., 2008). 
Varying techniques were employed to try and solidify the composite in the cavity i.e. 
thermal, air and UV methods. It was very difficult to pack the GP into the cavity of the 
electrode without the aid of the oil, as the GP was too dry, leading to the surface 
morphology being easily corrupted. Even with the techniques of heating, air drying and 
applying UV to the composite, the results obtained were not satisfactory. The ratio of the 
monomer was increased also to try and make the composite easier to pack but to no avail. 
Addition of the MMA monomer to the GP and various other methods employed to solidify 
the components in the cavity of the electrode, are displayed in Figure 4.3.4.1. 
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Figure 4.3.4.1: A bar chart for O2 calibrations in PBS (pH 7.4) using an oil free carbon based monomer 
electrode, carried out at -650 mV vs. SCE. 
 
Following the results shown in Figure 4.3.4.1, developing an oil free carbon based 
electrode was not as successful as the results attained for the MMCPEs and SMCPEs. 
Significant differences pre- and post-treatment with Triton
®
 X were obtained for 
MMA:GP-UV electrodes (shown in red) (P = 0.0401, paired t-test), MMA:GP-Air 
electrodes (shown in green) (P = 0.0486, paired t-test) and MMA:GP-Air electrodes 
(shown in purple) (P = 0.0239, paired t-test). The best result from the graphite-monomer 
electrode was a sensitivity (shown in black) of -2.3 ± 0.2 pre-treatment and -2.2 ± 0.2 post-
treatment with Triton
®
 X. The response of the electrodes was linear over the specified 
range with an R
2
 value of 0.99 pre-treatment and 0.99 post-treatment with Triton
®
 X. The 
results were not significantly different pre- and post-treatment (P = 0.7497, paired t-test).   
 
4.3.4.2 Styrene graphite powder electrode (SMGPE) 
 
The same procedure was carried out for SMGPEs as was described in the previous section 
for MMCPEs. Replacing the carbon paste with GP and then incorporating the Sty 
monomer, proved to be difficult, as the graphite was too dry without the oil for packing into 
the cavity of the electrode. Following the addition of the Sty monomer to the GP, the 
electrodes were placed in an oven at 70 
º
C for thirty minutes. This was the optimum result 
achieved by the MMGPE and therefore was utilised as the method of development for the 
SMGPE. The results obtained for the SMGPEs are displayed in Figure 4.3.4.2.  
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Figure 4.3.4.2: A current-concentration profile for O2 calibrations in PBS (pH 7.4) using SMGPEs 
baked at 70 
º
C for 30 minutes (n = 4) pre (black) and post (red) treatment with Triton
®
 X (10%) ON, 
carried out at -650 mV vs. SCE. 
 
Following the results shown in Figure 4.3.4.2, developing an oil free carbon based 
electrode was not as successful as the results attained for the MMCPEs and SMCPEs. The 
best result from the SMGPE gave a sensitivity of -2.0 ± 0.2 pre-treatment (black) and -1.8 ± 
0.1 post-treatment (red) with Triton
®
 X (10%) ON. The response of the electrodes was 
linear over the specified range with an R
2
 value of 0.99 pre-treatment and 0.99 post-
treatment with Triton
®
 X ON. The results were not significantly different pre- and post-
treatment (P = 0.1120, paired t-test).   
 
4.3.5 Biocompatibility studies  
 
After the successful development of the novel monomer CPEs, experiments were 
undertaken to determine the effect that proteins, lipids and brain tissue would have on these 
new electrodes. O2 calibrations pre- and post-treatment were initially carried out utilising 
the SMCPEs.  
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4.3.5.1 SMCPE-BSA (ON) 
 
  SMCPE (n = 8) SMCPE-BSA (10%) (n = 8) 
[O2], M  Mean I, nA SEM Mean I, nA  SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -1153.4 79.5 -1296.1 47.9 
1200.0 -3595.7 177.8 -3413.2 120.9 
 
Table 4.3.5.1: Table of results for O2 calibrations in PBS (pH 7.4) using SMCPEs (n = 8) pre- and post-
treatment with BSA (10%) carried out at -650 mV vs. SCE. Background values subtracted. Mean 
background current (SMCPE) = -177.1 ± 58.3 nA and (SMCPE-BSA (10%)-ON) = -65.9 ± 17.2 nA. 
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Figure 4.3.5.1: A current-concentration profile for O2 calibrations in PBS (pH 7.4) using SMCPEs (n = 
8) pre (black) and post (red) treatment with BSA (10%) ON, carried out at -650 mV vs. SCE. 
 
 
The results obtained for the O2 calibrations using the SMCPEs pre- and post-treatment with 
BSA (10%) ON, yielded sensitivities of –2.8 ± 0.4 nA/ µM, n = 8 and -2.7 ± 0.5 nA/ µM, n 
= 8, respectively. The response of the electrodes decreased in linearity over the specified 
range with an R
2
 value of 0.98 (pre-treatment) and 0.96 (post-treatment). The results pre- 
and post-treatment were not significantly different (P = 0.9932, paired t-test). When using 
BSA (10%) against standard CPEs it is observed that the harsh concentration alters the 
morphology of the sensor and blocks the active surface on the CPEs, thus decreasing the 
sensitivity recorded. With these novel sensors, the BSA does not seem to hamper the ability 
of the sensor to detect O2. 
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4.3.5.2 SMCPE-PEA (ON) 
 
 SMCPE (n = 8) SMCPE- PEA (10%) ON (n = 8) 
[O2], µM Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -1019.4 69.5 -996.2 55.9 
1200.0 -3256.6 68.9 -3402.2 94.2 
 
Table 4.3.5.2: Table of results for O2 calibrations in PBS (pH 7.4) using SMCPEs (n = 8) pre- and post- 
treatment with PEA (10%), carried out at -650 mV vs. SCE. Background values subtracted. Mean 
background current (SMCPEs) = -180. 6 ± 11.9 nA and (SMCPE PEA (10%) ON) = -321.2 ± 25.1 nA. 
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Figure 4.3.5.2: A current-concentration profile for O2 calibrations in PBS (pH 7.4) using SMCPEs pre 
(black) and post (red) treatment with PEA (10%), carried out at -650 mV vs. SCE. 
 
 
Figure 4.3.5.2 and Table 4.3.5.2 display data obtained for the O2 calibration pre- and post-
treatment with PEA (10%) using SMCPEs. Sensitivities of –2.6 ± 0.3 nA/ µM, n = 8 and -
2.7 ± 0.3 nA/ µM, n = 8 pre- and post-treatment were recorded. A linear response over the 
specified range pre and post was attained (R
2
 = 0.98) and (R
2
 = 0.99) respectively. It is 
clear that the results show no significant difference (P = 0.1792, paired t-test). This 
confirms that the sensor can withstand the treatment of PEA (10%) unlike the results 
observed for the CPEs.  
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4.3.5.3 SMCPE-BT (ON)  
 
 SMCPE (n = 6) SMCPE-BT-ON (n = 6) 
[O2], µM Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -843.7 95.8 -1077.1 69.2 
1200.0 -3828.9 278.5 -3516.1 228.7 
 
Table 4.3.5.3: Table of results for O2 calibrations in PBS (pH 7.4) using SMCPEs (n = 6) pre- and post-
treatment with BT ON, carried out at -650 mV vs. SCE. Background values subtracted. Mean 
background current (SMCPEs) = -94.0 ± 22.6 nA and (SMCPE-BT-ON) = -44.0 ± 16.4 nA. 
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Figure 4.3.5.3: A current-concentration profile for O2 calibrations in PBS (pH 7.4) using SMCPEs pre 
(black) and post (red) treatment with BT (ON), carried out at -650 mV vs. SCE. 
 
 
BT encompasses all of the fouling and interfering agents that could prevent the sensor from 
working at its optimum capability and therefore is utilised as a necessary treatment to 
determine the behaviour of the electrode in the presence of these agents. O2 calibrations 
using SMCPEs pre- (black) and post-treatment (red) in BT ON yielded a sensitivity of –3.2 
± 0.1 nA/ µM, n = 6 (pre-treatment) and -2.8 ± 0.3 nA/ µM, n = 6 (post-treatment). The 
response of the electrodes was linear over the specified range with an R
2
 value of 0.99 (pre-
treatment) and 0.99 (post-treatment). The results pre- and post-treatment were not 
significantly different (P = 0.1687, paired t-test). These results show promise that this 
sensor will not be affected by the harsh environment of the brain. 
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4.3.5.4 SMCPE-BT (3 days) 
 
 SMCPEs (n = 7) SMCPE-BT (3 days) (n = 7) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -933.7 84.2 -836.5 45.0 
1200.0 -3347.6 111.3 -2887.9 209.9 
 
Table 4.3.5.4: Table of results for O2 calibrations in PBS (pH 7.4) with SMCPEs (n = 7) pre- and post-
treatment with BT (3 days), carried out at -650 mV vs. SCE. Background values subtracted. Mean 
background currents (SMCPEs) = -14.1 ± 5.5 nA and (SMCPE-BT (3 days)) = -17.3 ± 2.4 nA. 
 
0 200 400 600 800 1000 1200
-3000
-2000
-1000
0
[O2], M
I,
 n
A
 
Figure 4.3.5.4: A current-concentration profile for O2 calibrations in PBS (pH 7.4) with SMCPEs pre- 
(black) and post- (red) treatment with BT (3 days), carried out at -650 mV vs. SCE. 
 
Leaving the sensors in BT for three days recorded more of an effect pre and post in 
comparison to the ON results. This is probably due to the BT constituents having more time 
to block the active surface resulting in a slight decrease in sensitivity. Pre- and post-
treatment in BT (3 days) displayed sensitivities of –2.7 ± 0.2 nA/ µM, n = 7 and -2.3 ± 0.2 
nA/ µM, n = 7, respectively, with no significant difference (P = 0.0759, paired t-test) 
observed. The response of the electrodes was linear over the specified range with an R
2
 
value of 0.99 (pre-treatment) and 0.99 (post-treatment). 
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4.3.5.5 SMCPE-BT (28 days) 
 
 SMCPEs (n = 4) SMCPE-BT (28 days) (n = 4) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -1129.2 97.5 -689.6 19.8 
1200.0 -4295.3 116.4 -3810.5 336.0 
 
Table 4.3.5.5: Table of results for O2 calibrations in PBS (pH 7.4) with MMCPEs (n = 4) pre- and post-
treatment with BT (28 days), carried out at -650 mV vs. SCE. Background values subtracted. Mean 
background current (MMCPEs) = -5.8 ± 0.4 nA and (MMCPE-BT (28 days)) = - 4.9 ± 0.5 nA. 
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Figure 4.3.5.5: A current-concentration profile for O2 calibrations in PBS (pH 7.4) with SMCPEs pre- 
(black) and post- (red) treatment with BT (28 days), carried out at -650 mV vs. SCE. 
 
 
The results obtained for O2 calibrations using the SMCPEs pre- and post-treatment with BT 
over 28 days yielded sensitivities of -3.5 ± 0.2 nA/ µM, n = 4 and -3.2 ± 0.1 nA/ µM, n = 4, 
respectively. A linear response was obtained pre- and post-treatment with BT (28 days) (R
2
 
= 0.99). A slight decrease in sensitivity was observed post-treatment, however, this yielded 
no significant difference (P = 0.5282, paired t-test) pre- and post-treatment over the 28 
days. This result was excellent in comparison to the CPE sensitivity following 28 days in 
BT. Not only did the sensor stay fully intact and unmodified over the course of 28 days, it 
retained a similar sensitivity to the pre treated sensor.  
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4.3.5.6 MMCPE-BSA (ON) 
 
 MMCPEs (n = 6) MMCPEs-BSA (10%) (n = 6) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -940.7 49.1 -1037.9 83.9 
1200.0 -4116.3 218.6 -3542.2 317.9 
 
Table 4.3.5.6: Table of results for O2 calibrations in PBS (pH 7.4) with MMCPEs (n = 6) pre- and post-
treatment with BSA (10%), carried out at -650 mV vs. SCE. Background values subtracted. Mean 
background current (MMCPE) = -18.3 ± 10.9 nA and (MMCPE-BSA (10%) ON) = -26.4 ± 10.4 nA. 
 
0 200 400 600 800 1000 1200
-4000
-3000
-2000
-1000
0
[O2], M
I,
 n
A
 
Figure 4.3.5.6: A current-concentration profile for O2 calibrations in PBS (pH 7.4) with MMCPEs pre- 
(black) and post- (red) treatment with BSA (10%) ON, carried out at -650 mV vs. SCE. 
 
 
There was no significant difference (P = 0.0611, paired t-test) recorded pre and post BSA 
(10%) with the MMCPEs. Sensitivities of –3.4 ± 0.1 nA/ µM, n = 6 (pre-treatment) and -
2.9 ± 0.3 nA/ µM, n = 6 (post-treatment) were obtained. The response of the electrodes was 
linear over the specified range with an R
2
 value of 0.99 (pre-treatment) and 0.99 (post-
treatment). BSA (10%) treatment carried out on the MMCPEs showed a slight effect on the 
sensors, revealing a good capability of the sensor to retain integrity under this harsh 
concentration of fouling agent. 
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4.3.5.7 MMCPE-PEA (ON) 
 
 MMCPE (n = 4) MMCPE-PEA (10%) (n = 4) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -1116.9 98.3 -1139.1 77.7 
1200.0 -3917.7 102.4 -3364.6 159.9 
 
Table 4.3.5.7: Table of results for O2 calibrations in PBS (pH 7.4) using MMCPEs (n = 4) pre- and post-
treatment with PEA (10%), carried out at -650 mV vs. SCE. Background values subtracted. Mean 
background current (MMCPEs) = -179.6 ± 19.8 nA and (MMCPE-PEA (10%) ON) = -367.0 ± 21.0 nA.  
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Figure 4.3.5.7: A current-concentration profile for O2 calibrations in PBS (pH 7.4) with MMCPEs pre- 
(black) and post- (red) treatment with PEA (10%) ON, carried out at -650 mV vs. SCE. 
 
 
Figure 4.3.5.7 and Table 4.3.5.7 display results attained for O2 calibrations using the 
MMCPEs pre- and post-treatment in PEA (10%) ON. Sensitivities of –3.2 ± 0.3 nA/ µM, n 
= 4 and -2.7 ± 0.4 nA/ µM, n = 4 pre- and post-treatment, respectively, were recorded. The 
response of the electrodes was linear over the specified range with an R
2
 value of 0.99 (pre-
treatment) and 0.98 (post-treatment). Although there is a slight decrease in the sensitivity 
post treatment, the results were not significantly different (P = 0.0506, paired t-test). PEA 
(10%) may be causing a slight barrier at the surface as has been previously observed, thus 
leading to a decrease in the response.  
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4.3.5.8 MMCPE-BT (ON) 
 
 MMCPE (n = 7) MMCPE-BT (ON) (n = 7) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -945.7 137.7 -921.3 41.9 
1200.0 -3764.9 258.7 -3340.2 149.3 
 
Table 4.3.5.8: Table of results for O2 calibrations in PBS (pH 7.4) with MMCPEs (n = 7) pre- and post-
treatment with BT (ON), carried out at -650 mV vs. SCE. Background values subtracted. Mean 
background current (MMCPE) = -12.4 ± 2.9 nA and (MMCPE-BT (ON)) = -16.9 ± 10.2 nA. 
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Figure 4.3.5.8: A current-concentration profile for O2 calibrations in PBS (pH 7.4) with MMCPEs pre- 
(black) and post- (red) treatment with BT (ON), carried out at -650 mV vs. SCE. 
 
 
O2 calibrations on MMCPEs pre- and post-treatment in BT ON, displayed sensitivities of –
3.1 ± 0.2 nA/ µM, n = 7 (pre-treatment) and -2.7 ± 0.2 nA/ µM, n = 7 (post-treatment). A 
linear response over the specified range was obtained yielding an R
2
 value of 0.99 (pre-
treatment) and 0.99 (post-treatment). The results pre- and post-treatment were not 
significantly different (P = 0.0544, paired t-test). BT ON did not seem to cause any 
considerable effect to the sensor, presenting an optimistic outlook for how this sensor will 
perform in-vivo.  
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4.3.5.9 MMCPE-BT (3 days) 
 
 MMCPEs (n = 8) MMCPE-BT (3 days) (n = 8) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -952.2 52.9 -1013.5 49.5 
1200.0 -4019.9 27.9 -2926.9 144.8 
 
Table 4.3.5.9: Table of results for O2 calibrations in PBS (pH 7.4) with MMCPEs (n = 8) pre- and post-
treatment with BT (3 days), carried out at -650 mV vs. SCE. Background values subtracted. Mean 
background current (MMCPEs) = -64.7 ± 18.1 nA and (MMCPE-BT (3 days)) = -78.0 ± 7.8 nA. 
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Figure 4.3.5.9: A current-concentration profile for O2 calibrations in PBS (pH 7.4) with MMCPEs pre 
(black) and post (red) treatment with BT (3 days), carried out at -650 mV vs. SCE. 
 
 
The results obtained for the O2 calibrations using the MMCPEs pre- and post-treatment in 
BT (3 days), yielded sensitivities of –3.3 ± 0.1 nA/ µM, n = 8 (pre-treatment) and -2.3 ± 0.4 
nA/ µM, n = 8 (post-treatment).The response of the electrodes was linear over the specified 
range with an R
2
 value of 0.99 (pre-treatment) and 0.97 (post-treatment). The decrease in 
sensitivity resulting in a significant difference (P < 0.0001, paired t-test) could be due to the 
BT components having more time to adsorb to the surface causing an obstruction of the 
sensor face therefore decreasing the response of the electrode to O2. 
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4.3.5.10 MMCPE-BT (28 days) 
 
 MMCPEs (n = 4) MMCPE-BT (28 days) (n = 4) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -1081.0 72.8 -837.9 130.7 
1200.0 -4433.7 223.4 -3251.1 210.1 
 
Table 4.3.5.10: Table of results for O2 calibrations in PBS (pH 7.4) with MMCPEs (n = 4) pre- and 
post-treatment with BT (28 days), carried out at -650 mV vs. SCE. Background values subtracted. 
Mean background currents (MMCPEs) = -3.6 ± 0.3 nA and (MMCPE-BT (28 days)) = -10.2 ± 2.7 nA. 
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Figure 4.3.5.10: A current-concentration profile for O2 calibrations in PBS (pH 7.4) with MMCPEs 
pre- (black) and post- (red) treatment with BT (28 days), carried out at -650 mV vs. SCE. 
 
 
Figure 4.3.5.10 and Table 4.3.5.10 display data obtained for the O2 calibration pre- and 
post-treatment with BT (28 days) using MMCPEs. Sensitivities of – 3.6 ± 0.2 nA/ µM, n = 
4 and – 2.6 ± 0.2 nA/ µM, n = 4, pre- and post-treatment were recorded. A linear response 
over the specified range pre and post was attained (R
2
 = 0.99) and (R
2
 = 0.99), respectively. 
The results were significantly different (P = 0.0296, paired t-test). Even though there was a 
decrease in sensitivity observed for the MMCPEs, a greater sensitivity was achieved in 
comparison to the CPEs post treatment with BT after 28 days. On inspection of the 
MMCPEs under the microscope, a flat surface remained after removal from the BT, 
demonstrating that they had not been morphologically altered. It is clear that the standard 
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CPEs are altered from contact with any elements encountered in the in-vivo environment 
which has been demonstrated by other groups previously (Ormonde & O'Neill, 1989, 1990; 
A. Kane & D. O'Neill, 1998). It appears from the biocompatibility studies that both sensor 
types show marked improvements in comparison to the conventional sensor type, with the 
SMCPE displaying the most reproducible and stable sensor surface.    
 
4.3.6 Post In-Vivo Comparison 
 
In the previous sections, the effects of biological solutions, surfactants and ex-vivo brain 
tissue samples on the SMCPE and MMCPE were observed and the results showed a lot of 
promise. In this section an investigation into the effects of the implantation of the 
electrodes into the rat brain is examined and pre and post O2 calibrations are compared. 
These calibrations were carried out as described in Section 3.7.2.4.  
 
4.3.6.1 SMCPE Comparison 
 
The effect of the living brain on the SMCPEs was investigated. The results obtained pre-
and post-implantation (electrodes were implanted for an average of 15.2 ± 3.0 days in 5 
animals) are presented in Table 4.3.6.1 and plotted graphically in Figure 4.3.6.1 (a).  
 
 
 
 
 
 
 
Table 4.3.6.1: Comparison table of mean current values for O2 calibrations with SMCPEs (n = 8) in 
PBS (pH 7.4) pre- and post-implantation, carried out at -650 mV vs. SCE. Background values 
subtracted. Mean background currents (SMCPE pre-implantation) = -17.5 ± 6.0 nA and (SMCPE post-
implantation) = -39.2 ± 16.2 nA. 
 
 SMCPE (pre-implantation)  
(n = 8: 5 animals) 
SMCPE (post-implantation)  
(n = 8: 5 animals) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -982.3 79.8 -487.6 32.8 
1200.0 -4048.2 299.5 -2170.1 125.8 
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Figure 4.3.6.1 (a): A mean current-concentration profile for O2 calibrations in PBS (pH 7.4) performed 
with SMCPEs, (n = 8: 5 animals), pre- (black) and post- (red) implantation, carried out at -650 mV. 
 
 
It is observed from the comparison of the calibration slopes (nA/ µM), -3.3 ± 0.1 nA/ µM 
for pre-implantation and -1.8 ± 0.1 nA/ µM for post-implantation, that the sensitivity of the 
SMCPEs decreased significantly following implantation (P = 0.0016, paired t-test). The 
response of the electrodes was linear over the specified range with an R
2
 value of 0.99, n = 
8, pre-implantation and 0.99, n = 8, post-implantation. Implantation of the sensor into the 
living brain causes a dramatic change in the sensitivity post implantation. This could be due 
to the harsh environment that is the brain; however, it could also be the effect of removal of 
the electrodes from the headpiece of the animal which may cause significant damage to the 
sensor. It is very difficult to perform a post in-vivo calibration due to these effects and also 
physiological effects such as gliosis. A comparison of the raw data from a typical O2 
calibration performed pre- and post-implantation is shown in Figure 4.3.6.1 (b). 
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Figure 4.3.6.1 (b): A comparison of the raw data from a typical O2 calibration performed on SMCPEs 
pre- and post-implantation in PBS (pH 7.4), carried out at -650 mV vs. SCE. 
 
 
 
Figure 4.3.6.1 (c): An SEM displaying the surface of a SMCPE pre-implantation. 
 
 
Figure 4.3.6.1 (c) displays an SEM of a pre-implanted SMCPE. This SEM can be used as a 
comparison when observing the SEMs in Figure 4.3.6.1 (d). Figure 4.3.6.1 (d) displays the 
SMCPEs post-implantation and it is clear that the surface remains flat when comparing the 
SEMs pre- and post-implantation. 
 
 
 
 
 
 
 
 
 
350 µm
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Figure 4.3.6.1 (d): (A), (B), (C) and (D); SEMs displaying the surface of different SMCPEs post-
implantation.  
 
 
The main aim for the implementation of the monomers into the manufacture of CPEs was 
to obtain a composite that was capable of withstanding morphological changes due to the 
in-vivo environment. The CPE surface is easily corrupted and therefore alters significantly 
by changing from a CPE to a carbon powder electrode. Although this is a positive attribute 
to have in a sensor as it provides the ability to record for long periods of time, by the 
removal of the poisons and fouling constituents from the sensor surface, it is not a great 
characteristic to have in a sensor for use in a clinical setting. On analysis of the SEMs 
pictured in Figure 4.3.6.1 (d), the surfaces remain fully intact after contact with the in-vivo 
environment. These results were outstanding, as the surfaces were clearly very capable of 
enduring a very complex and intricate environment. Some of the sensors contained a build 
250 µm 250 µm
250 µm 250 µm
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up of components from the brain environment on the surface of the sensor that had 
adsorbed, which can be seen very clearly in Figure 4.3.6.1 (d), image B. This observation 
could also be attributable to the decrease in sensitivity recorded in results from post-
implantation calibrations.  
 
4.3.6.2 MMCPE Comparison 
 
The effect of the living brain on the MMCPEs was investigated. The results obtained pre- 
and post-implantation (electrodes were implanted for 14.8 ± 1.4 days) are shown in Figure 
4.3.6.2 (a). 
 
 MMCPE (pre-implantation)  
(n = 8: 5 animals) 
MMCPE (post-implantation)  
(n = 8: 5 animals) 
[O2], M Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 
240.0 -906.3 96.5 -608.2 70.5 
1200.0 -4075.1 444.6 -2547.5 90.5 
 
Table 4.3.6.2: Comparison table of mean current values for O2 calibrations with MMCPEs (n = 8: 5 
animals) in PBS (pH 7.4) pre- and post-implantation, carried out at -650 mV vs. SCE. Background 
values subtracted. Mean background current (MMCPE pre-implantation) = -7. 5 ± 1.7 nA and 
(MMCPE post implantation) = -69.9 ± 51.7 nA.  
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Figure 4.3.6.2 (a): A mean current-concentration profile for O2 calibrations in PBS (pH 7.4) performed 
with MMCPEs, (n = 8), pre- (black) and post- (red) implantation, carried out at -650 mV. 
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It is observed from the comparison of the slopes (nA/ µM) of the electrodes, -3.4 ± 0.1 nA/ 
µM for pre-implantation and -2.1 ± 0.1 nA/ µM for post-implantation, that the sensitivity of 
the MMCPEs decreased significantly following implantation (P = 0.0073, paired t-test). 
The response of the electrodes was linear over the specified range with an R
2
 value of 0.99, 
n = 8, pre-implantation and 0.99, n = 8, post-implantation. As the sensor remained intact 
and not morphologically altered (see Figure 4.3.6.2 (d)) from the brain environment, a 
decrease in sensitivity could be attributable to a built up of constituents from the brain on 
the surface of the electrode. This decrease in sensitivity has been previously observed in the 
lab with other sensors like Pt sensors where the decrease was attributed to a build up of 
species on the surface.  
On examination of the in-vivo stability traces observed in Section 5.3.7.1 and 5.3.7.2, for 
the MMCPEs and SMCPEs respectively, a decrease of approximately 15.5 % (MMCPEs) 
and 14.4 % (SMCPEs) can be observed after day 1, respectively. After day 1 a stable 
current is obtained.  Even though the MMCPEs and SMCPEs display a decreased post 
implantation sensitivity, this sensitivity observed for the two sensor designs is higher than 
what is obtained for a standard pre-implanted CPE, even after being implanted for 
approximately 15 days in-vivo. These results really confirm the solid structural integrity of 
these novel O2 sensors. A comparison of the raw data from a typical O2 calibration 
performed pre- and post-implantation is shown in Figure 4.3.6.2 (b).  
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Figure 4.3.6.2 (b): A comparison of the raw data from a typical O2 calibration performed with 
MMCPEs pre- and post-implantation in PBS (pH 7.4), carried out at -650 mV vs. SCE.  
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Figure 4.3.6.2 (c): An SEM displaying the surface of a MMCPE pre-implantation. 
 
Figure 4.3.6.2 (c) displays an SEM of a pre-implanted MMCPE. This SEM can be used as a 
comparison when observing the SEMs in Figure 4.3.6.2 (d). Figure 4.3.6.2 (d) displays the 
MMCPEs post-implantation and it is clear that the surface remains flat when comparing the 
SEMs pre- and post-implantation. 
 
 
 
       
 
 
 
 
 
 
 
   
 
 
 
 
 
 
Figure 4.3.6.2 (d): (A), (B), (C) and (D); SEMs displaying the surface of different MMCPEs post 
implantation.  
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Inspection of the surface of the electrodes with SEM, confirmed that the surfaces are 
withstanding the in-vivo environment by retaining integrity and a flat uniform surface. 
Figure 4.3.6.2 (d), image B, shows a covering of constituents of the in-vivo environment on 
the surface of the sensor which may be giving a reason to speculate that the decrease 
observed in the sensitivity post implantation is due to this. On examination of the results 
obtained in this section, it can be seen that there is an effect on the electrodes after being 
implanted in the brain for 14.8 ± 1.4 days (MMCPEs, n =8) and 15.2 ± 3.0 days (SMCPEs, 
n = 8).  
There is a decrease in sensitivity for both the SMCPEs and the MMCPEs, pre- and post-
implantation. The SEMs displayed in Figure 4.3.6.1 (d) and Figure 4.3.6.2 (d) show that the 
surface of the electrodes has remained intact after implantation and on removal from the 
animal. The SEMs also show that constituents of the brain have adsorbed onto the surface 
of the electrodes and it is this that is most likely causing the decrease in sensitivity.  
 
4.3.7 Long term stability studies  
 
4.3.7.1 Stored at Room temperature (RT) 
 
It is well-known that the main advantage of CPEs, is their ability to sustain in-vivo stability 
over long periods of time, by altering surface morphology from a carbon paste to a carbon 
powder electrode in the presence of lipids (Ormonde & O'Neill, 1989). Long term stability 
studies were carried out on the SMCPEs and MMCPEs to compare their stability against 
standard CPEs. It was necessary for the sensors to retain stability over a specified time 
frame but to also hold surface integrity unlike the CPEs. The long term stability studies are 
vital to undertake. This is because in a clinical setting the optimum storage condition details 
would need to be known, as the sensors would not be used straight away. O2 calibrations 
were performed on the SMCPEs and MMCPEs over the course of 28 days which are 
detailed in Figure 4.3.7.1.1 and 4.3.7.1.2. They were stored at RT and intermittently tested 
over the specified days.    
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Figure 4.3.7.1.1: A bar chart for O2 calibrations in PBS (pH 7.4) with SMCPEs (n = 5) over the course 
of 28 days, carried out at -650 mV vs. SCE. 
 
 
The results obtained for the O2 calibrations using the SMCPEs over 28 days (see Table 
4.3.7.1.1), displayed excellent stability and yielded no significant difference over the course 
of the 28 days. Table 4.3.7.1.1 displays the P values obtained from day 1 to day 28. Paired 
t-tests were carried out, in order to determine if the stability of the sensors was 
compromised over time. 
 
Day P value Significance 
1 vs. 4 0.2091 ns 
1 vs. 7 0.9151 ns 
1 vs. 14 0.6443 ns 
1 vs. 21 0.2422 ns 
1 vs. 28 0.1242 ns 
 
Table 4.3.7.1.1: A summary displaying the P values obtained for the SMCPEs over 28 days at RT. 
 
The response of the electrodes was linear over the specified range with an R
2
 value of 0.99 
(day 1-28). These results signify the stability of the sensors over the 28 days of calibrations 
in-vitro, with day 28 yielding a P value that was not significantly different (P = 0.1242) in 
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comparison to day 1, demonstrating results that confirm the sensor stability over the course 
of a month. Repeated calibrations caused significant damage to the Pt based sensors 
discussed in Chapter 6, Section 6.3.8.1 and 6.3.8.2, whereas if they were only calibrated on 
a once off basis, a more stable result was obtained with no detrimental effect to the sensors. 
These results again demonstrate a more robust characteristic to the monomer modified 
sensors and show, that repetitive calibrations do not compromise the sensitivity and 
stability of the sensors.     
 
4.3.7.1.2 MMCPEs 
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Figure 4.3.7.1.2: A bar chart for O2 calibrations in PBS (pH 7.4) with MMCPEs (n = 4) over the course 
of 28 days, carried out at -650 mV vs. SCE. 
 
 
In Figure 4.3.7.1.2, O2 calibrations using the MMCPEs over 28 days are displayed. On 
analysis of the results, no significant difference was recorded over the 28 days of 
calibrations which is displayed in Table 4.3.7.1.2 figuratively. Paired t-tests were carried 
out, in order to determine if the stability of the sensors was compromised over time. 
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Day P value Significance 
1 vs. 4 0.0862 ns 
1 vs. 7 0.3034 ns 
1 vs. 14 0.4912 ns 
1 vs. 21 0.3377 ns 
1 vs. 28 0.1747 ns 
 
Table 4.3.7.1.2: A summary displaying the P values obtained for the MMCPEs over 28 days at RT 
 
A linear response of the electrodes over the specified range yielded R
2
 values of 0.99 (day 
1-28). The MMCPEs demonstrate an ability to remain stable in-vitro over time, like the 
SMCPEs. Although a similar trend of a decreasing sensitivity was observed over time with 
both sensors, the MMCPEs at day 28 did not show a significantly different sensitivity in 
comparison to day 1, just like the SMCPEs.  This maybe suggests that unlike the Pt based 
sensors discussed in Chapter 6, Section 6.3.8.1 and 6.3.8.2, there doesn‘t appear to be any 
effect of repeated calibration on the sensors which is representative of the different 
transducer substrates.  Subsequent to these results, long term stability studies were carried 
out utilising differing storage conditions. 
 
4.3.7.2 Stored in the fridge (4 
º
C) 
 
The results for the SMCPE and MMCPE stored in the fridge are displayed in Figure 
4.3.7.2.1 and Figure 4.3.7.2.2.   
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Figure 4.3.7.2.1: A bar chart for O2 calibrations in PBS (pH 7.4) with SMCPEs, n = 4, over the course 
of 21 days that were kept in the fridge and intermittently tested and carried out at -650 mV vs. SCE. 
 
Day P value Significance 
1 vs. 4 0.0553 ns 
1 vs. 7 0.3044 ns 
1 vs. 14 0.0830 ns 
1 vs. 21 0.1062 ns 
 
Table 4.3.7.2.1: A summary displaying the P values obtained for the SMCPEs over 21 days in the 
fridge. 
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4.3.7.2.2 MMCPEs 
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Figure 4.3.7.2.2: A bar chart for O2 calibrations in PBS (pH 7.4) with MMCPEs, n = 4, over the course 
of 21 days that were kept in the fridge and intermittently tested and carried out at -650 mV vs. SCE. 
 
 
Day P value Significance 
1 vs. 4 0.0392 * 
1 vs. 7 0.0576 ns 
1 vs. 14 0.5866 ns 
1 vs. 21 0.1166 ns 
 
Table 4.3.7.2.2: A summary displaying the P values obtained for the MMCPEs over 21 days in the 
fridge. 
 
The O2 calibrations undertaken with the SMCPEs displayed sensitivities that were not 
significantly different over the course of the particular days. Table 4.3.7.2.2 displays these 
results. The MMCPEs displayed a significantly different increased sensitivity to day 4; 
however, the following days were not significantly different.  For the SMCPEs, a linear 
response over the specified range was observed for Day 1 (R
2
 = 1.00), Day 4 (R
2
 = 0.99), 
Day 7 (R
2
 = 0.99), Day 14 (R
2
 = 1.00) and Day 21 (R
2
 = 0.99). For the MMCPEs a linear 
response was also obtained, Day 1 (R
2
 = 1.00), Day 4 (R
2
 = 0.99), Day 7 (R
2
 = 0.98), Day 
14 (R
2
 = 1.00) and Day 21 (R
2
 = 0.99). The SMCPEs and MMCPEs display varying 
sensitivities that look unstable over the course of the 21 days; this could be due to the drop 
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in temperature, altering the morphology of the sensors or it could be most likely due to an 
effect of repetitive calibrations.  
 
4.3.7.3 Stored in the freezer (-20 
º
C) 
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Figure 4.3.7.3.1: A bar chart for O2 calibrations in PBS (pH 7.4) using SMCPEs over the course of 21 
days that were kept in the freezer and intermittently tested and carried out at -650 mV vs. SCE. 
 
 
Day P value Significance 
1 vs. 4 0.0074 ** 
1 vs. 7 0.0085 ** 
1 vs. 14 0.0090 ** 
1 vs. 21 0.0186 * 
 
Table 4.3.7.3.1: A summary displaying the P values obtained for the SMCPEs over 21 days in the 
freezer. 
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4.3.7.3.2 MMCPEs 
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Figure 4.3.7.3.2: A bar chart for O2 calibrations in PBS (pH 7.4) using MMCPEs over the course of 21 
days that were kept in the freezer and intermittently tested and carried out at -650 mV vs. SCE. 
 
 
Day P value Significance 
1 vs. 4 0.7494 ns 
1 vs. 7 0.8141 ns 
1 vs. 14 0.4138 ns 
1 vs. 21 0.0880 ns 
 
Table 4.3.7.3.2: A summary displaying the P values obtained for the MMCPEs over 21 days in the 
freezer. 
 
Figure 4.3.7.3.1 and 4.3.7.3.2 display O2 calibrations using the SMCPEs and MMCPEs 
over 21 days. It is clear from the data that storing the sensors in the freezer causes a much 
greater drop in sensitivity in comparison to the results obtained at RT (see previous Section 
4.3.7.1) and the fridge (see previous 4 
°
C Section 4.3.7.2). The MMCPEs appear to remain 
stable over the course of the days studied with no significant difference observed over the 
specified days. This is depicted in Table 4.3.7.3.2. Storing the sensors in the fridge and 
freezer did not seem to show sensitivities that were as stable as RT studies for both sensors. 
It was decided that the optimum storage conditions would be at RT. 
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4.3.8 Interference studies 
 
Bolger et al., carried out O2 experiments on CPEs against a variety of potential interferents 
in order to fully characterise the sensor for use in-vivo (Bolger et al., 2011b). It was decided 
to carry out interference studies on the SMCPE and MMCPE utilising endogenous species 
that would be present in the brain and that would potentially cause impairment to the 
sensors ability to detect the analyte of choice by the electrode. A working potential of          
-650 mV vs. SCE was utilised. Figure 4.3.8 (a) and 4.3.8 (b) detail the results obtained.   
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Figure 4.3.8 (a): A bar chart displaying a calibration carried out at -650 mV vs. SCE, n = 4, utilising a 
SMCPE in PBS (pH 7.4). Different endogenous species at their physiological concentrations were 
injected into the electrochemical cell and the sensitivities of each detected by the SMCPE were 
analysed. 
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Figure 4.3.8 (b): A bar chart displaying a calibration carried out at -650 mV vs. SCE, n = 4, utilising a 
MMCPE in PBS (pH 7.4). Different endogenous species at their physiological concentrations were 
injected into the electrochemical cell and the sensitivities of each detected by the MMCPE were 
analysed. 
 
Bolger et al., found that although slightly positive changes occurred at the CPE by the 
interferents studied, they were deemed insignificant (Bolger et al., 2011b). The sensitivities 
obtained by each species for both the SMCPEs and the MMCPEs were also negligible in 
this body of work, in comparison to the O2 sensitivity detected at physiological 
concentrations.  
 
4.3.9 pH Calibrations  
 
The regulation of pH is very important in order for cells to function correctly. The increase 
or decrease of pH can compromise vital functions in the body (Chesler, 2003). In-vivo 
extracellular concentrations are constantly changing and can alter significantly with 
dramatic variation to normal physiology (Bolger et al., 2011a). pH experiments were 
therefore carried out on the sensors in order to verify that even with a change in the pH, the 
sensor would not be affected. Two pH values were utilised (pH 6.5 and pH 8.0), however, 
these are extreme values that can lead to apoptosis in-vivo, so these values were utilised as 
a means to determine the capabilities of the sensor under extreme conditions.  
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4.3.9.1  SMCPE Repeat Calibration Experiments 
 
Initially, the effect of repeated calibrations was determined for the SMCPE, as it was 
considered that carrying out repeated calibrations on the one set successively, may have a 
role in changing the sensitivity of the sensor each time. This could be due to the 
experimental set-up being changed for each calibration, therefore leading to more handling 
of the sensors and potential damage to the sensors. 
 
0 200 400 600 800 1000 1200
-6000
-4000
-2000
0
SMCPE (pH 7.4) 1st Cal
SMCPE (pH 7.4) 2nd Cal
SMCPE (pH 7.4) 3rd Cal
[O2], M
I,
 n
A
 
Figure 4.3.9.1 (a): A repeated O2 calibration undertaken with the SMCPEs, n = 4, at -650 mV vs. SCE 
in PBS (pH 7.4).  
 
Three consecutive O2 calibrations were carried out on the SMCPE; this was to determine 
the effect a repeated calibration would have on the electrodes in pH 7.4. Although there 
was not a significant difference between the sensitivities (P = 0.1150, one-way ANOVA), it 
is clear that the sensitivities did alter between each calibration. Sensitivities of -3.1 ± 0.3 
nA/ µM (black) for the initial calibration, -4.2 ± 0.1 nA/ µM (red) for the second and -2.8 ± 
0.3 nA/ µM (green) for the last calibration were obtained. The response of the electrodes 
was linear over the specified range, with an R
2
 value of 0.99 (1
st
 calibration), 1.00 (2
nd
 
calibration) and 0.99 (3
rd
 calibration). The pH concentrations were varied next, in order to 
determine whether a change in pH resulted in a markedly different sensitivity for each pH 
utilised.  
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Figure 4.3.9.1 (b): O2 calibrations undertaken with the SMCPEs, n = 4, at -650 mV vs. SCE in PBS (pH 
7.4, 6.5 and 8.0). 
 
No significant difference (P = 0.9903: one-way ANOVA) was observed for the three 
calibrations carried out in the different pH values. Sensitivities of -3.1 ± 0.3 nA/ µM 
(black) in pH 7.4, -2.7 ± 0.2 nA/ µM (red) in pH 6.5 and -2.9 ± 0.2 nA/ µM (green) in pH 
8.0 were obtained. The response of the electrodes was linear over the specified range, with 
an R
2
 value of 0.99 for each pH concentration. Succeeding the experiments carried out on 
the SMCPEs, experiments were undertaken on the MMCPEs in a similar manner. 
 
4.3.9.2  MMCPE Repeat Calibration Experiments 
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Figure 4.3.9.2 (a): A repeated O2 calibration carried out on MMCPEs, n = 4, at -650 mV vs. SCE in PBS 
(pH7.4). 
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Repeated O2 calibrations on the MMCPEs yielded sensitivities of -3.8 ± 0.1 nA/ µM 
(black) for the initial calibration, -4.2 ± 0.1 nA/ µM (red) for the second and -3.4 ± 0.3 nA/ 
µM (green) for the last calibration. The response of the electrodes was linear over the 
specified range, with an R
2
 value of 0.99 for all calibrations undertaken. No significant 
difference (P = 0.0821) was recorded for these calibrations suggesting that repeated 
experimental application was not a concern. The pH values were then altered and the 
results are depicted in Figure 4.3.9.2 (b). 
 
0 200 400 600 800 1000 1200
-5000
-4000
-3000
-2000
-1000
0
(pH 7.4)
(pH 6.5)
(pH 8.0)
[O2], M
I,
 n
A
 
Figure 4.3.9.2 (b): O2 calibrations carried out on MMCPEs, n = 4, at -650 mV vs. SCE in PBS (pH 7.4, 
6.5 and 8.0). 
 
In a similar manner to the results obtained with the SMCPEs, there was no significant 
difference between the sensitivities recorded (P = 0.9982) for the MMCPEs.  The results 
obtained for the O2 calibrations yielded sensitivities of -3.6 ± 0.2 nA/ µM (black) in pH 7.4, 
-3.4 ± 0.2 nA/ µM (red) and -3.7 ± 0.2 nA/ µM (green). The response of the electrodes was 
linear over the specified range, with an R
2
 value of 0.99 for each pH value. This result 
confirms that varying the pH will not affect the sensors ability to detect O2.  
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4.3.10  Temperature studies  
 
Metal based membrane covered O2 sensors have a predisposition of a significant 
temperature dependency (Bolger et al., 2011a). In order to determine that altering 
temperatures would not inhibit the workings of the electrode, the SMCPEs and MMCPEs 
were tested at 37 ºC. It was necessary to test the sensors against this temperature as it was 
the physiological temperature of the body and therefore it was necessary to confirm that a 
changing temperature had no effect on the sensors. These results are shown in Figures 
4.3.10.1 and 4.3.10.2 (a). A comparison of the two sensors is also displayed in Figure 
4.3.10.2 (b).  
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Figure 4.3.10.1: O2 calibrations performed at 25 
º
C (black) and 37 
º
C (red) utilising SMCPEs, n = 4, at -
650 mV vs. SCE in PBS (pH 7.4). 
 
In Figure 4.3.10.1 the O2 calibrations using the SMCPEs at 25 ºC and 37 ºC, recorded and 
depicted no difference pre and post altering temperature (P = 0.8934, paired t-test). 
Sensitivities of –2.9 ± 0.2 nA/ µM, n = 4, (black: 25 ºC) and -3.4 ± 0.3 nA/ µM, n = 4, (red: 
37 ºC) were obtained. The response of the electrodes was linear over the specified range 
with an R
2
 value of 0.99 (25 ºC) and 0.99 (37 
º
C). Increasing the temperature did not hinder 
the sensors ability to detect O2 and as a result, fluctuating temperatures that may be 
encountered in-vivo will have no effect on the O2 signal.  
 
  Chapter 4: In-Vitro Oxygen  
 
154  
 
4.3.10.2 MMCPEs 
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Figure 4.3.10.2 (a): O2 calibrations performed at 25 
º
C (black) and 37 
º
C (red) utilising MMCPEs, n = 4, 
at -650 mV vs. SCE in PBS (pH 7.4). 
 
The results obtained for the O2 calibrations using the MMCPEs at 25 ºC and 37 ºC, yielded 
sensitivities of –3.2 ± 0.1 nA/ µM, n = 4, (black: 25 ºC) and -3.7 ± 0.1 nA/ µM, n = 4, (red: 
37 ºC). The response of the electrodes was linear over the specified range with an R
2
 value 
of 1.00 (37 ºC) and 0.99 (25 ºC). No significant difference was observed for the two 
calibrations (P = 0.9415, paired t-test), confirming no dependence of sensitivity on 
increasing temperature. In Figure 4.3.10.2 (b), a comparison between the SMCPE and 
MMCPEs is shown. 
  
 
 
 
  Chapter 4: In-Vitro Oxygen  
 
155  
 
0 200 400 600 800 1000 1200
-5000
-4000
-3000
-2000
-1000
0
MMCPE (37 C)
MMCPE (25 C)
SMCPE (37 C)
SMCPE (25 C)
[O2], M
I,
 n
A
 
Figure 4.3.10.2 (b): An O2 calibration comparison of MMCPEs and SMCPEs performed at 25 
º
C and 
37 
º
C, n = 4, at -650 mV vs. SCE in PBS (pH 7.4). 
 
The SMCPE and the MMCPE demonstrate no significant difference in the detection of O2 
with an increase in temperature (P = 0.9988, one-way ANOVA).  
4.4 Conclusion 
 
The results presented in this chapter are very promising for possible utilisation of the novel 
monomer modified CPEs in a clinical environment. An intact and solid SMCPE and 
MMCPE were obtained. A sensor that provided the ability to withstand morphological 
alterations in a very complex and hazardous environment was the aim and ambition sought 
when carrying out this research. The results suggested that this aim was accomplished. 
Initial experiments undertaken on the biocompatibility of the CPE displayed a complete 
breakdown of the morphology of the sensors integrity. A significant decrease in sensitivity 
was observed in both BSA (P = 0.0258) and PEA (P < 0.0001) studies. On examination of 
the results recorded for BT and Triton
®
 X (10%), the sensors seemed to not be affected by 
these harsh treatments.  
BT ON results yielded a P value that was not significant (P = 0.1864, n = 4), however 
leaving the CPEs in BT for 28 days caused a significant difference in the sensitivity 
recorded (P = 0.0152, n = 4). As stated previously in Section 4.3.1.1.4, this could be due to 
the components of the BT altering the surface morphology and blocking the sensor surface, 
thus leading to a decrease in sensitivity. The Triton
®
 X results yielded a sensitivity that was 
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not significantly different (P = 0.3270, n = 8). On closer analysis of the CPEs, it suggests 
that the electrodes give a sensitivity that is similar to the sensitivities observed pre-
treatment due to the extensively published alteration from a carbon paste to a carbon 
powder electrode, therefore leading to greater electron transfer in the ‗dry‘ environment of 
the modified carbon electrode. This leads to a greater sensitivity obtained.  
The constituents of the CPE are predisposed to modification by the environment that they 
are placed into, whereas the MMCPEs and SMCPEs are much more robust and remain 
intact. The SMCPE and MMCPE displayed the ability to endure biocompatibility tests 
without the integrity of the surface being compromised. Figure 4.4 (a) and Table 4.4 (a) 
display a summary of all of the sensors combined and the differences in the treatments 
observed between the varying sensors studied.  
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Figure 4.4 (a): A bar chart displaying a summary of the three sensors sensitivities (CPE: black), 
(SMCPE: red) and (MMCPE: blue) after each treatment carried out at -650 mV vs. SCE.  
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 CPE (nA/µM) SMCPE (nA/µM) MMCPE (nA/µM) 
Treatment Mean SEM n Mean SEM n Mean SEM n 
Pre -1.8 0.1 52 -3.1 0.1 52 -3.3 0.2 52 
BSA (10%) -1.1 0.1 4 -2.7 0.5 8 -2.9 0.3 6 
PEA (10%) -1.0 0.1 4 -2.7 0.3 8 -2.7 0.4 4 
BT (ON) -1.5 0.1 4 -2.8 0.3 6 -2.7 0.2 7 
BT (28 days) -1.6 0.1 4 -3.2 0.1 4 -2.6 0.2 4 
 
Table 4.4 (a): A table displaying a summary of the treatment results (nA/µM) for each of the sensors 
(CPE), (SMCPE) and (MMCPE). 
 
 
It is clear that there are remarkable differences in how the sensors (CPEs, SMCPEs and 
MMCPEs) behave when treated with varying proteins, lipids, ex-vivo BT and surfactants. 
The SMCPEs display very stable results in terms of sensitivity, when they were treated 
with varying substances. All post treatment sensitivities displayed no significant difference 
in comparison to the pre-treatment sensitivities and the P values are presented in Table 4.4 
(b). 
 
 SMCPEs 
Treatment P Value n 
BSA (10%) 0.9932 8 
PEA (10%) 0.1792 8 
BT (ON) 0.1687 6 
BT (28 days) 0.5282 4 
 
Table 4.4 (b): Summary of the P values obtained for the pre- and post-treatments carried out on the 
SMCPEs at -650 mV vs. SCE. 
 
For the MMCPEs similar results were obtained with each treatment displaying no 
significant difference pre- and post-treatment, apart from the placement of the sensors in 
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BT for 28 days which yielded a significant decrease in the sensitivity (P = 0.0296). Even 
with this decrease in sensitivity it can be observed that the sensitivity obtained is much 
greater than the CPEs (see Figure 4.4 (a)).      
 
 MMCPEs 
Treatment P Value n 
BSA (10%) 0.0611 6 
PEA (10%) 0.0506 4 
BT (ON) 0.0544 7 
BT (28 days) 0.0296 4 
 
Table 4.4 (c): Summary of the P values obtained for the pre- and post-treatments carried out on the 
MMCPEs at -650 mV vs. SCE. 
 
Upon removal and post calibration of the sensors from the living brain, it can be seen that 
the implantation of electrodes into the brain‘s hostile environment had an effect on the 
sensitivity of the SMCPEs and MMCPEs. As was observed from the SEMs pre- and post-
implantation, the sensor remained undamaged and unaltered so a decrease in sensitivity was 
hypothesised to be a result of blockage of the surface by the many constituents of the BT 
environment. A decrease in sensitivity upon implantation into the brain is observed with all 
sensors including Pt based sensors that experience approximately a 40 % drop in 
sensitivity, which can be attributable to a build up of species on the surface of the sensor, as 
has been demonstrated by our research group. With the MMCPEs and SMCPEs a decrease 
of about 15.5 % and 14.4 % is observed. 
Long term stability studies were then carried out on the novel developed sensors, in order to 
determine how stable the sensors were over the specified times detailed in Section 4.3.7. 
These studies were also undertaken to gain knowledge about how the sensors behave over 
time and where best to store them. In a clinical setting these aspects would need to be 
known, as the clinicians would not use these sensors straight away, they would be stored 
until they were needed. Different storage conditions were examined on these sensors (see 
Section 4.3.7). The effect of long term exposure of the SMCPEs and MMCPEs was 
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established in order to determine whether the sensors were suitable for long term recording 
in-vivo. The long term stability of CPEs has been demonstrated and discussed in data 
published by O‘Neill (O‘Neill, 2005). However, this stability is due to the leeching of the 
oil from the paste to leave a carbon powder electrode (Ormonde & O'Neill, 1989, 1990). 
Figure 4.4 (b) displays a summary of the results graphically, for the long term stability 
studies with the two monomer modified sensors from day 1 to the final day that they were 
calibrated in the specified storage condition.  
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Figure 4.4 (b): A summary of the long term stability studies carried out with the SMCPEs (black) and 
MMCPEs (blue) under the different conditions. 
 
It was decided that the RT storage conditions would be the chosen optimum condition to 
use for the two sensors, as the fridge and freezer results gave varying sensitivities on the 
specified days (see Section 4.3.7.2 and 4.3.7.3). As discussed previously, the lower 
temperatures appear to affect the sensitivity, which may be due to the morphology of the 
composite. The temperature and pH experiments displayed no significant differences pre 
and post studies undertaken with the two sensors (SMCPEs and MMCPEs). This indicates 
a great characteristic of the two sensors being robust and resilient under varying tests. The 
interference studies carried out displayed negligible sensitivities for each interferent used, 
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in comparison to the sensitivities obtained for O2, for each sensor. Table 4.4 (d) displays 
these results with respect to percentage interference at physiological concentrations. 
Analyte MMCPE (%) SMCPE (%) 
O2 100.00 (n = 52) 100.00 (n = 52) 
AA 0.07 (n = 4) 0.20 (n = 4) 
L-cysteine 0.65 (n = 4) 0.39 (n = 4) 
Uric acid 0.40 (n = 4) 0.17 (n = 4) 
L-tryptophan 0.23 (n = 4) 0.05 (n = 4) 
DHAA 0.07 (n = 4) -0.04 (n = 4) 
L-tyrosine -0.02 (n = 4) -0.11 (n = 4) 
Dopamine -0.08 (n = 4) -0.15 (n = 4) 
5-HIAA -0.10 (n = 4) -0.16 (n = 4) 
DOPAC -0.11 (n = 4) -0.20 (n = 4) 
5-HT 0.02 (n = 4) -0.15 (n = 4) 
HVA -0.06 (n = 4) -0.20 (n = 4) 
L-glutathione -0.12 (n = 4) -0.21 (n = 4) 
  
Table 4.4 (d): A table summarising the percentage change in sensitivity with regards to O2 for all of the 
interferents studied. 
 
On analysis of the SMCPEs and MMCPEs, a significantly higher sensitivity (P < 0.0001) 
towards O2 was observed in comparison to the CPEs. However the sensitivities of the 
SMCPEs and MMCPEs themselves were not significantly different (P = 0.3883). Figure 
4.4 (c) and Table 4.4 (e) display a comparison of the sensitivities of the sensors graphically 
and figuratively.  
 
 CPEs (n = 52) SMCPEs (n = 52) MMCPEs (n = 52) 
[O2], M Mean I, nA SEM Mean I, nA SEM Mean I, nA SEM 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 
240.0 -452.1 16.7 -921.3 37.9 -977.5 37.7 
1200.0 -2152.2 82.6 -3782.5 97.5 -4002.5 72.6 
  
Table 4.4 (e): A comparison table comparing the sensitivities of CPEs, SMCPEs and MMCPEs, 
performed in PBS (pH 7.4) at –650 mV vs. SCE. 
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Figure 4.4 (c): A mean current concentration profile comparing the sensitivities of CPEs (black), 
SMCPEs (red) and MMCPEs (green) performed in PBS (pH 7.4) at –650 mV vs. SCE.  
 
The results obtained from the O2 calibrations yielded sensitivities of -1.8 ± 0.1 nA/ µM, n = 
52 (CPEs), -3.1 ± 0.1 nA/ µM, n = 52 (SMCPEs) and -3.3 ± 0.2 nA/ µM, n = 52 
(MMCPEs). Linear regression analysis was carried out and a R
2
 value of 0.99 was obtained 
for the CPEs, MMCPEs and SMCPEs. It is clear from the data collected for the sensors that 
the new monomer modified CPEs gave an enhanced sensitivity towards O2. This 
characteristic is exceptional as the sensitivity is nearly double that of what can be attained 
with the CPEs. The SEMs displayed in Figure 4.4 (e) show the extent of the modification 
of the CPEs by the in-vivo environment. The images show that the carbon paste is being 
pulled away from the cavity and also that the surface of the CPEs have been aggravated. In 
Figure 4.4 (e), image A, the leeching of the silicone oil can be seen spilling out over the 
electrode.  
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350 µm
 
Figure 4.4 (d): SEM displaying the surface of a CPE pre-implantation. 
 
 
    
                                         
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
Figure 4.4 (e): (A), (B), (C) and (D); SEMs displaying the surface of different CPEs post-implantation.  
 
With the SMCPEs and MMCPEs, all the components of the electrode remain inside the 
cavity, giving a surface that does not corrupt easily, unlike the CPEs. This is another very 
promising characteristic of the two monomer modified sensors. To have two individual 
sensors that perform similarly, withstand damage from a very complex environment and 
A B
C D
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that withstand the removal from that environment (which can cause detrimental harm to the 
sensor) whilst keeping the integrity of the electrode is a very exciting and promising result. 
It is critical for clinical integration that the surface remains intact to avoid unwanted 
leeching of carbon paste into human tissue. Strict regulatory guidelines exist when trying to 
get a novel medical device FDA or CE approved. Cytotoxity testing would need to be 
undertaken to confirm the sensors don‘t have any detrimental effects on tissue cells before 
they could be adopted clinically. 
The main aim of this chapter was to develop a new sensor that had all of the beneficial 
characteristics of CPEs but without the leeching of the oil (and potentially paste) from the 
cavity of the electrode. A CPE that incorporated the monomers Sty and MMA was 
successfully manufactured to detect O2. An increase in the sensitivity of O2 was also 
achieved utilising these two sensors, in comparison to the CPEs. The aim of the modified 
electrode was to retain good stability, without any modification to the components of the 
sensor. It can be seen from the results in the various sections of this chapter that the data 
obtained from the CPEs, SMCPEs and MMCPEs varied immensely when exposed to the 
different parameters tested on them. In order to fully distinguish between the CPEs and the 
SMCPEs and MMCPEs, their responses to the analyte O2 in-vivo is examined and 
discussed in Chapter 5. 
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5.1 Introduction 
 
Measuring and determining tissue O2 concentration in-vivo is of the utmost importance, as 
living organisms rely on O2 as a means of survival. It is essential that the brain along with 
the rest of the body obtains a continuous supply of O2 for normal functioning, with the 
brain consuming about 20 % of the O2 utilised by the body at any given time (Bolger et al., 
2011b). The balance between supply and utilisation is the main determinant of the tissue O2 
concentration (Lowry et al., 1997). One of the first reports of changes in brain tissue was 
demonstrated by Clark et al., using a noble metal electrode (Clark et al., 1958). Since this 
time, detecting O2 in-vivo has been widely documented in the literature (Lowry et al., 1996; 
Lowry & Fillenz, 2001; Bolger & Lowry, 2005; Kealy et al., 2013). 
The reported ECF O2 concentration ranges from 40 to 80 µM (O'Neill & Lowry, 2000). 
Brain tissue O2 reacts to a range of agitations which include electrical stimulation 
(McCreery et al., 1990) and neuromediator release (Kennedy et al., 1992) and it also has a 
faster turnover in the cerebral cortex in contrast to other brain regions (Nair et al., 1987). 
Different types of voltammetry can be employed to detect changes in the ECF, for example 
fast cyclic voltammetry (FCV), differential pulse voltammetry (DPV) and constant 
potential amperometry (CPA). For in-vivo studies, CPA is employed due to the high time 
resolution (Lowry & O'Neill, 2006) and has been the technique utilised for in-vivo 
experiments throughout this research and within our lab (Bolger & Lowry, 2005; Bolger et 
al., 2011b; Kealy et al., 2013). 
The utilisation of CPEs for the detection of O2 has been widely documented (Lowry et al., 
1996; Lowry et al., 1997; Bolger & Lowry, 2005). CPEs are highly advantageous over the 
use of noble metal electrodes, as they are not vulnerable to surface poisoning and it is not 
necessary to integrate membranes onto the surface in order to protect them. Metal 
electrodes are hampered by this characteristic and there are many reports of ways and 
means of trying to avoid this by modifying the surfaces of the noble metal electrodes 
(Wisniewski et al., 2000; Gifford et al., 2006). Another advantage of CPEs is their long 
term stability in-vivo. The silicone oil is removed from the carbon paste once it interacts 
with the brain environment, leading to the ability of the electrode to take any proteins, 
lipids or constituents that have adsorbed onto the surface of the electrode from the brain 
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surroundings and remove them along with the oil. This leads to the overall stability of the 
carbon paste sensor being highly durable (Ormonde & O'Neill, 1989, 1990). 
Although this is a great trait to have in a sensor when monitoring the in-vivo environment, 
it is not ideal for any constituents to leach out from the electrode compartment when 
monitoring in the clinical environment. For an electrode to be utilised in a clinical setting, 
sensitivity to impeding lipophilic ions or charged surfactants should not be an issue for the 
electrode (Czaban, 1985). The LICOX
®
 probe (see Figure 1.2.2), is a device that is utilised 
in the clinical environment and is electrochemical in nature. It has a lot of similarities to our 
proposed device; however, the sensing component‘s role is to diffuse O2 through a 
permeable membrane surrounding the probe and into an electrolyte solution where a signal 
is created. The LICOX
®
 probe has a design of a bulky housing component with a fragile 
membrane surrounding the probe. Alternative methods of measuring O2 levels currently 
utilised in hospitals include Pulse Oximetry and Arterial Blood Gas (ABG) analysis. 
Severe limitations exist with such techniques restricting their utility in measuring a medical 
emergency such as a patient with ischemia. ABG focuses on discrete measurements of O2 
levels in blood taken from the patient at varying time intervals. It does not monitor the 
trend in O2 levels on a continual basis. ‗At risk‘ patients would therefore not benefit from 
this technique since early diagnosis is of the utmost importance to the patient‘s outcome. 
The continuous real-time characteristic of the sensor technology within our lab will allow 
for millisecond changes in O2 levels to be recorded and presented for the clinician, 
significantly increasing timely intervention. It is for this reason that the CPEs were 
modified to produce a more robust and solid electrode that can withstand modification and 
morphology from a complex structure such as the living brain. This follows directly from 
the data presented in Chapter 4, where the MMCPEs and SMCPEs were characterised in 
the in-vitro environment. 
Characterising the novel monomer modified sensors in the in-vivo environment is a 
complex procedure, due to the vast differences between the two settings. The living brain 
encompasses an array of endogenous substances that include proteins, lipids and 
electrocatalysts like AA. The brain also limits mass transport to the sensor surface and 
reacts to the presence of the electrode physiologically (O'Neill, 1993). The body‘s defence 
system responds to the implanted device causing the body to react as if it is responding to 
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an injury. This defence system includes the three stages of wound healing (inflammation 
and debridement, repair and maturation (Mann et al., 2011)) and would therefore interact 
with the sensors properties. So, sensitivity, selectivity and stability of the sensor once it is 
placed in this in-vivo setting could weaken the capabilities of the electrode to perform as 
well as demonstrated in the in-vitro environment (Wisniewski et al., 2000; Gifford et al., 
2006). Therefore, the behaviour of the electrode in-vitro might well be different to its 
behaviour in the in-vivo milieu. 
Due to these reasons, it is clear that while in-vitro characterisation of the sensors is essential 
for determining the sensitivity and selectivity of the sensor, these parameters can alter once 
the sensor is placed into the biological setting as tissue components interfere with the 
sensor (O'Neill, 1993). 
 
5.2 Experimental 
 
The instrumentation and software for all experiments are described in Section 3.2. All 
chemicals and solutions are described in detail in Section 3.3.  The sensors utilised for these 
experiments consist of MMCPEs and SMCPEs. The manufacture of these sensors is 
detailed in Section 3.4. An applied potential of -650 mV vs. Ag wire was applied to the 
electrodes involved in these experiments. All O2 studies undertaken were performed in 
freely-moving animals. The surgical procedure undertaken for the implantation of the 
sensors is described in Section 3.8. Data is reported as mean ± SEM. The significance of 
differences observed was calculated using student t-tests. In each of the Sections, n denotes 
the number of perturbations carried out on a given number of sensors in a given number of 
animals, unless stated otherwise. 
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5.3 Results and Discussion 
 
It was concluded in Chapter 4, that the novel monomer modified sensors had the potential 
ability to remain intact and unmodified in the in-vivo environment while possessing a 
significantly increased sensitivity towards O2. This considerable improvement to the 
surface integrity is pivotal to the integration of these O2 sensors into clinical practice. It is 
imperative that the sensor surface remains intact and the possibility of paste leeching during 
implantation is negated. Since our primary area of expertise is preclinical brain monitoring, 
this results section comprises the data from experiments that were carried out with the 
objective being the in-vivo characterisation of the MMCPE and SMCPE for long term 
monitoring of brain tissue O2. However, due to the significantly higher regulatory hurdles 
associated with clinical brain monitoring, identification of peripheral O2 monitoring 
applications is more realistic option for the research group. Verification that the sensors 
responded to changing levels of oxygenation was achieved by the induction of states of 
mild hypoxia and hyperoxia in the subject.  
 
5.3.1 Hypoxia 
 
Hypoxia is defined as a decrease in the supply of O2 to tissue below physiological levels, 
even though there is sufficient perfusion of the tissue by blood (Dorland, 2011). The 
occurrence of hypoxia can be a sign of low O2 tension in arterial blood, the decreased 
ability of the blood to carry O2 (which is caused by anaemia or carbon monoxide 
poisoning) or a reduced tissue perfusion, (Höckel & Vaupel, 2001), these are just a couple 
of examples of hypoxia induced variables. In these experiments, the production of mild 
hypoxia was created by the administration of a N2/air mixture to the snout of the animal, 
through a plastic tube. The flow rate was kept low, in order to keep the animal at ease 
during the experiment.  
A similar method was undertaken in previous reports (Lowry et al., 1998a). The inhalation 
of N2 resulted in a response at the O2 sensors leading to a change in the O2 current.  
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5.3.1.1 MMCPE 
 
The effect of a typical 3-minute period of hypoxia recorded by the MMCPEs is displayed in 
Figure 5.3.1.1. The 3-minute period of hypoxia data in this section was analysed using the 
results from 54 perturbations with 16 sensors in 7 animals. 
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Figure 5.3.1.1: A typical example of a 3-minute period of hypoxia monitored at an MMCPE implanted 
in the striatum of a freely moving rat. The blue bar is indicative of the administration of a N2/air 
mixture. 
 
Figure 5.3.1.1, demonstrates how a 3-minute period of induced hypoxia caused an 
immediate and significant decrease (P < 0.0001) in the O2 current from a baseline level of -
176.9 ± 4.7 nA, n = 54, to a current of -101.3 ± 3.4 nA, n = 54. The max response time was 
at 2.5 ± 0.1 minutes, n = 54. A maximum decrease of 75.6 ± 4.0 nA, n = 54, representing a 
mean percentage change of 41.6 ± 1.8 %, n = 54, was obtained. Upon cessation of 
inhalation of the gas, the current immediately returned to baseline currents levels of -178.6 
± 4.9 nA, n = 54, (P = 0.2623), indicating a return to normoxic conditions after 7.1 ± 0.4 
minutes, n = 54.    
 
 
 
 
 
 
  Chapter 5: In-Vivo Oxygen 
 
173  
 
 
Table 5.3.1.1: Summary of results for the 3-minute period of hypoxia, with the MMCPEs implanted in the 
striatum of freely moving rats (n= 54, with 16 sensors in 7 animals).  
 
5.3.1.2 SMCPE 
 
The effect of induced hypoxia monitored with SMCPEs for 3-minutes is shown in Figure 
5.3.1.2. The 3-minute period of hypoxia data in this section was analysed using the results 
from 66 perturbations with 13 sensors in 6 animals. 
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Figure 5.3.1.2: A typical example of a 3 minute period of hypoxia monitored by a SMCPE in the 
striatum of a freely moving rat. The blue bar is indicative of the administration of a N2/air mixture. 
 
 
Analysis of the data confirms that the 3 minute period of hypoxia caused a decrease in the 
observed O2 current that was significant (P < 0.0001). The O2 level decreased by 49.9 ± 2.9 
nA, n = 66, from a baseline of -159.8 ± 6.3 nA, n = 66, to a level of 110.0 ± 4.7 nA, n = 66, 
which corresponds to a mean percentage decrease of 30.9 ± 1.4 %, n = 66. The max 
response was attained after 1.7 ± 0.1 minutes, n = 66. Upon termination of administration 
of the N2, the current returned to similar baseline levels as before of -161.0 ± 6.6 nA, n = 
 Hypoxia 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
MMCPEs 75.6 ± 4.0 41.6 ± 1.8  2.5 ± 0.1  7.1 ± 0.4  -176.9 ± 4.7  -178.6 ± 4.9 
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66, (P = 0.3064) after 6.2 ± 0.4 nA, n = 66, had elapsed, which is indicative of a return back 
to normal O2  conditions.  
 
 
 
Table 5.3.1.2: A table summarising the results for the 3-minute period of induced hypoxia, with the 
SMCPEs implanted in the striatum of freely moving rats (n = 66, with 13 sensors in 6 animals).    
 
5.3.1.3 Comparison 
 
On examination of the induced hypoxic responses obtained with the two sensors (MMCPEs 
and SMCPEs), it is observed that a similar O2 trace is obtained with both sensors. Upon 
administration of the N2/air mixture to the subject, the O2 current decreases significantly by 
41.6 ± 1.8 %, n = 54, 7 animals, (P < 0.0001) with the MMCPEs and 30.9 ± 1.4 %, n = 66, 
6 animals, (P < 0.0001) with the SMCPEs. Although the MMCPEs detected a greater O2 
decrease, the SMCPEs still achieved a good response at the electrodes. The MMCPEs took 
longer to return to baseline levels (7.1 ± 0.4 minutes, n = 54) in comparison to the SMCPEs 
which took less time (6.2 ± 0.4, n = 66) to achieve normal O2 conditions, although the 
return time for the SMCPEs was not significantly different (P = 0.1179) in comparison to 
the MMCPEs. Bolger et al., demonstrates an administration of N2/air, using CPEs. A 
decrease in O2 can be observed that yields a similar trace to what the MMCPEs and 
SMCPEs recorded. A decrease of 16.2 ± 4.3 nA (n = 4) was obtained with the CPEs for the 
administration of hypoxia (Bolger et al., 2011b).  
The MMCPEs and SMCPEs demonstrate a much greater decrease due to the administration 
of N2. A significant difference can be observed between the monomer modified sensors in 
comparison to the CPEs (MMCPEs vs. CPEs: P = 0.0004) and (SMCPEs vs. CPEs: P = 
0.0061). The increased sensitivity observed in-vivo correlates with the results obtained in 
 Hypoxia  
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
SMCPEs 49.9 ± 2.9 30.9 ± 1.4 1.7 ± 0.1 6.2 ± 0.4 -159.8 ± 6.3 -161.0 ± 6.6 
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Chapter 4, as an increased sensitivity was observed with the sensors in comparison to the 
CPEs (see Section 4.4, Figure 4.4 (c)). 
 
5.3.2 Hyperoxia 
 
Hyperoxia is defined as a greater O2 concentration than the normal atmospheric level 
(Voelkel & Rounds, 2009). Mild hyperoxia was established in the subject by the 
administration of an O2/air mixture to the snout of the subject through a plastic tube with a 
low flow rate. This prevents the animal from being startled or uneasy during the 
experiment. A similar method was reported in the literature (Lowry et al., 1998a). This 
process was carried out on subjects that had MMCPEs and SMCPEs implanted in the 
striatum and the results were examined for each. 
 
5.3.2.1 MMCPE 
 
The effect of a typical 5-minute period of hyperoxia recorded with the MMCPE is 
displayed in Figure 5.3.2.1. The 5-minute period of hyperoxia data in this Section was 
analysed using the results from 54 perturbations with 15 sensors in 7 animals. 
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Figure 5.3.2.1: A typical example of a 5-minute period of hyperoxia monitored by an MMCPE in the 
striatum of a freely moving rat. The blue bar is indicative of the administration of an O2/air mixture. 
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Figure 5.3.2.1, demonstrates how a 5-minute period of induced hyperoxia caused an 
immediate and significant increase (P < 0.0001) in the O2 current from a baseline level of -
170.7 ± 5.1 nA, n = 54, to a current of -250.9 ± 8.9 nA, n = 54. This yielded a maximum 
increase of 80.3 ± 6.3 nA, n = 54, after approximately 3.0 ± 0.2 minutes, n = 54, 
representing a mean percentage change of 50.8 ± 6.0 %, n = 54. Upon cessation of 
inhalation of the gas, the current immediately returned to baseline currents of -174.3 ± 5.0 
nA, n = 54, (P = 0.6067), indicating a return to normoxic conditions after 13.2 ± 0.7 
minutes, n = 54. 
 
 
Table 5.3.2.1: Summary of results for the 5-minute period of induced hyperoxia, with the MMCPEs 
implanted in the striatum of freely moving rats (n = 54, with 15 sensors in 7 animals).  
 
 
5.3.2.2 SMCPE 
 
The effect of a typical 5-minute period of hyperoxia recorded with the SMCPE is displayed 
in Figure 5.3.2.2. The 5-minute period of hyperoxia data in this Section was analysed using 
the results from 75 perturbations with 12 sensors in 6 animals.  
 
 Hyperoxia 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
MMCPEs 80.3 ± 6.3 50.8 ± 6.0 3.0 ± 0.2 13.2 ± 0.7 -170.7 ± 5.1 -174.3 ± 5.0 
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Figure 5.3.2.2: A typical example of a 5-minute period of hyperoxia monitored by an SMCPE in the 
striatum of freely moving rats. The blue bar is indicative of the administration of an O2/air mixture. 
 
 
Analysis of the data confirms that the 5-minute period of hyperoxia caused an increase in 
the observed O2 current that was significantly different from baseline (P < 0.0001). The O2 
level increased by 63.6 ± 3.7 nA, n = 75, after 2.9 ± 0.1 minutes, n = 75, from a baseline of 
-159.8 ± 6.4 nA, n = 75, to a level of -223.4 ± 9.3 nA, n = 75, which corresponds to a mean 
percentage decrease of 67.4 ± 3.8 nA, n = 75. Upon termination of administration of the O2, 
the current returned to a similar baseline levels as before of -159.3 ± 6.1 nA, n = 75, (P = 
0.6837) after 12.7 ± 0.7 nA, n = 75, had elapsed, which is indicative of a return back to 
normal O2  conditions. 
 
 
 
Table 5.3.2.2: Summary of results for the hyperoxia administration (5 minutes), with the SMCPEs 
implanted in the striatum of freely moving rats (n = 75, with 12 sensors in 6 animals).    
 
 
 Hyperoxia Administration 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
SMCPEs 63.6 ± 3.7 67.4 ± 3.8  2.9 ± 0.1  12.7 ± 0.7 -159.8 ± 6.4 -159.3 ± 6.1 
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5.3.2.3 Comparison 
 
The hyperoxia responses attained at the two sensors both demonstrated a significant 
increase in the O2 current (< 0.0001). The raw data traces for the two sensors showed 
similarity also. A percentage increase of 50.8 ± 6.0 %, (n = 54, 7 animals) and 67.4 ± 3.8 
%, (n = 66, 6 animals) where obtained for the MMCPEs and SMCPEs, respectively. This 
shows that the two sensors have the ability to detect changes in the O2 current. The 
SMCPEs returned to baseline levels at a similar time to the MMCPEs, yielding a time 
effect of 13.2 ± 0.7 minutes, n = 54, for the MMCPEs and 12.7 ± 0.7 minutes, n = 66, for 
the SMCPEs, displaying no significant difference (P = 0.6180) between the two time 
frames. On comparison to the results that Bolger et al., attained with the CPEs for an 
administration of O2/Air, the CPEs detected an increase in the O2 (50.1 ± 5.9 nA, n = 4), 
that was less than what the MMCPEs and SMCPEs achieved (Bolger et al., 2011b).  
However, no significant difference in the O2 sensitivity was obtained between the different 
sensors (MMCPEs vs. CPEs: P = 0.4062) and (SMCPEs vs. CPEs: P = 0.2018). Although 
no significant difference was observed, the results for the hyperoxia administration 
highlights how the monomer modified sensors have an increased sensitivity, as 
demonstrated in Chapter 4, which corresponds to the increased sensitivity achieved for the 
hyperoxia administration in comparison to the CPEs observed by Bolger et al., (Bolger et 
al., 2011b). 
 
5.3.3 Neuronal Activation 
 
Two forms of physiologically stimulated neuronal activation were utilised throughout the 
experiments; these were restraint stress and tail pinch. Each test was carried out for 5 
minutes. These types of experiments have been demonstrated previously in our lab (Lowry 
et al., 1997; Bolger & Lowry, 2005). The two stimuli, cause mild stress in the animal, 
leading to an increase in O2 recorded by the sensors. Stress is any unpleasant stimulus, 
which can perturb the normal physiological homeostasis of the body (Gold & Chrousos, 
2002). The capability to handle stressful stimuli plays a vital role in the determinants of 
health and disease (Gulati et al., 2006). The application of a stress response promotes 
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physiological changes that include increases in heart rate and blood pressure, altered blood 
flow to the brain and to the stressed body site (Gold & Chrousos, 2002).  
The introduction of the restraint test in order to promote a stress response has been 
demonstrated in the literature (Gulati et al., 2006; Gulati et al., 2007; Chakraborti et al., 
2008). The attachment of a paper clip to the tail of the subject has been demonstrated 
previously by Valente et al., and yields a well characterised behaviour pattern of gnawing, 
licking, eating and a universal increase in motor activity. This physiological stimulation 
also increases neuronal activation in the striatum and a simultaneous elevation of cerebral 
blood flow and O2 was also observed (Valente et al., 2012). 
 
5.3.3.1 Restraint 
 
5.3.3.1.1 MMCPE 
 
The effect of a 5-minute restraint stress recorded with an MMCPE in the striatum of a 
freely moving rat is shown in Figure 5.3.3.1.1. The restraint stress data in this Section was 
analysed using 29 perturbations with 13 sensors in 6 animals. 
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Figure 5.3.3.1.1: A typical raw data trace displaying the effects of a 5-minute restraint stress on the 
observed O2 current recorded with an MMCPE in the striatum of a freely moving rat. The blue bar is 
indicative of the induced stress.  
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The application of a 5-minute restraint stress test resulted in an immediate and rapid 
increase in the O2 current recorded at the MMCPEs by 26.8 ± 3.8 nA, n = 29, after 2.5 ± 0.3 
minutes, n = 29, from a mean baseline of -165.9 ± 5.8 nA, n = 29, to a current of -192.7 ± 
7.6 nA, n = 29. The mean percentage increase in response to the restraint test was 16.4 ± 
2.2 %, n = 29. The resulting O2 increase caused a significant difference in the O2 signal 
obtained (P < 0.0001) from baseline. On cessation of the stimulus, the baseline began to 
fall until another increase was observed shortly afterwards. A significantly different current 
(P < 0.0001) was observed subsequent to the first max response, after 6.1 ± 0.2 minutes, n 
= 29. A current change of 33.0 ± 3.6 nA, n = 29, which yielded a mean percentage change 
of 20.1 ± 2.2 %, n = 29, from the mean pre baseline of -165.9 ± 5.8 nA, n = 29, to a current 
of -198.9 ± 7.4 nA, n = 29, was recorded.     
A second O2 increase on cessation of the stimulus was observed due to how the O2 
concentration is controlled in the body. It is based on the supply and utilisation (Lowry et 
al., 1997), therefore once the stimulus was ceased, the supply exceeded the demand and an 
increase was observed, followed on by a subsequent decrease in the current. The current 
began to fall and returned to a baseline of -167.8 ± 5.5 nA (P = 0.1010) within 28.1 ± 4.3 
minutes, n = 29.  
 
 
Table 5.3.3.1.1: Summary of results for the first and second current change responses for a restraint 
stress (5-minutes), with the MMCPEs implanted in the striatum of freely moving rats (n = 29 with 13 
sensors in 6 animals),    
 
    
 Restraint stress 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
MMCPEs 26.8 ± 3.8 16.4 ± 2.2 2.5 ± 0.3 28.1 ± 4.3 -165.9 ± 5.8 -167.8 ± 5.5  
 Restraint stress (2nd current change) 
 (2nd) Current 
change 
(nA) 
(2nd) Current 
change 
(%) 
(2nd) Max 
response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
MMCPEs 33.0 ± 3.6 20.1 ± 2.2 6.1 ± 0.2 28.1± 4.3  -165.9 ± 5.8 -167.8 ± 5.5  
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5.3.3.1.2 SMCPE 
 
The effect of a typical 5-minute restraint stress monitored at a SMCPE in the striatum of a 
freely moving rat is depicted shown in Figure 5.3.3.1.2. The restraint stress data in this 
Section was analysed using 30 perturbations with 11 sensors in 5 animals. 
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Figure 5.3.3.1.2: A typical example of the effects of a 5-minute restraint stress on the observed O2 
current recorded with an SMCPE in the striatum of a freely moving rat. The blue bar indicates the 
onset and duration of the restraint stress. 
 
Figure 5.3.3.1.2, demonstrates how a 5-minute restraint test caused an immediate and 
significant increase (P < 0.0001) in the O2 current from a baseline level of -137.0 ± 8.4 nA, 
n = 30, to a current of -159.0 ± 10.6 nA, n = 30, after 2.6 ± 0.3 minutes, n = 30. This 
corresponds to a maximum increase of 22.0 ± 2.8 nA, n = 30, representing a mean 
percentage change of 15.2 ± 1.3 %, n = 30. On release of the subject, the current began to 
fall and then a subsequent increase was observed similar to what was observed with the 
MMCPEs. A current change of 29.8 ± 4.7 nA, n = 30, after 6.4 ± 0.1 minutes, n = 30, was 
observed from a current of -137.0 ± 8.4 nA, n = 30, to a current of -166.9 ±12.1 nA, n = 30. 
This yielded a percentage current change of 20.3 ± 2.5 % which was significantly different 
(P < 0.0028). The current began to fall and then returned to a baseline current of -143.8 ± 
8.9 nA, n = 30 (P < 0.0001) which indicated that the baseline signal had altered due to the 
stress imposed on the subject. The new baseline was achieved after 8.9 ± 0.7 minutes, n = 
30. The increase in the O2 current after the subject had been released was demonstrated 
previously with the MMCPEs and this phenomenon occurs when the supply of O2 surpasses 
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the utilisation yielding an increase until the supply and utilisation balances out which is 
observed in the fall of the O2 current back to baseline levels.       
 
 
Table 5.3.3.1.2: Summary of results for the first and second current change responses for a restraint 
stress (5-minutes), with the SMCPEs implanted in the striatum of freely moving rats (n = 30 with 11 
sensors in 5 animals).  
 
5.3.3.1.3 Comparison 
 
A similar percentage increase of 16.4 ± 2.2 %, n = 29, 6 animals and 15.2 ± 1.3 %, n = 30, 
5 animals, is observed at the MMCPEs and SMCPEs, respectively. Although there is a 
similar increase in the O2 current for the SMCPEs the return to baseline levels are much 
faster than achieved with the MMCPEs. It took 28.1 ± 4.3 minutes, n = 29 and 8.9 ± 0.7 
minutes, n = 30 for the MMCPEs and SMCPEs, respectively, to achieve normoxic levels. 
Kealy et al., carried out a restraint stress on rats (n = 13, 5 animals) using CPEs. They 
achieved ca. 9 % increase in the O2 current. Even though this was significantly different 
from the baseline levels (P < 0.05) (Kealy et al., 2013), it can be observed that the 
monomer modified CPEs discussed and analysed in this section can achieve a much greater 
sensitivity.  
 
 Restraint stress 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
SMCPEs 22.0 ± 2.8  15.2 ± 1.3 2.6 ± 0.3 8.9 ± 0.7 -137.0 ± 8.4 -143.8 ± 8.9 
 Restraint stress (2nd current change) 
 (2nd) Current 
change 
(nA) 
(2nd) Current 
change 
(%) 
(2nd) Max 
response 
Time (mins) 
Return 
Time 
(mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
SMCPEs 29.8 ± 4.7  20.3 ± 2.5 6.4 ± 0.1 8.9 ± 0.7 -137.0 ± 8.4 -143.8 ± 8.9 
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5.3.3.2 Tail Pinch 
 
5.3.3.2.1 MMCPE 
 
The effect of a 5-minute tail pinch stress recorded with an MMCPE in the striatum of a 
freely moving rat is shown in Figure 5.3.3.2.1. The tail pinch data in this Section was 
analysed using 23 perturbations with 12 sensors in 6 animals. 
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Figure 5.3.3.2.1: A typical example of the effects of a 5-minute tail pinch on the observed O2 current 
recorded with an MMCPE in the striatum of a freely moving rat. The blue bar indicates the onset and 
duration of the tail pinch. 
 
The application of a 5-minute tail pinch resulted in an instantaneous and rapid increase in 
the O2 current observed at the MMCPEs. An immediate and significant increase (P < 
0.0001) in the O2 current from a baseline level of -166.9 ± 5.8 nA, n = 23, to a current of -
198.3 ± 9.0 nA, n = 23, after 2.8 ± 0.3 minutes, n = 23. This yielded a maximum increase of 
31.4 ± 6.6 nA, n = 23, representing a mean percentage change of 19.1 ± 4.0 %, n = 23. 
Upon removal of the stimulus, the current began to fall and returned to a new baseline of -
175.0 ± 6.5 nA, n = 23, (P < 0.0001) after 28.3 ± 5.1 minutes, n = 23.    
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Table 5.3.3.2.1: Summary of results for the tail pinch (5-minutes), with the MMCPEs implanted in the 
striatum of freely moving rats (n = 23 with 12 sensors in 6 animals).      
 
5.3.3.2.2 SMCPE 
 
The effect of a 5-minute tail pinch stress recorded with an SMCPE in the striatum of a 
freely moving rat is shown in Figure 5.3.3.2.2. The tail pinch data in this section was 
analysed using 27 perturbations with 11 sensors in 5 animals. 
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Figure 5.3.3.2.2: A typical example of the effects of a 5-minute tail pinch stress on the observed O2 
current recorded with an SMCPE in the striatum of a freely moving rat. The blue bar indicates the 
onset and duration of the tail pinch. 
 
The mean percentage increase observed in response to the tail pinch was 18.7 ± 1.8 %, n = 
27. The increase in the O2 current recorded at the SMCPEs was 30.8 ± 3.1 nA, n = 27, after 
2.8 ± 0.2 minutes, n = 27, from a baseline of -162.0 ± 8.3 nA, n = 27, to a current of -192.7 
± 10.5 nA, n = 27 (P < 0.0001). On removal of the stimulus, the current returned to a 
baseline of -163.9 ± 7.8 nA, n = 27 (P = 0.2024) after 27.1 ± 3.2 minutes, n = 27. 
 Tail pinch 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
MMCPEs 31.4 ± 6.6 19.1 ± 4.0 2.8 ± 0.3 28.3 ± 5.1 -166.9 ± 5.8 -175.0 ± 6.5 
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Table 5.3.3.2.2: Summary of results for the tail pinch (5 minutes), with the SMCPEs implanted in the 
striatum of freely moving rats (n = 27 with 11 sensors in 5 animals). 
 
5.3.3.2.3 Comparison 
 
Analysis of the two O2 sensors upon application of a tail pinch yielded similar findings. The 
percentage increase in the O2 current obtained for the MMCPEs and SMCPEs yielded 
results of 19.1 ± 4.0 %, n = 23, 6 animals and 18.7 ± 1.8 %, n = 27, 5 animals  respectively. 
The time taken for the baseline to return to normoxic conditions was analogous for the two 
sensors 28.3 ± 5.1 minutes, n = 23, (MMCPEs) and 27.1 ± 3.2 minutes, n = 27 (SMCPEs). 
The results demonstrate how both sensors have the capability to detect changes in the O2 
concentration effectively.  Bolger et al., demonstrated an increase in the O2 current with the 
application of a tail pinch in freely moving rats, n = 8, 2 animals. An increase of 10.8 ± 1.9 
nA, n = 8, was achieved with the CPEs, however a much greater increase was achieved 
with the sensors discussed in this section. There was a significant difference between the O2 
increases, which demonstrates how the monomer modified sensors display a higher 
sensitivity, (MMCPEs vs. CPEs: P = 0.0416) and (SMCPEs vs. CPEs: P = 0.0017).      
 
 
 
 
 
 
 
 
 Tail pinch 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
SMCPEs 30.8 ± 3.1  18.7 ± 1.8 2.8 ± 0.2 27.1 ± 3.2 -162.0 ± 8.3 -163.9 ± 7.8 
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5.3.4 Saline Administration 
 
The effect of an intraperitoneal (i.p.) injection of saline on the striatal O2 current was 
examined as this was the route of administration for investigating the effect of drugs on the 
O2 response. Using saline would demonstrate the effect of the injection stress on the subject 
so it would be clear for future i.p. injections what effect the drugs are having on the O2 
response. The effect of an injection of saline (NaCl, 0.9 %, i.p.) on the O2 current was 
recorded with the MMCPEs and SMCPEs. 
 
5.3.4.1 MMCPE 
 
The effect of a typical i.p. injection of saline monitored by an MMCPE in the striatum of a 
freely moving rat is displayed in Figure 5.3.4.1. The saline injection data in this Section 
was analysed using the results from 8 perturbations with 8 sensors in 5 animals. 
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Figure 5.3.4.1: A typical raw data trace displaying the effect of an i.p. injection of saline (1.0 ml, 0.9 % 
NaCl) on the O2 response, recorded with an MMCPE, in the striatum of a freely moving rat. The arrow 
is indicative of the injection point. 
 
Analysis of the data shows an increase in the observed O2 current upon injection of saline. 
The current increased significantly (P = 0.0009), by 27.2 ± 6.0 nA, n = 8, after 1.5 ± 0.2 
minutes, n = 8, from a mean baseline of -153.3 ± 10.5 nA, n = 8 to a current of -180.5 ± 
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10.9 nA, n = 8, yielding a percentage increase of 19.6 ± 5.8 %, n = 8. The O2 signal 
returned to baseline levels of -159.0 ± 10.2, n = 8, (P = 0.0026), in 5.8 ± 1.0 minutes, n = 8. 
 
 
Table 5.3.4.1: Summary of results for a saline injection, with the MMCPEs implanted in the striatum of 
freely moving rats (n = 8 with 8 sensors in 5 animals). 
 
5.3.4.2 SMCPE 
 
The effect of a typical i.p. injection of saline monitored by an SMCPE in the striatum of a 
freely moving rat is shown in Figure 5.3.4.2. The saline injection data in this Section was 
analysed using the results from 11 perturbations with 8 sensors in 5 animals. 
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Figure 5.3.4.2: A typical raw data trace displaying the effect of an i.p injection of saline (1.0 ml, 0.9 % 
NaCl) on the O2 response, monitored with an SMCPE in the striatum of a freely moving rat. The arrow 
indicates the point of injection.  
 
 
 Saline Injection 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
MMCPEs 27.2 ± 6.0 19.6 ± 5.8  1.5 ± 0.2  5.8 ± 1.0 -153.3 ± 10.5 -159.0 ± 10.2 
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There was an immediate and significant increase in O2 (P < 0.0001) following the injection 
of saline from a baseline of -153. 2 ± 12.2 nA, n = 11, to -186.2 ± 13.9 nA, n = 11. This 
yielded a current change of 33.0 ± 3.6 nA, n = 11, after 1.2 ± 0.2 minutes, n = 11, which 
corresponds to a percentage change of 22.4 ± 3.4 %, n = 11. The O2 signal returned to a 
baseline of -159.1 ± 12.6 nA (P = 0.0017), n = 11, after 9.1 ± 2.0 minutes, n = 11.   
 
 
Table 5.3.4.2: Summary of results for a saline injection, with the SMCPEs implanted in the striatum of 
freely moving rats (n = 11 with 8 sensors in 5 animals).   
 
5.3.4.3 Comparison 
 
The administration of a saline injection to the subject caused a clear stress response 
observed in both sensors. A percentage increase in the O2 current of 19.6 ± 5.8 %, n = 8 and 
22.4 ± 3.4 %, n = 11, for the MMCPEs and SMCPEs, respectively, was obtained. The 
baseline current returned to new baseline currents after 5.8 ± 1.0 minutes, n = 8, 
(MMCPEs) and 9.1 ± 2.0 minutes, n = 11 (SMCPEs), respectively. This illustrates a 
transient effect following the control injection. Saline injections obtained with CPEs 
display a similar transient response; however, a much lower response was achieved at the 
CPEs in comparison to the MMCPEs and SMCPEs.  
Bolger et al., demonstrated an increase in the O2 current of 13.5 ± 3.7 nA, n = 4, whereas 
the MMCPEs and SMCPEs achieve an increase in the O2 current of 27.2 ± 6.0 nA, n = 8, 
and 33.0 ± 3.6 nA, n = 11, respectively (Bolger & Lowry, 2005). Although the responses 
achieved at the modified sensors were greater than the CPEs, they were not significantly 
different (MMCPEs vs. CPEs: P = 0.1607) and (SMCPEs vs. CPEs: P = 0.2090). 
 
 Saline Injection 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
SMCPEs 33.0 ± 3.6 22.4 ±  3.4  1.2 ± 0.2 9.1 ± 2.0 -153.2 ± 12.2 -159.1 ± 12.6 
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5.3.5 Effect of Anaesthesia 
 
Chloral hydrate is presented as colourless translucent crystals. It depresses the cerebrum, 
with loss of reflex excitability. It can be provided in an oral administration dissolved in 
water or injected through the use of an i.p. or intravenous injection. It can cause irritation to 
the mucosa in the stomach which would induce vomiting so dilution in water is necessary. 
It has been utilised with magnesium sulphate or magnesium sulphate and sodium 
pentobarbital for anaesthesia in horses and cattle which is stated to induce a quicker 
anaesthesia state, with a smoother emergence and a greater safety margin (Tranquilli et al., 
2013). It has also been used previously as a method of increasing striatal O2 levels (Lowry 
& Fillenz, 2001; Bolger & Lowry, 2005).  
Chloral hydrate is a non-volatile anaesthetic agent commonly utilised for animal surgery. It 
quickly metabolises into trichloroethanol and trichloroacetic acid creating general central 
nervous system (CNS) depression (Kawamoto et al., 1987). Trichloroethanol is alleged to 
be the active ingredient that induces anaesthesia (Tao & Auerbach, 1994). Figure 5.3.5.1, 
displays the effect of a typical administration of chloral hydrate (350 mg/kg i.p.) on the O2 
signal recorded with an MMCPE. 
  
5.3.5.1 MMCPE 
 
The effect of a typical i.p. injection of saline monitored by an MMCPE in the striatum of a 
freely moving rat is displayed in Figure 5.3.5.1. The chloral hydrate injection data in this 
Section was analysed using the results from 12 perturbations with 12 sensors in 7 animals. 
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Figure 5.3.5.1: A typical example of the effect of an injection of chloral hydrate (350 mg/kg, i.p.) on the 
O2 signal, monitored with an MMCPE in the striatum of a freely moving rat. Inset: Close-up of the 
signal recorded as a result of the chloral hydrate injection. The arrow is indicative of the point of 
injection.  
 
 
The i.p. injection of chloral hydrate demonstrated the same initial response as the i.p. saline 
injection; a brief increase in the O2 current (see inset, 5.3.5.1). However, this was followed 
by a much larger more long-lasting increase, which accompanied the behavioural changes 
associated with anaesthesia. Analysis of the data showed that the current increased 
significantly (P < 0.0001) from a baseline current of -158.1 ± 8.3 nA, n = 12, to a current of 
-264.0 ± 20.3 nA, n = 12, after 23.8 ± 4.4 minutes, n = 12, which equates to an increase of 
105.9 ± 16.4 nA, n = 12, representing a mean percentage change of 87.8 ± 6.4 %, n = 12. 
The current then decreased to a corresponding baseline level of -162.4 ± 8.2 nA, n = 12, (P 
= 0.0759) after 185.8 ± 15.2 minutes and the animals began to show recovery from the 
anaesthesia.      
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Table 5.3.5.1: Summary of results for a chloral hydrate injection, with the MMCPEs implanted in the 
striatum of freely moving rats (n = 12 with 12 sensors in 7 animals).   
 
5.3.5.2 SMCPE 
 
The effect of a typical administration of chloral hydrate (350 mg/kg i.p.) on the O2 signal, 
monitored with an SMCPE is presented in Figure 5.3.5.2. The chloral hydrate injection data 
in this Section was analysed using the results from 12 perturbations with 12 sensors in 5 
animals.  
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Figure 5.3.5.2: A raw data trace displaying a typical injection of chloral hydrate (350 mg/kg, i.p.) on the 
O2 signal, recorded with an SMCPE in the striatum of a freely moving rat. Inset: Close-up of the signal 
recorded as a result of the chloral hydrate injection. The blue arrow indicates the point of injection. 
 Chloral Hydrate Injection 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
MMCPEs 105.9 ± 16.4 87.8 ± 6.4 23.8 ± 4.4 185.8 ± 15.2 -158.1 ± 8.3 -162.4 ± 8.2 
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The initial response shown in the inset of Figure 5.3.5.2, displays a similar response to that 
attained with the saline i.p. injection which is similar to the result obtained for the 
MMCPE. A brief increase in the O2 current is observed, which has been shown to be due to 
the injection stress, followed by slower more long-lasting changes, which accompanied the 
behavioural changes associated with anaesthesia. Upon injection of chloral hydrate, there 
was a significant increase in the O2 response (P < 0.0001). A current change of 92.7 ± 13.4 
nA, n = 12, was achieved after 27.8 ± 5.3 minutes, n = 12, from a baseline of -158.6 ± 10.8 
nA, n = 12, to a current of -251.3 ± 21.9 nA, n = 12, representing a mean percentage change 
of 100.4 ± 1.6 %, n = 12. The current returned to a baseline level of -159.2 ± 11.3 nA, n = 
12, (P = 0.8239) after 215.0 ± 12.1 minutes, n = 12, had elapsed since the injection.   
 
 
 
Table 5.3.5.2: Summary of results for a chloral hydrate injection, with the SMCPEs implanted in the 
striatum of freely moving rats (n = 12 with 12 sensors in 5 animals).   
 
5.3.5.3 Comparison 
 
Direct comparison of the responses for both sensor types (MMCPEs) and (SMCPEs) 
reveals that for chloral hydrate administration, similar data traces are obtained. The 
percentage O2 change observed for MMCPEs and SMCPEs yielded a response of 87.8 ± 
6.4 %, n = 12 and 100.4 ± 1.6 %, n = 12, respectively, which depicts how the two sensors 
are equally capable of detecting O2 changes but also demonstrates how chloral hydrate 
increases the O2 current. A similar response was observed with CPEs as demonstrated by 
Bolger et al., (Bolger & Lowry, 2005). They attained an O2 current increase of 18.7 ± 3.1 
nA, n = 10. This was a much smaller change achieved with the CPEs in comparison to the 
responses obtained by the MMCPEs and SMCPEs. A significant difference was therefore 
 Chloral Hydrate Injection 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
SMCPEs 92.7 ± 13.4 100.4 ± 1.6 27.8 ± 5.3 215.0 ± 12.1 -158.6 ± 10.8 -159.2 ± 11.3 
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recorded for the different sensors (MMCPEs vs. CPEs: P = 0.0001) and (SMCPEs vs. 
CPEs: P < 0.0001).   
 
5.3.6 Acetazolamide (Diamox) Administration 
 
Acetazolamide (Diamox) is a carbonic anhydrase inhibitor that on systematic 
administration has been shown to increase brain tissue O2 (Dixon et al., 2002; Bolger & 
Lowry, 2005). Acetazolamide is used as an exploratory tool in cerebral blood flow 
experiments and also for the treatment of several diseases long term (Vorstrup et al., 1984). 
Measuring the cerebral blood flow response to diamox is a common test used to calculate 
the vasodilatory capacity of the cerebral circulation and is called the ACZ test (Okazawa et 
al., 2001). The use of DMSO as a vehicle for diamox administration was utilised also. 
DMSO has been implemented as a vehicle for diamox in the literature (Zhou & Kost, 2006; 
Shinohara et al., 2007; Mokhtari et al., 2013). 
DMSO is utilised as a solvent in many in-vitro and in-vivo studies and can cause many 
pharmacological effects (Yoon et al., 2006).  It has been demonstrated recently that the use 
of DMSO can cause an effect on the O2 current (Kealy et al., 2013), therefore the 
implementation of it as a vehicle and control with diamox, would cause inaccuracies in the 
results. Control studies were carried out using diamox in saline and DMSO in saline in 
order to determine if DMSO contributes to the current change. The effect of an 
administration of acetazolamide on the O2 current was monitored with MMCPEs and 
SMCPEs. 
 
 
 
 
 
 
 
  Chapter 5: In-Vivo Oxygen 
 
194  
 
5.3.6.1 MMCPEs 
 
The effect of a typical i.p. injection of diamox/DMSO, diamox/saline and DMSO/saline 
monitored by an MMCPE in the striatum of a freely moving rat is displayed in Figure 
(5.3.6.1.1), (5.3.6.1.2) and (5.3.6.1.3), respectively.  
 
5.3.6.1.1 Diamox (DMSO) Administration 
 
The diamox/DMSO injection data in this Section was analysed using the results from 5 
perturbations with 5 sensors in 2 animals. 
 
0 50 100 150 200 250 300
-300
-250
-200
-150
Time, mins
I,
 n
A
0 5 10 15 20 25 30
-300
-250
-200
-150
-100
Time, mins
I,
 n
A
 
Figure 5.3.6.1.1: A typical example of the effect of an administration of diamox (50 mg/kg) in DMSO 
(0.5 mL) and saline (1.0 mL) on the O2 response, recorded with an MMCPE in the striatum of a freely-
moving animal. The arrow is indicative of the point of injection. Inset: Close-up of the signal recorded 
as a result of the diamox (DMSO) injection. The arrow is indicative of the point of injection.  
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Upon administration of diamox, initially an injection stress response is observed as was 
observed with the saline and chloral hydrate injections (see Figure 5.3.6.1 inset). Following 
this response, there is an increase in the O2 current from a baseline of -163.1 ± 2.8 nA, n = 5 
to a current of -263.0 ± 7.1 nA, n = 5, (P = 0.0010). This yielded an increase of 99.9 ± 5.6 
nA, n = 5, after 12.0 ± 1.2 minutes, n = 5, representing a mean percentage increase of 61.3 
± 3.2 %, n = 5. A new baseline current of -176.1 ± 4.0 nA, which was significantly different 
(P = 0.0010) from pre baseline currents was achieved after 120.0 ± 1.0 minutes, n = 5. 
Previous work carried out in the lab using DMSO as a vehicle suggests an independent 
effect on O2 and glucose levels recorded using electrochemical sensors (Kealy et al., 2013). 
In order to determine if the effects observed were from the diamox alone, a solution of 
diamox and saline was administered. 
 
 
Table 5.3.6.1.1: Summary of results for a diamox (DMSO) injection, with the MMCPEs implanted in 
the striatum of freely moving rats (n = 5 with 5 sensors in 2 animals).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 Diamox (DMSO) Injection 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
MMCPEs 99.9 ± 5.6 61.3 ± 3.2 12.0 ± 1.2 120.0 ± 1.0 -163.1 ± 2.8 -176.1 ± 4.0 
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5.3.6.1.2 Diamox (Saline) Administration 
 
The diamox/saline injection data in this Section was analysed using the results from 3 
perturbations with 3 sensors in 3 animals. 
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Figure 5.3.6.1.2: A typical example of the effect of an administration of diamox (50 mg/kg) in saline (1.0 
mL) on the O2 response, recorded with an MMCPE in the striatum of a freely-moving rat. The arrow is 
indicative of the point of injection. Inset: Close-up of the signal recorded as a result of the diamox 
(saline) injection. The arrow is indicative of the point of injection. 
 
 
Figure 5.3.6.1.2, demonstrates how an injection of diamox in saline caused an increase in 
the O2 current that was not significant (P = 0.0761), from a baseline level of -135.0 ± 18.7 
nA, n = 3 to a current of -173.6 ± 26.8 nA, n = 3, after 117.5 ± 91.3, n = 3. This yielded a 
maximum O2 current increase of 38.6 ± 11.3 nA, n = 3, representing a mean percentage 
change of 28.1 ± 6.9 %, n = 3. The current returned to baseline currents of -138.4 ± 18.1 
nA, n = 3 (P = 0.2230) indicating a return to normoxic conditions after 450.0 ± 229.1 
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minutes, n = 3. Subsequent to these results, a solution of DMSO and saline was 
administered in order to determine the effects that DMSO has on the O2 response. 
 
 
Table 5.3.6.1.2: Summary of results for a diamox (DMSO) injection, with the MMCPEs implanted in 
the striatum of freely moving rats (n = 3 with 3 sensors in 3 animals).  
 
5.3.6.1.3 DMSO (Saline) Administration 
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Figure 5.3.6.1.3: A typical example of the effect of an administration of DMSO in saline on the O2 
response, recorded with an MMCPE in the striatum of a freely-moving rat. The arrow is indicative of 
the point of injection. 
 
 
The injection of a DMSO and saline mixture resulted in a slight increase in the O2 current 
recorded at the MMCPEs by 5.8 ± 3.5 nA, n = 3, from a mean baseline of -154.8 ± 6.8 nA, 
n = 3, to a current of -160.6 ± 4.2 nA, n = 3 after 57.0 ± 1.0 seconds, n = 3. The mean 
percentage increase in response to the DMSO/saline injection was 3.9 ± 2.4 %, n = 3. The 
resulting O2 increase was not significant (P = 0.2461). The current immediately began to 
fall and returned to a baseline of -156.0 ± 5.8 nA (P = 0.4703) within 7.0 ± 0.5 minutes, n = 
 Diamox (Saline) Injection 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
MMCPEs 38.6 ± 11.3 28.1 ±  6.9  117.5 ± 91.2  450.0 ± 229.1 -135.0 ± 18.7 - 138.4 ± 18.1 
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3. This result demonstrates how an injection of DMSO/saline does not seem to have an 
effect on the O2 current, an initial injection stress is observed on application of the injection 
which corresponds to the results obtained for the injection of saline in Figure 5.3.4.1. This 
validates the use of diamox/DMSO injections to increase striatal O2 levels since a 
significant increase was observed compared to diamox/saline. The reason for the 
insignificant increase from baseline can be attributed to the insolubility of diamox in saline 
alone. The SMCPEs were studied using the same experiments outlined previously for the 
MMCPEs.  
 
 
Table 5.3.6.1.3: Summary of results for a DMSO (saline) injection, with the MMCPEs implanted in the 
striatum of freely moving rats (n = 3 with 3 sensors in 1 animals).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DMSO (Saline) Injection 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (secs) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
MMCPEs 5.8 ± 3.5 3.9 ± 2.4 57.0 ± 1.0 7.0 ± 0.5 -154.8 ± 6.8 -156.0 ± 5.8 
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5.3.6.2 SMCPEs 
 
The effect of a typical i.p. injection of diamox/DMSO, diamox/saline and DMSO/saline 
monitored by an SMCPE in the striatum of a freely moving rat is displayed in Figure 
(5.3.6.2.1), (5.3.6.2.2) and (5.3.6.2.3), respectively. 
 
5.3.6.2.1 Diamox (DMSO) Administration 
 
The diamox (DMSO) injection data in this Section was analysed using the results from 7 
perturbations with 7 sensors in 2 animals. 
 
0 50 100 150 200 250 300
-400
-350
-300
-250
-200
-150
Time, mins
I,
 n
A
0 5 10 15 20
-400
-300
-200
-100
Time, mins
I,
 n
A
 
Figure 5.3.6.2.1: A typical example of the effect of an administration of diamox (50 mg/kg) in DMSO on 
the O2 response, recorded with an SMCPE in the striatum of a freely-moving rat. The arrow is 
indicative of the point of injection. Inset: Close-up of the signal recorded as a result of the diamox 
(DMSO) injection. The arrow is indicative of the point of injection. 
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Upon administration of diamox, there is a significant increase (P = 0.0003) in the O2 
current from a baseline of -170.1 ± 16.5 nA, n = 7 to a current of -303.2 ± 33.3 nA, n = 7. 
This yielded an increase of 133.0 ± 17.3 nA, n = 7, after 7.5 ± 2.1 minutes, n = 7, 
representing a mean percentage increase of 77.2 ± 4.6 %, n = 7. A corresponding baseline 
current returned after 135.7 ± 16.2 minutes, n = 7, yielding a current of -175.6 ± 4.6 nA, n 
= 7, (P = 0.0791). Similar to the MMCPEs a solution of diamox and saline was 
administered in order to determine the response of diamox without DMSO at the SMCPEs 
and if it compares to the result attained from the MMCPEs.   
 
 
 
Table 5.3.6.2.1: Summary of results for a diamox (DMSO) injection, with the SMCPEs implanted in the 
striatum of freely moving rats (n = 7 with 7 sensors in 2 animals).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Diamox (DMSO) Injection 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
SMCPEs 133.0 ± 17.3 77.2 ± 4.6 7.5 ± 2.1 135.7 ± 16.2 -170.1 ± 16.5 -175.6 ± 4.6 
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5.3.6.2.2 Diamox (Saline) Administration 
 
The diamox (saline) injection data in this section was analysed using the results from 2 
perturbations with 2 sensors in 2 animals. 
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Figure 5.3.6.2.2: A typical example of the effect of an administration of Diamox (50 mg/kg) in saline (1.0 
mL) on the O2 response, recorded with an MMCPE in the striatum of a freely-moving rat. The arrow is 
indicative of the point of injection. Inset: Close-up of the signal recorded as a result of the diamox 
(saline) injection. The arrow is indicative of the point of injection. 
 
 
Figure 5.3.6.2.2, demonstrates how an injection of diamox in saline caused an increase in 
the O2 current, from a baseline level of -176.7 ± 20.1 nA, n = 2, to a current of -286.3 ± 
14.7 nA, n = 2 which yielded a maximum O2 current increase of 109.6 ± 34.7 nA, n = 2, 
after 22.0 ± 10.5 minutes, n = 2 and representing a mean percentage change of 65.1 ± 27.0 
%, n = 2. The current returned to a new baseline level of -199.0 ± 24.8 nA, n = 2, indicating 
a return to normoxic conditions after 102.5 ± 2.5 minutes, n = 2. Subsequent to these 
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results, a solution of DMSO and saline was administered in order to determine the effects 
that DMSO has on the O2 response. 
 
 
Table 5.3.6.2.2: Summary of results for a diamox (DMSO) injection, with the SMCPEs implanted in the 
striatum of freely moving rats (n = 2 with 2 sensors in 2 animals). 
 
5.3.6.2.3 DMSO (Saline) Administration 
 
The diamox/saline injection data in this section was analysed using the results from 3 
perturbations with 3 sensors in 1 animal. 
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Figure 5.3.6.2.3: A typical example of the effect of an administration of DMSO in saline on the O2 
response, recorded with an SMCPE in the striatum of a freely-moving rat. The arrow is indicative of 
the point of injection. 
 
 
Figure 5.3.6.2.3, demonstrates how an injection of DMSO in saline caused a slight increase 
in the O2 current that was significant (P = 0.0263), from a baseline level of -153.6 ± 19.6 
 Diamox (Saline) Injection 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
SMCPEs 109.6 ± 34.7 65.1 ± 27.0 22.5 ± 10.5 102.5 ± 2.5 -176.7 ± 20.1  -199.0 ± 24.8 
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nA, n = 3 to a current of -174.5 ± 23.0 nA, n = 3. This yielded a maximum O2 current 
increase of 20.8 ± 3.5 nA, n = 3, after 3.0 ± 0.5 minutes, n = 3, representing a mean 
percentage change of 13.4 ± 0.7 %, n = 3. The current immediately returned to baseline 
currents of -155.5 ± 19.8 nA, n = 3 (P = 0.2504) indicating a return to normoxic conditions 
after 7.0 ± 0.5 minutes, n = 3. The SMCPEs response attained for a DMSO and saline 
injection yielded a result similar to what was observed with the MMCPEs in Figure 
5.3.6.1.3. It suggests that DMSO does not interfere with the increasing O2 current obtained 
when using it as a vehicle for diamox administration. 
 
 
Table 5.3.6.2.3: Summary of results for a DMSO (saline) injection, with the SMCPEs implanted in the 
striatum of a freely moving rat (n = 3 with 3 sensors in 1 animal).  
 
5.3.6.2.4 Comparison 
 
Similar results were obtained for the two sensors (MMCPEs and SMCPEs) for the diamox 
and control administrations in this section. Administration of diamox in DMSO for both 
sensors yielded an increase in the O2 response. Comparable percentage increases of 61.3 ± 
3.2 %, n = 5 and 77.2 ± 4.6 %, n = 7, were obtained for the MMCPEs and SMCPEs 
respectively. On administration of the control injection of diamox and saline, a percentage 
increase of 28.1 ± 6.9 %, n = 3, was obtained for the MMCPEs and 65.1 ± 27.0 %, n = 2, 
for the SMCPEs. The result for the SMCPEs was quite similar to the administration of 
diamox and DMSO, however, an explanation for the MMCPEs result could have been due 
to the difficulty of getting diamox to dissolve into a solution of saline causing a smaller 
amount of diamox being injected into the subject, therefore leading to a lower increase in 
O2.   
Comparable results were recorded for the administration of DMSO in saline for both the 
MMCPEs and SMCPEs. A percentage increase of 3.9 ± 2.4 %, n = 3, and 13.4 ± 0.7 %, n = 
 DMSO (Saline) Injection 
 Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
SMCPEs 20.8 ± 3.5  13.4 ± 0.7 3.0 ± 0.5 7.0 ± 0.5  -153.6 ± 19.6  -155.5 ± 19.8 
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3, were obtained for the MMCPEs and SMCPEs, respectively. A return to baseline was 
observed after 7.0 ± 0.5 minutes, n = 3 for the MMCPEs and after 7.0 ± 0.5 minutes, n = 3, 
for the SMCPEs, signifying that this increase was due to injection stress. Similar responses 
were also obtained for the saline injections. Previous work undertaken in the lab using 
DMSO as a vehicle suggested an independent effect on O2 and glucose levels recorded 
using electrochemical sensors. It was confirmed in this section that DMSO does not have 
an effect on the O2 signals and that it can be utilised as a vehicle without hampering the 
effect of diamox.  Observation of the results obtained with the standard CPEs displayed a 
current change of 43.0 ± 10.0 nA, n = 5, with an i.p injection of diamox in DMSO, 
however, the results displayed in this section show a greater response at the monomer 
modified sensors.     
 
5.3.7 Stability of O2 sensors 
 
In Chapter 4 the long term stability of the sensor in-vitro was determined over 28 days. The 
results demonstrated that the two sensors over the period of 28 days remained stable. When 
the long-term BT treatments were undertaken over 28 days the SMCPEs demonstrated no 
significant difference pre- and post-treatment (P = 0.5282). There was a slight decrease in 
O2 detection recorded at the MMCPEs after the 28 days that was significant (P = 0.0296), 
however, a high O2 sensitivity remained. The need to characterise the sensors in-vivo is due 
to the vast differences between the in-vivo and in-vitro environments. Also, the stability of 
the sensors needs to be examined in this harsh and complex biological milieu. In this 
section the stability of the sensors was determined in-vivo over the specified days and the 
results for both sensors are depicted in Figure 5.3.7.1 and 5.3.7.2. The O2 current was taken 
at approximately the same time every day so that an accurate representation of the baseline 
could be achieved.     
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5.3.7.1 MMCPE 
 
The baseline data in this section was analysed using the results from 6 animals with 12 
sensors over 12 Days. 
 
 MMCPE (% O2) decrease 
Day Mean (% O2) SEM n 
1.0 100.0 0.0 12 
2.0 84.5 3.8 12 
3.0 82.4 4.6 12 
4.0 87.0 4.9 12 
5.0 86.5 4.1 12 
6.0 83.7 5.4 12 
7.0 85.9 5.9 12 
8.0 83.8 6.4 12 
9.0 84.2 6.3 12 
10.0 81.6 5.4 12 
11.0 86.4 5.9 12 
12.0 83.5 5.9 12 
 
Table 5.3.7.1: The mean percentage table displaying the % decrease in O2 after implantation with 12 
sensors over 12 days in the striatum of 6 freely moving rats. 
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Figure 5.3.7.1: The averaged percentage O2 decrease vs. day profile of the MMCPEs over the course of 
12 days in the striatum of 6 freely moving rats with 12 sensors. 
 
The results displayed in Table 5.3.7.1 and Figure 5.3.7.1 demonstrates how stable the 
MMCPEs are over the 12 days of implantation in the in-vivo environment. Initially there is 
approximately a 15.5 % decrease in the O2 current that remains stable over the specified 
  Chapter 5: In-Vivo Oxygen 
 
206  
 
days. The in-vitro BT results displayed a decrease of 26.7 % with 4 sensors over 28 Days 
(see Section 4.3.5.5). The decrease observed in-vivo was slightly lower than this and a 
shorter period of time was spent in-vivo in comparison to the 28 Days spent in the ex-vivo 
BT, however both of these results are comparable. One-way ANOVA analysis revealed that 
the results for the in-vivo stability were not significantly different (P = 0.5813) over the 
course of the study.  
 
5.3.7.2 SMCPE 
 
The baseline data in this section was analysed using the results from 6 animals with 12 
sensors over 13 Days. 
 
 
 SMCPE (% O2) decrease 
Day Mean (% O2) SEM n 
1.0 100.0 0.0 12 
2.0 85.7 4.1 12 
3.0 88.3 3.3 12 
4.0 88.0 4.9 12 
5.0 87.2 5.3 12 
6.0 91.8 6.2 12 
7.0 90.8 6.6 12 
8.0 92.3 7.5 12 
9.0 97.9 8.1 12 
10.0 88.1 7.0 12 
11.0 92.1 7.2 12 
12.0 86.8 6.4 12 
13.0 90.7 9.0 12 
 
Table 5.3.7.2: The mean percentage table displaying the % decrease in O2 after implantation over 13 
days in the striatum of 6 freely moving rats with 12 sensors.  
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Figure 5.3.7.2: The averaged percentage O2 decrease vs. day profile of the SMCPEs over the course of 
13 days in the striatum of 6 freely moving rats with 12 sensors. 
 
 
The SMCPEs displayed a similar stability result to the MMCPEs over the specified time. A 
percentage decrease of approximately 14.4 % occurs after day 1 and the sensitivity remains 
stable thereafter, which indicates that the SMCPEs are quite robust and can remain constant 
after the specified time implanted. The in-vitro BT results displayed a decrease of 11.3 % 
with 4 sensors over 28 days (see Section 4.3.5.10). The decrease observed in-vivo was 
slightly higher than this and a shorter period of time was spent in-vivo in comparison to the 
28 days spent in the ex-vivo BT, however both of these results are comparable. One-way 
ANOVA analysis indicated no significant difference (P = 0.9322), between the currents 
obtained on the days specified.      
 
5.4 Conclusion 
 
Previously, CPEs were implanted for the detection of O2 in-vivo with both DPA and CPA 
techniques utilised due to their great stability over long periods of time (Lowry et al., 1996; 
Lowry et al., 1997; Bolger & Lowry, 2005). However, these sensors have been studied 
extensively and on interaction with the in-vivo environment the alteration of the sensors 
surface is inevitable. Even though this characteristic is the reason behind how stable the 
CPE sensors are whilst in a biological medium, the novel monomer modified sensors 
utilised in this chapter were created in order to try and retain stability over long periods of 
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time, whilst maintaining a good sensitivity without the alteration of the surface in any way. 
No leeching of constituents from the sensor is paramount for integration of this sensor into 
the clinical environment. 
Presented in this chapter are the results which confirm that both these sensors (MMCPE 
and SMCPE) detect changes in O2 resulting from the introduction of periods of hypoxia 
and hyperoxia by the administration of N2/air and O2/air mixtures to the snout of the 
subject. The effects of neuronal activation, administration of saline, chloral hydrate and 
diamox on the O2 sensors were also investigated. The compilation of all of these results led 
to the conclusion that both of these sensors would work as O2 sensors in a clinical 
environment. Table 5.4 (a) and 5.4 (b), detail a summary of all of the results for the 
MMCPEs and SMCPEs, respectively. They possess characteristics of stability, robustness 
and retaining structural integrity. They are very stable over the course of the days implanted 
and sensitivity only decreased slightly after day 1 in both sensor types.  
Due to the results attained by Kealy et al., with regards to DMSO causing a change in the 
O2 current upon administration, experiments were undertaken in order to replicate and 
confirm the results obtained by using the variety of administrations of diamox, DMSO and 
saline (Kealy et al., 2013). However, upon administration of DMSO and saline as a control, 
no long-term effect was observed at both the MMCPEs and SMCPEs. An injection stress 
was recorded just like that obtained from the saline injections, demonstrating that DMSO 
could be utilised as a vehicle for diamox administration without causing anomalies in the 
resulting O2 increase by diamox.  
The data presented in this chapter reveals how capable these O2 sensors are at detecting 
changes in O2 without the risk of biofouling, degradation or decaying of the sensors 
properties. Not only are these characteristics very promising but the increased sensitivity of 
the MMCPEs and SMCPEs in comparison to the CPEs is a very exciting and optimistic 
aspect of these monomer modified sensor designs. However the key finding from this body 
of work is the possible adoption of these novel sensors by clinical experts. The SEMs 
displayed in Chapter 4, Section 4.3.6.1 and 4.3.6.2, show that the sensors remain intact and 
are not modified upon removal from the harsh setting of the living brain. This indicates that 
the two sensors are good candidates for a prospective future in a clinical setting.         
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Table 5.4 (a) and 5.4 (b) summarise all the results attained for the characterisation of the 
MMCPEs and SMCPEs, respectively, in-vivo. 
 
 MMCPEs 
Administration Current change 
Δ I (nA) 
Max response 
(min) 
Return to baseline 
(min) 
Hypoxia 75.6 ± 4.0 2.5 ± 0.1 7.1 ± 0.4 
Hyperoxia 80.3 ± 6.3 3.0 ± 0.2 13.2 ± 0.7 
Restraint 26.8 ± 3.8 2.5 ± 0.3 28.1 ± 4.3 
Tail Pinch 31.4 ± 6.6 2.8 ± 0.3 28.3 ± 5.1 
Saline 27.2 ± 6.0 1.5 ± 0.2 5.8 ± 1.0 
Chloral hydrate 105.9 ±16.4 23.8 ± 4.4 185.8 ± 15.2 
Diamox (DMSO) 99.9 ± 5.6 12.0 ± 1.2 120.0 ± 1.0 
Diamox (saline) 38.6 ± 11.3 117.5 ± 91.2 450.0 ± 229.1 
DMSO (saline) 5.8 ± 3.5 57.0 ± 1.0 (secs) 7.0 ± 0.5 
 
Table 5.4 (a): Summary of in-vivo characterisation data for the MMCPE O2 sensor. 
 
 SMCPEs 
Administration Current change 
Δ I (nA) 
Max response 
(min) 
Return to baseline 
(min) 
Hypoxia 49.9 ± 2.9 1.7 ± 0.1 6.2 ± 0.4 
Hyperoxia 63.6 ± 3.7 2.9 ± 0.1 12.7 ± 0.7 
Restraint 22.0 ± 2.8 2.6± 0.3 8.9 ± 0.7 
Tail Pinch 30.8 ± 3.1 2.8 ± 0.2 27.1 ± 3.2 
Saline 33.0 ± 3.6 1.2 ± 0.2 9.1 ± 2.0 
Chloral hydrate 92.7 ± 13.4 27.8 ± 5.3 215.0 ± 12.1 
Diamox (DMSO) 133.0 ± 17.3  7.5 ± 2.1 135.7 ± 16.2 
Diamox (saline) 109.6 ± 34.7 22.5 ± 10.5 102.5 ± 2.5 
DMSO (saline) 20.8 ± 3.5 3.0 ± 0.5  7.0 ± 0.5 
 
Table 5.4 (b) Summary of in-vivo characterisation data for the SMCPE O2 sensor. 
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of Nitric Oxide Sensors 
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6.1 Introduction 
 
NO is one of the smallest molecules found in nature and is a gaseous free radical. It has 
been implicated in a variety of physiological and pathophysiological processes. It has a role 
in the regulation of vascular tone and some of the diseases that it has been linked to include 
hypertension, Parkinson‘s disease and Alzheimer‘s disease (Brown et al., 2005). In the late 
80‘s, NO was characterised as the endothelium derived relaxing factor (EDRF) (Ignarro et 
al., 1987; Palmer et al., 1987). The concentration of NO in physiological conditions has 
been established at around 0.1 µM (Hall & Garthwaite, 2009), which makes NO difficult to 
measure in-vivo but also to have the required specificity, sensitivity and speed in a sensor to 
detect it. It has a short half-life (typically < 10 s) due to the reactions with different 
molecules (Lancaster Jr, 1997).  
Due to the significance of this molecule with regards to biological functions and its role in 
many disease states, it is important to quantify levels of NO production in both abnormal 
and normal tissue. A sensor for the detection of NO has previously been characterised in-
vitro and in-vivo by our research group. This involved the use of Nafion
®
, which was 
thermally annealed to the electrode surface incorporating 5 pre-coats and 2 subsequent dip-
bake layers. Nafion
®
 has been utilised previously in the development of carbon fibre 
electrodes for the detection of NO (Friedemann et al., 1996; Pontié et al., 1999; Patel et al., 
2006) and dopamine (Rice & Nicholson, 1989).  
The negatively charged sulfonate groups on the Nafion
®
 layers repel negatively charged 
species like AA and NO2
-
 but facilitate neutral species like NO to pass through the 
membrane to the electrode surface (Yang et al., 2004; Zheng et al., 2009). This sensor 
resulted in the elimination of interferent signals like AA (which is the principal interferent 
in the brain), while effectively detecting NO (Brown et al., 2009). A potential of +900 mV 
vs. SCE was utilised as the optimum applied potential for the NO sensors. The electrodes 
were held at this potential as it corresponds to the applied potential utilised within our 
research group for the sensors (Brown et al., 2009). This potential has also been 
demonstrated in other literature (Pallini et al., 1998).  
In this chapter NO sensors that involve the Nafion
®
 layer, while incorporating an outer o-
PD layer are described. These sensors were developed by Brown et al., in order to try and 
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improve the response time of the sensor with respect to the detection of NO (Brown et al., 
2009). The utilisation of less Nafion
®
 layers meant that o-PD had to be incorporated into 
the design of the sensor as a permselective film against interferents. The monomer o-PD 
has previously been implemented in sensor designs as an effective barrier against 
electroactive species like AA (Friedemann et al., 1996; Kirwan et al., 2007; O‘Neill et al., 
2008).  
 
6.2 Experimental 
 
The instrumentation and software utilised are described in Section 3.2. All chemicals and 
solutions are detailed in Section 3.3. The manufacture of the various NO sensors is 
described in Section 3.4. All modifications to the sensors are detailed in Section 3.5. All 
data was carried out in PBS (pH 7.4) unless mentioned otherwise. A potential of +900 mV 
vs. SCE was applied to all working electrodes involved in the NO calibrations. The 
experimental calibrations were carried out by introducing aliquots of stock NO (synthesised 
as described in Section 3.10, (Brown et al., 2005) or from an NO cylinder (see Section 
3.10) into the electrochemical cell (see Figure 3.7). AA calibrations were performed 
subsequent to NO calibrations except for those discussed in Section 6.3.8, 6.3.12 and 
6.3.13. This resulted in the calibrations being performed when the NO current was 
returning back to baseline levels, so the drift observed below baseline is attributed to the 
removal of NO from solution.  
The data is represented as mean ± SEM and n represents the number of electrodes used 
unless mentioned otherwise. The slope (pA/µM) is used as an index of sensitivity which is 
defined as the change in response which results from a change in the concentration of the 
analyte. All statistical analysis was carried out using paired and unpaired t-tests which 
yielded a P value that was an indication of the significance of the results. Table 6.2 displays 
a summary of the P values and their significance. 
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P value Significance No. of asterisks 
< 0.001 Extremely significant *** 
0.001 to 0.01 Very significant ** 
0.01 to 0.05 Significant * 
> 0.05 Not significant ns 
 
Table 6.2: A table displaying a summary of the correspondence of the P value to the number of 
asterisks. 
 
6.3 Results and Discussion 
 
6.3.1 Bare Pt electrodes vs. NO sensors 
 
Initially, experiments were carried out utilising bare Pt electrodes to demonstrate how an 
unmodified sensor performs when calibrating with NO and AA. Although Pt electrodes 
detect NO, they also detect electroactive species that are present in abundance in the in-vivo 
environment owing to the lack of protective barrier layers on the sensor to block any 
unwanted species. AA is the main interferent that can inhibit an electrode‘s ability to detect 
a chosen analyte. It is present in the brain at a concentration of approximately 500 µM 
(Miele & Fillenz, 1996a). It is a water soluble vitamin that is known for its preventative 
role in the disease scurvy (Terpstra & Gruetter, 2004). It is utilised in the food industry as 
an antioxidant, to stabilise and prolong storage of manufactured goods (Casella & Guascito, 
1997).  
With regards to the body, it is essential for normal physiological function and is crucial for 
tissue growth and the healing of wounds (Iqbal et al., 2004). AA has been implemented in 
the health care industry where it can down-regulate cholesterol and lower blood sugar 
levels and insulin requirements, therefore decreasing the risk of cardiovascular disease 
(Rath & Pauling, 1990). The detection of AA has been demonstrated previously by Miele et 
al., and Lowry et al., utilising CPEs (Lowry et al., 1996; Miele & Fillenz, 1996a). AA is 
used extensively as an antioxidant agent in foods and drinks. It is also utilised in the health 
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care sector for therapeutic purposes (Raoof et al., 2001). Results recorded for AA 
calibrations on Pt sensors are displayed in Figure 6.3.1.1 and Table 6.3.1.1.   
 
6.3.1.1 AA detection at Pt Sensors 
 
 
 
 
 
 
 
 
Table 6.3.1.1: Average 0 to 1000 µM AA response obtained from calibrations using bare Pt electrodes, 
n = 14, carried out at + 900 mV vs. SCE. Background values subtracted. Mean background current = 
652 ± 88 pA. 
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Figure 6.3.1.1: (A) A current-concentration profile for AA at bare Pt disk electrodes (n = 14) at +900 
mV vs. SCE. (B) A typical raw data trace displaying the currents obtained using an electrode from (A). 
The blue arrows are indicative of an injection of AA. 
 
Calibrating the unmodified Pt electrodes over a range of 0 - 1000 µM AA concentration 
range yielded a sensitivity of 37 ± 1 pA/ µM, n = 14. The response of the sensor was linear 
over the specified range with an R
2
 value of 0.99. This result demonstrates how difficult it 
would be to detect NO at an unmodified electrode, as AA among other electroactive species 
 Pt Sensor (n = 14) 
[AA], M Mean I, pA  SEM 
0 0 0 
200 8115 683 
400 15616 1233 
600 22974 1770 
800 30443 2484 
1000 37063 2991 
A B
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would cause substantial interference. The detection of NO with a bare Pt electrode is 
discussed in Figure 6.3.1.2 and Table 6.3.1.2. 
 
6.3.1.2 NO detection at Pt Sensors 
 
 
 
 
 
 
 
 
Table 6.3.1.2: Average 0 to 1 µM NO response obtained from calibrations using bare Pt electrodes, n = 
14, carried out at +900 mV vs. SCE. Background values subtracted. Mean background current = 445 ± 
81 pA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 6.3.1.2 (A): A current-concentration profile for NO at bare Pt disk electrodes (n = 14) at 
+900 mV vs. SCE. (B): A typical raw data trace displaying the currents obtained using an electrode 
from (A). The blue arrows are indicative of an injection of NO. 
 
 
 Pt Sensor (n = 14) 
[NO], M Mean I, pA SEM 
0.0 0 0 
0.2 62 7 
0.4 139 9 
0.6 224 14 
0.8 296 19 
1.0 352 25 
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The NO response attained at unmodified Pt electrodes over a range of 0 - 1 µM NO 
concentration range yielded a sensitivity of 364 ± 10 pA/ µM, n = 14. The response of the 
sensor was linear over the specified range (R
2
 = 0.99). These results demonstrate that NO 
can be detected at an unmodified Pt electrode. The detection of NO is very low on a bare Pt 
electrode and with the interference from different species in the brain, working with an 
unmodified Pt electrode would be impossible. It is hypothesised that a possible reason for 
the low detection of NO at an unmodified electrode is due to adsorbed oxidation products 
from the oxidation of NO, decreasing the sensitivity at electrodes not modified with 
Nafion
®
 (Brown et al., 2009). The detection of AA and NO at Nafion
®
 modified Pt sensors 
are described in the following sections.  
 
6.3.2 Type 1 NO Sensor  
 
The Type 1 NO Sensor involves 5 pre-coats of Nafion
®
 (5 % solution in lower aliphatic 
alcohols/H2O mix) and two subsequent dip-bake layers annealed at 210 
º
C (see Section 
3.4.5.1). The extensive characterisation of this sensor in-vitro and in-vivo was carried out 
by Brown et al., (Brown et al., 2009; Finnerty et al., 2012a; Finnerty et al., 2012b). The 
results obtained during this body of work are shown in Figure 6.3.2.1 and Table 6.3.2.1 The 
purpose of these investigations was to determine if there was an increase in sensitivity 
observed with the newly developed Type 2 and Type 3 NO sensors when compared against 
this extensively characterised sensor type.  
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6.3.2.1 NO detection at Type 1 NO Sensors 
 
 
 
 
 
 
 
 
 
Table 6.3.2.1: Average 0 to 1 µM NO response obtained from calibrations using Type 1 NO Sensors, n = 
17, carried out at + 900 mV vs. SCE. Background values subtracted. Mean background current = 178 ± 
22 pA. 
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Figure 6.3.2.1: (A) A current-concentration profile for Type 1 NO Sensors (n = 17) at + 900 mV vs. 
SCE. (B) A typical raw data trace displaying the currents obtained using an electrode from (A). The 
blue arrows are indicative of an injection of NO. 
 
 
A sensitivity of 1104 ± 46 pA/ µM, n = 17 was observed for the Type 1 NO sensor over a 
concentration range of 0 - 1 µM NO. A linear response was achieved (R
2
 = 0.99). The 
results obtained, demonstrate a more sensitive sensor, with an increased detection of NO. 
The Nafion
®
 layer that is negatively charged, is highly permeable to NO (Cadenas & 
 Type 1 NO Sensor (n = 17) 
[NO], M Mean I, pA  SEM 
0.0 0 0 
0.2 232 24 
0.4 498 42 
0.6 728 48 
0.8 927 51 
1.0 1082 50 
A B
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Packer, 2002). Nafion
® 
contains a perfluorocarbon backbone that is hydrophobic and 
sulfonic groups that are hydrophilic. The hydrophobic nature of neutral NO assists 
hydrophobic interactions leading to permeation through the Nafion
® 
layer (Brown et al., 
2009). The response time of the Type 1 NO sensors has been deemed slow, yielding a time 
of 34 ± 3 s, n = 14, in comparison to bare Pt electrodes that have a response time that is 
much quicker (6.8 ± 1.1 s, n =28) (Brown et al., 2009). In order to try and improve the 
response time, Type 2 and 3 NO sensors were manufactured. AA calibrations were carried 
out on the Type 1 NO sensors following the NO calibrations in order to confirm that 
Nafion
®
 acts as a barrier against the interferent.  
 
6.3.2.2 AA detection at Type 1 NO Sensors 
 
 
 
 
 
 
 
 
 
 
Table 6.3.2.2: Average 0 to 1000 µM AA response obtained from calibrations using Type 1 NO Sensor, 
n = 17, carried out at + 900 mV vs. SCE. Background values subtracted. Mean background current = 
151 ± 13 pA. 
 
 
 
 
 
 
 
 
 
 
 
 Type 1 NO sensor (n = 17) 
[AA], M Mean I, pA SEM 
0 0 0 
200 -1 1 
400 -1 1 
600 -2 1 
800 -2 1 
1000 -3 1 
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Figure 6.3.2.2: (A) A current-concentration profile for Type 1 NO Sensors (n = 17) at +900 mV vs. SCE. 
(B) A typical raw data trace displaying the currents obtained using an electrode from (A). The blue 
arrows are indicative of an injection of AA. 
 
 
Calibrating the Type 1 NO sensors over the specified concentration range yielded a current 
at 1000 µM  of -3 ± 1 pA, n = 17. The results observed exhibit how the Nafion
®
 layers on 
the sensor repel AA from the surface. This is due to Nafion
® 
consisting of sulfonate 
functional groups that prevent the diffusion of anions to the surface of the sensor (Cadenas 
& Packer, 2002). The Type 1 NO sensor completely blocked AA interference and a 
negative sensitivity was obtained due to the observed baseline drift described in Section 
6.2. This observation can be attributed to the different NO sensors, (Type 2 NO sensors: see 
Section 6.3.3.2 and Type 3 NO sensors: see Section 6.3.4.2). 
 NO has a very short half-life (Lancaster Jr, 1997) and so to detect the analyte in-vivo, a 
sensor needs to respond very quickly to changes in the concentrations of NO. In order to 
develop a sensor that had a quicker response time, Brown et al., reduced the thickness of 
the Nafion
®
 layers in combination with a poly(o-PD) layer (Brown et al., 2009). The 
following sections describe the different types of NO sensors that contain less layers of 
Nafion
®
 and have an outer layer of o-PD.  
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6.3.3 Type 2 NO sensor 
 
The Type 2 NO sensor involves 1 pre-coat, 2 applications of Nafion
®
 (5 % solution in 
lower aliphatic alcohols/H2O mix), annealed after each coat at 210 ºC, followed by 
polymerisation with o-PD for 30 minutes (see Section 3.4.5.2). The results obtained are 
described in Figure 6.3.3.1 and Table 6.3.3.1.  
 
6.3.3.1 NO detection at Type 2 NO sensors 
 
  
 
 
 
 
 
 
Table 6.3.3.1: Average 0 to 1 µM NO response obtained from calibrations using Type 2 NO Sensor, n = 
38, carried out at + 900 mV vs. SCE. Background values subtracted. Mean background current = 43 ± 
19 pA. 
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Figure 6.3.3.1: (A) A current-concentration profile for Type 2 NO Sensors (n = 38) at +900 mV vs. SCE. 
(B) A typical raw data trace displaying the currents obtained using an electrode from (A). The blue 
arrows are indicative of an injection of NO. 
 Type 2 NO Sensor (n = 38) 
[NO], M Mean I, pA  SEM 
0.0 0 0 
0.2 195 10 
0.4 424 19 
0.6 644 24 
0.8 873 29 
1.0 1047 34 
A B
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The response attained at Type 2 NO sensors over a concentration range of 0 - 1 µM NO 
yielded a sensitivity of 1070 ± 19 pA/ µM, n = 38. A linear response was observed (R
2
 = 
0.99). The results achieved demonstrate how the Nafion
®
 layers on the surface of the sensor 
retain a good sensitivity towards NO. According to the results attained in literature for the 
Type 2 NO sensors, a response of 19.0 ± 3.4 seconds was obtained (Brown et al., 2009). 
This was similar to the response achieved in this research with the Type 2 NO sensors (18 ± 
2 seconds, n = 38). This demonstrated a much faster response time than previously 
observed for the Type 1 NO sensor. AA calibrations were carried out subsequent to the NO 
calibrations in order to confirm that Nafion
®
 along with the PPD layer was an adequate 
barrier against the interferent.  
 
6.3.3.2 AA detection at Type 2 NO sensors 
 
 
 
 
 
 
 
 
 
Table 6.3.3.2: Average 0 to 1000 µM AA response obtained from calibrations using Type 2 NO sensor, 
n = 38, carried out at + 900 mV vs. SCE. Background values subtracted. Mean background current = 
199 ± 23 pA. 
 
 
 
 
 
 
 
 
 
 
 Type 2 NO sensor (n = 38) 
[AA], M Mean I, pA SEM 
0 0 0 
200 -6 4 
400 -6 4 
600 -7 4 
800 -6 5 
1000 -6 6 
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Figure 6.3.3.2 (A) A current-concentration profile for Type 2 NO Sensors (n = 38) at +900 mV vs. SCE. 
(B) A typical raw data trace displaying the currents obtained using an electrode from (A). The blue 
arrows are indicative of an injection of AA. 
 
At a concentration of 1000 µM a current of -6 ± 6 pA, n = 38 was observed at the Type 2 
NO sensors. The results obtained demonstrate how the Nafion
®
 layers along with the PPD 
layer on the surface of the sensor repel AA. The Type 2 NO sensor completely blocked AA 
interference and a negative sensitivity was obtained due to baseline drift. 
 
6.3.4 Type 3 NO sensor 
 
The Type 3 NO sensor involved applying 2 pre-coats of Nafion
®
 (5 % solution in lower 
aliphatic alcohols/H2O mix), followed by 1 application of Nafion
®
, annealed at 210 ºC, then 
1 dip into 5% Nafion
®
 solution, annealed at 210 ºC and finally polymerisation with o-PD 
for 30 minutes. The results obtained are displayed below in Figure 6.3.4.1 and Table 
6.3.4.1.  
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6.3.4.1 NO detection at Type 3 NO Sensors 
 
 
 
 
 
 
 
 
Table 6.3.4.1: Average 0 to 1 µM NO response obtained from calibrations using Type 3 NO Sensor, n = 
38, carried out at + 900 mV vs. SCE. Background values subtracted. Mean background current = 148 ± 
56 pA.  
 
 
 
 
 
 
 
 
  
Figure 6.3.4.1: (A) A current-concentration profile for Type 3 NO Sensors (n = 38) at + 900 mV vs. 
SCE. (B) A typical raw data trace displaying the currents obtained using an electrode from (A). The 
blue arrows are indicative of an injection of NO. 
 
 
Calibrating the Type 3 NO sensors over a range of 0 - 1 µM NO concentration yielded a 
sensitivity of 990 ± 14 pA/ µM, n = 38. A linear response over the specified range was 
obtained (R
2
 = 0.99). The results achieved demonstrate how even though a different method 
is utilised for the manufacture of the Type 3 NO sensor with Nafion
®
 and PPD, a similar 
sensitivity towards NO is retained. Also the response time is improved once more, 
displaying a much quicker reaction at the surface in comparison to the Type 1 NO sensors 
 Type 3 NO Sensor (n = 38) 
[NO], M Mean I, pA SEM 
0.0 0 0 
0.2 170 9 
0.4 378 18 
0.6 582 27 
0.8 789 36 
1.0 975 46 
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(16 ± 2 seconds, n = 38).  AA calibrations were carried out subsequent to the NO 
calibrations, these result are shown in Figure 6.3.4.2 and Table 6.3.4.2. 
 
6.3.4.2 AA detection at Type 3 NO Sensors 
 
 
 
 
 
 
 
 
 
Table 6.3.4.2: Average 0 to 1000 µM AA response obtained from calibrations using Type 3 NO Sensor, 
n = 38, carried out at + 900 mV vs. SCE. Background values subtracted. Mean background current = 
226 ± 27 pA.  
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Figure 6.3.4.2: (A) A current-concentration profile for Type 3 NO Sensors (n = 38) at +900 mV vs. SCE. 
(B) A typical raw data trace displaying the currents obtained using an electrode from (A). The blue 
arrows are indicative of an injection of AA. 
 
At a concentration of 1000 µM a current of -18 ± 6 pA, n = 38 was observed at the Type 3 
NO sensors. The results obtained demonstrate how the Nafion
®
 layers along with the PPD 
layer on the electrode prevent AA from being detected by the sensor. The Type 3 NO 
sensor completely blocked AA interference and a negative sensitivity was obtained due to 
 Type 3 NO Sensor (n = 38) 
[AA], M Mean I, pA SEM 
0 0 0 
200 0 2 
400 -5 4 
600 -7 3 
800 -10 3 
1000 -18 6 
A B
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baseline drift. This drift in current is due to AA calibrations occurring subsequent to the NO 
calibrations. The PBS is purged with N2 to remove the NO present; therefore the 
calibrations were performed on a decreasing current which had not settled fully. Figure 
6.3.5, displays NO and AA calibration comparisons of all the sensors.  
 
6.3.5 Comparison of Sensors 
 
6.3.5.1 NO Detection  
 
The detection of NO at the varying sensors is compared in Figure 6.3.5.1 (a). There is a 
large increase in the detection of NO at the modified sensors in comparison to the 
unmodified Pt sensors.  
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Figure 6.3.5.1 (a): A bar chart displaying a comparison of all NO sensitivities attained at each sensor, 
carried out at +900 mV vs. SCE.  
 
 
A significant difference was observed between the unmodified Pt sensor and the modified 
Nafion
®
 and PPD sensors (P < 0.0001). This is due to the negative charges of Nafion
®
 that 
attract the NO to the surface of the sensor and prevent HNO2 which is a product of the NO 
oxidation from adsorbing to the surface and thus decreasing the detection of NO (Brown et 
al., 2009). This demonstrates the advantages of modifying the Pt sensor for detection of 
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NO. In Figure 6.3.5.1 (b) an AA comparison between the sensors is depicted, confirming 
the utmost importance of applying modifications to the sensor for preventing the detection 
of AA. A significant difference was recorded for all the sensors against the bare Pt sensor 
(P < 0.0001). 
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Figure 6.3.5.1 (b): A bar chart displaying a comparison of all AA sensitivities obtained at each sensor, 
carried out at +900 mV vs. SCE at 1000 µM AA. 
 
 
It is clear from Figure 6.3.5.1 (b) that the modified Pt sensors offer a much improved 
selectivity over the unmodified Pt sensor. A large AA response is detected at the Pt 
electrode whilst the altered Pt sensors give little or no response to AA, indicating that these 
sensors are sensitive and selective for detection of the analyte NO.   
 
6.3.6 NO cylinder vs. NO synthesis 
 
6.3.6.1 NO Synthesis 
 
In this Section, the synthesis of NO, along with a comparison of the two types of NO 
sensor‘s sensitivity with relation to the different methods of NO collection will be 
discussed. In Chapter 3, Section 3.10, an illustration of the NO synthesis is portrayed. The 
synthesis of NO has been demonstrated by many research groups utilising varying ways of 
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synthesis (Mesároš et al., 1997; Casero et al., 2002; Zhang et al., 2002b).  The use of a pure 
NO commercial gas cylinder has been reported in the literature and is quite a common 
method of producing NO standard solutions (Pallini et al., 1998; Casero et al., 2000; 
Meulemans, 2002).  
At the beginning of this research the synthesis of NO was produced in-house by a method 
previously demonstrated in our group (Brown et al., 2005). Brown et al., modified methods 
of NO production, that were previously reported in literature (Zhang et al., 2002a; Zhang et 
al., 2002b). After some issues of reproducibility had occurred, an NO cylinder was utilised 
thereafter, as a means of collecting NO effectively. Once the NO gas had been collected, 
the determination of the concentration of the NO stock solution was undertaken utilising 
commercially available reagents and UV-visible spectroscopy. This method of analysis was 
implemented by our group however it was originally demonstrated by Nims et al., (Nims et 
al., 1995).  
After deciding to use the NO cylinder instead of the NO synthesis, responses attained at the 
sensors along with the reproducibility of the NO concentration yielded values previously 
achieved in our lab with these sensors. A comparison of the two sensors utilising the NO 
synthesis and cylinder are illustrated in Chapter 3, Figure 6.3.7.1 and Figure 6.3.7.2. 
 
6.3.7 Comparison of NO Synthesis and NO Cylinder 
 
During the course of the research it was noted that the in-house synthesis of NO (Brown & 
Lowry, 2003) demonstrated variations in response at the NO sensors. It was sometimes not 
reliable and yielded results that were not consistent. The NO cylinder was chosen so that a 
saturated concentration of NO would be attained and a more consistent NO response would 
occur each time the NO was collected. A comparison utilising the two different types of 
sensors is detailed in Figure 6.3.7.1 and Figure 6.3.7.2.  
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6.3.7.1 Type 2 NO sensor (synthesis vs. cylinder) 
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Figure 6.3.7.1: A current-concentration profile displaying a comparison between the NO synthesis and 
cylinder in PBS (pH 7.4), at +900 mV vs. SCE, carried out with Type 2 NO sensors. 
 
 
Figure 6.3.7.1 displays the calibrations carried out on the Type 2 NO sensors using the NO 
synthesis (n = 82) and NO cylinder (n = 32). Sensitivities of 715 ± 11 pA/µM (NO 
synthesis) and 1143 ± 14 pA/µM (NO cylinder) were obtained. There was a very distinct 
difference between the NO synthesis and NO cylinder data recorded yielding a significant 
difference (P < 0.0001). In order to determine that it was the inconsistency of the NO 
synthesis and not just the sensors. The Type 3 NO sensors were studied in a similar manner 
to confirm the discrepancy in the synthesis. The results are demonstrated in Figure 6.3.7.2.   
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6.3.7.2 Type 3 NO sensor (synthesis vs. cylinder) 
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Figure 6.3.7.2: A current-concentration profile displaying a comparison between the NO synthesis and 
cylinder in PBS (pH 7.4), at +900 mV vs. SCE, carried out with Type 3 NO sensors. 
 
 
Calibrations carried out on the Type 3 NO sensors using the NO synthesis (n = 77) and NO 
cylinder (n = 35) are displayed in Figure 6.3.7.2. Sensitivities of 639 ± 6 pA/µM (NO 
synthesis) and 982 ± 8 pA/µM (NO cylinder) were obtained. There was a significant 
difference (P < 0.0001) between the NO synthesis and NO cylinder data recorded. From the 
results obtained with the Type 2 and Type 3 NO sensors it has been established that the NO 
cylinder gave a more reliable NO response with each of the sensors. This way of collecting 
NO was utilised throughout the rest of the research as it was consistent, easy to use and did 
not take as long to collect the NO, in comparison to the production of the NO through the 
synthesis pathway.      
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6.3.8 Selectivity studies 
 
6.3.8.1 Long term stability investigations on PPD layer 
 
Stability studies were carried out on the PPD layer that is incorporated into the manufacture 
of Type 2 and 3 NO sensors as an outer layer against the interferent AA. Experiments were 
carried out utilising different storage conditions and calibrated at specified days. The days 
chosen varied as we wanted to confirm whether successive calibrations caused substantial 
damage to the interference layer on the sensor or whether it was the sensors ability to retain 
selectivity, deteriorating over time. The sensors were also kept in different conditions, in 
order to determine the optimum setting for storage.  
The use of Pt (PPD) sensors for neurochemical monitoring, has been demonstrated by 
many research groups (Lowry & O'Neill, 1994; Kirwan et al., 2007; Ariffin et al., 2012; 
Govindarajan et al., 2013). The sole purpose of the PPD layer on these sensors has been to 
reject interference from unwanted electroactive species. The electrodes were also stored in 
PBS in the fridge at 4 
º
C when not in use. This storage condition was utilised, along with 
other storage conditions to demonstrate the stability of the sensor in varying environments.  
Figure 6.3.8.1.1.1 and Table 6.3.8.1.1.1 (a) displays the results from the Pt (PPD) sensors 
stored in an enclosed dry container in the fridge at 4 
º
C. Repeated calibrations were carried 
out on these sensors and in between the calibration days the sensors were placed back in the 
fridge. 
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6.3.8.1.1 Pt (PPD) Sensor  
 
6.3.8.1.1.1 Storage: Fridge at 4 
°
C (Enclosed container)  
 
 [AA], 1000 µM  
Day Mean I, pA SEM 
1 138 19 
3 147 10 
7 150 53 
14 590 224 
28 1847 684 
56 2707 1031 
 
Table 6.3.8.1.1.1 (a): Average AA response obtained from calibrations at 1000 µM, using Pt electrodes 
modified with PPD, Day 1 to Day 56 (n = 4), carried out at +900 mV vs. SCE. Background values 
subtracted. Mean background current = 300 ± 36 pA (Day 1), 210 ± 42 pA (Day 3), 267 ± 46 pA (Day 7), 
279 ± 26 pA (Day 14), 359 ± 56 pA (Day 28) and 178 ± 24 pA (Day 56).  
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Figure 6.3.8.1.1.1: A bar chart displaying the AA sensitivity obtained at a concentration of 1000 µM 
with PPD modified Pt electrodes, (n=4), at +900 mV vs. SCE.  
 
Figure 6.3.8.1.1.1 and Table 6.3.8.1.1.1 (a) demonstrate a rise in AA detection over the 56 
days of repeated calibrations. A significant difference was observed after day 28 (see Table 
6.3.8.1.1.1 (b)). 
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Day P value Significance 
1 vs. 3 0.6749 ns 
1 vs. 7 0.8343 ns 
1 vs. 14 0.0905 ns 
1 vs. 28 0.0466 * 
1 vs. 56 0.0471 * 
 
Table 6.3.8.1.1.1 (b): A summary displaying the P values obtained for the Pt (PPD) sensor over 56 Days 
at 4 
°
C in an enclosed container. 
 
A current of 138 ± 19 pA (day 1) and 2707 ± 1031 pA (day 56) at 1000 µM AA 
concentration was obtained. This shows a degradation of the PPD rejection layer over the 
period of days studied. In order to confirm that this was in fact the deterioration of the 
electrode and not the amount of repeated calibrations carried out on the sensors, fewer 
calibrations were carried out on another set of Pt (PPD) sensors at day 1, day 56 and day 
168 utilising the same storage conditions.  
 
6.3.8.1.1.2 Storage: Fridge at 4 °C (Enclosed container) 
 
 Day 1 Day 56 Day 168 
[AA], M Mean I, pA SEM Mean I, pA SEM Mean I, pA SEM 
1000 19 4 24 2 3490 1276 
 
Table 6.3.8.1.1.2: Average AA responses obtained at 1000 M from calibrations using Pt electrodes 
modified with PPD (n = 4), on Day 1 to Day 168, carried out at +900 mV vs. SCE. Background values 
subtracted. Mean background current = 78 ± 3 pA (Day 1), 54 ± 2 pA (Day 56) and 3565 ± 228 pA (Day 
168). 
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Figure 6.3.8.1.1.2: A bar chart displaying the AA sensitivity obtained at a concentration of 1000 µM 
with PPD modified Pt electrodes, (n = 4), at +900 mV vs. SCE.  
 
At an AA concentration of 1000 µM, a current of 19 ± 4 pA (day 1) and 24 ± 2 pA (day 56) 
was recorded yielding no significant difference in the AA current after 56 days (P = 
0.3280). This result demonstrates a correlation between the amount of repeated calibrations 
carried out on the one set of sensors over time and the degradation of the PPD layer. A 
significant difference (P = 0.0471) was observed between the repeated calibration (day 1-
56) on the Pt (PPD) sensors shown in Figure 6.3.8.1.1.1, whereas these results highlight 
that there is no significant difference (day 1-56) on the Pt (PPD) sensors (P = 0.3280). The 
result obtained at 1000 µM AA concentration on day 168 displayed an AA response that 
was significantly different (P = 0.0346). The response was higher (3490 ± 1276 pA) than 
the response recorded at day 56, demonstrating a deterioration of the PPD layer after this 
amount of time.  
As previously stated, Pt (PPD) sensors have been stored by other research groups in PBS in 
the fridge when not in use (Lowry & O'Neill, 1994; Kirwan et al., 2007). This storage 
condition was then employed to see if the stability of the sensor would be improved by 
applying the same experimental procedures as in the previous section i.e. repeating 
calibrations frequently over 56 Days and repeated calibrations less frequent over 168 Days. 
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6.3.8.1.1.3 Storage: Fridge at 4 
°
C (Enclosed container with N2 Saturated PBS) 
 
 [AA], 1000 µM  
Day Mean I, pA SEM 
1 201 25 
3 134 20 
7 406 131 
14 934 218 
28 1364 359 
56 2319 637 
 
Table 6.3.8.1.1.3 (a): Average AA responses observed at 1000 M from calibrations using Pt electrodes 
modified with PPD (n = 4), on Day 1 to Day 56, carried out at +900 mV vs. SCE. Background values 
subtracted. Mean background current = 227 ± 54 pA (Day 1), 247 ± 60 pA (Day 3), 304 ± 80 pA (Day 7), 
314 ± 48 pA, 1044 ± 17 pA (Day 28) and 278 ± 106 pA (Day 56). 
 
 
D
ay
 1
D
ay
 3
D
ay
 7
D
ay
 1
4
D
ay
 2
8
D
ay
 5
6
0
200
400
600
1000
2000
3000
4000
Day 1
Day 3
Day 7
Day 14
Day 28
Day 56
I,
 n
A
*
*
*
 
Figure 6.3.8.1.1.3: A bar chart displaying the AA sensitivity obtained at a concentration of 1000 µM 
with PPD modified Pt electrodes, (n = 4), at +900 mV vs. SCE.  
 
The results displayed in Figure 6.3.8.1.1.3 and Table 6.3.8.1.1.3 (a), depict that over the 56 
days a similar degradation of the AA rejecting PPD layer can be observed as was seen with 
the repeated calibrations undertaken in Figure 6.3.8.1.1.1 in the dry enclosed container. 
Table 6.3.8.1.1.3 (b) details the resulting P values for each of the Days. 
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Day P value Significance 
1 vs. 3 0.0805 ns 
1 vs. 7 0.1736 ns 
1 vs. 14 0.0155 * 
1 vs. 28 0.0179 * 
1 vs. 56 0.0160 * 
 
Table 6.3.8.1.1.3 (b): A summary displaying the P values obtained for the Pt (PPD) sensor over 56 Days 
at 4 
°
C in an enclosed container with N2 saturated PBS. 
 
A significantly different AA response from Day 14 was recorded. Subsequent to this result, 
fewer calibrations were undertaken utilising the same experimental conditions in Figure 
6.3.8.1.1.4, to demonstrate whether the repeated calibrations are a cause of the deteriorating 
PPD layer or is the storage conditions playing a part in the diminishing AA barrier. 
 
6.3.8.1.1.4 Storage: Fridge at 4 
°
C (Enclosed container with N2 Saturated PBS) 
 
[AA], M Day 1 Day 56 Day 168 
 Mean I, pA SEM Mean I, pA SEM Mean I, pA SEM 
1000 18 7 1123 121 4057 122 
 
Table 6.3.8.1.1.4 (a): Average AA responses obtained at 1000 M from calibrations using Pt electrodes 
modified with PPD (n = 4), on Day 1 to Day 168, carried out at +900 mV vs. SCE. Background values 
subtracted. Mean background current = 111 ± 17 pA (Day 1), 79 ± 4 pA (Day 56) and 4471 ± 158 pA 
(Day 168). 
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Figure 6.3.8.1.1.4: A bar chart displaying the AA sensitivity obtained at a concentration of 1000 µM 
with PPD modified Pt electrodes (n = 4), at +900 mV vs. SCE. 
 
Figure 6.3.8.1.1.4 and Table 6.3.8.1.1.4 (a) demonstrate currents of 18 ± 7 pA (Day 1), 
1123 ± 121 pA (Day 56) and 4057 ± 122 pA (Day 168). There is a significant difference 
from day 1 - day 56 (P < 0.0001) and from day 1 to day 168 (P < 0.0001). These results 
were not expected as the sensors were only calibrated once prior to day 56. It was 
hypothesised that keeping the sensors in PBS is not the optimum storage condition for the 
sensors. More studies were undertaken to try and confirm this theory. Calibrations were 
carried out less frequently as results recorded for repeated calibrations in Figure 6.3.8.1.1.1 
and Figure 6.3.8.1.1.3 suggest that constant calibrations on the sensor diminishes the PPD 
layer prematurely. The sensors were placed in a N2 saturated dry enclosed container and 
calibrated at day 1, day 56 and day 168, the results are illustrated in Table 6.3.8.1.1.5 and 
Figure 6.3.8.1.1.5. 
 
6.3.8.1.1.5 Storage: Fridge at 4 
°
C (Enclosed container N2 saturated) 
 
 
 
 
 
Table 6.3.8.1.1.5: Average AA responses obtained at 1000 M from calibrations using Pt electrodes 
modified with PPD (n = 8), on day 1 to day 168, carried out at +900 mV vs. SCE. Background values 
subtracted. Mean background currents = 139 ± 31 pA (Day 1), 2029 ± 103 pA (Day 56) and 2735 ± 375 
pA (Day 168). 
[AA], M Day 1 Day 56 Day 168 
 Mean I, pA SEM Mean I, pA SEM Mean I, pA SEM 
1000 251 27 295 105 222 131 
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Figure 6.3.8.1.1.5: A bar chart displaying the AA sensitivity obtained at a concentration of 1000 µM 
with PPD modified Pt electrodes (n = 8), at +900 mV vs. SCE. 
 
 
The response attained day 1 - day 168 at an AA concentration of 1000 µM, displayed a 
slight increase on day 56 that was not significant (P = 0.6952) and after day 168 the AA 
response was also not significantly different (P = 0.8310). This was a very promising result, 
as the sensors did not seem to be degrading over time and even after the three calibrations. 
This provides more evidence that a dry environment is the optimum condition for storing 
the Pt (PPD) sensors. The final place of storage for the sensors was the freezer and these 
results are displayed in Figure 6.3.8.1.1.6 and Table 6.3.8.1.1.6.  
 
6.3.8.1.1.6 Storage: Freezer at -20 
°
C (Enclosed container)  
 
[AA], M Day 1 Day 56 Day 168 
 Mean I, pA SEM Mean I, pA SEM Mean I, pA SEM 
1000 139 23 804 302 1706 615 
 
Table 6.3.8.1.1.6: Average AA responses at 1000 M obtained from calibrations using Pt electrodes 
modified with PPD (n = 8), on day 1 to day 168, carried out at +900 mV vs. SCE. Background values 
subtracted. Mean background currents = 324 ± 53 pA (Day 1), 132 ± 21 pA (Day 56) and 2049 ± 269 pA 
(Day 168). 
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Figure 6.3.8.1.1.6: A bar chart displaying the AA sensitivity obtained at a concentration of 1000 µM 
with PPD modified Pt electrodes (n = 8), at +900 mV vs. SCE.   
 
 
A current of 139 ± 23 pA (day 1), 804 ± 302 pA (day 56) and 1706 ± 615 pA (day 168) was 
observed for the Pt (PPD) sensors at an AA concentration of 1000 µM. The results were 
significantly different day 1 to day 56 (P = 0.0451). Day 1 to day 168 displayed a 
significant difference in the AA response also (P = 0.0232). Similar to the results observed 
with the Pt (PPD) sensors in N2 saturated PBS, placing the sensors in the freezer does not 
offer an environment that keeps the PPD layer stable. From all of the results obtained and 
discussed in this section, it is confirmed that the necessary conditions for the PPD layer on 
the Pt (PPD) sensors to remain stable is a dry environment in the fridge at 4 
°
C. These 
studies have not been performed before and it has become more important as our group 
looks at commercialising these sensors. Customers will want to know what the optimum 
conditions are for storage and how long the sensors can be stored, without an effect on the 
sensors performance. Following on from this section, long term storage stability 
experiments were undertaken utilising the Type 1 NO Sensor which contains Nafion
®
 alone 
as the design (see Section 3.4.5.3).    
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6.3.8.2 Long term stability studies on different types of NO sensors   
 
6.3.8.2.1 Type 1 NO Sensor 
 
6.3.8.2.1.1 Storage: Fridge at 4 
°
C (Enclosed container) 
 
 [AA], 1000 µM  
Day Mean I, pA SEM 
1 131 29 
3 260 211 
7 592 328 
14 1254 902 
28 1598 1099 
56 3239 1175 
 
Table 6.3.8.2.1.1 (a): Average AA responses at 1000 M obtained from calibrations using Type 1 NO 
sensors (n = 3), on Day 1 to Day 56, carried out at +900 mV vs. SCE. Background values subtracted. 
Mean background current = 72 ± 4 pA (Day 1), 48 ± 6 pA (Day 3), 41 ± 6 pA (Day 7), 56 ± 3 (Day 14), 
34 ± 5 pA (Day 28) and 19 ± 2 pA (Day 56).  
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Figure 6.3.8.2.1.1: A bar chart displaying the AA sensitivity obtained at a concentration of 1000 µM 
with Type 1 NO sensors (n = 4), at +900 mV vs. SCE.  
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The results recorded with the Type 1 NO sensor displays no significance from day 1 to day 
28; P values are depicted in Table 6.3.8.2.1.1 (b). However, a significant increase is 
observed at day 56 (P = 0.0383). This demonstrates a trend of deterioration in the sensor 
with each calibration undertaken. 
 
Day P value Significance 
1 vs. 3 0.5650 ns 
1 vs. 7 0.2119 ns 
1 vs. 14 0.2597 ns 
1 vs. 28 0.2306 ns 
1 vs. 56 0.0383 * 
 
Table 6.3.8.2.1.1 (b): A summary displaying the P values obtained for the Pt (PPD) sensor over 56 Days 
at 4 
°
C in an enclosed container. 
 
 A similar trend was encountered with the Pt (PPD) sensors (see Section 6.3.8.1.1). The 
same experiments were undertaken in order to confirm if it was an effect of repeated 
calibrations on the sensor or time that deteriorated the sensors ability to block AA.       
 
6.3.8.2.1.2 Storage: Fridge at 4 
°
C (Enclosed container) 
 
[AA], M Day 1 Day 56 Day 168 
 Mean I, pA SEM Mean I, pA SEM Mean I, pA SEM 
1000.0 -2 0 -5 1 -22 3 
 
Table 6.3.8.2.1.2: Average AA responses obtained at 1000 M from calibrations using Type 1 NO 
sensors (n = 3), on Day 1 to Day 68, carried out at +900 mV vs. SCE. Background values subtracted. 
Mean background current = 63 ± 6 pA (Day 1), 21 ± 7 pA (Day 56) and 585 ± 339 (Day 168). 
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Figure 6.3.8.2.1.2: A bar chart displaying the AA sensitivity obtained at a concentration of 1000 µM 
with Type 1 NO Sensors (n = 3), at +900 mV vs. SCE.  
 
 
The results were significantly different over the course of the specified days. Day 56 and 
day 168 displayed significantly different AA responses (P = 0.0339) and (P = 0.0021), 
respectively. Even though these results were significantly different in comparison to day 1, 
no AA had been detected at all. The Type 1 NO sensor completely blocked AA interference 
and a negative sensitivity was obtained due to baseline drift, which displays the current 
dropping slightly below the background current upon additions of AA into the 
electrochemical cell. This result is very encouraging, as a sensitivity of 1417 ± 743 pA at 
1000 µM AA was observed at day 56 on the same sensors calibrated repeatedly, however 
the results here at day 56 yield a current of -5 ± 1 pA. This confirms again the theory that 
repetitive calibrations cause damage to the layers on the electrode that act as a barrier. Due 
to this result, fewer calibrations were carried out on the sensors in order to discover the 
required environment in which to store these sensors.      
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6.3.8.2.1.3 Storage: Fridge at 4 
°
C (Enclosed container with N2 Saturated PBS) 
 
[AA], M Day 1 Day 56 Day 168 
 Mean I, pA SEM Mean I, pA SEM Mean I, pA SEM 
1000 -14 5 -1 1 22 10 
 
Table 6.3.8.2.1.3: Average AA response at 1000 M obtained from calibrations using Type 1 NO 
sensors (n = 4), on Day 1 to Day 168, carried out at +900 mV vs. SCE. Background values subtracted. 
Mean background current = 91 ± 3 pA (Day 1), 51 ± 11 pA (Day 56) and 144 ± 26 pA (Day 168). 
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Figure 6.3.8.2.1.3: A bar chart displaying the AA sensitivity obtained at a concentration of 1000 µM 
with Type 1 NO Sensors (n = 4), at +900 mV vs. SCE.  
 
 
The results recorded for the Type 1 NO Sensors in N2 saturated PBS yielded currents of -14 
± 5 pA (day 1), -1 ± 1 pA (day 56) and 22 ± 10 pA (day 168).  There was a slight detection 
of AA after day 168 but this detection was negligible and after 168 days is excellent. A 
significant difference was observed after day 56 (P = 0.0454) and after day 168 there was a 
significant difference in the AA response also (P = 0.0176). Nafion
®
 seems to be more 
stable in a PBS environment, unlike Pt (PPD) sensors. Following this storage condition, a 
N2 saturated enclosed container was utilised and the results are discussed in the next 
section.  
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6.3.8.2.1.4 Storage: Fridge at 4 
°
C (Enclosed container N2 saturated) 
 
[AA], M Day 1 Day 56 Day 168 
 Mean I, pA SEM Mean I, pA SEM Mean I, pA SEM 
1000 -17 2 48 20 259 61 
 
Table 6.3.8.2.1.4: Average AA responses at 1000 M obtained from calibrations using Type 1 NO 
sensors (n = 3), on Day 1 to Day 168, carried out at +900 mV vs. SCE. Background values subtracted. 
Mean background current = 70 ± 5 pA (Day 1), 49 ± 8 pA (Day 56) and 260 ± 40 pA (Day 168). 
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Figure 6.3.8.2.1.4: A bar chart displaying the AA sensitivity obtained at a concentration of 1000 µM 
with Type 1 NO sensors (n = 3), at +900 mV vs. SCE. 
 
The results obtained in Figure 6.3.8.2.1.4 and Table 6.3.8.2.1.4 for the Type 1 NO sensors 
kept in an enclosed N2 saturated container yielded currents of -17 ± 2 pA (day 1), 48 ± 20 
pA (day 56) and 259 ± 61 pA (day 168). After day 56 and after day 168 a significant 
difference (P = 0.0334 and P = 0.0105) was observed, respectively. Even though the results 
were significantly different from day 1, day 56 and day 168 were still more stable in 
comparison to the repeated calibration in Figure 6.3.8.2.1.1. These results demonstrate a 
good stability over the course of the specified days, however, not as stable as the results 
observed in Figure 6.3.8.2.1.2 and Figure 6.3.8.2.1.3. 
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6.3.8.2.1.5 Storage: Freezer at -20 
°
C (Enclosed container)  
 
[AA], M Day 1 Day 56 Day 168 
 Mean I, pA SEM Mean I, pA SEM Mean I, pA SEM 
1000 -39 1 4 1 65 7 
 
Table 6.3.8.2.1.5: Average AA responses at 1000 M obtained from calibrations using Type 1 NO 
sensors (n = 4), on day 1 to day 168, carried out at +900 mV vs. SCE. Background values subtracted. 
Mean background current = 57 ± 3 pA (Day 1), 32 ± 3 pA (Day 56) and 516 ± 13 pA (Day 168). 
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Figure 6.3.8.2.1.5: A bar chart displaying the AA sensitivity obtained at a concentration of 1000 µM 
with Type 1 NO sensors (n = 4), at +900 mV vs. SCE.  
 
 
Type 1 NO sensors stored in the freezer display a good stability over the specified times. 
This storage environment did not seem to cause substantial degradation to the sensor until 
day 168, however a significant difference was observed in the AA response (P < 0.0001), 
but yet, there was still not much detection of AA at Type 1 NO sensors after that amount of 
time. A significant difference was observed after day 56 (P < 0.0001), in comparison to day 
1, however the AA response was miniscule. The results exhibited in this section, yield a 
sensor that displays a very robust and stable characteristic in any storage environment. Over 
the 168 days the sensors kept in the fridge in an enclosed container displayed no AA 
detection (see Figure 6.3.8.2.1.2). It was also confirmed that repeatedly calibrating the 
sensors causes damage to the electrodes rejection layer as can be seen in Figure 6.3.8.2.1.1. 
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If the sensors are manufactured, calibrated and then stored immediately, they retain stability 
over long periods of time.  
Following on from this, studies were undertaken with the two other types of NO sensors in 
the next section. As these sensors not only contain Nafion
®
 but a PPD layer too, it was 
decided to utilise the storage conditions of a dry environment and N2 saturated PBS 
environment to determine which condition was more suitable for these sensors. The 
repeated calibrations as well as the less frequent calibrations were employed in order to 
fully determine that the results obtained for the other sensors were transferable across all 
types of sensors.      
 
6.3.8.2.2 Type 2 NO Sensor 
 
6.3.8.2.2.1 Storage: Fridge at 4 
°
C (Enclosed container) 
 
 
 [AA], 1000 µM  
Day Mean I, pA SEM 
1 -59 10 
3 141 107 
7 2583 944 
14 2910 1000 
28 3299 1049 
56 6539 1504 
 
Table 6.3.8.2.2.1 (a): Average AA responses at 1000 M obtained from calibrations using Type 2 NO 
sensors (n = 4), on day 1 to day 56, carried out at +900 mV vs. SCE. Background values subtracted. 
Mean background current = 191 ± 38 pA (Day 1), 285 ± 64 pA (Day 3), 585 ± 314 pA (Day 7), 84 ± 36 
pA (Day 14), 115 ± 4 pA (Day 28) and 36 ± 50 pA (Day 56). 
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Figure 6.3.8.2.2.1: A bar chart displaying the AA current obtained at a concentration of 1000 µM with 
Type 2 NO sensors, (n = 4), at +900 mV vs. SCE.  
 
AA calibrations carried out on Type 2 NO sensors (n = 4) over the specified time intervals 
displayed a familiar trend seen with the other sensors discussed previously. A characteristic 
increase in AA with continual calibration is depicted in the Figure 6.3.8.2.2.1. No 
significant difference was observed between day 1 and day 3 (P = 0.1127), however, a 
steady increase and significant difference in the AA response from day 3 can be observed.  
 
Day P value Significance 
1 vs. 3 0.1127 ns 
1 vs. 7 0.0312 * 
1 vs. 14 0.0250 * 
1 vs. 28 0.0186 * 
1 vs. 56 0.0046 ** 
 
Table 6.3.8.2.2.1 (b): A summary displaying the P values obtained for the Type 2 NO sensor over 56 
Days at 4 
°
C in an enclosed container. 
 
The same conditions were utilised in Figure 6.3.8.2.2.2 and the Type 2 NO sensors were 
calibrated less frequent to highlight the effect of repeated calibrations on the sensors. 
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6.3.8.2.2.2 Storage: Fridge at 4 
°
C (Enclosed container) 
 
[AA], µM Day 1 Day 56 Day 168 
 Mean I, pA SEM Mean I, pA SEM Mean I, pA SEM 
1000 6 1 60 30 117 40 
 
Table 6.3.8.2.2.2: Average AA responses at 1000 M obtained from calibrations using Type 2 NO 
sensors (n = 4), on day 1 to day 56, carried out at +900 mV vs. SCE. Background values subtracted. 
Mean background current = 13 ± 3 pA (Day 1), 4 ± 3 pA (Day 56) and 959 ± 198 (Day 168). 
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Figure 6.3.8.2.2.2: A bar chart displaying the AA current obtained at a concentration of 1000 µM with 
Type 2 NO sensors (n = 4), at +900 mV vs. SCE. 
 
The results yielded no significant difference in the AA response after day 56 (P = 0.1232), 
however there was a significant difference (P = 0.0324) after 168 days. An AA current of 
60 ± 30 pA on day 56 and 117 ± 40 pA on day 168 in comparison to the result obtained at 
day 56 with the repeated calibrations (6539 ± 1504 pA) proves that the sensors 
deterioration over time, is due to the repetitive calibrations causing substantial destruction 
to the sensors PPD layer.     
 
 
 
  Chapter 6: In-Vitro Nitric Oxide  
 
251  
 
6.3.8.2.2.3 Storage: Fridge at 4 
°
C (Enclosed container with N2 Saturated PBS) 
 
 [AA], 1000 µM  
Day Mean I, pA SEM 
1 1 1 
3 5 2 
7 71 24 
14 387 54 
28 407 73 
56 444 61 
 
Table 6.3.8.2.2.3 (a): Average AA responses at 1000 M obtained from calibrations using Type 2 NO 
sensors (n = 3), on day 1 to day 56, carried out at +900 mV vs. SCE. Background values subtracted. 
Mean background current = 14 ± 3 pA (Day 1), 53 ± 10 pA (Day 3), 38 ± 9 pA (Day 7), 134 ± 65 pA (Day 
14), 49 ± 12 pA (Day 28) and 71 ± 12 pA (Day 168). 
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Figure 6.3.8.2.2.3: A bar chart displaying the AA current obtained at a concentration of 1000 µM with 
Type 2 NO sensors, (n = 3), at +900 mV vs. SCE.  
 
The repeated calibrations undertaken with the Type 2 NO sensors (n = 3), using the storage 
condition of N2 saturated PBS, yielded currents at 1000 µM AA concentration (day 56) of 
444 ± 61 pA. This result depicts the deterioration of the electrode surface PPD layer due to 
the consecutive calibrations carried out on the sensors. From day 7 there was a significant 
difference (see Table 6.3.8.2.2.3 (b)) in the AA response obtained with the sensors. The 
characteristic trend of an increasing AA response was observed also.  
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Day P value Significance 
1 vs. 3 0.1585 ns 
1 vs. 7 0.0402 * 
1 vs. 14 0.0020 ** 
1 vs. 28 0.0050 ** 
1 vs. 56 0.0019 ** 
 
Table 6.3.8.2.2.3 (b): A summary displaying the P values obtained for the Type 2 NO sensors over 56 
days at 4 
°
C in an enclosed container with N2 saturated PBS. 
 
6.3.8.2.2.4 Storage: Fridge at 4 
°
C (Enclosed container with N2 Saturated PBS) 
 
[AA], M Day 1 Day 56 Day 168 
 Mean I, pA SEM Mean I, pA SEM Mean I, pA SEM 
1000 -1 4 85 29 780 211 
 
Table 6.3.8.2.2.4: Average AA responses at 1000 M obtained from calibrations using Type 2 NO 
sensors (n = 4), on day 1 to day 56, carried out at +900 mV vs. SCE. Background values subtracted. 
Mean background current = 62 ± 6 pA (day 1), 54 ± 5 pA (day 56) and 2578 ± 1611 pA (day 168). 
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Figure 6.3.8.2.2.4: A bar chart displaying the AA current obtained at a concentration of 1000 µM with 
Type 2 NO sensors, (n = 4), at +900 mV vs. SCE.  
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The results recorded with the N2 saturated PBS storage environment, showed a greater 
increase in the AA response that was significantly different (day 56, P = 0.0257) and (day 
168, P = 0.0100), in comparison to storing the sensors dry in the fridge at 4 
°
C. These 
results obtained, still depict good stability over long periods of time. A result of 444 ± 61 
pA on day 56 for the repeated calibrations in comparison to 85 ± 29 pA for the once off 
calibrations on day 56 really highlights the damage caused to the sensors properties when 
calibrated repeatedly, whilst once off calibrations show a more accurate result of 
degradation to the sensor. Type 3 NO sensors were subsequently studied in the same 
manner as the previous sensors discussed in this chapter.  
 
6.3.8.2.3 Type 3 NO Sensor 
 
6.3.8.2.3.1 Storage: Fridge at 4 
°
C (Enclosed container) 
 
 [AA], 1000 µM  
Day Mean I, pA SEM 
1 2 10 
3 8 1 
7 473 156 
14 1328 408 
28 2231 594 
56 4434 665 
 
Table 6.3.8.2.3.1 (a): Average AA responses at 1000 M obtained from calibrations using Type 3 NO 
sensors (n = 4), on day 1 to day 56, carried out at +900 mV vs. SCE. Background values subtracted. 
Mean background current = 69 ± 8 pA (Day 1), 18 ± 1 pA (Day 3), 83 ± 35 pA (Day 7), 72 ± 31 pA (Day 
14), 183 ± 16 pA (Day 28) and 221 ± 13 pA (Day 56).  
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Figure 6.3.8.2.3.1: A bar chart displaying the AA currents obtained at a concentration of 1000 µM with 
Type 3 NO sensors, (n = 4), at +900 mV vs. SCE.  
 
The Type 3 NO sensors displayed a current of 4434 ± 665 pA (day 56); this result was not 
out of the ordinary as this trend had been observed with the other sensors. Table 6.3.8.2.3.1 
(b) depicts a summary of the P values. 
 
Day P value Significance 
1 vs. 3 0.5742 ns 
1 vs. 7 0.0236 * 
1 vs. 14 0.0175 * 
1 vs. 28 0.0095 ** 
1 vs. 56 0.0006 *** 
 
Table 6.3.8.2.3.1 (b): A summary displaying the P values obtained for the Type 3 NO sensors over 56 
days at 4 
°
C in an enclosed container with N2 saturated PBS. 
 
Less frequent calibrations are depicted in Figure 6.3.8.2.3.2 and Table 6.3.8.2.3.2 for this 
storage condition using the Type 3 NO sensors. 
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6.3.8.2.3.2 Storage: Fridge at 4 
°
C (Enclosed container) 
 
[AA], M Day 1 Day 56 Day 168 
 Mean I, pA SEM Mean I, pA SEM Mean I, pA SEM 
1000 3 1 1 1 -32 7 
 
Table 6.3.8.2.3.2: Average AA responses at 1000 M obtained from calibrations using Type 3 NO 
sensors (n = 4), on day 1 to day 168, carried out at +900 mV vs. SCE. Background values subtracted. 
Mean background current = 19 ± 1 pA (Day 1), 27 ± 2 pA (Day 56) and 758 ± 19 pA (Day 168). 
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Figure 6.3.8.2.3.2: A bar chart displaying the AA sensitivity obtained at a concentration of 1000 µM 
with Type 3 NO sensors, (n = 4), at +900 mV vs. SCE.  
 
 
The AA currents observed with the Type 3 NO sensors over the course of 56 days 
demonstrated a minuscule response that was deemed negligible (P = 0.1435). On day 168 a 
significant difference was recorded (P = 0.0021), however, no AA response was detected 
with the Type 3 NO sensors. After approximately 6 months stored in the fridge in an 
enclosed container, this was a remarkable result. This storage condition seemed to be the 
optimal state for the sensors to be stored in.      
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6.3.8.2.3.3 Storage: Fridge at 4 
°
C (Enclosed container with N2 Saturated PBS) 
 
 [AA], 1000 µM  
Day Mean I, pA SEM 
1 -6 2 
3 4 28 
7 4344 915 
14 4303 1556 
28 4642 1105 
56 3937 781 
 
Table 6.3.8.2.3.3 (a): Average AA responses at 1000 M obtained from calibrations using Type 3 NO 
sensors (n = 4), on day 1 to day 56, carried out at +900 mV vs. SCE. Background values subtracted. 
Mean background current = 74 ± 9 pA (Day 1), 87 ± 28 pA (Day 3), 168 ± 33 pA (Day 7), 71 ± 19 pA 
(Day 14), 502 ± 248 pA (Day 28) and 1692 ± 784 pA (Day 56). 
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Figure 6.3.8.2.3.3: Average AA responses at 1000 M obtained from calibrations using Type 3 NO 
sensors (n = 4), on Day 1 to day 56, carried out at +900 mV vs. SCE. 
 
 
The repeated calibrations depicted above in Figure 6.3.8.2.3.3, demonstrate that the more 
one calibrates the sensor, the quicker the sensor deteriorates. Table 6.3.8.2.3.3 (b), details 
the P values for all the days calibrated with the Type 3 NO sensor. 
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Day P value Significance 
1 vs. 3 0.6405 ns 
1 vs. 7 0.0018 ** 
1 vs. 14 0.0065 ** 
1 vs. 28 0.0056 ** 
1 vs. 56 0.0023 ** 
 
Table 6.3.8.2.3.3 (b): A summary displaying the P values obtained for the Type 3 NO sensors over 56 
days at 4 
°
C in an enclosed container with N2 saturated PBS. 
 
 
After day 3, a greater AA detection is obvious. In Figure 6.3.8.2.3.4 fewer calibrations were 
carried out on the Type 3 NO sensors. An AA detection that is much lower than the 
observed AA response for the repeated calibrations at day 56 is obtained.  
 
 
6.3.8.2.3.4 Storage: Fridge at 4 
°
C (Enclosed container with N2 Saturated PBS) 
 
[AA], M Day 1 Day 56 Day 168 
 Mean I, pA SEM Mean I, pA SEM Mean I, pA SEM 
1000 4 1 246 71 696 112 
 
Table 6.3.8.2.3.4: Average AA responses at 1000 M obtained from calibrations using Type 3 NO 
sensors (n = 4), on day 1 to day 68, carried out at +900 mV vs. SCE. Background values subtracted. 
Mean background current = 7 ± 1 pA (day 1), 53 ± 5 pA (day 56) and 996 ± 46 pA (day 168).   
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Figure 6.3.8.2.3.4: Average 1000 M AA responses obtained from calibrations using Type 3 NO sensors 
(n = 4), on day 1 to day 56, carried out at +900 mV vs. SCE.   
 
 
It is clear from the results depicted in Figure 6.3.8.2.3.4, that keeping the sensors in a N2 
saturated PBS environment does not retain the stability of the sensors, in comparison to 
keeping the sensors in a dry environment. A significant difference in the AA response was 
attained on day 56 (P = 0.0140) and day 168 (0.0005). A higher AA response was recorded 
at day 56 (246 ± 71 pA) whereas the dry environment at day 56 yielded an AA response of 
1 ± 1 pA at 1000 µM. After compiling and discussing all of the results that have been 
illustrated for each of the sensors in these sections, it was decided that the most favourable 
storage for all the sensors would be enclosed in a container in the fridge at 4 
°
C.      
 
6.3.9 Stability of the NO sensitivity of Type 2 NO sensors over time 
 
Table 6.3.9 and Figure 6.3.9 display the NO sensitivities on day 1 and after 56 days for 
Type 2 NO sensors (n = 10). Sensitivities of 945 ± 12 pA/ µM (day 1) and 859 ± 18 pA/ 
µM (day 56) were obtained. As the optimum storage condition was chosen in the previous 
section to be an enclosed container at 4 
°
C for all the different types of NO sensors, that 
storage condition was therefore utilised as the one to carry on with throughout the research. 
There was a slight decrease in the NO sensitivity after 56 days but this did not yield a 
significant difference (P = 0.7739). A linear response was also attained at day 1 and day 56 
(R
2
 = 0.99).  
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 Type 2 NO Sensor  
Day 1 (n = 10) 
Type 2 NO Sensor  
Day 56 (n = 10) 
[NO], M Mean I, pA SEM Mean I, pA SEM 
0.0 0 0 0 0 
0.2 176 24 158 18 
0.4 377 43 351 49 
0.6 571 69 538 84 
0.8 763 93 688 117 
1.0 932 120 847 144 
 
Table 6.3.9: Average AA responses at 0 - 1 M obtained from calibrations using Type 2 NO sensor (n = 
4), on day 1 to day 56, carried out at +900 mV vs. SCE. Background values subtracted. Mean 
background current = 204 ± 63 pA (day 1) and 425 ± 149 pA (day 56). 
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Figure 6.3.9: A current-concentration profile displaying the NO sensitivities obtained day 1 to day 56 
with the Type 2 NO sensors (n = 4), carried out at +900 mV vs. SCE. 
 
 
6.3.10 Stability of the NO sensitivity of Type 3 NO sensors over time 
 
The NO responses recorded at the Type 3 NO sensors day 1 to day 56 are displayed in 
Table 6.3.10 and Figure 6.3.10. There was an increase in the NO after 56 days which 
demonstrates that the sensor not only can retain a stable PPD layer over time (see Section 
6.3.8.2.3.2), but can retain the ability to detect NO over time also. The sensitivities were not 
significant day 1 to day 56 (P = 0.1580). A linear response was obtained at day 1 and day 
56 (R
2
 = 0.99).  
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 Type 3 NO Sensor  
Day 1 (n = 11) 
Type 3 NO Sensor  
Day 56 (n = 11) 
[NO], M Mean I, pA SEM Mean I, pA SEM 
0.0 0 0 0 0 
0.2 135 18 187 24 
0.4 295 35 375 43 
0.6 443 51 565 60 
0.8 586 71 702 85 
1.0 719 94 881 111 
 
Table 6.3.10: Average 1 M AA responses obtained from calibrations using Type 3 NO sensors (n = 11), 
on day 1 to day 56, carried out at +900 mV vs. SCE. Background values subtracted. Mean background 
current = 227 ± 33 pA (day 1) and 557 ± 157 pA (day 56). 
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Figure 6.3.10: A current-concentration profile displaying the NO sensitivities obtained day 1 to day 56 
with the Type 3 NO sensors (n = 11), carried out at +900 mV vs. SCE. 
 
 
Following these results, interference studies were carried out in order to determine the 
selectivity of the sensor. 
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6.3.11 Interference studies Type 2 and Type 3 NO Sensor 
 
Brown et al., carried out interference studies which compared bare Pt electrodes and Type 1 
NO sensors against a range of potential endogenous electroactive interferents at reported 
physiological concentrations (Brown et al., 2009). They found that there was little or no 
detection of the chosen analytes at the Type 1 NO sensor; however, the bare Pt electrode 
detected the different analytes due to a lack of a rejection membrane to block out any of the 
electroactive species. The same analytes were chosen to test against the Type 2 and Type 3 
NO sensors, which will be discussed in this section. A working potential of + 900 mV vs. 
SCE was utilised, as this was the potential employed for the NO sensors for the detection of 
NO and would be the potential required for the NO in-vivo studies.     
 
6.3.11.1 [5-HT] Serotonin Type 2 and Type 3 NO sensor 
 
 
 
 
 
 
 
 
 
 
Table 6.3.11.1: An averaged table of results displaying a 5-HT calibration in PBS (pH 7.4), at +900 mV 
vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 4). Background values subtracted. 
Mean background current of Type 2 NO and Type 3 NO Sensor = 650 ± 75 pA and 707 ± 107 pA, 
respectively. 
 
 Type 2 NO Sensor  
(n = 4)  
Type 3 NO Sensor 
(n = 3) 
[5-HT], M  Mean I, pA SEM Mean I, pA SEM 
0.000 0 0 0 0 
0.004 -3 4 9 11 
0.008 -7 9 15 19 
0.012 -9 11 14 19 
0.016 -12 15 14 20 
0.020 -16 20 12 19 
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Figure 6.3.11.1: A current-concentration profile displaying a 5-HT calibration in PBS (pH 7.4), at +900 
mV vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 4). 
 
 
5-HT (Serotonin) is an important derivative of the amino acid L-tryptophan (Sidransky, 
2010). The ECF concentration of 5-HT is between 1 and 10 nM (O'Neill & Lowry, 2000). 
5-HT is positively charged at pH 7 (Chattopadhyay et al., 1996) which is of concern for a 
Nafion
® 
 modified sensor, as Nafion
®
 possesses a negative charge which would lead to an 
ion exchange membrane accommodating species that encompass a positive charge. Since 
the two NO sensors described in this section contain not only Nafion
® 
but a PPD layer, this 
concern is diminished. At a concentration of 0.020 µM, negligible currents of -15.6 ± 19.5 
pA and 54.0 ± 43.2 pA for Type 2 and Type 3 NO sensors were obtained. This suggests 
that this interferent would not prove problematic for the NO sensors described in this body 
of work. Subsequent to this, DOPAC calibrations were carried out.    
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6.3.11.2 [DOPAC] Type 2 and Type 3 NO sensor 
 
 
 
 
 
 
 
 
 
 
Table 6.3.11.2: An averaged table of results displaying a DOPAC calibration in PBS (pH 7.4), at +900 
mV vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 4). Background values 
subtracted. Mean background current of Type 2 NO and Type 3 NO Sensor = 675 ± 138 pA and 575 ± 
60 pA, respectively. 
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Figure 6.3.11.2: A current-concentration profile displaying a DOPAC calibration in PBS (pH 7.4), at 
+900 mV vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 4). 
 
 
DOPAC is a metabolite of dopamine (Wallace & Traeger, 2012). The ECF concentration of 
DOPAC is approximately 1 to 20 µM (O'Neill & Lowry, 2000). It contains a negative 
charge (Lowry et al., 1996; O'Neill et al., 1998) and so should be repelled by the negatively 
charged Nafion
®
 layer. The DOPAC currents obtained were insignificant. At a 
 Type 2 NO Sensor 
(n = 4) 
Type 3 NO Sensor 
(n = 4) 
[Dopac], M Mean I, pA SEM Mean I, pA SEM 
0 0 0 0 0 
10 -10 23 5 4 
20 -10 29 4 8 
30 -7 30 1 10 
40 -7 31 -4 10 
50 -6 32 -5 12 
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concentration of 50 µM, currents of -6 ± 32 pA (Type 2 NO sensor) and -5 ± 12 pA (Type 3 
NO sensor) were observed, highlighting how capable the sensor is at blocking this 
interferent from being detected. A negative current is obtained due to a slight drift in 
current below the background current.  
 
6.3.11.3 [Dopamine] Type 2 and Type 3 NO sensor 
 
Dopamine is a very important neurotransmitter that is implicated in Parkinson‘s disease 
(Wightman et al., 1988). The brain ECF concentration of dopamine is around 1 to 50 nM 
(O'Neill & Lowry, 2000). Table 6.3.11.3 and Figure 6.3.11.3 display the currents obtained 
at a concentration of 1.0 µM for the two sensors.  
 
 
 
 
 
 
 
 
 
 
Table 6.3.11.3: An averaged table of results displaying a dopamine calibration in PBS (pH 7.4), at +900 
mV vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 6). Background values 
subtracted. Mean background current of Type 2 NO and Type 3 NO Sensor = 564 ± 132 pA and 396 ± 
58 pA, respectively. 
 
 Type 2 NO Sensor 
(n = 4) 
Type 3 NO Sensor 
(n = 6) 
[Dopamine], M Mean I, pA SEM Mean I, pA SEM 
0.0 0 0 0 0 
0.2 -3 1 -6 8 
0.4 -6 3 -1 6 
0.6 -6 4 5 5 
0.8 -2 4 5 6 
1.0 5 3 8 7 
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Figure 6.3.11.3: A current-concentration profile displaying a dopamine calibration in PBS (pH 7.4), at 
+900 mV vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 6). 
 
It can be seen from Figure 6.3.11.3 that there was a slight dopamine response from the 
sensors after injecting a concentration of 1.0 µM into the electrochemical cell. The 
dopamine results achieved for Type 2 and Type 3 NO sensors would not cause a problem 
for the detection of the chosen analyte NO as the detection is miniscule. 
 
6.3.11.4 [Glutathione] Type 2 and Type 3 NO sensor 
 
Glutathione is a key substance found to play a role in antioxidant defence, nutrient 
metabolism and the regulation of cellular events. It has an ECF concentration of 
approximately 50 µM. Insufficient glutathione contributes to oxidative stress which in turn 
has a role in the pathogenesis of some diseases (Wu et al., 2004). It also partakes in the 
transport of some amino acids across membranes in the kidneys (Chailapakul et al., 2001). 
Table 6.3.11.4 and Figure 6.3.11.4 illustrate the currents recorded for the two sensors. 
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Table 6.3.11.4: An averaged table of results displaying a glutathione calibration in PBS (pH 7.4), at 
+900 mV vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 4). Background values 
subtracted. Mean background current of Type 2 NO and Type 3 NO Sensor = 467 ± 47 pA and 434 ± 71 
pA, respectively. 
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Figure 6.3.11.4: A current-concentration profile displaying a glutathione calibration in PBS (pH 7.4), at 
+900 mV vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n=4). 
 
 
The results displayed a slight change in the observed current upon additions of glutathione 
into the cell. A current of 2 ± 6 pA and 9 ± 14 pA was recorded at 100 µM for the Type 2 
and Type 3 NO sensors, respectively. Therefore, glutathione would not hamper the sensors 
ability to detect the analyte NO.  
 
 
 Type 2 NO Sensor  
(n = 4) 
Type 3 NO Sensor  
(n = 4) 
[Glutathione], M Mean I, pA SEM Mean I, pA SEM 
0 0 0 0 0 
20 -2 1 -1 2 
40 -2 2 -6 4 
60 -1 4 -6 6 
80 1 5 -5 8 
100 2 6 9 14 
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6.3.11.5 [H2O2] Type 2 and Type 3 NO sensor 
 
H2O2 is an important species that plays a role in cell signalling pathways that are essential 
for a living organism‘s development, growth and well being. However, disparity of H2O2 
production can lead to oxidative stress which can initiate damage to tissues and organs 
(Van de Bittner et al., 2010). H2O2 is a neutral molecule that can be oxidised at a similar 
potential to NO (Zhang et al., 2002a) and has an ECF concentration of approximately 1.0 
µM, however this could be an over estimation of the H2O2 concentration, due to excess 
levels being produced following tissue damage caused by the large size of the probe.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.3.11.5: An averaged table of results displaying a H2O2 calibration in PBS (pH 7.4), at +900 mV 
vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 4). Background values subtracted. 
Mean background current of Type 2 NO and Type 3 NO Sensor = 538 ± 42 pA and 231 ± 21 pA, 
respectively. 
 
 
 Type 2 NO Sensor 
(n = 4) 
Type 3 NO Sensor  
(n = 4) 
[H2O2], M Mean I, pA SEM Mean I, pA SEM 
0 0 0 0 0 
1 8 2 -6 7 
2 14 2 37 20 
5 36 5 94 57 
10 69 6 161 77 
20 153 12 212 82 
50 428 25 341 90 
100 848 53 562 98 
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Figure 6.3.11.5: A current-concentration profile displaying a H2O2 calibration in PBS (pH 7.4), at +900 
mV vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 4). 
 
The maximum current detected by the Type 2 and Type 3 NO sensor was 848 ± 53 pA and 
562 ± 98 pA, respectively at 100 µM concentration of H2O2. This is a very high detection 
and would cause problems if this was the concentration found in the brain, however, since 
the H2O2 concentration in the brain is around 1 to 3 µM (Bedioui & Griveau, 2013) and this 
concentration value could be an overestimation due to tissue damage causing an increased 
H2O2 concentration, H2O2 would not hamper the electrodes ability to detect NO 
successfully.  
 
6.3.11.6 [5-HIAA] Type 2 and Type 3 NO sensor 
 
5-HIAA is the main metabolite of 5-HT and has been utilised as a measurement tool in 
order to determine if a patient has carcinoid syndrome (Lee et al., 2000). 5-HIAA possesses 
a much greater ECF concentration than NO and therefore could potentially become a 
problem. At an estimated range of 1 to 10 µM, it would be a cause of concern for the NO 
sensor (Lowry et al., 1996; O'Neill et al., 1998).       
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Table 6.3.11.6: An averaged table of results displaying 5-HIAA calibrations in PBS (pH 7.4), at +900 
mV vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 4). Background values 
subtracted. Mean background current of Type 2 NO and Type 3 NO Sensor = 627 ± 65 pA and 458 ± 75 
pA, respectively. 
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Figure 6.3.11.6: A current-concentration profile displaying a HIAA calibration in PBS (pH 7.4), at +900 
mV vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 4). 
 
  
The design of the Type 2 and Type 3 NO sensors demonstrated a great ability to block 
interferents from this analyte. Currents of -6 ± 16 pA and -2 ± 6 pA for the Type 2 and 
Type 3 NO sensors, respectively, were obtained. Negative currents were achieved due to 
baseline drift.    
 
 
 Type 2 NO Sensor 
(n = 4) 
Type 3 NO Sensor 
(n = 4) 
[5-HIAA], M Mean I, pA SEM Mean I, pA SEM 
0 0 0 0 0 
20 -8e-01 3 0 4 
40 -3 7 -1 5 
60 -5 9 -1 4 
80 -2 16 -4 5 
100 -6 16 -2 6 
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6.3.11.7 [HVA] Type 2 and Type 3 NO sensor 
 
HVA is a metabolite of dopamine (Kopin et al., 1988). Monitoring urinary levels of HVA 
has been utilised as a means of neuroblastoma tumour detection (Jones, 2010). The ECF 
concentration of HVA is approximately 1 to 10 µM which is greater than the concentrations 
observed for NO which could increase the risk of potential interference of the NO signal. 
 
 
 
 
 
 
 
 
Table 6.3.11.7: An averaged table of results displaying a HVA calibration in PBS (pH 7.4), at +900 mV 
vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 4). Background values subtracted. 
Mean background current of Type 2 NO and Type 3 NO Sensor = 580 ± 151 pA and 725 ± 249 pA, 
respectively. 
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Figure 6.3.11.7: A current-concentration profile displaying a HVA calibration in PBS (pH 7.4), at +900 
mV vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 4). 
 
 
 Type 2 NO Sensor  
(n = 3) 
Type 3 NO Sensor  
(n = 4)  
[HVA], M Mean I, pA SEM Mean I, pA SEM 
0 0 0 0 0 
5 -21 17 -1 13 
10 -27 18 2 21 
15 -28 19 7 30 
20 -30 20 7 32 
25 -13 7 6 33 
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The results recorded at the Type 2 and Type 3 NO sensors for the HVA calibration would 
not prove problematic as they are negligible. A negative current of -33 ± 21 pA was 
observed from the Type 2 NO sensors (n = 4) and 6 ± 33 pA was attained by the Type 3 
NO sensors (n = 4).  
 
6.3.11.8 [NO2
-
] Type 2 and Type 3 NO sensor 
 
NO2
- 
is an interferent that causes great concern for the detection of NO at an 
electrochemical sensor. However, due to the negatively charged attribute of Nafion
®
, the 
NO2
-
 is repelled making NO detection possible  ( & Zálešáková, 2002). Linear 
regression was carried out on the Type 2 and Type 3 NO sensors yielding sensitivities of 
0.072 ± 0.002 pA/ µM and 0.032 ± 0.005 pA/ µM, respectively. With an ECF concentration 
in the brain of 100 µM, this would yield miniscule interference from NO2
-
.     
 
 
 
 
 
 
 
 
 
 
Table 6.3.11.8: An averaged table of results displaying an NO2
-
 calibration in PBS (pH 7.4), at +900 mV 
vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 6). Background values subtracted. 
Mean background current of Type 2 NO and Type 3 NO Sensor = 394 ± 38 pA and 482 ± 125 pA, 
respectively. 
 
 
 Type 2 NO Sensor 
(n = 4) 
Type 3 NO Sensor 
(n = 6) 
[NO2-], M Mean I, pA SEM Mean I, pA SEM 
0 0 0 0 0 
200 12 5 1 2 
400 30 8 6 3 
600 41 12 12 6 
800 59 15 20 8 
1000 71 20 33 14 
  Chapter 6: In-Vitro Nitric Oxide  
 
272  
 
0 200 400 600 800 1000
0
20
40
60
80
100
Type 2 NO Sensor
Type 3 NO Sensor
[NO2
-
], M
I,
 p
A
 
Figure 6.3.11.8: A current-concentration profile displaying a NO2
-
 calibration in PBS (pH 7.4), at +900 
mV vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 4). 
 
 
The currents observed after injecting 1000 µM concentration of NO2
- 
into the 
electrochemical cell were very small and would not cause any issues to arise when 
detecting NO. Linear regression analysis was carried out on the Type 2 and Type 3 NO 
sensors to reveal sensitivities of 0.07 ± 0.002 pA/µM and 0.03 ± 0.005 pA/µM, 
respectively. The response was linear for Type 2 NO sensors (R
2
 = 0.99) and Type 3 NO 
sensors (R
2
 = 0.92). These sensitivities are very small and negligible. 
 
6.3.11.9 [Uric acid] Type 2 and Type 3 NO sensor 
 
Uric acid is a weak acid that is created during the metabolism of purines. It is also produced 
by the degradation of xanthine by the enzyme xanthine oxidase (Schrier, 2007).  The 
quantification and determination of uric acid in-vivo has been of great importance as an 
increased urate level has been implicated in medical conditions like leukaemia and 
pneumonia (Miland et al., 1996). Uric acid is found at much higher concentrations than NO 
in the ECF of the brain and has an approximate concentration of around 5 to 50 µM 
(Bedioui & Griveau, 2013). Its presence is due to tissue damage (Duff & O'Neill, 1994).   
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Table 6.3.11.9 (a): An averaged table of results displaying a uric acid calibration in PBS (pH 7.4), at 
+900 mV vs. SCE, carried out on Type 2 (n = 3) and Type 3 NO Sensors (n = 4). Background values 
subtracted. Mean background current of Type 2 NO (n = 3) and Type 3 NO Sensor (n = 4) = 748 ± 90 
pA and 2835 ± 791 pA, respectively. 
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Figure 6.3.11.9: A current-concentration profile displaying a uric acid calibration in PBS (pH 7.4), at 
+900 mV vs. SCE, carried out on Type 2 (n = 4) and Type 3 NO Sensors (n = 4). 
 
 
There was limited or no detection of uric acid at the two sensors (see Figure 6.3.11.9). With 
this being the last interferent studied, it can be hypothesised that the sensors presented and 
discussed in this section would be free from interference from other analytes and that the 
sensor can be deemed selective to NO without concern of interference from other 
electroactive species. 
 
 Type 2 NO Sensor  
(n = 4) 
Type 3 NO Sensor  
(n = 4) 
[Uric Acid], M Mean I, pA SEM Mean I, pA SEM 
0 0 0 0 0 
10 0 2 -6 4 
20 0 7 -9 4 
30 -6 6 -20 5 
40 -10 2 -27 8 
50 4 3 -20 6 
60 5 2 -11 6 
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Analyte NO Response (pA) % of NO signal 
 Type 2 Type 3 Type 2 Type 3 
NO 1047 ± 34  975 ± 46 100 100 
5-HT -6 ± 6 -18 ± 6 ≤ 1 ≤ 1 
Dopac -16 ± 20 12 ± 19 ≤ 1 ≤ 1 
Dopamine -6 ± 32 -5 ± 12 ≤ 1 ≤ 1 
Glutathione 5 ± 3 8 ± 7 ≤ 1 ≤ 1 
H2O2 2 ± 6 9 ± 14 ≤ 1 ≤ 1 
5-HIAA 8 ± 2 -6 ± 7 ≤ 1 ≤ 1 
HVA -6 ± 16 -2 ± 6 ≤ 1 ≤ 1 
NO2- -13 ± 7 6 ± 33 ≤ 1 ≤ 1 
UA 5 ± 2 -11 ± 6 ≤ 1 ≤ 1 
 
Table 6.3.11.9 (b): A summary of all the sensitivities of the interferents and their percentage effect on 
the NO signal. 
6.3.12 Biocompatibility  
 
6.3.12.1 Type 2 NO Sensor 
 
In this section the sensors ability to refrain from fouling and modification by interactions in 
the brain was assessed, as a stable sensor in-vivo is of the upmost importance. The 
environment of the brain contains many harsh variables that may interact with the sensor 
causing the sensor to underperform under the harsh conditions. Calibrations were 
undertaken to determine the effect that proteins, lipids and other variables would have on 
the sensors. The sensors were placed in enclosed containers that included each of the 
treatments and calibrated approximately one month after placement in each of the solutions. 
As the PPD layer is the most vulnerable component of the sensor and is essential for the 
rejection of interferences, AA calibrations were carried out at +900 mV vs. SCE.  
AA was chosen as the analyte to utilise because a much clearer result would be obtained 
from the AA calibrations in comparison to NO calibrations. It has been demonstrated that a 
similar NO sensitivity is obtained post in-vivo studies, however, on analysis of the AA 
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detection on the same set of sensors post in-vivo studies a degradation of the rejection layer 
on the sensor can be observed (see Section 6.3.15.1 and 6.3.15.2). This confirms the reason 
to use AA instead of NO as the analyte of choice when determining the biocompatibility of 
these sensors.       
 
6.3.12.1.1 BSA (10%) 
 
 Type 2 NO Sensor  
(n=4) 
Type 2 NO Post BSA (10%)  
(28 Days) (n = 4) 
[AA], M Mean I, pA SEM Mean I, pA SEM 
0 0 0 0 0 
200 40 9 84 15 
400 80 10 164 30 
600 88 4 239 45 
800 91 4 305 60 
1000 99 6 369 74 
 
Table 6.3.12.1.1: An averaged table of results displaying AA calibrations in PBS (pH 7.4), at +900 mV 
vs. SCE, carried out on Type 2 NO Sensors prior to treatment with BSA (10%) and the results obtained 
post treatment with BSA (10%). Background values subtracted. Mean background current (Type 2 NO 
Sensor) and Type 2 NO Sensor BSA (10%) = 718 ± 48 pA and 589 ± 88 pA, respectively.  
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Figure 6.3.12.1.1 (a): Mean current-concentration profile for AA calibrations in PBS at +900 mV vs. 
SCE using Type 2 NO Sensor pre (black) and post treatment (red) with BSA (10%) (28 Days).  
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AA calibrations on Type 2 NO sensors (n = 4) pre- and post-BSA (10%) (28 days) yielded 
currents of 99 ± 6 pA and 369 ± 6 pA, respectively at 1000 µM. The results observed 
highlighted a significant increase in the detection of AA at the electrodes post BSA (10%) 
treatment (P = 0.0297). This displays a degradation of the PPD layer on the surface of the 
sensor as more AA is gaining access through the layer to be detected. SEMs are displayed 
in Figure 6.3.12.1.1 (b) to illustrate the effect that BSA (10%) had on the Type 2 NO 
sensors.  
 
 
 
 
 
 
      
 
 
  
 
Figure 6.3.12.1.1 (b): An SEM displaying the surface of a Type 2 NO sensor (A) pre BSA (10%) 
treatment and (B) post treatment with BSA (10%) 28 Days. 
 
It is clear from the image that BSA (10%) caused the PPD layer to be damaged slightly, 
revealing some of the Pt surface. BSA (10%) is a very harsh concentration to use and 
would not be encountered in the environment of the brain. One month is also a long time to 
keep the sensors in this harsh solution. 
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6.3.12.1.2 PEA (10%) 
 
 Type 2 NO Sensor  
(n = 8) 
Type 2 NO Post PEA (10%)  
(28 Days) (n = 8) 
[AA], M Mean I, pA SEM Mean I, pA SEM 
0 0 0 0 0 
200 14 4 66 25 
400 24 6 128 59 
600 27 9 185 53 
800 27 10 243 72 
1000 29 13 299 95 
 
Table 6.3.12.1.2: An averaged table of results displaying AA calibrations in PBS (pH 7.4), at +900 mV 
vs. SCE, carried out on Type 2 NO Sensors prior to treatment with PEA (10%) (28 days) and the 
results obtained post treatment with PEA (10%) (28 days). Background values subtracted. Mean 
background current (Type 2 NO Sensor) and (Type 2 NO Sensor PEA (10%) 28 Days) = 610 ± 138 pA 
and 934 ± 213 pA, respectively.  
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Figure 6.3.12.1.2 (a): Mean current concentration profile for an AA calibration in PBS at +900 mV vs. 
SCE using Type 2 NO Sensor pre (black) and post treatment (red) with PEA (10%) 28 days.  
 
 
Currents pre and post PEA (10%) of 29 ± 13 pA and 299 ± 95 pA, respectively, was 
recorded at the Type 2 NO sensors (n = 8). Similar to the BSA (10%) results, a higher 
detection of AA was obtained at the sensors, yielding a significant increase in AA detection 
(P = 0.0234). Figure 6.3.12.1.2 (b) displays an SEM of the Type 2 NO sensor pre and post 
treatment with PEA (10%). The surface has been distorted demonstrating the damaging 
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effect that PEA (10%) had on the sensor over the 28 days. PEA (10%) is a very harsh 
concentration utilised and would not be found in the in-vivo environment. The brain ECF 
would not contain such high levels of protein and lipids. 
 
 
 
 
 
 
 
 
  
 
Figure 6.3.12.1.2 (b): An SEM displaying the surface of a Type 2 NO sensor (A) pre PEA (10%) 
treatment and (B) post PEA (10%) 28 days treatment.  
 
Subsequent to the results obtained with BSA and PEA, it was decided to treat the sensors 
with ex-vivo BT as this treatment encompasses all variables that could potentially harm the 
sensors ability to detect the chosen analyte NO, and so has the capability to mimic the in-
vivo environment to a greater extent than just the proteins and lipids.   
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6.3.12.1.3 BT (28 Days)  
 
 Type 2 NO Sensor  
(n = 4) 
Type 2 NO Post BT (28 Days) 
(n = 4) 
[AA], M Mean I, pA SEM Mean I, pA SEM 
0 0 0 0 0 
200 74 55 78 96 
400 81 58 213 117 
600 87 58 349 127 
800 91 60 452 139 
1000 103 60 540 152 
 
Table 6.3.12.1.3: An averaged table of results displaying AA calibrations in PBS (pH 7.4), at +900 mV 
vs. SCE, carried out on Type 2 NO Sensors prior to treatment with BT (28 days) and the results 
obtained post treatment with BT (28 days). Background values subtracted. Mean background current 
Type 2 NO Sensor and Type 2 NO Sensor BT (28 days) = 610 ± 138 pA and 934 ± 213 pA, respectively.  
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Figure 6.3.12.1.3 (a): Mean current-concentration profile for an AA calibration in PBS at +900 mV vs. 
SCE using Type 2 NO Sensor pre (black) and post treatment (red) with BT (28 days).  
 
 
The results obtained for the Type 2 NO sensors post BT (28 days), displayed a much 
greater detection of AA, which was significantly different from the results observed pre BT 
(P = 0.0450). The PPD rejection layer has been compromised by placing the sensors in BT 
for a month. The SEM displayed in Figure 6.3.12.1.3 (b), image B, shows a sensor with the 
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Pt surface showing more, due to the removal of the polymer, leading to a much greater 
detection of AA. 
 
 
 
 
 
 
 
 
 
Figure 6.3.12.1.3 (b): An SEM displaying the surface of the Type 2 NO sensor (A) pre BT and (B) post 
BT (28 Days). 
 
After the results obtained from the Type 2 NO sensors, the same experiments were 
undertaken with the Type 3 NO sensors, in order to validate how stable the sensors were 
when being tested against these harsh conditions. 
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6.3.13 Biocompatibility  
 
6.3.13.1 Type 3 NO Sensor 
 
6.3.13.1.1 BSA (10%) 
 
 Type 3 NO Sensor 
(n = 4) 
Type 3 NO Post BSA (10%)  
(28 Days) (n = 4) 
[AA], M Mean I, pA SEM Mean I, pA SEM 
0 0 0 0 0 
200 -11 10 48 13 
400 -17 13 101 22 
600 -21 15 155 31 
800 -25 16 204 40 
1000 -29 18 271 48 
 
Table 6.3.13.1.1: An averaged table of results displaying AA calibrations in PBS (pH 7.4), at +900 mV 
vs. SCE, carried out on Type 3 NO Sensors prior to treatment with BSA (10%) (28 days) and the 
results obtained post treatment with BSA (10%) (28 days). Background values subtracted. Mean 
background current (Type 3 NO Sensor) and (Type 3 NO Sensor BSA (10%) (28 days) = 520 ± 36 pA 
and 1260 ± 131 pA, respectively.  
 
0 200 400 600 800 1000
0
100
200
300
[AA], M
I,
 p
A
 
Figure 6.3.13.1.1 (a): Mean current concentration profile for an AA calibration in PBS at +900 mV vs. 
SCE using Type 3 NO Sensor (n = 4) pre (black) and post treatment (red) with BSA (10%) 28 days.  
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Similar to the results obtained for the Type 2 NO sensors an increase in AA detection was 
observed at the Type 3 NO sensor. Currents of -29 ± 18 pA and 271 ± 48 pA pre and post 
treatment with BSA (10%), respectively, was obtained at an AA concentration of 1000 µM. 
A significant difference pre and post was obtained (P = 0.0226). The SEM in Figure 
6.3.13.1.1 (b), image B displays damage to the right side of the sensor which leads to a 
greater detection of AA.    
 
 
 
 
 
 
 
 
 
 
   
Figure 6.3.13.1.1 (b): An SEM displaying the surface of the Type 3 NO sensor pre- and post-treatment 
with BSA (10%) 28 days. 
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6.3.13.1.2 PEA (10%) 
 
 Type 3 NO Sensor 
(n = 8) 
Type 3 NO Post PEA (10%)  
28 Days (n = 8) 
[AA], M Mean I, pA SEM Mean I, pA SEM 
0 0 0 0 0 
200 37 16 101 35 
400 27 8 193 64 
600 17 9 274 86 
800 22 16 338 106 
1000 45 43 396 124 
 
Table 6.3.13.1.2: An averaged table of results displaying AA calibrations in PBS (pH 7.4), at +900 mV 
vs. SCE, carried out on Type 3 NO Sensors (n = 8) prior to treatment with PEA (10%) (28 days) and 
the results obtained post treatment with PEA (10%) (28 days). Background values subtracted. Mean 
background current (Type 3 NO Sensor) and (Type 3 NO Sensor PEA (10%) 28 days) = 648 ± 206 pA 
and 776 ± 178 pA, respectively.  
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Figure 6.3.13.1.2 (a): Mean current concentration profile for an AA calibration in PBS at +900 mV vs. 
SCE using Type 3 NO Sensor (n = 8) pre- (black) and post-treatment (red) with PEA (10%) 28 days.  
 
Again, analogous results were obtained for the Type 3 NO sensors (n = 8) pre and post 
PEA (10%), as was seen with the Type 2 NO sensors (n = 8). An increase in AA detection 
was seen post PEA treatment yielding a sensitivity of 395.7 ± 123.9 pA and a significant 
difference (P = 0.0204). Figure 6.3.13.1.2 (b), image B, displays the SEM post PEA 
treatment and it is clear that this treatment alters the surface leading to part of the Pt wire 
being revealed.  
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Figure 6.3.13.1.2 (b): An SEM displaying the surface of a Type 3 NO sensor (A) pre PEA (10%) 
treatment an (B) post PEA (10%) treatment.  
 
6.3.13.1.3 BT (28 Days) 
 
 Type 3 NO Sensor 
(n = 8) 
Type 3 NO Post BT (28 Days) 
(n = 8) 
[AA], M Mean I, pA SEM Mean I, pA SEM 
0 0 0 0 0 
200 32 12 116 28 
400 27 6 226 52 
600 21 8 324 71 
800 25 13 404 89 
1000 42 32 480 106 
 
Table 6.3.13.1.3: An averaged table of results displaying AA calibrations in PBS (pH 7.4), at +900 mV 
vs. SCE, carried out on Type 3 NO Sensors (n = 8) prior to treatment with BT (28 days) and the results 
obtained post treatment with BT (28 days). Background values subtracted. Mean background current 
Type 3 NO Sensor and Type 3 NO Sensor BT (28 Days) = 650 ± 75 pA and 707 ± 107 pA, respectively.  
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Figure 6.3.13.1.3 (a): Mean current concentration profile for an AA calibration in PBS at +900 mV vs. 
SCE using Type 3 NO Sensor (n = 8) pre (black) and post treatment (red) with BT (28 days).  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3.13.1.3 (b): An SEM displaying the surface of the Type 3 NO sensor (A) pre BT and (B) post 
BT (28 Days).  
 
AA calibrations carried out on the Type 3 NO sensors in BT pre- and post-treatment 
yielded currents of 42 ± 32 pA and 480 ± 106 pA, respectively at a 1000 µM AA 
concentration. A significant difference was observed (P = 0.0202). The BT treatment 
caused the PPD layer to be altered and change, which is clear from the SEM demonstrated 
in Figure 6.3.13.1.3 (b), image B. 
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6.3.14 Temperature studies on Type 2 Sensor and Type 3 NO Sensor 
 
Temperature studies were undertaken on Type 2 and Type 3 NO sensors in this section to 
determine if a changing temperature would cause an alteration in the sensitivity of NO. 
Similar studies were carried out by Brown et al., on Type 1 NO sensors. They achieved an 
analogous sensitivity at 37 
°
C which yielded no significant difference to the sensitivity they 
attained at 25 
°
C (P = 0.5002) (Brown et al., 2009). It is necessary to verify how the sensor 
works at an elevated temperature of 37 
°
C in order to mimic the temperature experienced by 
NO sensors in-vivo.  
 
[NO], M Type 2 NO (Temp 37oC) 
(n = 6) 
Type 3 NO (Temp 37oC) 
(n = 6) 
 Mean I, pA SEM Mean I, pA SEM 
0.0 0 0 0 0 
0.2 207 33 106 34 
0.4 493 54 353 42 
0.6 699 47 453 61 
0.8 1057 36 602 73 
1.0 1251 79 790 111 
 
Table 6.3.14: An averaged table of results displaying an NO calibration in PBS (pH 7.4), at +900 mV vs. 
SCE, carried out on Type 2 (n = 6) and Type 3 NO Sensors (n = 6) at 37 
º
C. Background values 
subtracted. Mean background current of Type 2 NO and Type 3 NO Sensor = 1405 ± 156 pA and 1037 
± 239 pA, respectively. 
 
0.0 0.2 0.4 0.6 0.8 1.0
0
300
600
900
1200
1500
[NO], M
I,
 p
A
 
 
Figure 6.3.14: A current-concentration profile displaying an NO calibration in PBS (pH 7.4), at +900 
mV vs. SCE (37 
º
C), carried out on Type 2 (n = 6) and Type 3 NO Sensors (n = 6). 
 
  Chapter 6: In-Vitro Nitric Oxide  
 
287  
 
Calibrating the two types of NO sensors at a temperature of 37 
°
C yielded sensitivities of 
1287.0 ± 47.7 pA/ µM (R
2
 = 0.99) and 790.9 ± 40.6 pA/ µM (R
2
 = 0.99) for the Type 2 NO 
and Type 3 NO sensors respectively. There was no significant difference between the 
sensitivities obtained for the Type 2 NO sensors at 25 
°
C and 37 
°
C (P = 0.7400) and the 
Type 3 NO sensors at 25 
°
C and 37 
°
C (P = 0.6231). Although there was no disparity 
observed between the sensitivities at 25 
°
C and 37 
°
C for the two sensor types, a difference 
in the response time was achieved for the two sensors at 37 
°
C. Brown et al., achieved a 
very promising result of an improved response time in an altered temperature setting of 37 
°
C with Type 1 NO sensors. They identified a significant decrease (P = 0.0029) in the 
response time from 33.7 ± 3.7 seconds, n = 14, at 25 
°
C to 14.0 ± 2.5 seconds, n = 5, at 37 
°
C (Brown et al., 2009).   
Just like the result obtained by Brown et al., for the Type 1 NO sensor, a similar outcome 
was achieved with the Type 2 and 3 NO sensors. A response time of 18.1 ± 1.7 seconds, n 
= 38, at 25 
°
C, to 14.4 ± 0.2 seconds, n = 6, at 37 
°
C was obtained with the Type 2 NO 
sensors. For the Type 3 NO sensors, a response time of 15.9 ± 2.2 seconds, n = 38, at 25 
°
C 
to 10.3 ± 1.0 seconds, n =6, at 37 
°
C was attained. Although both of these results do not 
yield significant decreases (P = 0.3968 and P = 0.3234) for Type 2 and Type 3 NO sensors, 
respectively, the characteristic decrease in response time upon placement into an elevated 
temperature is observed. 
 
6.3.15 Post Calibrations in-vivo Type 2 NO Sensor  
 
In this section an investigation into the effects of the implantation of the electrodes into the 
in-vivo brain is examined, pre and post NO and AA calibrations are compared (n = 7, 6 
animals implanted for 11 days). These calibrations were carried out as described in Section 
3.7.2.4.  
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6.3.15.1 Pre and post in-vivo NO calibrations 
 
 
 
 
 
 
 
 
 
Table 6.3.15.1: An averaged table displaying the results pre and post in-vivo calibrations for Type 2 NO 
sensors at +900 mV vs. SCE. Background values subtracted. Mean background current for Type 2 NO 
sensor (n = 7) pre and post in-vivo calibrations = 205 ± 69 pA and 257 ± 85 pA, respectively. 
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Figure 6.3.15.1: A current-concentration profile displaying a pre and post in-vivo NO calibration in 
PBS (pH 7.4), at +900 mV vs. SCE, carried out on Type 2 NO Sensors (n = 7). 
 
It is observed from the comparison of the slopes (pA/ µM) of the electrodes, 1100 ± 19 pA/ 
µM for pre implantation and 974 ± 18 pA/ µM for post implantation, that the sensitivity of 
the Type 2 NO sensors did not alter dramatically. No significant difference was observed 
(P = 0.7229). The response of the electrodes was linear over the specified range with an R
2
 
value of 0.99, n = 7, pre implantation and 0.99, n = 7, post implantation. Following this, 
AA calibrations were carried out on the same sensors as detailed in Section 3.7.2.1.  
 
 Type 2 NO Sensor  
Pre In-Vivo (n = 7) 
Type 2 NO Sensor  
Post In-Vivo (n = 7) 
[NO], M Mean I, pA SEM Mean I, pA SEM 
0.0 0 0 0 0 
0.2 228 20 168 16 
0.4 467 41 388 42 
0.6 689 64 594 66 
0.8 898 84 780 91 
1.0 1094 98 955 117 
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6.3.15.2 Pre and post in-vivo AA calibrations 
 
 Type 2 NO Sensor 
Pre  In-Vivo (n = 7) 
Type 2 NO Sensor 
Post In-Vivo (n = 7) 
[AA], M Mean I, pA SEM Mean I, pA SEM 
0 0 0 0 0 
200 4 2 1196 467 
400 3 3 2339 963 
600 15 13 2458 960 
800 19 16 3081 1261 
1000 27 21 2691 923 
 
Table 6.3.15.2: An averaged table displaying the results pre and post in-vivo AA calibrations for Type 2 
NO sensors (n = 7) at +900 mV vs. SCE. Background values subtracted. Mean background current for 
Type 2 NO Sensor pre and post in-vivo calibrations = 183 ± 67 pA and 622 ± 31 pA, respectively. 
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Figure 6.3.15.2 (a): A current-concentration profile displaying a pre and post in-vivo AA calibration in 
PBS (pH 7.4), at +900 mV vs. SCE, carried out on Type 2 NO Sensors (n = 7). 
 
There is a large increase in the AA response at the electrodes post implantation that yields a 
significant difference pre and post (P = 0.0020). Although there is a large increase, the AA 
response remains relatively stable between 0.4 and 1.0 µM.  Implantation of the sensor into 
the living brain causes a dramatic change in the sensitivity post-implantation. This could be 
due to the harsh environment that is the brain; however, it could also be the effect of 
removal of the electrodes from the headpiece of the animal which may cause significant 
damage to the sensors PPD layer. This has been observed with other PPD coated sensors in 
our group. Gliosis results in glial cells adhering to implanted sensors and a strong grip is 
formed around the mesh like structure of PPD. Upon removal of the sensors from the brain, 
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part of the membrane is removed as a result of this affect of gliosis. It is very difficult to 
post calibrate in-vivo sensors for this reason.   
In Figure 6.3.15.2 (b), SEMs display the surface of the Type 2 NO sensor pre- and post-
implantation. It is evident from the images that a smooth surface is obtained initially prior 
to insertion into the brain environment, conversely on analysis of the surface of the sensor 
post implantation, it is apparent that the PPD layer had been aggravated and distorted, 
therefore allowing an enhanced detection of AA. 
 
 
 
 
 
 
 
 
    
 
Figure 6.3.15.2 (b): SEMs displaying the surface of (A); Type 2 NO sensor prior to implantation (B); 
Type 2 NO sensor post implantation. 
 
6.3.16 Post Calibrations in-vivo Type 3 NO Sensor  
 
In this section the effect of implanting the electrodes into the in-vivo brain is examined, pre 
and post NO and AA calibrations are compared (n = 6, 6 animals implanted for 10 days). 
These calibrations were carried out as described in Section 3.7.2.4. 
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6.3.16.1 Pre and post in-vivo NO calibrations 
 
 
 
 
 
 
 
 
 
 
Table 6.3.16.1: An averaged table displaying the results pre and post in-vivo NO calibrations for Type 3 
NO sensors (n = 6) at +900 mV vs. SCE. Background values subtracted. Mean background current for 
Type 3 NO sensor pre and post in-vivo calibrations = 322 ± 94 pA and 247 ± 208 pA, respectively. 
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Figure 6.3.16.1 (a): A current-concentration profile displaying a pre and post in-vivo NO calibration in 
PBS (pH 7.4), at +900 mV vs. SCE, carried out on Type 3 NO Sensors (n = 6). 
 
 
It is observed from the comparison of the slopes (pA/ µM) of the electrodes, 1128 ± 13 pA/ 
µM for pre-implantation and 1273 ± 32 pA/ µM for post-implantation, that the sensitivity 
of the Type 3 NO sensors did not alter. No significant difference was observed (P = 
0.8709). The response of the electrodes was linear over the specified range with an R
2
 value 
of 0.99, n = 6, pre-implantation and 0.99, n = 6, post-implantation. Following this, AA 
calibrations were carried out on the same sensors as detailed in Section 3.7.2.1.  
 
 Type 3 NO Sensor  
pre In-Vivo (n = 6) 
Type 3 NO Sensor  
post In-Vivo (n = 6) 
[NO], M Mean I, pA SEM Mean I, pA SEM 
0.0 0 0 0 0 
0.2 216 28 184 22 
0.4 448 53 468 43 
0.6 689 69 746 69 
0.8 908 92 999 94 
1.0 1115 107 1238 125 
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6.3.16.2 Pre and post in-vivo AA calibrations 
 
 
 
 
 
 
 
 
 
Table 6.3.16.2: An averaged table displaying the results pre and post in-vivo AA calibrations for Type 3 
NO sensors at +900 mV vs. SCE. Background values subtracted. Mean background current for Type 3 
NO sensor pre and post in-vivo calibrations = 367 ± 60 pA and 482 ± 201 pA, respectively. 
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Figure 6.3.16.2: A current-concentration profile displaying a pre and post in-vivo AA calibration in 
PBS (pH 7.4), at +900 mV vs. SCE, carried out on Type 3 NO Sensors (n = 6). 
 
There is a large increase in the AA response at the electrodes post-implantation that yields a 
significant difference pre and post (P = 0.0083). This could be as a result of the ruthless 
environment that is the brain; alternatively, it could also be the effect of removal of the 
electrodes from the headpiece of the animal which may cause significant damage to the 
sensors PPD layer. In Figure 6.3.16.2 (b), SEMs display the surface of the Type 3 NO 
sensor pre- and post-implantation. 
 
 
 Type 3 NO Sensor  
pre In-Vivo (n = 6) 
Type 3 NO Sensor  
post In-Vivo (n = 6) 
[AA], M Mean I, pA SEM Mean I, pA SEM 
0.0 0 0 0 0 
200.0 18 6 1027 651 
400.0 24 10 1987 1239 
600.0 33 17 3555 2295 
800.0 50 25 4398 2779 
1000.0 66 33 4893 3050 
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Figure 6.3.16.2 (b): SEMs displaying the surface of (A); Type 3 NO sensor prior to implantation (B); 
Type 3 NO sensor post-implantation. 
 
It is evident from the images in Figure 6.3.16.2 (b), that an even and uniform surface is 
attained prior to introduction into the brain environment, conversely on analysis of the 
surface of the sensor post-implantation, it is clear that the PPD layer had been damaged and 
deformed, therefore allowing some detection of AA. 
 
6.4 Conclusion 
 
The main focus of this chapter was to extensively characterise the Type 2 and Type 3 NO 
sensors in-vitro for their potential use in-vivo. A determination of the sensitivity and 
selectivity of the Type 2 and Type 3 NO sensors was undertaken, to observe whether these 
sensors were on par with the NO sensor already utilised in our lab and reported in the 
literature (Brown & Lowry, 2003; Brown et al., 2005; Brown et al., 2009; Finnerty et al., 
2012a; Finnerty et al., 2012b). A comparison of the Type 1, Type 2 and Type 3 NO sensor 
sensitivities to NO are detailed in Figure 6.4 (a). 
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Figure 6.4 (a): A current-concentration profile displaying the NO sensitivities obtained in PBS (pH 7.4), 
at +900 mV vs. SCE, with the Type 1 (n = 17), Type 2 (n = 38) and Type 3 NO sensors (n = 38). 
 
 
Although the Type 1 NO sensor produced a greater NO sensitivity, the Type 2 and 3 NO 
sensors displayed sensitivities that were not significantly different. Type 1 vs. Type 2 (P = 
0.8440), Type 1 vs. Type 3 (P = 0.6823) and Type 2 vs. Type 3 (P = 0.8332). A bar chart 
comparing the NO sensitivities of the three types of NO sensors against the Pt sensor 
highlights the vast differences in the detection of NO and the advantages of modifying the 
NO sensors to make detecting NO more efficient is displayed in Figure 6.4 (b). 
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Figure 6.4 (b): A bar chart displaying a comparison of all NO sensitivities attained at each sensor, 
carried out at +900 mV vs. SCE. 
 
 
  Chapter 6: In-Vitro Nitric Oxide  
 
295  
 
There is a significant difference between the sensitivities obtained for the Pt sensors against 
the other types of NO sensor, which is very evident in the bar chart displayed in Figure 6.4 
(b). On comparison of the individual NO sensors against the bare Pt sensor, a P value of < 
0.0001 was recorded, signifying the observed distinction between the sensors. 
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Figure 6.4 (c): A bar chart displaying the AA currents obtained at 1000 µM AA in PBS (pH 7.4), at 
+900 mV vs. SCE, with the Pt (n = 14), Type 1 (n = 17), Type 2 (n = 38) and Type 3 NO sensors (n = 38). 
 
The AA calibration displayed in Figure 6.4 (c), achieved no AA detection with all of the 
NO sensors yielding no significant difference between them, Type 1 vs. Type 2 (P = 
0.6264), Type 2 vs. Type 3 (P = 0.0772) and Type 2 vs. Type 3 (P = 0.2553). However, a 
significant difference was recorded between the Pt sensor and all of the different types of 
NO sensor, Pt vs. Type 1 (P < 0.0001), Pt vs. Type 2 (P < 0.0001) and Pt vs. Type 3 (P < 
0.0001). The long-term stability research carried out on these sensors revealed information 
that would change the way studies over extended periods of time were carried out in the 
lab. It was observed that on repeated calibration of the sensors, that the surface of each 
sensor was altered and modified more extensively than when the sensors were calibrated 
less frequently. Negligible results were presented after 56 days of storage and in 
comparison to the repeated calibrations displayed in this chapter, these results were very 
promising. The storage conditions were the same for all three sensors (enclosed container at 
4 
°
C) and a summary is presented in Table 6.4 (a) of all of these results. 
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 Day 1 (pA) Day 56 (pA) Day 168 (pA) 
Sensor Type Mean (1000 µM) SEM Mean (1000 µM)  SEM Mean (1000 µM) SEM 
Pt-PPD (n = 4) 19 4 24 2. 3490 1276 
Type 1 NO (n = 3) -2 0 -5 1 -22 3 
Type 2 NO (n = 4) 6 1 60 40 117 113 
Type 3 NO (n = 4) 3 1 1 1 -32 7 
 
Table 6.4 (a): A table summarising the responses attained with the individual sensors from day 1 to day 
168 utilising the chosen storage condition of enclosed in a container dry at 4 
°
C in the fridge. 
 
As the full characterisation of the Type 1 NO sensor had already been completed by Brown 
et al., and Finnerty et al., (Brown et al., 2009; Finnerty et al., 2012a; Finnerty et al., 
2012b), biocompatibility studies of the Type 2 and Type 3 NO sensors were undertaken. 
An effect was observed at the two sensors when treated with the proteins and lipids. 
Placement into BT yielded the most dramatic increase in AA detection on both sensors. 
Brown et al., detailed a drop in NO sensitivity at the Type 1 NO sensor after treatment with 
BSA (10%) and PEA (10%) for a period of 72 hours in either solution (Brown et al., 2009). 
They did not determine if there was any degradation of the sensor‘s layers after this time in 
each treatment.  Reports utilising amperometric biosensors have observed between 20 and 
50 % decreases in sensitivity after exposure to BT (Garguilo & Michael, 1994; Hu et al., 
1994). The sensors studied in this thesis were placed in the treatments for a month. This is 
an extensive time for the sensors to be immersed in treatments in comparison to what 
Brown et al., completed (Brown et al., 2009).     
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Figure 6.4 (d): A bar chart summarising the biocompatibility studies for each sensor described above 
over the course of 28 days.  
 
Interference studies carried out on the sensors yielded no possibility for detection of any 
analyte other than NO, due to insignificant currents obtained for different interferents. 
Table 6.4 (b) depicts a summary of all the analytes and the percentage contribution to the 
overall NO signal. Subsequent to this Table, a summary of the in-vitro response attained 
with the potential interferents utilising bare Pt electrodes courtesy of Brown, F.O. (Brown, 
F.O. 2003) is depicted. This highlights the need for modification of the sensor with 
Nafion
®
, as the interferents can cause a substantial influence on the NO signal. 
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Analyte NO Response (pA) % of NO signal 
 Type 2 Type 3 Type 2  Type 3 
NO 1047 ± 34 974 ± 46 100 100 
AA -6 ± 6 -18 ± 6  ≤ 1 ≤ 1 
5-HT -16 ± 20 12 ± 19 ≤ 1 ≤ 1 
Dopac -6 ± 32 -5 ± 12 ≤ 1 ≤ 1 
Dopamine 5 ± 3 8 ± 7 ≤ 1 ≤ 1 
Glutathione 2 ± 6 9 ± 14 ≤ 1 ≤ 1 
H2O2 8 ± 2 -6 ± 7 ≤ 1 ≤ 1 
5-HIAA -6 ± 16 -2 ± 6 ≤ 1 ≤ 1 
HVA -13 ± 7 6 ± 33 ≤ 1 ≤ 1 
NO2- 7 ± 0 3 ± 1 ≤ 1 ≤ 1 
UA 5 ± 2 -11 ± 6 ≤ 1 ≤ 1 
 
Table 6.4 (b): A summary of all the sensitivities of the interferents and their percentage effect on the 
NO signal with Type 2 and Type 3 NO sensors. 
 
 
 
Analyte NO Response (pA) 
 Bare Pt electrode 
NO 352 ± 25 (n = 14) 
AA 37063 ± 2992 (n = 14) 
5-HT ≤ 1 (n = 4) 
Dopac 940 ± 170 (n = 4) 
Dopamine 9 ± 1 (n = 4) 
Glutathione 9 ± 1 (n = 4) 
H2O2 4 ± 1 (n = 3) 
5-HIAA 990 ± 100 (n = 4) 
HVA 100 ± 10 (n = 4) 
NO2- 560 ± 110 (n = 3) 
UA 1530 ± 50 (n = 4) 
 
Table 6.4 (c): A summary of all the sensitivities of the interferents obtained with Pt electrodes (Brown, 
F.O. 2003). 
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Temperature studies undertaken with the Type 2 and Type 3 NO sensors displayed no 
significant difference (P = 0.7400 and P = 0.6231), respectively, on elevation of the 
temperature to 37 
°
C. Figure 6.4 (e) displays a summary of the results obtained for the two 
sensors. 
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Figure 6.4 (e): A bar chart depicting the temperature elevation NO sensitivity results for Type 2 and 
Type 3 NO sensors at 25 
°
C and 37 
°
C. 
 
As a slow response time was a major hindrance of the Type 1 NO sensor (34 ± 3 s, n = 14), 
the two NO sensors (Type 2 and Type 3) were manufactured in order to try and alleviate 
this problem, while retaining the sensitivity and selectivity of the sensor. This was 
accomplished, yielding response times of 18 ± 2 s, n = 38 and 16 ± 2 s, n = 38, for Type 2 
and Type 3 NO sensors, respectively. When the temperature was elevated to 37 
°
 C, which 
is the temperature found in-vivo, the response times for the two sensor types decreased, 
which was also demonstrated previously with the Type 1 NO sensor by Brown et al., 
(Brown et al., 2009). The response times were found to have decreased to 14 ± 1 seconds, n 
= 6 and 10 ± 1 seconds, n = 6, for the Type 2 and Type 3 NO sensors respectively.  
Figure 6.4 (f), details the NO sensitivities obtained for the Type 2 and Type 3 NO sensors 
pre- and post-implantation. There was no significant difference recorded for the Type 2 NO 
sensor (P = 0.7229) and Type 3 NO sensor (P = 0.8709). However, with regards to the AA 
response pre- and post-implantation a significant difference was observed for the Type 2 
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NO sensor (P = 0.0020) and Type 3 NO sensor (P = 0.0083) (see Section 6.3.15 and 
6.3.16). As previously stated, this could be due to the complex and harsh environment of 
the brain, however, it could also be the effect of removal of the sensors from the headpiece 
of the animal which can cause significant damage to the PPD layer of the sensor. Overall, 
the results observed for these two sensors indicate a potential use in-vivo.   
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Figure 6.4 (f): A bar chart illustrating the NO sensitivities obtained pre and post implantation for the 
Type 2 and 3 NO sensor. 
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7.1 Introduction 
 
Subsequent to the in-vitro characterisation of the Type 2 and Type 3 NO sensors in Chapter 
6, an investigation into the performance of the sensors under physiological conditions was 
undertaken. While the results obtained from the in-vitro characterisation specify that the 
Type 2 and Type 3 NO sensors have the necessary properties with regards to selectivity, 
sensitivity and stability for the neurochemical monitoring of NO in-vivo, it is important to 
perform an in-vivo characterisation of the sensors to ensure that the results obtained in-vitro 
can be sustained in the more complex target biological setting. A challenge that is facing 
science today is the comprehension of the living brain, how it works and what happens at 
any giving moment upon initiation of a stimulus or a drug. The brain comprises of neurons 
and glial cells that interact through chemicals released into the extracellular space and it is 
due to this fact that monitoring these chemical messengers is of great importance (Kennedy 
et al., 2002). The incorporation of electrochemistry in-vivo entails the use of amperometric 
electrodes and voltammetry techniques in order to detect electroactive species (O'Neill et 
al., 1998). 
Although the in-vitro setting is ideal for sensor development and can give a valuable insight 
into how a sensor might perform under certain conditions, detecting NO in the in-vivo 
environment yields a more complex and difficult environment for a sensor to withstand. In 
addition to being very diverse and complicated, BT comprises of surfactants (lipids), 
poisons (proteins), and electrocatalysts (AA) along with other species that may be 
detrimental to the sensors performance. Another concern is the restricted mass transport of 
the particular analyte to the surface of the sensor (O'Neill, 1993). This can give rise to very 
difficult conditions when trying to detect a very small molecule like NO, that is short-lived 
and highly reactive (Finnerty et al., 2012a). NO is a gaseous free radical and one of the 
smallest molecules found in nature. It has been found to play a role in a range of 
physiological and pathophysiological processes. The regulation of vascular tone and some 
diseases have been found to be linked to NO, some of which include hypertension, 
Parkinson‘s disease and Alzheimer‘s disease (Brown et al., 2005). In addition to all of these 
factors, the NO concentration in the brain extracellular fluid has been established as 
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approximately 0.1 µM (Hall & Garthwaite, 2009), making NO a very difficult molecule to 
detect.  
The characterisation of the NO sensors in this chapter involved the systemic administration 
of the NO precursor L-arginine, the nitric oxide synthase (NOS) inhibitor L-NAME, a 
control injection of saline and an interference test injection of sodium L-ascorbate. This 
characterisation protocol of NO sensors has previously been demonstrated by Finnerty et 
al., (Finnerty et al., 2012a; Finnerty et al., 2012b). The main aim of this chapter was to 
follow on from the previous NO characterisation in-vitro chapter and confirm the 
sustainability and viability of the Type 2 and Type 3 NO sensors in-vivo, by administration 
of potential interferents, inducers and inhibitors of NO. 
 
7.2 Experimental 
 
The instrumentation and software utilised are described in Section 3.2. All chemicals and 
solutions are detailed in Section 3.3. The manufacture of the different NO sensors is 
described in Sections 3.4. All modifications to the sensors are detailed in Section 3.5. A 
potential of +900 mV vs. Ag wire was applied to all working electrodes involved in the NO 
calibrations. The surgical procedure undertaken for the implantation of the sensors is 
detailed in Section 3.8.2. All i.p. injections were prepared in normal saline or otherwise 
stated. All in-vivo experiments were undertaken as described in Section 3.8. All 
experiments were carried out in freely moving animals. 
Data is reported as mean ± S.E.M. All statistical analysis was carried out using student t-
tests. These tests were performed using GraphPad prism and yielded a P-value result, 
which is the probability value that specifies if the results observed are significantly 
different. In each of the Sections, n denotes the number of perturbations carried out on a 
given number of sensors in a given number of animals, unless stated otherwise. 
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7.3 Results and Discussion 
 
This results section comprises the data from experiments undertaken to characterise the 
Type 2 and Type 3 NO sensors in-vivo. As the route of administration for investigating the 
effect of drugs on the NO response was through an i.p injection, the effect of an i.p. 
injection of saline on the NO current was examined. Using saline, demonstrates the effect 
of the injection stress on the NO response. An injection of saline (NaCl, 0.9 %, i.p.) on the 
NO current was recorded with the Type 2 and Type 3 NO sensors and is demonstrated in 
Figure 7.3.1.1 and 7.3.1.2. A significant change in the baseline levels in NO sensors 
implanted in the striatum of rats have been demonstrated previously, however it is short 
lived and a corresponding return to baseline is observed (Finnerty et al., 2012a). A similar 
observation was obtained by Bolger et al., for tissue O2 (Bolger et al., 2011b) and Lowry et 
al., for glucose (Lowry et al., 1998b). 
 
7.3.1 Saline Administration  
 
A typical example of the effect of a saline administration (NaCl, 0.9 %, i.p.) on the NO 
current for Type 2 and Type 3 NO sensors is depicted in Figure 7.3.1.1 and 7.3.1.2.   
 
7.3.1.1 Type 2 NO sensor 
 
The saline injection data in this Section was analysed using the results from 8 perturbations 
with 8 sensors in 6 animals. 
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Figure 7.3.1.1: A typical example of an i.p. injection of saline (1 mL (NaCl) 0.9 %) monitored by a Type 
2 NO sensor implanted in the striatum of a rat. The arrow is indicative of the point of injection. 
 
 
The results in Figure 7.3.1.1 demonstrate how the NO sensor reacts to an i.p. injection of 
saline. A transient increase occurred in the oxidation current that was not significantly 
different (P = 0.0819) from baseline levels. The increase occurred after approximately 3 ± 1 
minutes, n = 8, from a baseline of 378 ± 169 pA, n = 8, to a current of 405 ± 181 pA, n = 8, 
yielding a current change of 27 ± 13 pA, n = 8. This corresponded to a percentage change 
of 7 ± 3 %, n = 8. The increase returned to a post injection baseline level (388 ± 179 pA, n 
= 8), that was not significantly different (P = 0.4642) from the pre-injection baseline after 
18 ± 5 minutes, n = 8. These results demonstrate that an initial increase in the oxidation 
current was recorded, due to the injection stress which causes an increase in the NO current 
very briefly, and an analogous NO baseline return. 
 
 
Table 7.3.1.1: Summary of results for saline administration (1 mL (NaCl) 0.9 %), on Type 2 NO sensors, 
implanted in the striatum of freely moving rats (n = 8 with 8 sensors in 6 animals).    
Saline (i.p. injection) 
Current change 
(pA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (pA) 
Baseline Post 
Injection (pA) 
 
27 ± 13 
 
7 ± 3 
 
3 ± 1 
 
18 ± 5 
 
378 ± 169 
 
388 ± 179 
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7.3.1.2 Type 3 NO sensor 
 
The saline injection data in this Section was analysed using the results from 8 perturbations 
with 8 sensors in 5 animals. 
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Figure 7.3.1.2: A typical example of an i.p. injection of saline (1 mL (NaCl) 0.9 %) monitored by a Type 
3 NO sensor implanted in the striatum of a rat. The arrow is indicative of the point of injection. 
 
 
On analysis of the results, a short-lived increase occurred in the NO signal that was not 
significantly different (P = 0.0768) from baseline levels, after approximately 3 ± 1 minutes, 
n = 8. A current change of 43 ± 21 pA, n = 8, from a baseline of 621 ± 202 pA, n = 8, to a 
current of 663 ± 220 pA, n = 8, was obtained which corresponded to a percentage change of 
4 ± 2 %, n = 8. These increases returned to corresponding baseline levels that were not 
significantly different (P = 0.1155) from baseline levels, after 9 ± 2 minutes, n = 8, to 
currents of 645 ± 212 pA, n = 8. These results demonstrate that an initial increase in the NO 
current was recorded, but this was very short-lived and due to this being the route for all 
injections, it shows that the injection stress itself causes an increase in the NO current, 
however, an analogous NO baseline returns quite quickly. 
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Table 7.3.1.2: Summary of results for saline administration (1 mL (NaCl) 0.9 %), on Type 3 NO sensors, 
implanted in the striatum of freely moving rats (n = 8 with 8 sensors in 5 animals).    
 
7.3.2 L-NAME Administration 
 
There are many NOS inhibitors in the literature that are widely utilised as pharmacological 
agents to inhibit NOS in varying biological systems (Alderton et al., 2001). L-NAME has 
been identified as contending with arginine, the pre-cursor for NO production, for its 
binding site (Lajoix et al., 2004) on the NOS isozyme. N
G
-nitro-L-arginine (L-NOARG) 
and L-NAME were found to be effective inhibitors of endothelial and neuronal NOS in the 
1990‘s (Miilsch & Busse, 1990; Rees et al., 1990b), however, despite having analogous 
structures, L-NAME was observed as being less potent than L-NOARG (Pfeiffer et al., 
1996). The use of L-NAME as an NO synthesis inhibitor has been demonstrated by many 
research groups (Rees et al., 1990b; Miller et al., 1993; Losonczy et al., 1996).     
The involvement of NO in the migration, invasiveness and carcinogenesis of tumors has 
been hypothesised by a number of in-vitro and in-vivo investigations that have been 
undertaken (Yu et al., 2005). The utilisation of L-NAME in applying anti-cancer effects to 
human head and neck cancer as well as mammary tumors has been demonstrated in-vitro 
(Gallo et al., 1998; Jadeski & Lala, 1999). Phencyclidine (PCP) administration has been 
incorporated into studies to yield a pharmacological animal model for schizophrenia (Javitt 
& Zukin, 1991; Johansson et al., 1997; Pålsson et al., 2009). It was demonstrated that NO 
levels were increased upon administration of the drug PCP; conversely upon pre-treatment 
with the NOS inhibitor L-NAME, this increase was counteracted. This suggested that L-
NAME could block the effects of PCP-induced characteristics.  
Saline (i.p. injection) 
Current change 
(pA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (pA) 
Baseline Post 
Injection (pA) 
 
43 ± 21 
 
4 ± 2 
 
3 ± 1 
 
9 ± 2 
 
621 ± 202 
 
645 ± 212 
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The main aim of this section was to provide real-time confirmation that L-NAME decreases 
NO concentrations when administered systemically. Figures 7.3.2.1 and 7.3.2.2 
demonstrate the responses attained at a Type 2 and 3 NO sensor upon administration of an 
i.p. injection of L-NAME. 
 
7.3.2.1 Type 2 NO Sensor 
 
The L-NAME injection data in this Section was analysed using the results from 8 
perturbations with 8 sensors in 6 animals. 
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Figure 7.3.2.1: A typical example of an i.p. injection of L-NAME (30 mg/kg in 1 ml saline) monitored at 
a Type 2 NO sensor implanted in the striatum of a rat. The arrow is indicative of the point of injection. 
 
 
An immediate and short-lived increase in the oxidation current can be seen upon injection 
of L-NAME which is similar to the response observed upon injection of saline shown in 
Figure 7.3.1.1, demonstrating the initial stress response following injection. This response 
is brief and has been demonstrated previously in the literature (Finnerty et al., 2012a). 
Subsequent to this stress response, is the response attained from the L-NAME injection. As 
L-NAME is a NOS inhibitor, the expected result is to observe a decrease in the NO signal. 
In Figure 7.3.2.1, a typical NO response to L-NAME demonstrates this decrease. The 
overall decrease in oxidation current (32 ± 13 pA, n = 8), was significantly different (P = 
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0.0388) from pre-baseline levels. The current decreased from a baseline level of 465 ± 174 
pA, n = 8, to a current of 434 ± 164 pA, n = 8, yielding a percentage change of 7 ± 2 %, n = 
8. The maximum decrease was reached after approximately 58 ± 10 minutes, n = 8 and a 
corresponding baseline occurred after 134 ± 21 minutes, n = 8, that was not significantly 
different (P = 0.6480) from the baseline level prior to the injection. 
 
 
Table 7.3.2.1: Summary of results for L-NAME administration on Type 2 NO sensors, implanted in the 
striatum of freely moving rats (n = 8 with 8 sensors in 6 animals).    
 
7.3.2.2 Type 3 NO Sensor 
 
The L-NAME injection data in this Section was analysed using the results from 6 
perturbations with 6 sensors in 4 animals. 
 
0 50 100 150 200
550
600
650
700
Time, mins
I,
 p
A
 
Figure 7.3.2.2: A typical example of an i.p. injection of L-NAME (30 mg/kg in 1 ml saline) monitored by 
a Type 3 NO sensor implanted in the striatum of a rat. The arrow is indicative of the point of injection. 
L-NAME (i.p. injection) 
Current change 
(pA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (pA) 
Baseline Post 
Injection (pA) 
 
32 ± 13 
 
7 ± 2 
 
58 ± 10 
 
134 ± 21 
 
465 ± 174 
 
420 ± 171 
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Upon initial injection of L-NAME, a sharp increase in the baseline can be seen which 
corresponds to the injection stress observed previously for saline administrations. After 83 
± 16 minutes, n = 6, a decrease in the NO response was observed from a baseline of 583 ± 
45 pA, n = 6, to an NO current of 531 ± 38 pA, n = 6, yielding a current change of 52 ± 15 
pA, n = 6, and a corresponding percentage change of 9 ± 2 %, n = 6. The decrease attained 
on the NO current was significantly different (P = 0.0161) from baseline and a return to an 
equivalent baseline (532 ± 46, n = 6), occurred after 142 ± 25, n = 6, to a baseline that was 
not significantly different (P = 0.0764) from pre-injection levels.  
 
 
 
Table 7.3.2.2: Summary of results for L-NAME administrations on Type 3 NO sensors, implanted in the 
striatum of freely moving rats (n = 6 with 6 sensors in 4 animals).    
 
7.3.3 L-Arginine Administration 
 
The synthesis of NO involves a two step process, one of which L-arginine plays a vital role. 
The NO precursor L-arginine is transformed to arginine-hydroxide in a reaction that is 
catalysed by NOS. Subsequent to this, arginine-hydroxide is then transformed to NO and 
citrulline, the synthesis involves cofactors also, which include calcium/calmodulin, O2 and 
nicotinamide adenine dinucleotide phosphate (Bredt & Snyder, 1992). Previous 
publications have discussed the use of an amperometric sensor to detect the NO response to 
L-arginine administration in the prefrontal cortex, nucleus accumbens and the striatum of a 
freely moving rat, with results displaying an increase in NO levels (Brown et al., 2009; 
Finnerty et al., 2012a; Finnerty et al., 2012b).  
L-NAME (i.p. injection) 
Current change 
(pA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (pA) 
Baseline Post 
Injection (pA) 
 
52 ± 15 
 
9 ± 2 
 
83 ± 16 
 
142 ± 25 
 
583 ± 45 
 
532 ± 46 
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In other animal studies the antioxidant effects of L-arginine in brain ischemia were 
confirmed. After administration of L-arginine, decreases in the concentrations of lipid 
peroxidation products and increases in the concentrations of the antioxidant effects were 
observed (Maksimovich et al., 2006). L-arginine has been utilised in order to improve 
disorders where NO is hypothesised as playing a part. For example, Creager et al., 
demonstrated that the introduction of L-arginine improved the endothelium-dependent 
vasodilation in the disorder hypercholesterolemia in humans, by possibly enhancing the 
synthesis of NO (Creager et al., 1992). Another study undertaken by Drexler et al., 
demonstrated how administration of L-arginine partially restored the endothelium-
dependent vasodilation in the disorder hypercholesterolemia (Drexler et al., 1991).  
Measurements of NO production in erythrocytes during stimulation by L-arginine has been 
demonstrated by Carvalho et al., using a commercial NO sensor (Carvalho et al., 2004). 
Research carried out which involved the long term oral supplementation of L-arginine for 6 
months was found to improve coronary small vessel endothelial function. This significantly 
improved the symptoms associated with the disorder coronary endothelial dysfunction 
(Lerman et al., 1998). Contradictory studies undertaken that incorporate the 
supplementation of L-arginine demonstrate that L-arginine does not increase NO synthesis 
or improve vascular reactivity and also could potentially do more damage to patients with 
peripheral arterial disease (Wilson et al., 2007). In this section, data is presented that 
outlines the NO response to systemic administration of L-arginine in the striatum of a freely 
moving rat. 
 
7.3.3.1 Type 2 NO Sensor 
 
The L-arginine injection data in this Section was analysed using the results from 7 
perturbations with 6 sensors in 5 animals. 
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Figure 7.3.3.1: A typical example of an i.p. injection of L-arginine (300 mg/kg in 1 ml saline) monitored 
by a Type 2 NO sensor implanted in the striatum of a rat. The arrow is indicative of the point of 
injection. 
 
It can be seen from Figure 7.3.3.1, that following the systemic administration of L-arginine, 
the oxidation current increases. Following the injection of L-arginine, a stress signal is 
observed which was demonstrated previously for the other i.p. injections, as a transient 
increase in the NO current before a rapid return to baseline. Following this, a maximum 
current change of 25 ± 7 pA, n = 7, was observed after 19 ± 4 minutes, n = 7, from a 
baseline of 380 ± 185 pA, n = 7, to a current of 404 ± 186 pA, n = 7. This yielded a 
percentage change of 12 ± 5 %, n = 7. The increase recorded was significantly different (P 
= 0.0160) from baseline and a corresponding baseline returned after 98 ± 12 minutes, n = 7, 
that was not significantly different (P = 0.1889) from pre-injection baseline levels.  
 
 
Table 7.3.3.1: Summary of results for L-NAME administration on Type 2 NO sensors, implanted in the 
striatum of freely moving rats (n = 7 with 6 sensors in 5 animals).    
L-Arginine (i.p. injection) 
Current change 
(pA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (pA) 
Baseline Post 
Injection (pA) 
 
25 ± 7 
 
12 ± 5 
 
19 ± 4 
 
98 ± 12 
 
380 ± 185 
 
407 ± 202 
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7.3.3.2 Type 3 NO Sensor 
 
The L-arginine injection data in this Section was analysed using the results from 7 
perturbations with 5 sensors in 3 animals. 
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Figure 7.3.3.2: A typical example of an i.p. injection of L-arginine (300 mg/kg in 1 ml saline) monitored 
by a Type 3 NO sensor implanted in the striatum of a rat. The arrow is indicative of the point of 
injection. 
 
 
For the Type 3 NO sensors, an increase in the NO current after administration of L-arginine 
was recorded. Injection stress can be seen initially by the transient increase in the NO 
current. Subsequent to this, a larger increase is observed in the NO signal yielding a current 
change of 28 ± 12 pA, n = 7, from a baseline level of 462 ± 39 pA, n = 7, to an new current 
of 490 ± 35 pA, n = 7. This increase was significantly different (P = 0.0069) from baseline 
with a percentage change of 7 ± 4 % occurring after 32 ± 4 minutes, n = 7. The signal 
returned to a new baseline level of 465 ± 43 pA, n = 7, after 103 ± 23 minutes, n = 7, which 
was significantly different (P = 0.8878) from pre-injection baseline levels. 
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Table 7.3.3.2: Summary of results for the L-arginine administration from Type 3 NO sensors, 
implanted in the striatum of freely moving rats (n = 7 with 5 sensors in 3 animals).    
 
7.3.4  Sodium Ascorbate Administration 
 
In Chapter 6, the Type 2 and 3 NO sensors demonstrated excellent selectivity towards NO 
in-vitro against a wide range of electroactive interferents (e.g. ascorbic acid, dopamine, 
DOPAC, NO2
-
, serotonin) found in the brain ECF (see Figure 6.3.11). Ascorbic acid or in 
this case it‘s mineral salt sodium ascorbate was chosen as the main interferent to test the 
selectivity of the NO sensors against in-vivo, as it is the primary endogenous interferent 
present in the brain (Brown et al., 2009). It is ubiquitous, with a concentration in the ECF 
stated as approximately 500 µM (Miele & Fillenz, 1996a). In order to characterise any 
sensor thoroughly, it is necessary to characterise the selectivity of sensor designs prior to 
implantation. This has been demonstrated with many sensors including glucose sensors 
(Lowry & O'Neill, 1992; Lowry et al., 1998a; Kealy et al., 2013) or in this case NO sensors 
(Brown & Lowry, 2003; Ferreira et al., 2005; Brown et al., 2009).   
Sodium ascorbate is one of a number of mineral salts of ascorbic acid also referred to as 
vitamin C. Ascorbic acid has been known to be more acidic than its mineral salts, due to the 
fact that these mineral salts are buffered (Higdon & Drake, 2011). Ascorbic acid can cause 
the animal discomfort and aggravation around the injection site due to the acidity, so an i.p. 
injection of sodium ascorbate, which is milder, was chosen. This will confirm that the 
sensor design was still intact and the rejection layer had not been compromised during the 
implantation of the sensors. It is imperative to confirm that the two Types of NO sensors 
reported in this chapter have not degraded and that the sensors still exhibit similar 
selectivity characteristics to those recorded in-vitro. In Figure 7.3.4.1 (a) and 7.3.4.2, the 
L-Arginine (i.p. injection) 
Current change 
(pA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (pA) 
Baseline Post 
Injection (pA) 
 
28 ± 12 
 
7 ± 4 
 
32 ± 4 
 
103 ± 23 
 
462 ± 39 
 
465 ± 43 
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responses acquired with the Type 2 and 3 NO sensors from the injection of sodium 
ascorbate are depicted. 
     
7.3.4.1 Type 2 NO Sensor 
 
The sodium ascorbate injection data in this Section was analysed using the results from 9 
perturbations with 9 sensors in 6 animals. 
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Figure 7.3.4.1 (a): A typical example of an i.p. injection of sodium ascorbate (1g/kg in 1 ml of saline) 
monitored by a Type 2 NO sensor implanted in the striatum of a rat. The arrow is indicative of the 
point of injection. 
 
The Type 2 NO sensor response to an i.p. injection of sodium ascorbate demonstrates a 
brief increase in the NO response which corresponds to injection stress. This response has 
been observed throughout each of the injections carried out on the animals. An initial rapid 
increase occurs, however, returns back to a steady baseline quite quickly and the NO 
current remains relatively stable, demonstrating no detection of AA. This leads to the 
confirmation that the structural design of the sensor has not been damaged from the 
implantation protocol or aggravated from being situated in a harsh and complex 
environment that is the living brain. It has been previously illustrated with CPEs, that if any 
response to sodium ascorbate was to occur it would do so within a time range of 60 minutes 
(Finnerty et al., 2012a). Figure 7.3.4.1 (c), displays the response to a sodium ascorbate 
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injection using CPEs, taken from Finnerty et al., 2012. It can be observed that there has 
been a response at the CPEs and it is clear from the Type 2 NO sensor data that there is no 
significant change (P = 0.2052) in the oxidation current (-44 ± 30 pA, n = 9), over the 60 
minutes post ascorbate injection. The decrease in the current can be attributed to 
fluctuations in NO levels associated with circadian rhythms. Figure 7.3.4.1 (b) 
demonstrates these fluctuations recorded over a 3 hour period which further validates the 
selectivity of the sensor towards NO over ascorbate. A summary table of the results 
obtained for 6 animals is displayed in Table 7.3.4.1.  
 
 
 
 
 
 
 
Table 7.3.4.1: Summary of results for sodium ascorbate administration on Type 2 NO sensors, 
implanted in the striatum of freely moving rats (n = 9 with 9 sensors in 6 animals).    
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Figure 7.3.4.1 (b): A time vs. percentage change graph of baseline NO currents monitored by NO 
sensors (Type 2 and Type 3 NO sensors), displaying a stable baseline over the course of three hours in-
vivo (15 sensors in 5 animals) 
 
 
 
Sodium ascorbate (i.p. injection) 
Current change 
(pA) 
Current change 
(%) 
Significance 
-44 ± 30 8 ± 10 P = 0.2052 
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Figure 7.3.4.1 (c): A typical example of the effect of an i.p injection of sodium ascorbate on the response 
of a CPE implanted in rat striatum (Finnerty et al., 2012a). 
 
7.3.4.2 Type 3 NO Sensor 
 
The sodium ascorbate injection data in this Section was analysed using the results from 9 
perturbations with 8 sensors in 5 animals. 
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Figure 7.3.4.2: A typical example of an i.p. injection of sodium ascorbate (1g/kg in 1 ml of saline)  
monitored by a Type 3 NO sensor implanted in the striatum of a rat. The arrow is indicative of the 
point of injection. 
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The sodium ascorbate i.p. injection for the Type 3 NO sensor displayed a similar response 
attained by the Type 2 NO sensors. An initial increase in the NO current related to the 
stress of the injection and a return to baseline was observed. If any change in the oxidation 
current was to occur from this ascorbate injection, it would take place within 60 minutes 
(see Figure 7.3.4.1 (c)). An overall current change of -21 ± 14 pA, n = 9, was obtained. 
There was no significant difference (P = 0.2214) between the initial pre-injection baseline 
(696 ± 274 pA, n = 9) and the new recorded level of 674 ± 262, n = 9. A slight decrease in 
current was observed which can be attributed to the fluctuation in the NO current (see 
Figure 7.3.4.1 (b)) recorded over the 60 minutes. A similar trend has been reported by 
Brown et al., during in-vitro investigations (Brown & Lowry, 2003). This confirms that the 
Type 3 NO sensors once implanted retained their integrity and the surface of the sensor 
remained intact which blocked the detection of sodium ascorbate.      
 
 
 
 
 
 
 
 
Table 7.3.4.2: Summary of results for sodium ascorbate administration on Type 3 NO sensors, 
implanted in the striatum of freely moving rats (n = 9 with 8 sensors in 5 animals) 
 
 
 
 
 
 
 
 
 
 
Sodium ascorbate (i.p. injection) 
Current change 
(pA) 
Current change 
(%) 
Significance 
-21 ± 14 -0.3 ± 1.5 P = 0.2214 
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7.3.5 Stability of the NO sensors 
 
In Chapter 6 the long term stability of the sensors in-vitro was determined over 56 days and 
for the calibrations that were carried out less frequently, a calibration at day 168 was tested 
also (see Section 6.3.8.2). The results demonstrated that the two NO sensors over the period 
of 56 days remained stable, when calibrated once prior to day 56. The chosen optimum 
storage condition (4 
°
C, enclosed container) displayed an AA response at a concentration of 
1000 µM, of 60 ± 30 pA for the Type 2 NO sensors and 1 ± 1 pA for the Type 3 NO 
sensors after 56 days. When the long-term BT treatments were undertaken over 28 days the 
Type 2 and Type 3 NO sensors demonstrated a significant difference pre- and post-
treatment (P = 0.0450 and P = 0.0202), respectively. The need to characterise the sensors 
in-vivo is due to the vast differences between the in-vivo and in-vitro environments. In this 
Section the stability of the sensors was determined in-vivo over the specified days and the 
results for both sensors are depicted in Figure 7.3.5.1 and 7.3.5.2. The NO current was 
taken at approximately the same time every day so that an accurate representation of the 
baseline could be achieved.     
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7.3.5.1  Type 2 NO sensor 
 
The baseline data in this section was analysed using the results from 5 animals with 8 
sensors over 11 Days. 
 
 Type 2 NO sensor (% NO) decrease 
Day Mean (% O2) SEM n 
1 100 0 8 
2 71 11 8 
3 65 12 8 
4 66 12 8 
5 67 13 8 
6 65 14 8 
7 66 13 8 
8 66 14 8 
9 68 15 8 
10 72 11 8 
11 72 15 8 
 
Table 7.3.5.1: The mean percentage table displaying the % decrease in NO after implantation with 8 
Type 2 NO sensors over 11 days in the striatum of 5 freely moving rats. 
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Figure 7.3.5.1: The averaged percentage NO decrease vs. day profile of the Type 2 NO sensors over the 
course of 11 days in the striatum of 5 freely moving rat with 8 sensors 
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The results displayed in Table 7.3.5.1 and Figure 7.3.5.1 demonstrates how stable the Type 
2 NO sensors are over the 11 days of implantation in the in-vivo environment. Initially there 
is approximately a 29 % decrease in the NO current that remains stable over the specified 
days. One-way ANOVA analysis revealed that the results for the in-vivo stability were not 
significantly different (P = 0.7763) over the course of the study. The Type 3 NO sensor 
stability data is displayed in Section 7.3.5.2.  
 
7.3.5.2  Type 3 NO Sensor 
 
The baseline data in this section was analysed using the results from 5 animals with 8 
sensors over 10 Days. 
 
 Type 3 NO sensor (% NO) decrease 
Day Mean (% O2) SEM n 
1 100 0 8 
2 75 10 8 
3 78 9 8 
4 78 6 8 
5 84 5 8 
6 85 4 8 
7 87 3 8 
8 72 7 8 
9 73 9 8 
10 86 12 8 
 
Table 7.3.5.2: The mean percentage table displaying the % decrease in NO after implantation with 8 
Type 3 NO sensors over 10 days in the striatum of 5 freely moving rats. 
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Figure 7.3.5.2: The averaged percentage NO decrease vs. day profile of the Type 3 NO sensors over the 
course of 10 days in the striatum of 5 freely moving rat with 8 sensors 
 
The Type 3 NO sensors displayed a similar stability result to the Type 2 NO sensors over 
the specified time. A percentage decrease of approximately 25 % occurs after day 1 and the 
sensitivity remains relatively stable thereafter. One-way ANOVA analysis indicated no 
significant difference (P = 0.2457), between the currents obtained on the days specified. 
Overall the two sensors behaved quite stable in the in-vivo environment over the days 
specified.       
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7.4 Conclusion 
 
Reported in this chapter is the in-vivo characterisation of the Type 2 and Type 3 NO sensor 
in the striatum of freely moving rats. The characterisation of the Type 1 NO sensor has 
been demonstrated previously in the literature by Finnerty et al., in the striatum using local 
and systemic administrations (Finnerty et al., 2012a). To characterise the two sensors in-
vivo, systemic administrations of known inducers and inhibitors of NO production and the 
corresponding changes in the NO current were investigated. The first experiments carried 
out were control saline injections. Since all administrations were by i.p. injection it was 
important to validate the response attained by the injection itself, therefore utilising saline 
to verify this. The response recorded by the Type 2 NO sensor demonstrated that the 
injection caused a sharp increase with a quick return to baseline revealing no effect from 
the saline itself. An increase that was not significant (P = 0.0819), of 27 ± 13 pA, n = 8, 
after 3 ± 1 minutes, n = 8, with a return to an analogous baseline after 18 ± 5 minutes, n = 
8, was very short-lived.  
A similar saline administration response was obtained with the Type 3 NO sensor. A 
current change of 43 ± 21 pA, n = 8, after 3 ± 1 minutes, n = 8, that was not significant (P = 
0.0768) was attained. The baseline returned quicker in comparison to the Type 2 NO sensor 
with a steady baseline observed after 9 ± 2 minutes, n = 8. The NO signal traces observed 
for the two sensors were quite similar, demonstrating the ability of the two different designs 
to detect rapid changes in the NO response. As the injection responses were now verified, 
the next step was to try and perturb the NO signalling pathway by introducing inducers or 
inhibitors of NO through systemic injections. The first i.p. injection utilised was L-NAME 
which is a non-selective NOS inhibitor. The expected result to observe from this injection 
was a decrease in the NO signal. In the literature an observation of a decrease in the NO 
after administration of L-NAME has been demonstrated (Kurose et al., 1993; Jones et al., 
2004; Finnerty et al., 2012a; Finnerty et al., 2012b).  
It has been hypothesised that L-NAME is in competition with the NO pre-cursor L-arginine 
to bind with the NOS enzyme (Da Cunha et al., 2005), decreasing the enzymes availability 
for NO synthesis thus reducing the production of NO. For the Type 2 NO sensors a 
significant change (P = 0.0388) in the NO response was observed after the L-NAME 
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administration. A clear decrease was observed with all of the Type 2 NO sensors after 58 ± 
10 minutes, n = 8. The results for the Type 3 NO sensors yielded a significant decrease in 
the observed NO current (P = 0.0161) after approximately 83 ± 16 minutes, n = 6. This 
confirms that L-NAME causes an effect on the NO, which was recorded as a decrease in 
both sensors studied.  
L-arginine, which is the precursor for NO production in the body, was administered 
systemically by i.p. injection. As expected, this administration produced a significant 
increase in the NO signal for the Type 2 (P = 0.0160), n = 7 and Type 3 NO sensors (P = 
0.0069), n = 7. A similar trace was obtained for both sensors shown in Figure 7.3.3.1 and 
7.3.3.2. This corresponds to results obtained within our group by Brown et al., and Finnerty 
et al., (Brown et al., 2009; Finnerty et al., 2012a; Finnerty et al., 2012b). Also these results 
corroborate previous indirect results postulated by various groups (Ashab et al., 1995; 
Carvalho et al., 2004; Maksimovich et al., 2006). Following confirmation that the two 
sensors were detecting changes in NO production, it was important to investigate if the 
sensors had lost their selectivity following implantation or from being placed into the 
complex environment of proteins, lipids and other biofouling agents. An investigation of 
this was undertaken by ascorbate administration, as it is the most abundant interferent 
present in the brain (Miele & Fillenz, 1996a). 
The administration of sodium ascorbate resulted in an NO response that was similar to that 
which was attained by the administration of saline. A transient increase in the NO current 
was observed, followed by a quick return to baseline levels after a short amount of time. It 
has been previously illustrated with CPEs, that if any response to sodium ascorbate was to 
occur it would do so within a time range of 60 minutes (Finnerty et al., 2012a). The result 
obtained by the Type 2 and Type 3 NO sensors displayed no significant difference (P = 
0.2052) and (P = 0.2214), respectively, between the pre- and post-baseline levels over the 
60 minutes analysed. These results show how the initial stress of the injection causes a brief 
increase in the NO response followed shortly by a return to baseline levels, which 
corresponds to the results obtained from the saline injections. This leads to the confirmation 
that the sensors have in fact remained intact and the sensor design has not been 
compromised which would allow the detection of the interferent. In Section 7.3.5, the 
stability of the NO sensors can be observed during the days implanted in the in-vivo 
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environment. A decrease of 29 % and 25 % was observed for the Type 2 and Type 3 NO 
sensors, respectively, after day 1 in-vivo. However, the two sensors remained relatively 
stable for the rest of the days implanted thereafter. 
In summary, this chapter presents results of investigations into the systemic effects of well 
documented inhibitors and inducers of NO production. It details the changes observed in 
the NO current recorded by each of the NO sensors implanted. The results demonstrate how 
capable the Type 2 and Type 3 NO sensors are at detecting a molecule that is so small and 
short-lived in an environment that is so intricate and complicated. Table 7.4 (a) and 7.4 (b), 
display a summary of the characterisation data for the Type 2 and Type 3 NO sensors 
respectively.     
 
Type 2 NO Sensor Current change  
(ΔI, pA) 
Max response 
time (mins) 
Return to baseline 
time (mins) 
Administrations    
Saline 27 ± 13 (n = 8) 3 ± 1 (n = 8)  18 ± 5 (n = 8) 
L-NAME 32 ± 13 (n = 9) 58 ± 10 (n = 9)  134 ± 21 (n = 9) 
L-Arginine 25 ± 7 (n = 7) 19 ± 4 (n = 7) 98 ± 12 (n = 7) 
Ascorbate -44 ± 30 (n = 8)  n/a n/a 
 
Table 7.4 (a): A summary of the in-vivo characterisation data for the Type 2 NO sensor. 
 
Type 3 NO Sensor Current change  
(ΔI, pA) 
Max response 
time (mins) 
Return to baseline 
time (mins) 
Administrations    
Saline 43 ± 21 (n = 8)  3 ± 1 (n = 8) 9 ± 2 (n = 8) 
L-NAME 52 ± 15 (n = 9) 83 ± 16 (n = 9)  142 ± 25 (n = 9) 
L-Arginine 28 ± 12 (n = 7)  32 ± 4 (n = 7)   103 ± 23 (n = 7) 
Ascorbate -21 ± 14 (n = 6) n/a n/a 
 
Table 7.4 (b): A summary of the in-vivo characterisation data for the Type 3 NO sensor.                 
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8.1 Introduction 
 
NO is a small molecule that possesses an unpaired electron. Due to this fact, NO is a highly 
reactive free radical with a short half-life. It has been linked to a wide range of 
physiological and pathophysiological processes. It regulates vascular tone and is 
hypothesised in playing a part in hypertension, Parkinson‘s disease and Alzheimer‘s disease 
(Brown et al., 2005). It is biosynthesised from L-arginine yielding a co-product of L-
citrulline and catalysed by one of three NOS isoenzymes. It requires nicotinamide adenine 
dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), flavin 
mononucleotide (FMN), tetrahydrobiopterin (BH4), calmodulin, O2 and heme in order for 
the reaction to take place (Dinerman et al., 1993; Schmidt et al., 1993). The various NOS 
enzymes responsible for the synthesis of NO are of, neuronal (nNOS), endothelium (eNOS) 
and inducible NOS (iNOS) forms (Alderton et al., 2001). The nNOS and eNOS are calcium 
and calmodulin dependent (Mungrue et al., 2003), whereas, iNOS is calcium and 
calmodulin independent. The latter is expressed in response to immunological or an 
inflammatory stimulation in macrophages, astrocytes, microglia and other cells producing 
NO that last for hours or even days (Iadecola et al., 1995). 
In 1988, Garthwaite et al., observed that upon activation of the NMDA receptors, the 
release of NO occurred (Garthwaite et al., 1988). It has been stated that nNOS is the main 
source of NO in neurons and localises to synaptic spines (Zhou & Zhu, 2009). It has also 
been demonstrated that in the striatum, NO is mainly produced via the nNOS enzyme 
(Bredt et al., 1990; Bredt et al., 1991). Upon binding of glutamate to the NMDA receptors, 
the calcium channels open. An influx of calcium causes the activation of the nNOS inside 
the neurons and the subsequent production of NO is triggered (Piknova et al., 2011). 
Ignarro et al., reported that the EDRF is an unstable substance that is released from the 
endothelium to promote smooth muscle relaxation (Ignarro et al., 1987). In the late 1980‘s, 
there were three main groups that independently reported that the EDRF might be NO. All 
three found that NO and the EDRF possessed identical biological and chemical 
characteristics and each established substantial evidence that made this claim plausible 
(Ignarro et al., 1987; Palmer et al., 1987; Furchgott, 1988). 
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The eNOS enzyme is the major isoform expressed in the cardiovascular system (Mungrue 
et al., 2003). The release of NO from endothelial cells is believed to be an essential 
vasodilator mechanism responsible for the maintenance of vasomotor function. In both the 
cerebral and peripheral blood vessels, the decrease in NO concentration results in a major 
change of vascular function which includes vasoconstriction and increases in arteriole 
blood pressure (Katusic & Austin, 2013). It has been demonstrated by Macrae et al., that 
inhibition of the synthesis of NO resulted in a long lasting decrease in CBF in rats (Macrae 
et al., 1993). It is evident that NO plays a role in the regulation of CBF and this statement 
has been widely accepted (Lindauer et al., 1999).  
It has been shown that the direct real-time measurement of brain tissue O2 can act as an 
indicator for increases in CBF (Lowry et al., 1997). Further to this, the hydrogen clearance 
technique has also been utilised previously as a measurement tool for local blood flow 
(Aukland et al., 1964; Aukland, 1965). This technique is inexpensive and involves the 
inhalation of hydrogen gas. Once the administration of hydrogen has ceased the rate of 
clearance which is proportional to local blood flow is monitored by a Pt electrode. 
However, this technique has some downfalls with difficulty of administration in freely 
moving animals. It is believed that an alternative measurement demonstrated by Lowry et 
al., which measures changes in the concentration of the substance delivered to the tissue by 
the blood stream i.e. O2, can accurately and reliably give an indication of changes in CBF. 
O2 concentration has been described as the balance between its supply as a result of blood 
flow from the capillaries and its utilisation which occurs as a result of metabolism in cells. 
Upon the rise in CBF under physiological stimulation, the supply of O2 will surpass the 
utilisation, ensuing in a net increase in O2 (Lowry et al., 1997).  
CBF is fundamental to the living brain and there is an increase in the need for more blood 
flow upon the rise in neuronal activity (Liao et al., 2013). Neurovascular coupling describes 
the relationship between local neural activity and the subsequent changes that occur in CBF 
(Zheng et al., 2010). Understanding how neurovascular coupling works is important for 
many reasons, one of which is brain imaging. Brain imaging relies on this coupling in order 
to map brain activity. Non-invasive imaging of the brain involves techniques that utilise 
this coupling, provide an insight into how the brain works in extraordinary detail and has 
been established by Raichle et al., (Raichle, 1998). One such brain imaging technique is 
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functional magnetic resonance imaging (fMRI). Functional MRI is the main neuroimaging 
technique for research carried out in humans (Moreno et al., 2013). It is non-invasive and a 
quick technique, however, despite the advantages that it possesses, it faces challenges 
especially in the clinical environment. This technique does not directly determine neuronal 
activation, but the related signals that are associated with neuronal activity. It also has the 
drawback of exclusion of certain patients that don‘t fulfil the necessary requirements for the 
imaging protocols in the clinical setting. Patients with movement disorders and patients that 
have difficulty with completing the tasks needed for fMRI analysis due to cognitive 
impairments are excluded and this can be a significant limitation of fMRI (Faro & 
Mohamed, 2010). 
In some brain pathologies the communication between the cerebral blood vessels and 
neuronal activity are disturbed and the ensuing imbalance could contribute to the 
dysfunction of the brain. This can be observed in disorders like hypertension and 
Alzheimer‘s disease (Girouard & Iadecola, 2006). Hypertension changes the construction 
of cerebral blood vessels and weakens how they function (Faraci et al., 1990; Dickinson, 
2001). The alteration of neurovascular coupling from hypertension has been hypothesised 
by Kasama et al., (Kazama et al., 2003). Alzheimer‘s disease demonstrates an alteration in 
cerebrovascular structure, cerebral micro vessels decrease in number, endothelial cells are 
compressed and there is a degeneration in the smooth muscle cells (Farkas & Luiten, 2001). 
In 2010, Lowry et al., demonstrated the real time simultaneous monitoring of blood 
oxygenation level dependant (BOLD) fMRI and brain tissue O2. The findings demonstrated 
the possibility of achieving real-time metabolite information during fMRI acquirement and 
that the O2 sensor could provide an indicator for alterations of the BOLD response, leading 
to a substitute for brain imaging in rodents which facilitates behavioural testing (Lowry et 
al., 2010).  
The importance of NO in the brain is determined by its involvement in neurodegenerative 
diseases and neuronal, glial and vascular physiological effects. This gives rise to the 
potential pharmacological treatments concentrating on the NO metabolic pathways. Figure 
8.1, depicts a scheme that defines physiological changes that link neural responses and 
vascular responses. In this chapter the simultaneous real-time monitoring of NO and O2 is 
explored during periods of hypoxia and hyperoxia, neuronal activation and i.p. injections of 
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chloral hydrate, diamox, L-NAME and L-arginine. Interesting and unpredicted results were 
obtained and are discussed fully in the subsequent sections.  
 
 
 
Figure 8.1: A summary of physiological changes linking neural responses and vascular responses. 
Redrawn from http://www.scholarpedia.org/article/Neurovascular_coupling. 
 
8.2 Experimental 
 
The instrumentation and software utilised are described in Section 3.2. All chemicals and 
solutions are detailed in Section 3.3. The manufacture of the varying NO and O2 sensors are 
described in Section 3.4. O2 sensors were co-implanted with NO sensors in the striatum of 
rats. A potential of +900 mV vs. Ag wire was applied to all the NO working electrodes and 
a potential of -650 mV vs. Ag wire was applied to all the O2 working electrodes. All i.p. 
injections were prepared in normal saline or otherwise stated. All in-vivo experiments were 
undertaken as described in Section 3.8. All experiments were carried out in freely moving 
animals. The surgical procedure undertaken for the implantation of the sensors is detailed in 
Section 3.8.2. Data is reported as mean ± S.E.M. All statistical analysis was carried out 
using student t-tests. These tests were performed using GraphPad prism and yielded a P-
value result, which is the probability value that specifies if the results observed are 
significantly different.  
Vasoactive chemical agents,
Metabolites (e.g., K+ , NO, 
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O2 consumption 
Glucose consumption
ATP
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In each of the sections, n denotes the number of perturbations carried out on a number of 
sensors in a certain amount of animals, unless stated otherwise. The NO currents are 
presented in pA and NO sensitivity in pA/µM. The O2 currents are presented in nA and O2 
sensitivity in nA/µM. All data presented had baselines normalised to 100 % illustrating the 
overall change in current as % of the pre-perturbation baseline level. This removes both 
inter-electrode and inter-animal variability by ensuring that the presented NO changes are 
representative of the data from all animals utilised in each study undertaken. All max 
response times and return to baseline times are taken from post administration/perturbations 
and not from time zero. 
 
8.3 Results and Discussion 
 
This results section comprises the data from experiments undertaken to monitor the changes 
in NO and O2 in-vivo, simultaneously. The NO and O2 results within this chapter are from 
the monitoring of the NO and O2 molecules with the combined sensors (Type 2 and Type 3 
NO sensors) and (SMCPEs and MMCPEs). There was little difference between the 
SMCPEs and MMCPEs for the monitoring of O2 and the Type 2 and Type 3 sensors for the 
monitoring of NO, with regards to sensitivity and overall behaviour in-vivo (see Chapter 5 
and Chapter 7, respectively), so it was deemed appropriate to collate the sensors for this 
chapter. In Figure 8.3.1 (a) and 8.3.1 (b), baseline recordings are displayed over a three 
hour period for NO and O2 which demonstrate how baseline levels remain stable whilst the 
animal is in a state of ease. 
 
8.3.1 Baseline recordings 
 
The baseline recordings data in this section was analysed using the results from 15 sensors 
in 5 animals for the NO sensors and 5 sensors in 5 animals for the O2 sensors. 
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Figure 8.3.1 (a): A time vs. percentage change graph of baseline NO currents monitored by NO sensors 
(Type 2 and Type 3 NO sensors), displaying a stable baseline over the course of three hours in-vivo (15 
sensors in 5 animals) 
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Figure 8.3.1 (b): A time vs. percentage change graph of baseline O2 currents monitored by O2 sensors 
(MMCPEs and SMCPEs), displaying a stable baseline over the course of three hours in-vivo, (5 sensors 
in 5 animals). 
 
Figure 8.3.1 (a) and 8.3.1 (b) display baseline levels for NO and O2 respectively, over the 
course of three hours. The data demonstrates how the levels remain stable whilst the animal 
is in a state of rest. The results in this Chapter demonstrate how different experiments 
undertaken with these sensors, cause a distinct change from stable baselines levels, which 
are discussed in more detail in the subsequent sections.     
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8.3.2 Hypoxia 
 
In these experiments, the production of mild hypoxia was created by the administration of a 
N2/air mixture to the snout of the animal, through a plastic tube. The flow rate was kept 
low, in order to keep the animal as comfortable as possible, during the experiment. The 
effect of a 3-minute period of hypoxia recorded by the NO and O2 sensors simultaneously, 
is displayed in Figure 8.3.2. The 3-minute period of hypoxia data in this section was 
analysed using the results from 17 perturbations with 12 sensors in 5 animals for the NO 
data and 17 perturbations with 8 sensors in 5 animals for the O2 data. 
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Figure 8.3.2: Time vs. percentage change graphs during a 3-minute period of hypoxia monitoring (A) 
NO (Type 2 and Type 3 NO sensors, n = 17: 5 animals) and (B) O2 (MMCPEs and SMCPEs, n = 17: 5 
animals). (C) A typical raw data example displaying the combined data of the percentage change in NO 
and O2. The black bar is indicative of the duration of the administration.  
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Figure 8.3.2, demonstrates how a 3-minute period of induced hypoxia caused an immediate 
decrease in both O2 and NO currents from baseline levels. The decrease in the O2 levels 
achieved, were significantly different (P < 0.0001) from pre-hypoxia baseline levels. A 
decrease was observed in the NO currents, that was also significantly different (P < 0.0001) 
from the pre-baseline levels obtained. A percentage change of 6.3 ± 1.5 %, n = 17 and 35.7 
± 1.2 %, n = 17, was achieved for NO and O2, respectively. The maximum response time 
for O2 and NO was 2.5 ± 0.1 mins, n = 17 and 2.0 ± 0.1 mins, n = 17, respectively. Upon 
cessation of inhalation of the gas, the O2 and NO levels returned to corresponding baseline 
currents of -168.9 ± 4.3 nA, n = 17, (P = 0.8315) and 628.2 ± 149.1 pA, n = 17, (P = 
0.7440), after 6.6 ± 0.3 mins, n = 17 and 7.0 ± 0.6 mins, n = 17, respectively.  
A summary of the results for the 3-minute period of hypoxia on the O2 and NO currents is 
given in Table 8.3.2 (a) and 8.3.2 (b). 
 
 
Table 8.3.2 (a): Averaged results table for a 3-minute period of hypoxia, recorded with NO sensors 
(Type 2 and Type 3 NO Sensor, implanted in the striatum of 5 freely moving rats (n = 17 with 12 
sensors).    
 
 
Table 8.3.2 (b): Averaged results table for a 3-minute period of hypoxia, recorded with O2 sensors 
(MMCPEs and SMCPEs), implanted in the striatum of 5 freely moving rats (n = 17 with 8 sensors).   
 
 
Hypoxia (NO Sensors) 
Current change 
(pA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (pA) 
Baseline Post 
Injection (pA) 
20.1 ± 3.4 
 
6.3 ± 1.5 2.0 ± 0.1 7.0 ± 0.6 
 
631.1 ± 145.2 
 
628.2 ± 149.1 
Hypoxia (O2 Sensors) 
Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
-167.5 ± 4.1 35.7 ± 1.2 
 
2.5 ± 0.1 
 
6.6 ± 0.3 
 
-167.5 ± 4.1 
 
-168.9 ± 4.3 
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In the literature it has been suggested that eNOS activity is enhanced by hypoxia (Pearce et 
al., 1989; Pearce et al., 1990). So if we were observing a current change by which eNOS 
had been activated then this statement suggests an increase in NO would have occurred. 
Studies have also suggested that O2 is required for NOS activity and that NO production 
would decrease under low O2 tension (Coggins & Bloch, 2007). As O2 is one of the 
substrates required for the production of NO, a lack of O2 during hypoxia would cause 
inhibition of the enzyme activity even if intracellular calcium increases (Leone et al., 
1991). Pelligrino et al., reported that a reduction in O2 supply in rats may decrease the NO 
generating capacity in the brain (Pelligrino et al., 1993). The observation of a decrease in 
the NO response after a N2/air administration suggests that the decrease in NO production 
is directly due to a decrease in the O2 supply. It has to be noted also, that the majority of 
literature studies are based on indirect measurements of NO, however, in this body of 
research the direct real-time measurement of NO is achieved. The slight over shoot in NO 
after the administration had ceased suggests a return of reoxygenation back into the system 
and the subsequent NO/NMDA pathway trying to re-establish an NO baseline.          
 
8.3.3 Hyperoxia 
 
Mild hyperoxia was established in the subject by the administration of O2/air to the snout of 
the animal through a plastic tube with a low flow rate. This prevents the animal from being 
startled or uneasy during this procedure. The effects of a typical 5-minute period of 
hyperoxia recorded with the NO and O2 sensors are displayed in Figure 8.3.3. The 5-minute 
period of hypoxia data in this section was analysed using the results from 18 perturbations 
with 12 sensors in 4 animals for the NO data and 18 perturbations with 4 sensors in 4 
animals for the O2 data. 
  
 
 
 
 
 
  Chapter 8: In-Vivo Oxygen and Nitric Oxide  
 
343  
 
0 5 10 15 20 25 30
100
120
140
Time, mins
I,
 N
O
 %
0 5 10 15 20 25 30
100
120
140
160
Time, mins
I,
 O
2
 %
 
 
 
 
 
 
 
 
 
 
 
0 10 20 30
100
110
120
130
100
120
140
160
Time, mins
I,
 N
O
 %
I, O
2  %
 
Figure 8.3.3: Time vs. percentage change graphs during a 5-minute period of hyperoxia monitoring (A) 
NO (Type 2 and Type 3 NO sensors, n = 18: 4 animals) and (B) O2 (MMCPEs and SMCPEs, n = 18: 4 
animals). (C) A typical raw data example displaying the combined data of the percentage change in NO 
and O2. The black bar is indicative of the duration of the administration. 
 
Figure 8.3.3, demonstrates how a 5 minute period of induced hyperoxia caused an 
immediate and significant increase (P < 0.0001) in the O2 current, however, although an 
increase in the NO signal was observed, it was not significantly different (P < 0.0001) from 
pre-baseline levels. A percentage change of 44.5 ± 2.8 %, n = 18, after approximately 2.9 ± 
0.1 mins, n = 18, was achieved with the O2 sensors. The NO signal yielded a percentage 
change of 5.7 ± 1.0 %, n = 18, after approximately 3.6 ± 0.2 mins, n = 18. Upon cessation 
BA
C
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of inhalation of the gas, the O2 and NO currents returned to baseline levels of -165.6 ± 4.2 
nA, n = 18, (P = 0.8307) and 352.2 ± 41.2 pA, n = 18, (P = 0.1932), respectively. Table 
8.3.3 (a) and 8.3.3 (b), detail a summary of the results from the administration of O2/air.  
It is observed that it takes slightly longer for the NO currents to return to corresponding 
baseline levels (NO: 14.5 ± 1.9 mins, n = 18 and O2: 12.9 ± 0.5 mins, n = 18), however not 
significantly different (P = 0.4211).  
 
 
Table 8.3.3 (a): Averaged results table for a 5-minute period of hyperoxia, recorded with NO sensors 
(Type 2 and Type 3 NO Sensor), implanted in the striatum of 4 freely moving rats (n = 18 with 12 
sensors).    
 
 
Table 8.3.3 (b): Averaged results table for a 5-minute period of hyperoxia, recorded with O2 sensors 
(MMCPEs and SMCPEs), implanted in the striatum of 4 freely moving rats (n = 18 with 4 sensors).    
 
The increase in NO after the period of hyperoxia could be due to the increased availability 
of O2, therefore causing a rise in the production of NO. In-vitro studies demonstrated that 
O2 can affect the expression of NOS and NO production in cultured cells exposed to 
hyperoxia (Liao et al., 1995). It has also been demonstrated by Vacchiano et al., that 
macrophages obtained from the bronchoalveolar lavage of animals exposed to O2, have 
been shown to produce NO (Vacchiano & Tempel, 1994). Again, the indirect 
measurements of these molecules can only provide a certain amount of information 
Hyperoxia (NO Sensors) 
Current change 
(pA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (pA) 
Baseline Post 
Injection (pA) 
17.3 ± 2.7 5.7  ± 1.0 3.6 ± 0.2 
 
14.5 ± 1.9 
 
341.3 ± 38.8 
 
352.2 ± 41.2 
Hyperoxia (O2 Sensors) 
Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
70.6 ± 3.5  44.5 ± 2.8 
 
2.9 ± 0.1 
 
12.9 ± 0.5 
 
-164.3 ± 4.3 -165.6 ± 4.2 
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whereas, the hyperoxia results shown in this body of research demonstrate real time in-vivo 
detection of changes in O2 and NO. 
 
8.3.4 Restraint stress 
 
Two forms of physiological stimulation were utilised throughout the experiments; these 
were restraint stress and tail pinch. Tail pinch results are presented in the next section (see 
Section 8.3.5). Each test was carried out for 5-minutes. The two stimuli, cause neuronal 
activation in the animal, leading to changes in the currents recorded by the sensors. The 5-
minute period of a restraint stress data in this section was analysed using the results from 
12 perturbations with 12 sensors in 5 animals for the NO data and 12 perturbations with 5 
sensors in 5 animals for the O2 data. 
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Figure 8.3.4 (a): Time vs. percentage change graphs during a restraint stress monitoring (A) NO (Type 
2 and Type 3 NO sensors, n = 12: 5 animals) and (B) O2 (MMCPEs and SMCPEs, n = 12: 5 animals). 
(C) A typical raw data example displaying the combined data of the percentage change in NO and O2. 
The black bar is indicative of the duration of the stimulus. 
 
The application of a 5-minute restraint stress resulted in a rapid increase in the O2 current 
recorded at the O2 sensors. A percentage change of 15.8 ± 1.3 %, n = 12 after 2.6 ± 0.2 
mins, n = 12, that was significantly different (P = 0.0088) from pre-baseline levels was 
achieved by the O2 sensors. The NO sensors displayed a percentage change of 3.9 ± 2.0 %, 
n = 12, that was significantly different (P = 0.0271) from pre-baseline levels. Upon 
cessation of the stimulus, the O2 baseline currents began to fall until another increase in the 
O2 current was observed shortly afterwards. A second O2 increase on cessation of the 
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stimulus was observed most likely due to O2 concentration regulation in the body. It is 
based on supply and utilisation (Lowry et al., 1997), therefore once the stimulus was 
ceased, the supply exceeded the demand and an increase was observed, followed on by a 
subsequent decrease in the current.  
A significantly different (P = 0.0017) baseline O2 current was observed, subsequent to the 
first maximum response, after 6.1 ± 0.1 mins, n = 12. A percentage change of 20.2 ± 1.6 %, 
n = 12, was recorded from the second maximum response. The O2 current returned to 
corresponding baseline levels of -155.6 ± 5.5 nA, n = 12, after 18.4 ± 2.5 mins, n = 12, (P = 
0.5750), however the NO current remained at a new recorded level of 447.4 ± 91.3 pA, n = 
12, (P = 0.0122). The O2 returned back to pre-baseline levels, whereas, the NO failed to do 
so within that time frame. The de-synchronisation between the NO and O2 currents suggests 
that the NO that we are detecting is not endothelial, since O2 returns to baseline levels, but 
instead it remains elevated more than likely due to the NMDA receptor activity brought 
about by the neuronal activation. Table 8.3.4 (a) and 8.3.4 (b) display a summary of all the 
results obtained by the NO and O2 sensors.  
 
 
Table 8.3.4 (a): Averaged results table for restraint stress, recorded with NO sensors (Type 2 and Type 
3 NO Sensor), implanted in the striatum of 5 freely moving rats (n = 12 with 12 sensors). The dashed 
line (under return time), corresponds to the NO response remaining elevated and not returning back to 
baseline levels, during the time frame specified in the graph.     
  
 
Restraint Stress (NO Sensors) 
Current Change 
(pA) 
Current Change 
(%) 
Max Response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (pA) 
New Recorded 
Baseline Level (pA) 
14.2 ± 5.9 3.9 ± 2.0 2.2 ± 0.3 
 
------- 
 
432.4 ± 87.1 
 
447.4 ± 91.3 
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Table 8.3.4 (b): Summary of results for the first and second current change responses for a restraint 
stress (5-minutes), with the O2 sensors implanted in the striatum of freely moving rats (n = 12 with 5 
sensors in 5 animals).  
 
A similar response from NO after a restraint stress was observed within our group with the 
Type 1 NO sensor. There was an increase in the NO signal upon initiation of the restraint 
and it remained elevated after the restraint stress had ceased. Figure 8.3.4 (b) displays the 
Type 1 NO sensor trace in response to the restraint stress (courtesy of Dr. Niall Finnerty). 
The Type 1 NO sensor has been fully characterised in-vitro and in-vivo within our research 
group (Brown et al., 2009; Finnerty et al., 2012a; Finnerty et al., 2012b). These results 
demonstrate that the NO signal that was observed is not sensor specific and has been 
observed utilising other sensor designs. Figure 8.3.4 (c), displays the result of a restraint 
stress recorded by a glutamate sensor courtesy of Dr. Fiachra Bolger.  
An elevated response of glutamate that does not return back to baseline levels after the 
stimulus had ceased, yielded a very similar elevated response obtained by the NO sensors.  
As glutamate is linked to the activation of the NMDA receptors (VanDongen, 2008), it can 
be postulated that the glutamate response observed by Dr. Fiachra Bolger, after a 5-minute 
restraint stress, is strongly linked to the increase in NO observed in this section after a 5-
minute restraint stress. An increase in glutamate could possibly cause the activation of the 
NMDA receptor and thus an increase in NO.    
 
Restraint stress O2 Sensors 
Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
24.3 ± 2.3 15.8 ± 1.3 
 
2.6 ± 0.2 
 
18.4 ± 2.5 
 
-151.2 ± 5.4 
 
-155.6 ± 5.5 
Restraint stress (2nd current change) 
(2nd) Current 
change 
(nA) 
(2nd) Current 
change 
(%) 
(2nd) Max 
response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
31.4 ± 3.0 20.2 ± 1.6 
 
6.1 ± 0.1 
 
18.4 ± 2.5 
 
-151.2 ± 5.4 
 
-155.6 ± 5.5 
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Figure 8.3.4 (b): A time vs. percentage graph displaying the NO percentage change response attained 
from a 5-minute period of restraint stress with Type 1 NO sensors, n = 9, in 3 animals (Courtesy of Dr. 
Niall Finnerty). 
 
 
Figure 8.3.4 (c): A typical example of a time vs. current response graph, displaying the increase in the 
glutamate response detected with a glutamate sensor, in the striatum of a freely moving rat after a 5-
minute period of a restraint stress administration (Courtesy of Dr. Fiachra Bolger). 
 
 
Since NMDA-glutamate receptors are coupled to nNOS (Buerk et al., 2003), it is possible 
that the increase in neuronal activity and subsequent NO production in the striatum that was 
observed, is from nNOS, although eNOS contribution cannot be ruled out. The interesting 
observation was the elevated NO response after the restraint stress had ceased. This result 
was shown not only in the Type 2 and Type 3 NO sensors but also in the Type 1 NO sensor 
(courtesy of Dr. Niall Finnerty). As the O2 current returned to baseline levels and O2 can be 
utilised as a reliable index of cerebral blood flow (Lowry et al., 1997), it is suggested that if 
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the eNOS enzyme was the main NO producing enzyme signal observed for the restraint 
stress, then a return to pre-baseline levels would have been observed. Therefore, the eNOS 
enzyme is not causing this increase and therefore it is believed the NMDA/receptor nNOS 
pathway is the main contributor to this production of NO.  
 
8.3.5 Tail Pinch 
 
The application of a 5-minute tail pinch causes physiological stimulation that increases 
neuronal activation in the striatum and a simultaneous elevation of CBF and O2 (Valente et 
al., 2012). The 5-minute period of a tail pinch stress data in this section was analysed using 
the results from 18 perturbations with 13 sensors in 5 animals for the NO data and 18 
perturbations with 5 sensors in 5 animals for the O2 data. Figure 8.3.5 (a) displays the 
results achieved for both NO and O2.  
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Figure 8.3.5 (a): Time vs. percentage change graphs during a restraint stress monitoring (A) NO (Type 
2 and Type 3 NO sensors, n = 18: 5 animals) and (B) O2 (MMCPEs and SMCPEs, n = 18: 5 animals). 
(C) A typical raw data example displaying the combined data of the percentage change in NO and O2. 
The black bar is indicative of the duration of the stimulus. 
 
The application of a 5-minute tail pinch resulted in an instantaneous and rapid increase in 
the O2 and NO current observed at the O2 and NO sensors. An immediate and significant 
increase (P = 0.0010) in the O2 current was observed. The NO sensors displayed an 
increase in the NO current that remained elevated after the stimulus had ceased, displaying 
a current that was significantly different (P = 0.0387) from pre-baseline levels. The NO and 
O2 currents achieved a maximum response after 2.3 ± 0.4 mins, n = 18 and 2.8 ± 0.2 mins, 
n = 18, that corresponded to a percentage change of 9.4 ± 2.2 %, n = 18 and 18.9 ± 2.1 %, n 
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= 18, respectively. A return to baseline levels of -168.9 ± 5.2 pA, n = 18, (P = 0.5212) for 
the O2 was achieved after 27.7 ± 2.9 mins, n = 18, however the NO response remained 
elevated at a baseline of 589.0 ± 140 pA, n = 18, (P = 0.0098). A similar observation was 
demonstrated with the application of the restraint stress (see Section 8.3.4).   
 
 
Table 8.3.5 (a): Averaged results for tail pinch, recorded with NO sensors (Type 2 and Type 3 NO 
Sensor), implanted in the striatum of 5 freely moving rats (n = 18 with 13 sensors). The dashed line 
(under return time), corresponds to the NO response remaining elevated and not returning back to 
baseline levels, during the time frame specified in the graph.     
    
 
Table 8.3.5 (b) Averaged results for tail pinch, with O2 sensors (MMCPEs and SMCPES), implanted in 
the striatum of 5 freely moving rats (n = 18 with 5 sensors).   
 
The NO response obtained from the tail pinch with the Type 2 and Type 3 NO sensors in 
this section, has been previously observed within our laboratory utilising other NO sensor 
designs. A lack of a return back to pre-administration NO baseline levels was demonstrated 
previously utilising the Type 1 NO sensor, showing that the response again was not sensor 
specific. Figure 8.3.5 (b), displays the result of a tail pinch recorded by the Type 1 NO 
sensor courtesy of Dr. Niall Finnerty. Figure 8.3.5 (c), displays the result of a tail pinch 
recorded by a glutamate sensor courtesy of Dr. Fiachra Bolger. An elevated response of 
glutamate that does not return back to baseline levels after the stimulus had ceased, yielded 
Tail Pinch (NO Sensors) 
Current Change 
(pA) 
Current Change 
(%) 
Max Response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (pA) 
New Recorded 
Baseline Level (pA) 
60.5 ± 27.0 9.4 ± 2.2 2.3 ± 0.4 
 
------- 
 
533.5 ± 126.8 
 
589.0 ± 140.0 
Tail Pinch (O2 Sensors) 
Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
31.1 ± 3.4 18.9 ± 2.1 
 
2.8 ± 0.2 
 
27.7 ± 2.9 
 
-164.2 ± 5.2 
 
-168.9 ± 5.2 
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a very similar elevated response obtained by the NO sensors for the tail pinch stress. An 
identical hypothesis is proposed for this elevated glutamate and NO response with reference 
to the response obtained for the restraint stress (see Section 8.3.4).  
NO has been demonstrated to regulate CBF since its establishment as the EDRF in the 
1980‘s (Ignarro et al., 1987; Furchgott, 1988). As the O2 levels return to normoxic 
conditions, the NO current remains elevated. It is postulated that if there had been a 
contribution from eNOS then the NO would have returned to corresponding baseline levels 
along with the O2. O2 can be utilised as a reliable index of cerebral blood flow (Lowry et 
al., 1997) under these circumstances and therefore, it appears that the eNOS enzyme is not 
causing this increase and therefore it is believed the NMDA/receptor nNOS pathway is the 
main contributor to this production of NO.  
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Figure 8.3.5 (b): A time vs. percentage graph displaying the NO percentage change response attained 
from a 5-minute period of tail pinch stress with Type 1 NO sensors, n = 14, in 4 animals. The bar is 
indicative of the duration of the tail pinch (Courtesy of Dr. Niall Finnerty). 
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Figure 8.3.5 (c): A typical example of a time vs. current response graph, displaying the increase in the 
glutamate response detected with a glutamate sensor after a 5-minute period of a tail pinch 
administration in the striatum of a freely moving rat (Courtesy of Dr. Fiachra Bolger). 
 
8.3.6 Chloral Hydrate 
 
Chloral hydrate depresses the cerebrum, with loss of reflex excitability. It has been used 
previously as a method of increasing the striatal O2 levels in rats (Lowry & Fillenz, 2001; 
Bolger & Lowry, 2005). Figure 8.3.6, displays results attained from the administration of 
chloral hydrate (350 mg/kg i.p.) on the O2 and NO signals recorded with the O2 (MMCPEs 
and SMCPEs) and NO (Type 2 and Type 3) sensors. The chloral hydrate injection data in 
this section was analysed using the results from 17 perturbations with 15 sensors in 5 
animals for the NO data and 6 perturbations with 5 sensors in 5 animals for the O2 data. 
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Figure 8.3.6: Time vs. percentage change graphs for an i.p. injection of chloral hydrate (350mg/kg in 
1ml of saline) for (A) NO (Type 2 and Type 3 NO sensors, n = 17: 6 animals) and (B) O2 (MMCPEs and 
SMCPEs, n = 17: 6 animals). (C) A typical raw data example displaying the combined data of the 
percentage change in NO and O2. The arrow is indicative of the point of injection and the pink bars are 
indicative of the movement of the animal. 
 
The chloral hydrate injection yielded an increase in the O2 current that was significantly 
different (P = 0.0009) from pre-baseline O2 currents. A contrasting result was obtained 
from the NO sensors upon the injection of chloral hydrate. A decrease in the NO signal was 
observed, displaying no correlation between the O2 and NO behaviour. Analysis of the data 
showed that the NO current decrease was significantly different (P = 0.0007) from pre-
baseline levels, however, a clear decrease can be observed, especially in comparison to 
baseline NO data taken over the period of three hours (see Section 8.3.1). The maximum 
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response time observed for the NO sensors was 75.7 ± 18.6 mins, n =17 and 14.0 ± 2.6 
mins, n = 17 for the O2 sensors response time. These response time results signify the extent 
of the different effects on the two molecules by the chloral hydrate injection. The O2 
response time is much quicker than the response time observed by the NO sensors (P = 
0.0025). 
The chloral hydrate effect on suppressing neuronal activity is quick, resulting in the 
increase in O2  due to the supply of O2 exceeding the utilisation of O2. However, the 
NMDA mediated effect is much slower and occurs over a longer time frame. This also 
shows the advantage of real-time in-vivo monitoring with sensors, instead of conventional 
indirect methods, as the time disparity between these two molecules would not be noticed. 
O2 and NO currents returned to corresponding baseline levels after 198.7 ± 16.7 mins, n = 
17, (P = 0.8108) and 181.1 ± 52.5 mins, n = 17, (P = 0.9666), respectively and the animals 
began to show recovery from the anaesthesia. The pink bars display the movement data for 
the animals. The animals began to move at approximately 120 minutes; however, they 
displayed signs of waking up prior to this, but did not begin to move until the time 
indicated on the graphs by the movement data. Table 8.3.6 (a) and 8.3.6 (b) give a summary 
of the response attained at both the NO and O2 sensor.    
 
 
Table 8.3.6 (a): Averaged table of results for an i.p. injection of chloral hydrate with NO sensors (Type 
2 and Type 3 NO sensor, implanted in the striatum of 6 freely moving rats (n = 17 with 15 sensors).    
 
 
 
 
 
Chloral Hydrate Injection (NO Sensors) 
Current change 
(pA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (pA) 
Baseline Post 
Injection (pA) 
37.7 ± 8.5 13.8 ± 3.8 75.7 ± 18.6 
 
181.1 ± 52.5 
 
317.5 ± 51.9 
 
314.8 ± 91.4 
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Table 8.3.6 (b): Averaged table of results for an injection of chloral hydrate with O2 sensors (MMCPEs 
and SMCPES, implanted in the striatum of 5 freely moving rats (n = 6 with 5 sensors).    
 
The results observed for the chloral hydrate injection were very interesting. An increase in 
the O2 current was obtained which should have meant an increase in NO, as more O2 would 
suggest an increased production of NO, however the complete opposite occurred. Evidence 
has suggested that the NMDA receptors are targets of anaesthetic agents in the central 
nervous system and that some of the biological actions created by the anaesthetics effect the 
NMDA receptors. It was demonstrated in a study undertaken by LacKamp et al., that 
chloral hydrate caused the loss of surface expressed NMDA receptors (LacKamp et al., 
2009). So if there is an inhibition of chloral hydrate on the NMDA receptors, NO 
production would therefore be reduced leading to a decrease in the NO signal observed at 
the NO sensors.   
In another study carried out by Kreuter et al., they found that chloral hydrate seemed to 
reduce glutamate release and decrease activation of glutamate receptors (Kreuter et al., 
2004). The results obtained in this section strongly suggest that the production of NO 
throughout the results obtained has been from the nNOS enzyme as opposed to the eNOS 
enzyme. Further clarifying what other research groups have suggested, that nNOS is more 
ubiquitous in the brain. If the NMDA receptors are activated, calcium channels open and 
there is an influx of calcium causing activation of nNOS and therefore NO production 
(Santos et al., 2012). However, when NMDA receptors are inhibited, as in this case, 
calcium influx cannot be achieved, which is a prerequisite for the production of NO to 
occur. The decrease in NO current observed can be attributed to this hypothesised NMDA 
receptor inhibition.   
 
Chloral Hydrate Injection (O2 Sensors) 
Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
111.2 ± 19.2 67.6 ± 10.4 
 
14.0 ± 2.6 
 
198.7 ± 16.7 
 
-163.9 ± 11.5 
 
-167.9 ± 11.7 
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8.3.7 Diamox 
 
Acetazolamide (Diamox) is a carbonic anhydrase inhibitor that has been shown to increase 
brain tissue O2 (Dixon et al., 2002; Bolger & Lowry, 2005). It has been used as an 
exploratory tool in cerebral blood flow experiments and also for the treatment of several 
diseases long term (Vorstrup et al., 1984). It has been demonstrated that extracellular pH 
decreases after diamox induced carbonic anhydrase inhibition (Severinghaus & Cotev, 
1968; Bickler et al., 1988). It is also known that pH is an inhibitor of NMDA receptor 
activation (Tang et al., 1990; Traynelis & Cull-Candy, 1990). The frequency by which the 
NMDA receptor channel opens is decreased by protons above the physiological range and 
at pH 6.0, receptor activation is suppressed (Traynelis et al., 1995). Diamox has an effect 
on the NMDA receptors and any shift in the pH sensitivity can up regulate or down regulate 
the receptor function (Low et al., 2003). The effect of an administration of acetazolamide 
on the O2 and NO current was monitored with the O2 (MMCPEs and SMCPEs) and NO 
(Type 2 and Type 3) sensors, simultaneously. The diamox injection data in this section was 
analysed using the results from 15 perturbations with 15 sensors in 5 animals for the NO 
data and 5 perturbations with 5 sensors in 5 animals for the O2 data. 
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Figure 8.3.7: Time vs. percentage change graphs for an i.p. injection of diamox (50mg/kg in 1ml of 
saline) for (A) NO (Type 2 and Type 3 NO sensors, n = 15: 5 animals) and (B) O2 (MMCPEs and 
SMCPEs, n = 5: 5 animals). (C) A typical raw data example displaying the combined data of the 
percentage change in NO and O2. The arrow is indicative of the point of injection. 
 
 
Figure 8.3.7 demonstrates the results obtained by the NO and O2 sensors after an i.p. 
injection of diamox. A characteristic increase in the O2 current was observed which was 
significantly different (P = 0.0356) from pre-baseline currents. However, similar to the 
chloral hydrate injection, NO displayed a decrease in the NO current after the injection of 
diamox which was significantly different (P = 0.0010) from pre-baseline levels. It is clear 
from the graphs that there has been a change in the two currents, similar to what was 
observed by the chloral hydrate injection. On comparison of the baseline recordings 
obtained in Section 8.3.1 for NO and O2 over the course of three hours, a clear indication of 
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a change in the NO and O2 current can be observed. Table 8.3.7 (a) and 8.3.7 (b) display a 
summary of the results.  
 
 
Table 8.3.7 (a): Averaged table of results for an injection of diamox with NO sensors (Type 2 and Type 
3 NO sensor, implanted in the striatum of 5 freely moving rats (n = 14 with 14 sensors).    
 
 
Table 8.3.7 (b): Averaged table of results for an injection of diamox with O2 sensors (MMCPEs and 
SMCPES, implanted in the striatum of 5 freely moving rats (n = 5 with 5 sensors)   
 
The maximum response time observed for the NO sensors was 92.0 ± 6.6 mins, n =14 and 
30.0 ± 1.5 mins, n = 5 for the O2 sensors. These response time results demonstrate the 
extent of the varying effects on the two molecules following diamox injection. The O2 
response time is much quicker than that observed for the NO sensors (P < 0.0001). The 
effect of the diamox on the O2 response is quick and a resulting increase is observed, 
validating its choice as a method of increasing tissue O2 and a subsequent increase in 
cerebral blood flow. The increase in cerebral blood flow is caused by a decrease in the pH 
levels which induces the dilation of blood vessels (Bolger & Lowry, 2005). The NO 
response is much slower and occurs over a longer period of time suggesting that alternative 
pathways are involved.  
pH is reported to be an inhibitor of NMDA function and it has been shown to decrease the 
expression of the NMDA receptors thus decreasing the production of NO (Tang et al., 
Diamox Injection (NO Sensors) 
Current change 
(pA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (pA) 
Baseline Post 
Injection (pA) 
89.4 ± 42.3 23.3 ± 10 92.0 ± 6.6 
 
153.6 ± 8.8 
 
397.6 ± 77.1 
 
423.5 ± 91.6 
Diamox Injection (O2 Sensors) 
Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
67.0 ± 21.5 42.9 ± 1.5 30.0 ± 6.7 
 
167.8 ± 36.0 
 
-151.7 ± 15.8 
 
-162.6 ± 1.7 
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1990; Traynelis & Cull-Candy, 1990). Therefore, the observed NO decrease, suggests that 
the NO production is inhibited, due to the suppression of the NMDA receptor by the 
diamox induced decrease in pH. O2 and NO currents returned to corresponding baseline 
levels after 167.8 ± 36.0 mins, n = 5 (P = 0.0929) and 153.6 ± 8.8 mins, n = 14, (P = 
0.2460), respectively. It would be of great interest to monitor concurrently pH, NO and O2 
in the diamox drug model, to investigate the effect of NMDA receptor protonation. 
 
8.3.8 L-NAME 
 
L-NAME is a non-selective inhibitor of the NOS enzyme and causes a decrease in the 
production of NO. It  has been identified as competing with arginine, the pre-cursor for NO 
production, for its binding site (Lajoix et al., 2004) on the NOS isozyme. The injection of 
L-NAME data in this section was analysed using the results from 15 perturbations with 15 
sensors in 5 animals for the NO data and 5 perturbations with 5 sensors in 5 animals for the 
O2 data. Figure 8.3.8 displays the results recorded at the NO and O2 sensors after an i.p 
injection of L-NAME. 
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Figure 8.3.8: Time vs. percentage change graphs for an i.p. injection of L-NAME (30mg/kg in 1ml of 
saline) for (A) NO (Type 2 and Type 3 NO sensors, n = 15: 5 animals) and (B) O2 (MMCPEs and 
SMCPEs, n = 5: 5 animals). (C) A typical raw data example displaying the combined data of the 
percentage change in NO and O2. The arrow is indicative of the point of injection. 
 
As L-NAME is a NOS inhibitor, the expected result is to observe a decrease in the NO 
signal. In Figure 8.3.8, a typical NO response to L-NAME demonstrates this decrease 
which was significantly different (P = 0.0010) from pre-baseline currents. The O2 signal 
also displayed a decrease in the current of approximately 17.3 ± 3.2 %, n = 15, after 48.9 ± 
11.2 mins, n = 15, which was significantly different (P = 0.0045) from pre-baseline levels. 
New baseline levels for NO and O2 were obtained after 142.4 ± 17.1 mins, n = 14, (P = 
0.0186) and 93.3 ± 23.7 mins, n = 14, (P = 0.0044), respectively. L-NAME inhibits all of 
the NOS enzymes. There is also a decrease in vasculature conductance, arterial pressure 
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and a reduction in heart rate (Jones et al., 2004). The observed O2 decrease would be due to 
a decrease in the cerebral blood flow therefore a decrease in the O2 supply, which was 
detected by the O2 sensors.  
The inhibition of the NOS enzymes by L-NAME causes the decrease in the NO production 
and therefore the constriction of the blood vessels causes the subsequent decrease in the O2 
response recorded at the O2 sensors. Table 8.3.8 (a) and 8.3.8 (b) display a summary of the 
results. 
 
 
Table 8.3.8 (a): Averaged table of results for an injection of L-NAME with NO sensors (Type 2 and 
Type 3 NO sensor, implanted in the striatum of 5 freely moving rats (n = 15 with 15 sensors).    
 
 
Table 8.3.8 (b): Averaged table of results for an injection of L-NAME with O2 sensors (MMCPEs and 
SMCPES, implanted in the striatum of 5 freely moving rats (n = 5 with 5 sensors).    
 
8.3.9 L-Arginine 
 
The NO precursor L-arginine is transformed to arginine-hydroxide in a reaction that is 
catalysed by NOS. Subsequent to this, arginine-hydroxide is then transformed to NO and L-
citrulline, the synthesis involves cofactors also, which include calcium/calmodulin, O2 and 
nicotinamide adenine dinucleotide phosphate (Bredt & Snyder, 1992) thus, L-arginine plays 
L-NAME Injection (NO Sensors) 
Current change 
(pA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (pA) 
Baseline Post 
Injection (pA) 
40.5 ± 10.3 7.7 ± 1.5 68.4 ± 10.0 
 
142.4 ± 17.1 
 
515.9 ± 107.2 
 
467.6 ± 105.5 
L-NAME Injection (O2 Sensors) 
Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
28.2 ± 6.4 17.3 ± 3.2 
 
48.9 ± 11.2 
 
93.3 ± 23.7 
 
-153.8 ± 16.3 
 
-130.5 ± 13.7 
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a vital role in the production of NO. In this section, data is presented that outlines the NO 
and O2 responses to systemic administration of L-arginine. The injection of L-arginine data 
in this section was analysed using the results from 12 perturbations with 10 sensors in 5 
animals for the NO data and 5 perturbations with 4 sensors in 5 animals for the O2 data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3.9: Time vs. percentage change graphs for an i.p. injection of L-arginine (300mg/kg in 1ml of 
saline) for (A) NO (Type 2 and Type 3 NO sensors, n = 12: 5 animals) and (B) O2 (MMCPEs and 
SMCPEs, n = 5: 5 animals). (C) A typical raw data example displaying the combined data of the 
percentage change in NO and O2. The arrow is indicative of the point of injection. 
 
The injection of L-arginine produced an increase in both the O2 and NO signal. A 
percentage change of 9.4 ± 3.1 %, n = 12 and 10.6 ± 2.2 %, n = 5, was obtained for NO and 
O2, respectively. The percentage increase of NO and O2 was significantly different (P = 
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0.0018 and 0.0193) from pre-baseline levels, respectively, after the injection of L-arginine. 
The NO and O2 baseline levels returned after 100.4 ± 12.5 mins, n = 12, (P = 0.1511) and 
146.6 ± 44.2 mins, n = 5, (P = 0.4318), respectively. This result was expected, as an 
increase in NO would cause an increase in O2 due to the increased blood supply. As L-
arginine is vital for the production of NO, having an increased level of L-arginine available 
for the production of NO would suggest an increased amount of NO being synthesised 
through the nNOS and eNOS pathways with the latter causing an increase in the cerebral 
blood flow thus showing an increased O2 response at the O2 sensors. Table 8.3.9 (a) and 
8.3.9 (b), display a summary of the results attained at the NO and O2 sensors.       
 
 
 
Table 8.3.9 (a): Averaged table of results for an injection of L-Arginine with NO sensors (Type 2 and 
Type 3 NO sensor, implanted in the striatum of 5 freely moving rats (n = 10 with 5 sensors).    
 
 
 
Table 8.3.9 (b): Averaged table of results for an injection of L-Arginine with O2 sensors (MMCPEs and 
SMCPES, implanted in the striatum of 5 freely moving rats (n = 5 with 4 sensors).    
 
 
 
 
L-Arginine Injection (NO Sensors) 
Current change 
(pA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (pA) 
Baseline Post 
Injection (pA) 
26.1 ± 6.6 9.4 ± 3.1 25.2 ± 3.0 
 
100.4 ± 12.5 
 
421.0 ± 91.6 
 
436.2 ± 99.7 
L-Arginine Injection (O2 Sensors) 
Current change 
(nA) 
Current change 
(%) 
Max response 
Time (mins) 
Return 
Time (mins) 
Baseline Pre 
Injection (nA) 
Baseline Post 
Injection (nA) 
15.6 ± 3.3 10.6 ± 2.2 
 
60.0 ± 20.7 
 
146.6 ± 44.2 
 
-162.3 ± 34.6 
 
-170.0 ± 37.6 
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8.3.10 Day vs. night study 
 
Preliminary work displayed in Figure 8.3.10 (a) and 8.3.10 (b), identifies the NO and O2 
percentage change over the course of 6 hours during night (Figure 8.3.10 (a)) and day 
(Figure 8.3.10 (b)). Movement data was added to the graph in order to observe how the 
signals changed over the course of the 6 hours and if the movement of the animal caused 
any significant changes observed in the currents. The data observed in this section was 
analysed using sensors that were simultaneously recording NO and O2, along with the 
movement in the one animal over the course of a day and night.       
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Figure 8.2.10 (a): A time vs. percentage change profile over the course of 6 hours (8pm to 2am) 
recorded with O2 (1 sensor) and NO (3 sensors) in the striatum of a freely moving rat. The pink bars 
are indicative of movement. 
 
 
The NO and O2 baselines remained stable over the course of the 6 hours, however, there 
was more deviation in the O2 trace. It is known that the supply and utilisation of O2 will 
cause slight variations in the O2 signal over time (Lowry et al., 1997). The movement data 
also demonstrates how active the animal is during the night. This suggests that NO 
fluctuations are not associated with the movement of the animal.   
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Figure 8.3.10 (b): A time vs. percentage change profile over the course of 6 hours (8am to 2pm) 
recorded with O2 (1 sensor) and NO (3 sensors) in the striatum of a freely moving rat. The pink bars 
are indicative of movement. 
 
The NO and O2 trace observed in Figure 8.3.10 (b), seems to deviate much more than was 
observed with the baselines recorded during the night (8pm to 2am). In general, when 
experiments are not being carried out on the animals during the day, the activity of the 
animal is less frequent than the activity during the night. A clearer display of this can be 
observed in Figure 8.3.10 (c), where the NO and O2 baseline along with the movement data 
from one animal was recorded over two Days continuously. NO has been implicated in the 
regulation of sleep (Obal Jr & Krueger, 2003; Calabrese et al., 2007; Wisor et al., 2011; 
Kostin et al., 2013). In a study undertaken by Kostin et al., with the use of the Type 1 NO 
sensor extensively developed within our lab (Brown et al., 2009; Finnerty et al., 2012a; 
Finnerty et al., 2012b), extracellular levels of NO across a spontaneous sleep-wake cycle in 
response to sleep deprivation and during light vs. dark phases in freely moving animals was 
monitored (Kostin et al., 2013).  
The main findings from the research carried out by Kostin et al., was that endogenous NO 
levels were at their highest during waking, intermediate in the deepest stage of sleep that is 
rapid eye movement (REM) sleep and lowest during non-REM sleep. They also reported 
data which demonstrated that NO levels exhibit diurnal modulation (Kostin et al., 2013). 
The fluctuating NO response during the day (see Figure 8.3.10 (b)) in comparison to the 
stable NO baseline observed during the night (see Figure 8.3.10 (a)) when the rat is most 
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active, suggests that what is being observed here is the diurnal modulation of NO, which 
was observed by Kostin et al., (Kostin et al., 2013).  
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 Figure 8.3.10 (c): A time vs. percentage change profile over the course of 2 days recorded with O2 (1 
sensor) and NO (3 sensors) in the striatum of a freely moving rat. The pink bars are indicative of 
movement. 
 
The animal displays a more active persona during the dark phase in comparison to the light 
phase. During the day is when the animal would try to sleep as they are naturally nocturnal. 
It is clear from Figure 8.3.10 (c), that NO is much more dynamic during the day i.e. sleep.    
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8.4 Conclusion 
 
Reported in this chapter is the simultaneous monitoring of NO and O2 in the striatum of 
freely moving rats. The coupling of the O2 (SMCPEs and MMCPEs) and NO (Type 2 and 
Type 3 NO) sensors was deemed applicable, as the results attained in the preceding 
characterisation chapters displayed little difference between the sensors, with regards to 
their capabilities of detecting NO and O2 in the in-vivo environment. Various experiments 
were undertaken to try and determine the relationship between the two molecules in an in-
vivo setting. The simultaneous NO and O2 baseline recordings displayed in Figure 8.4 (a), 
demonstrate how stable the sensors are in-vivo. The currents did not deviate much from 
baseline levels over the course of three hours. This data is utilised as a control to 
demonstrate the effects of the different perturbations which can be attributed to the 
particular procedure/administration.  
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 Figure 8.4 (a): A time vs. percentage change graph of baseline NO and O2 currents monitored by NO 
sensors (Type 2 and Type 3 NO sensors, 15 sensors in 5 animals) and O2 sensors (MMCPEs and 
SMCPEs, 5 sensors in 5 animals) displaying a stable baseline over the course of three hours in-vivo. 
 
 
Subsequent to this, 3- and 5-minute periods of hypoxia and hyperoxia were performed, 
respectively. The results suggested a correlation between the two molecules. Upon the 
decrease in the O2 levels, there was a decrease in NO and a similar occurrence was 
observed after the 5 minute period of hyperoxia (an increase in O2 yielded an increase in 
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NO). Figure 8.4 (b), displays the percentage changes observed from the two sensors after 
the 3- and 5-minute periods of hypoxia and hyperoxia, respectively.   
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Figure 8.4 (b): A graph displaying the percentage changes observed with the NO (Type 2 and Type 3 
NO sensors) and O2 sensors (MMCPEs and SMCPEs) after hypoxia and hyperoxia was induced in the 
animals. 
 
After the exogenous perturbations had ceased the return to corresponding baseline levels 
were similar for the NO and O2 responses. A return time of 7.0 ± 0.6 mins, n = 17, 5 
animals and 6.6 ± 0.3 mins, n = 17, 5 animals was observed for NO and O2 during an 
administration of N2/air, respectively. A return time of 14.5 ± 1.9 mins, n = 18, 4 animals 
and 12.9 ± 0.5 mins, n = 18, 4 animals was recorded for the NO and O2 during an 
administration of O2/air, respectively. As stated previously, research undertaken by Pearce 
et al., suggests that eNOS activity is enhanced by hypoxia (Pearce et al., 1989; Pearce et 
al., 1990). If this was the case then it is postulated that if we were observing an NO current 
change by an eNOS induced pathway, then a resulting NO increase would have been 
observed. However, a decrease in NO was observed, which suggests that the decrease in O2 
that is needed for the synthesis of NO contributed to the decrease in NO monitored at the 
NO sensors. It is hypothesised that this NO production that is observed is in fact occurring 
through an NMDA receptor/ nNOS pathway, however it cannot be ruled out at present that 
eNOS could be contributing also. The increase in NO after the period of hyperoxia could be 
due to the increased availability of O2, thus, causing a rise in the production of NO. O2 is a 
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vital component of the synthesis of NO (see Figure 1.4) and Liao et al., have demonstrated 
that hyperoxia can affect the expression of NOS and NO production in cultured cells (Liao 
et al., 1995).  
Neuronal activation experiments were then undertaken to try and achieve more information 
about the association between NO and O2. The restraint stress and tail pinch would yield 
more information about endogenous perturbations that may cause changes in NO and O2. In 
Figure 8.4 (c), a graph displays the percentage change that occurred in O2 and NO 
simultaneously. 
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          Figure 8.4 (c): A graph displaying the percentage changes observed with the NO (Type 2 and 
Type 3 NO sensors) and O2 sensors (MMCPEs and SMCPES) after restraint stress and tail pinch 
studies.  
 
The results obtained with the restraint stress and tail pinch displayed a concurrent increase 
in NO and O2, as was seen with the hypoxia and hyperoxia induced states. Again this 
would seem like a correlation between NO and O2 is occurring, however, what was 
interesting about these results was the elevated NO response after the stimulus had ceased. 
The NO current remained high after the O2 had returned to corresponding baseline levels. 
These results again suggest that there is another mechanism of NO production responsible 
and not the production of NO through the eNOS enzyme which is known to act on the 
dilation and constriction of blood vessels (see Figure 8.3.4 (a) and 8.3.5 (a)).  
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Following on from this, i.p. injections of chloral hydrate and diamox were performed. The 
recorded currents obtained for NO after the two i.p. injections were fascinating results, as 
both injections displayed no association with O2. The O2 increase observed for both 
injections were expected, however from the results obtained prior to this we were also 
expecting an increase in NO. However, we observed a decrease in NO for both i.p. 
injections. Figure 8.4 (d) displays the percentage change in both the O2 and NO.    
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Figure 8.4 (d): A graph displaying the percentage changes observed with the NO (Type 2 and Type 3 
NO sensors) and O2 sensors (MMCPEs and SMCPES) after an i.p. injection of chloral hydrate 
(350mg/kg) and diamox (50mg/kg). 
 
 
Evidence has suggested that the NMDA receptors are targets of anaesthetic agents in the 
central nervous system and that some of the biological actions created by the anaesthetics 
affect the NMDA receptors. So, if there is a loss of surface expressed NMDA receptors, 
this would lead to a decreased NO production. Chloral hydrate increases striatal O2 and that 
is why an increase in observed in the O2 current. If eNOS was the enzyme producing the 
NO and causing an increase in cerebral blood flow an increase in NO would have been 
observed, however we did not observe this, which suggests that it is the nNOS enzyme that 
is producing the NO through the activation of the NMDA receptors. 
The diamox result yielded a similar conclusion. Diamox is a carbonic anhydrase inhibitor 
that is known to increase O2 and it is also known that it induces a decrease in pH. The 
NMDA receptors are inhibited by a decreased pH and it has been shown that the frequency 
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by which the NMDA receptor channel opens is decreased by protons above the 
physiological range and at pH 6.0, receptor activation is suppressed. These results lead to a 
hypothesis that the NO being detected is from the NMDA-receptor pathway involving 
nNOS, however, it cannot be ruled out that some contribution may be occurring from other 
sources of NO. Following on from this result, i.p. injections of L-NAME and L-arginine 
were administered. Figure 8.4 (e) displays the percentage change observed from the NO 
and O2 sensors after the injections. 
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Figure 8.4 (e): A graph displaying the percentage changes observed with the NO (Type 2 and Type 3 
NO sensors) and O2 sensors (MMCPEs and SMCPES) after an i.p. injection of L-NAME (30mg/kg) and 
L-arginine (300mg/kg). 
 
The results obtained for the L-NAME injection were as expected as it is known that L-
NAME inhibits eNOS, nNOS and iNOS. This would therefore lead to a decreased NO 
production and a reduction in cerebral blood flow which would yield a decrease in O2. The 
L-arginine result was the opposite of this. L-arginine produces a greater amount of NO, 
which increases blood supply and thus increases O2.  
In Figure 8.3.10 (a), (b) and (c), the data observed for the NO, O2 baseline and movement 
data highlight the activity of the rat during different times over a 6 hour period (Figure 
8.3.10 (a) and (b)) and over the course of a 2 day period (8.3.10 (c)). The fluctuation in the 
NO current observed during the day is suggested to be an effect of diurnal modulation 
which has been reported in the literature (Kostin et al., 2013). A clear difference can be 
observed between the two graphs (during the day and during the night). Due to the 
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nocturnal nature of the rat, they are more active during the night and we observe a more 
stable NO current during this time. 
It can be observed from the results in this chapter, that the NO molecule did not behave the 
way we anticipated. It has been suggested that there is a correlation between NO and O2 
and this is due to the connection the two molecules have with CBF. O2 is known to reliably 
act as an index of CBF (Lowry et al., 1997) and NO is known to cause vasodilation or 
constriction of cerebral blood vessels by the production of NO derived from endothelial 
cells i.e. eNOS (Moncada et al., 1991). It would suggest from the results obtained for the 
hypoxia and hyperoxia studies, that there was a correlation between the O2 and NO signal 
obtained, as the increases and decreases observed seemed to behave the same (Park et al., 
2010). However, the more studies that were completed, the more contradicting the findings 
became. The restraint stress and tail pinch studies displayed a different NO behaviour. The 
two studies showed an elevation in the NO current upon initiation of the stimulus and upon 
cessation of the stimulus, an elevated NO response remained, whilst the O2 current was 
observed to have returned to pre-baseline currents. However, it is imperative to mention 
that the NO did return to pre-baseline levels a short time after. Thus, suggesting an 
involvement of the NMDA receptor and the nNOS enzyme contributing to the NO response 
that we were observing with the sensors. Studies carried out involving rodents and primates 
have shown that nNOS is ubiquitous in the brain (Calabrese et al., 2007).  
The chloral hydrate and diamox studies displayed results that were not foreseen. These 
results showed a total separation in the correlation of the two molecules. It was very 
interesting to observe how both of these drugs, caused two different behaviours in the 
molecules, thus validating an independent function of NO that is not correlated to O2. From 
all of the results studied in this Chapter, it would suggest that the NO in which we are 
detecting is from the NMDA receptor/nNOS mediated synthesis of NO and it would 
confirm many hypothesis in literature that suggest that nNOS is the enzyme in abundance 
in the brain.  
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One of the greatest challenges facing science today is the understanding of the brain. How 
does it control behaviour, how does it malfunction in brain disorders, such as 
schizophrenia, Parkinson‘s disease, Alzheimers disease and many more. The rectification 
of such malfunctions by gaining knowledge about the mechanisms of the brain is a 
challenging objective undertaken by many scientists. The brain comprises of a very 
complex network of neurons and glial cells that interact with each other producing different 
chemical messengers into the ECF and it is these chemicals that are of interest to monitor 
(Kennedy et al., 2002). The measurement of real-time in-vivo recordings is a supreme 
technique that allows the researcher to observe instantaneous chemical changes in the living 
brain with the use of the specific analyte monitoring sensors. Investigating the functions 
and roles of certain neurochemicals in neuronal signalling, drug action and behaviour with 
these sensors provides a lot of interesting and exciting information about the inner 
workings of the body. 
This thesis attempts to further the area of neurochemical monitoring by developing novel 
O2 sensors that could potentially be utilised in a clinical setting, specifically sensors that 
can withstand morphological changes in a harsh environment, such as the human body. 
Also the characterisation of novel Type 2 and Type 3 NO sensors for faster detection of NO 
in-vivo was undertaken in order to try and discover more about the inner workings of the 
NO molecule in the in-vivo environment. There has been much research into the detection 
of O2, owing to the fact that it is a vital biological substrate that is involved in the many 
mechanisms that maintain the functioning of our bodies. Previous methods of detection 
include the use of carbon-based sensors such as CPEs (Lowry et al., 1996; Lowry et al., 
1997; Bolger & Lowry, 2005; Bolger et al., 2011b) and carbon fibre electrodes 
(Zimmerman & Wightman, 1991).  
CPEs are very efficient for the detection of O2 due to the great stability observed over 
extended periods of time. The only problem associated with this sensor, especially with the 
hope of integrating it into a clinical environment, is the surface alteration it undergoes when 
in the presence of lipids and proteins. The CPE changes to a carbon powder electrode upon 
the interaction with BT, due to the leeching of the silicone oil from the paste (Ormonde & 
O'Neill, 1989, 1990). Therefore, the removal of the oil into the central or peripheral 
compartment of the human body would not be considered ideal. It was for this reason that 
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the monomer modification of the CPEs was undertaken. In order to achieve a composite 
electrode that was very robust and that was not easily modified by whatever environment it 
was placed into. 
Presented in the first of the results chapters (Chapter 4) is the in-vitro characterisation of 
the MMCPEs and SMCPEs. The main goal of this chapter was to obtain an electrode with a 
composite surface that was not as prone to leeching by whatever physiological environment 
it was placed into (Dai et al., 2008), whilst retaining sensitivity and stability. The results 
suggest that this aim was achieved. Biocompatibility experiments were carried out on the 
CPEs to directly compare differences between the monomer modified sensors and the 
CPEs. There were very distinguishable differences observed from the effects of the 
biocompatibility experiments between the CPEs, SMCPEs and MMCPEs.  
 
 
Table 9 (a): A table displaying a summary of the treatment results (nA/µM) for each of the sensors 
(CPE), (SMCPE) and (MMCPE). 
 
Table 9 (a) displays a summary of the results for each of the sensors and each of the main 
treatments undertaken with them. It can clearly be observed that there is an increase in the 
sensitivity obtained with the SMCPEs and MMCPEs in comparison to the CPEs. This has 
been hypothesised as being due to the increase in the rate of electron transfer due to the Sty 
and MMA within the carbon paste. The SMCPE and MMCPE sensitivities observed 
yielded a significantly different sensitivity (P < 0.0001) in comparison to the CPEs. During 
the biocompatibility studies the CPE surface was easily altered by the different treatments 
undertaken, whilst the SMCPEs and MMCPEs surfaces remained intact and unaltered by 
these harsh conditions. As the CPEs are known for their great stability characteristic in-vivo 
 CPEs (nA/µM) SMCPEs (nA/µM) MMCPEs (nA/µM) 
 Mean  SEM n Mean SEM n Mean SEM n 
Pre treatment -1.8 0.1 52 -3.1 0.1 52 -3.3 0.2 52 
BSA (10%) -1.1 0.1 4 -2.7 0.5 8 -2.9 0.3 6 
PEA (10%) -1.0 0.1 4 -2.7 0.3 8 -2.7 0.4 4 
BT (O.N) -1.5 0.1 4 -2.8 0.3 6 -2.7 0.2 7 
BT (28 Days) -1.6 0.1 4 -3.2 0.1 4 -2.7 0.2 4 
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(O‘Neill, 2005),  it was attempted to try and achieve a similar stability with the monomer 
modified sensors without alteration of the composite surface.    
The long term stability studies would provide information, especially for clinicians, on the 
storage and stability life of the sensors, as they would not use the sensors straight away. 
The long term stability studies of the SMCPEs and MMCPEs were very promising. The RT 
storage condition was chosen as the optimum storage condition. The results from the 
SMCPEs over the 28 days showed no significant difference from day 1 to day 28 (P = 
0.1242) and likewise with the MMCPEs (P = 0.1747). The ECF of the brain contains a 
wide array of endogenous species that could potentially interfere with the sensors 
sensitivity (O'Neill & Lowry, 2006).  Interference tests carried out on the SMCPEs and 
MMCPEs all displayed negligible results with all interferents studied contributing < 1% to 
the overall signal (see Section 4.3.8). Temperature and pH changes did not affect the ability 
of the SMCPEs and MMCPEs to detect O2 (see Section 4.3.9 and 4.3.10). Sensors need to 
be able to withstand temperature and pH changes in-vivo, especially since the temperature 
of the body is 37 
°
C. Changes in pH also occur in-vivo, however, they are tightly regulated 
by mechanisms in the body (Chesler, 2003). It has also been shown that pH can be altered 
in disorders such as depression and ischemia (Mutch & Hansen, 1984). Table 9 (b) displays 
the P values (one-way ANOVA and a paired t-test) obtained for the temperature and pH 
data respectively, all results showed no significant difference.        
 
One-way ANOVA SMCPEs MMCPEs Paired t-tests SMCPEs MMCPEs 
pH P value Temperature P value 
7.4/6.5/8.0 0.9903 0.9982 25°C/37°C 0.8934 0.9415 
 
Table 9 (b): A table displaying a summary of the pH and temperature P value results obtained with the 
MMCPEs and SMCPEs. 
 
To further validate how these sensors would behave in a very complex environment such as 
the living brain, they were implanted in the striatum of freely moving rats over the course 
of 12 and 13 days using the MMCPEs and SMCPEs respectively. Chapter 5 details the in-
vivo characterisation of the SMCPEs and MMCPEs. Upon examination of the results 
presented in Chapter 5, it can be seen that the response obtained by the SMCPEs and 
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MMCPEs after various perturbations such as hypoxia, hyperoxia, neuronal activation, 
exposure to anaesthesia and the carbonic anhydrase inhibitor acetazolamide, yielded a 
better sensitivity than the CPEs. This corroborates the in-vitro studies undertaken and the 
higher sensitivity achieved. The MMCPEs and SMPCEs were much more effective in 
detecting the subtle changes in the O2 concentration as opposed to the CPEs (Bolger et al., 
2011b).  
Pre- and post-implantation results displayed a decrease in the O2 sensitivity that yielded 
significantly different sensitivities for the MMCPEs (P = 0.0073) and SMCPEs (P = 
0.0016), however, the sensitivity remained higher than that of the untreated CPEs (see 
Section 4.3.6.1 and 4.3.6.2). The CPEs are susceptible to alteration by the in-vivo 
environment, so it was vital that this did not occur with the MMCPEs and SMCPEs, as 
clinical integration necessitates a robust composite that does not leech out into the 
surrounding tissue. The results obtained were very promising with regards to the structural 
integrity of the two monomer modified sensors. SEM data (shown in Section 4.3.6.1 (d) 
and 4.3.6.2 (d)) displayed the SMCPEs and MMCPEs post implantation, where the surface 
remained intact with deposits of the in-vivo environment left behind on the surface. 
However, the morphology of the sensor did not alter, which was the main goal of this 
research and one that we feel was very successful, thus, concluding that these sensors could 
potentially be utilised in the clinical setting.  
The other major aspect of this thesis was the characterisation of the sensors (Type 2 and 
Type 3 NO sensor) for the amperometric detection of brain extracellular NO. Described in 
Chapter 6 is the research carried out into the characterisation of the novel Type 2 and Type 
3 NO sensors. Initially, studies were carried out with the more commonly utilised Type 1 
NO sensor that has been extensively characterised within our lab (Brown et al., 2009; 
Finnerty et al., 2012a; Finnerty et al., 2012b). The sensitivities achieved with the Type 1, 
Type 2 and Type 3 NO sensors displayed no significant difference between each of the 
sensors. Table 9 (c), displays the P values obtained. 
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 Type 1 vs. Type 2 Type 1 vs. Type 3 Type 2 vs. Type 3 
P value 0.8440 0.6823 0.8332 
 
Table 9 (c): A table summarising the P values obtained for the sensitivities of the Type 1, Type 2 and 
Type 3 NO sensors 
 
Long term stability tests gave very promising results. It was observed that on repeated 
calibration of the sensors, the surface was altered and modified more extensively than when 
the sensors were calibrated less frequently. Negligible results were presented after 56 Days 
of storage for all the sensors and in comparison to the repeated calibrations displayed in 
Section 6.3.8, it was confirmed that the repetitive calibrations were the cause of the 
degradation of the sensor and not the sensors composition deteriorating over time. 
Biocompatibility studies were undertaken that displayed an effect on the sensors after 28 
days immersed in each of the treatments. AA calibrations were carried out in order to 
determine the extent of the damage caused by the different treatments to the sensors. It has 
been observed that NO calibrations would not give any information on the damage done to 
the sensors, as a similar sensitivity to pre implanted sensors is obtained with post implanted 
sensors (see Section 6.3.15 and 6.3.16). The amount of AA being detected by the sensors 
would yield information about the condition of the rejection layer, in this case the o-PD 
layer. 
The BT results displayed the most damage to the sensor surface with 540.0 ± 151.6 pA for 
the Type 2 NO sensors and 479.9 ± 106.1 pA for the Type 3 NO sensors being detected at 
an AA concentration of 1000 µM. Interference tests undertaken with the Type 2 and Type 3 
NO sensors yielded negligible results detected with the sensors (see Section 6.3.11) for 
some of the principle endogenous species found in the ECF of the brain. The temperature 
studies undertaken with the Type 2 and Type 3 NO sensors displayed no significant 
difference (P = 0.7400) and (P = 0.6231), respectively, on elevation of the temperature to 
37 
°
C.  It has been observed previously by Brown et al., that on alteration of the 
temperature to 37 
°
C the response of the Type 1 NO sensor became quicker (Brown et al., 
2009). A quicker response time was also achieved with the Type 2 and Type 3 NO sensors 
(see Section 6.3.14). Pre- and post-implantation results for the NO sensitivities obtained for 
the Type 2 and Type 3 NO sensors displayed no significant difference (P = 0.7229) and (P 
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= 0.8709), respectively. However, with regards to the AA response pre- and post- 
implantation, a significant difference was observed for the Type 2 NO sensor (P = 0.0020) 
and Type 3 NO sensor (P = 0.0083) (see Section 6.3.15 and 6.3.16), showing a breakdown 
of the rejection layer.  
Chapter 7 details the in-vivo characterisation of the Type 2 and Type 3 NO sensor, 
subsequent to the in-vitro characterisation. To characterise the two sensors in-vivo, 
systemic administrations of known inducers and inhibitors of NO production and the 
corresponding changes in the NO current were investigated. The first experiments carried 
out were control saline injections, since all administrations were by i.p. injection it was 
important to validate the response attained by the injection itself, therefore utilising saline 
to verify this. Following on from this, L-NAME, L-arginine and finally sodium ascorbate 
was administered. The saline injections displayed a short lived change in the NO current for 
the Type 2 NO sensor and Type 3 NO sensor that was not significantly different (P = 
0.0819) and (P = 0.0768) from pre baseline levels, respectively. The L-arginine injections 
caused an increase in the NO current that was significantly different (P = 0.0819) and (P = 
0.0768) from pre baseline currents for Type 2 and Type 3 NO sensors respectively.  
The ascorbate injection which is undertaken to determine if the rejection layer on the 
sensors is still intact, displayed no change in the observed oxidation current. It has 
previously been illustrated with CPEs, that if any response to sodium ascorbate was to 
occur it would do so within a time range of 60 minutes (Lowry et al., 1996). The result 
obtained by the Type 2 and Type 3 NO sensors displayed no significant difference (P = 
0.2052) and (P = 0.2214), respectively, between the pre and post baseline levels over the 60 
minutes analysed. The final results chapter (Chapter 8), demonstrates the versatility of the 
sensors as analytical tools in the field of neurochemistry. The O2 (SMCPEs and MMCPEs) 
and NO (Type 2 and Type 3) sensors for this chapter were implanted in the striatum of 
freely moving rats, simultaneously. There were no differences in how the MMCPEs and 
SMCPEs behaved in the in-vivo environment (see Chapter 5) so it was deemed satisfactory 
to combine them. This was the same for the Type 2 and Type 3 NO sensors (see Chapter 7).  
Various experiments were undertaken to try and determine the relationship between the two 
molecules (NO and O2) in an in-vivo setting. The initial experiments carried out were 
periods of induced hypoxia and hyperoxia. The results suggested a correlation between NO 
  Chapter 9: Conclusion  
 
387  
 
and O2 as the two molecules behaved in the same manner. The following experiments 
carried out displayed an NO response that caused us to reconsider whether NO and O2 were 
actually behaving in correlation or whether there was a desynchronisation of the two 
molecules. Firstly during periods of neuronal activation, it was observed that although NO 
and O2 displayed an increase in their response simultaneously, the NO response was 
slightly longer and remained elevated (see Figure 8.3.4 (a) and 8.3.5 (a)). This was 
observed with the restraint stress and tail pinch experiments undertaken. 
These results suggest that NO is behaving independently through the NMDA 
receptor/nNOS pathway (see Section 8.3.5). The O2 levels return to normoxic conditions 
after cessation of the two stimuli and the NO current remains elevated. It is postulated that 
if the NO that we were detecting was from eNOS then the NO would have returned to 
corresponding baseline levels along with the O2 current. However, we did not observe this 
and so it is hypothesised from these experiments that the synthesis of NO from the nNOS 
enzyme through the NMDA receptors pathway is the NO we are mostly detecting. The next 
results displayed total desynchronisation of the NO and O2 currents after the same 
perturbation. Chloral hydrate and diamox results displayed a decrease in the NO current, 
whilst the O2 current increased. The increase in the O2 current was expected as chloral 
hydrate and diamox both increase the levels of O2 (see Figure 8.3.6 and 8.3.7). However, 
the NO decreases observed in both cases were unexpected.  
It has always been thought that a correlation between NO and O2 exists, which means we 
should have observed an increase with NO upon an increase of O2. It is known that the 
NMDA receptors are suppressed upon administration of chloral hydrate (LacKamp et al., 
2009). Diamox is also known to induce a decrease in pH, which suppresses activity of the 
NMDA receptors (Bickler et al., 1988; Tang et al., 1990). It is therefore strongly postulated 
that the decrease in the NMDA receptor activity would cause a decrease in the production 
of NO, which is what we observed with the chloral hydrate and diamox results (see Figure 
8.3.6 and 8.3.7). All of the results observed in Chapter 8, strongly suggest that the NO in 
which we are detecting is from the NMDA receptor/nNOS mediated synthesis of NO, 
however the contribution from eNOS cannot be ruled out. Continuation of this body of 
work would initially require the use of specific selective inhibitors to try and determine if 
the NO being produced in the brain is in fact from the nNOS enzyme. This would also 
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determine if nNOS is the enzyme that is in abundance in the brain, which has previously  
been stated in the literature (Calabrese et al., 2007; Zhou & Zhu, 2009).  
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